

# October 2023

## Volume 11

### Editor:

Kaye Wilson & Ayeshah Khan  
email: [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)  
Telephone +64 4 460 4990  
Level 9, 40 Mercer Street  
PO Box 10 254 Wellington 6143

### Freephone Information Line

0800 66 00 50 (9am – 5pm weekdays)

### Circulation

You can register to have an electronic version of the Pharmaceutical Schedule, Section H for Hospital Pharmaceuticals (link to PDF copy) emailed to your nominated email address each month by subscribing at [schedule.pharmac.govt.nz/subscribe](http://schedule.pharmac.govt.nz/subscribe).

### Production

Typeset automatically from XML and T<sub>E</sub>X.  
XML version of the Schedule available from [schedule.pharmac.govt.nz/pub/HML](http://schedule.pharmac.govt.nz/pub/HML)

### Programmers

Anrik Drenth & John Geering

email: [texschedule@pharmac.govt.nz](mailto:texschedule@pharmac.govt.nz)

©Pharmaceutical Management Agency



ISSN 1179-3708 pdf

This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to Pharmac and abide by the other licence terms. To view a copy of this licence, visit: [creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/). Attribution to Pharmac should be in written form and not by reproduction of the Pharmac logo. While care has been taken in compiling this Schedule, Pharmac takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

<b>Part I</b>	General Rules	<b>4</b>
---------------	---------------	----------

<b>Part II</b>	Alimentary Tract and Metabolism	<b>5</b>
	Blood and Blood Forming Organs	<b>29</b>
	Cardiovascular System	<b>43</b>
	Dermatologicals	<b>67</b>
	Genito-Urinary System	<b>74</b>
	Hormone Preparations	<b>78</b>
	Infections	<b>88</b>
	Musculoskeletal System	<b>111</b>
	Nervous System	<b>118</b>
	Oncology Agents and Immunosuppressants	<b>146</b>
	Respiratory System and Allergies	<b>243</b>
	Sensory Organs	<b>252</b>
	Various	<b>259</b>
Extemporaneous Compounds (ECPs)	<b>267</b>	
Special Foods	<b>270</b>	
Vaccines	<b>287</b>	

<b>Part III</b>	Optional Pharmaceuticals	<b>298</b>
-----------------	--------------------------	------------

	Index	<b>299</b>
--	-------	------------

# Introducing Pharmac

The Pharmaceutical Management Agency (Pharmac) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. Pharmac negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list.

## Pharmac's role:

***"to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided."***

Pae Ora (Healthy Futures) Act 2022

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about Pharmac and the way we make funding decisions can be found on the Pharmac website at <https://www.pharmac.govt.nz/about>.

## Glossary

### Units of Measure

gram .....	g	microgram.....	mcg	millimole.....	mmol
kilogram.....	kg	milligram.....	mg	unit.....	u
international unit.....	iu	millilitre.....	ml		

### Abbreviations

application .....	app	enteric coated.....	EC	solution.....	soln
capsule.....	cap	granules.....	grans	suppository.....	suppos
cream.....	crm	injection.....	inj	tablet.....	tab
dispersible.....	disp	liquid.....	liq	tincture.....	tinc
effervescent.....	eff	lotion.....	lotn		
emulsion.....	emul	ointment.....	oint		

HSS Hospital Supply Status

# Guide to Section H listings

## Example

ANATOMICAL HEADING			
	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
<b>THERAPEUTIC HEADING</b>			
Generic name listed by therapeutic group and subgroup	<b>CHEMICAL A - Restricted</b> see terms below		
	⚡ Presentation A.....10.00	100	<b>Brand A</b>
	➔ <b>Restricted</b> Only for use in children under 12 years of age		
Indicates only presentation B1 is Restricted	<b>CHEMICAL B - Some items restricted</b> see terms below		
	⚡ Presentation B1.....1,589,00	1	Brand B1 e.g. <i>Brand B2</i>
	➔ <b>Restricted</b> Oncologist or haematologist		
From 1 January 2012 to 30 June 2014, at least 99% of the total volume of this item purchased must be Brand C	<b>CHEMICAL C</b>		
	Presentation C <b>-1% DV Limit Jan-12 to 2014</b> .....15.00	28	<b>Brand C</b>
	<b>CHEMICAL D - Restricted</b> see terms below		
	⚡ Presentation D <b>-1% DV Limit Mar-13 to 2014</b> .....38.65	500	<b>Brand D</b>
Standard national price excluding GST	➔ <b>Restricted</b> <i>Limited to five weeks' treatment</i> Either: 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or 2 For the prophylaxis of venous thromboembolism following a total knee replacement.		
Form and strength	<b>CHEMICAL E</b> Presentation E		e.g. <i>Brand E</i>
⚡ Item restricted (see above); ⚡ Item restricted (see below) Products with Hospital Supply Status (HSS) are in <b>bold</b>			

## PART I: GENERAL RULES

---

General Rules for Section H of the Pharmaceutical Schedule are included in Section A.

Read the [General Rules](https://www.pharmac.govt.nz/section-a) : <https://www.pharmac.govt.nz/section-a>.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Antacids and Antiflatulents</b>			
<b>Antacids and Reflux Barrier Agents</b>			
ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETICONE			
Tab 200 mg with magnesium hydroxide 200 mg and simeticone 20 mg			e.g. <i>Mylanta</i>
Oral liq 400 mg with magnesium hydroxide 400 mg and simeticone 30 mg per 5 ml			e.g. <i>Mylanta Double Strength</i>
SIMETICONE			
Oral drops 100 mg per ml			
Oral drops 20 mg per 0.3 ml			
Oral drops 40 mg per ml			
SODIUM ALGINATE WITH MAGNESIUM ALGINATE			
Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet			e.g. <i>Gaviscon Infant</i>
SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE			
Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg			e.g. <i>Gaviscon Extra Strength</i>
Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml.....	7.50	500 ml	Acidex
SODIUM CITRATE			
Oral liq 8.8% (300 mmol/l) – 5% DV Jan-22 to 2024 .....	25.00	90 ml	<b>Biomed</b>
<b>Phosphate Binding Agents</b>			
ALUMINIUM HYDROXIDE			
Tab 600 mg			
CALCIUM CARBONATE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Oral liq 250 mg per ml (100 mg elemental per ml) .....	47.30	473 ml	Calcium carbonate PAI
	39.00	500 ml	Roxane
➔ <b>Restricted (RS1698)</b>			
<b>Initiation</b>			
Only when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate..			
<b>Antidiarrhoeals and Intestinal Anti-Inflammatory Agents</b>			
<b>Antipropulsives</b>			
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE			
Tab 2.5 mg with atropine sulphate 25 mcg			
LOPERAMIDE HYDROCHLORIDE			
Tab 2 mg .....	10.75	400	Nodia
Cap 2 mg – 5% DV Jan-23 to 2025 .....	7.25	400	<b>Diamide Relief</b>
<b>Rectal and Colonic Anti-Inflammatories</b>			
BUDESONIDE – <b>Restricted</b> see terms <a href="#">on the next page</a>			
↓ Cap 3 mg			

# ALIMENTARY TRACT AND METABOLISM

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted (RS1723)**

**Initiation – Crohn's disease**

Both:

- 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
- 2 Any of the following:
  - 2.1 Diabetes; or
  - 2.2 Cushingoid habitus; or
  - 2.3 Osteoporosis where there is significant risk of fracture; or
  - 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
  - 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
  - 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
  - 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

**Initiation – Collagenous and lymphocytic colitis (microscopic colitis)**

Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

**Initiation – Gut Graft versus Host disease**

Patient has gut Graft versus Host disease following allogenic bone marrow transplantation.

**Initiation – non-cirrhotic autoimmune hepatitis**

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has autoimmune hepatitis\*; and
- 2 Patient does not have cirrhosis; and
- 3 Any of the following:
  - 3.1 Diabetes; or
  - 3.2 Cushingoid habitus; or
  - 3.3 Osteoporosis where there is significant risk of fracture; or
  - 3.4 Severe acne following treatment with conventional corticosteroid therapy; or
  - 3.5 History of severe psychiatric problems associated with corticosteroid treatment; or
  - 3.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
  - 3.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated); or
  - 3.8 Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth).

Note: Indications marked with \* are unapproved indications.

**Continuation – non-cirrhotic autoimmune hepatitis**

*Re-assessment required after 6 months*

Treatment remains appropriate and the patient is benefitting from the treatment.

**HYDROCORTISONE ACETATE**

Rectal foam 10%, CFC free (14 applications) .....	26.55	15 g 21.1 g	Colifoam Colifoam
---	-------	----------------	----------------------

**HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE**

Topical Aerosol foam, 1% with pramoxine hydrochloride 1%

**MESALAZINE**

Tab EC 400 mg .....	49.50	100	Asacol
Tab long-acting 500 mg .....	56.10	100	Pentasa
Tab 800 mg .....	85.50	90	Asacol
Modified release granules 1 g .....	118.10	100 g	Pentasa
Suppos 500 mg .....	22.80	20	Asacol
Suppos 1 g .....	50.96	28	Pentasa
Enema 1 g per 100 ml .....	41.30	7	Pentasa

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
OLSALAZINE			
Tab 500 mg .....	93.37	100	Dipentum
Cap 250 mg .....	53.00	100	Dipentum
PREDNISOLONE SODIUM			
Rectal foam 20 mg per dose (14 applications) .....	74.10	1	Essential Prednisolone
SODIUM CROMOGLICATE			
Cap 100 mg			
SULFASALAZINE			
Tab 500 mg .....	16.52	100	Salazopyrin
Tab EC 500 mg .....	17.86	100	Salazopyrin EN

**Local Preparations for Anal and Rectal Disorders**

**Antihæmorrhoidal Preparations**

CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE			
Oint 5 mg with hydrocortisone 5 mg per g .....	15.00	30 g	Proctosedyl
Suppos 5 mg with hydrocortisone 5 mg per g .....	9.90	12	Proctosedyl
FLUCORTOLONE CAPROATE WITH FLUCORTOLONE PIVALATE AND CINCHOCAINE			
Oint 950 mcg with flucortolone pivalate 920 mcg and cinchocaine hydrochloride 5 mg per g .....	11.06	30 g	Ultraproct
Suppos 630 mcg with flucortolone pivalate 610 mcg and cinchocaine hydrochloride 1 mg .....	7.30	12	Ultraproct

**Management of Anal Fissures**

GLYCERYL TRINITRATE			
Oint 0.2% – 5% DV Sep-21 to 2024 .....	22.00	30 g	<b>Rectogesic</b>

**Rectal Sclerosants**

OILY PHENOL [PHENOL OILY]			
Inj 5%, 5 ml vial			

**Antispasmodics and Other Agents Altering Gut Motility**

GLYCOPYRRONIUM BROMIDE			
Inj 200 mcg per ml, 1 ml ampoule – 5% DV Sep-23 to 2025 .....	19.00	5	<b>Robinul</b>
HYOSCINE BUTYLBROMIDE			
Tab 10 mg .....	6.35	100	Buscopan
Inj 20 mg, 1 ml ampoule – 5% DV Dec-23 to 2026 .....	6.35	5	Buscopan
	1.91	1	<b>Spazmol</b>
<i>(Buscopan Inj 20 mg, 1 ml ampoule to be delisted 1 December 2023)</i>			
MEBEVERINE HYDROCHLORIDE			
Tab 135 mg – 5% DV Dec-23 to 2026 .....	8.50	90	<b>Colofac</b>

**Antilcerants**

**Antisecretory and Cytoprotective**

MISOPROSTOL			
Tab 200 mcg .....	47.73	120	Cytotec

# ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## H2 Antagonists

### CIMETIDINE

Tab 200 mg

Tab 400 mg

### FAMOTIDINE

Tab 20 mg

Tab 40 mg

Inj 10 mg per ml, 2 ml vial

Inj 10 mg per ml, 4 ml vial

### RANITIDINE – **Restricted** see terms [below](#)

↓ Tab 150 mg

↓ Tab 300 mg

↓ Inj 25 mg per ml, 2 ml ampoule

➔ **Restricted (RS1703)**

#### Initiation

Either:

1 For continuation use; or

2 Routine prevention of allergic reactions..

## Proton Pump Inhibitors

### LANSOPRAZOLE

Cap 15 mg – **5% DV Dec-21 to 2024**.....4.20

100

**Lanzol Relief**

Cap 30 mg – **5% DV Dec-21 to 2024**.....5.26

100

**Lanzol Relief**

### OMEPRAZOLE

↓ Tab dispersible 10 mg

➔ **Restricted (RS1027)**

#### Initiation

Only for use in tube-fed patients.

↓ Tab dispersible 20 mg

➔ **Restricted (RS1027)**

#### Initiation

Only for use in tube-fed patients.

Cap 10 mg – **5% DV Mar-24 to 2026**.....2.06

90

**Omeprazole actavis 10**

Cap 20 mg – **5% DV Mar-24 to 2026**.....2.02

90

**Omeprazole actavis 20**

Cap 40 mg – **5% DV Mar-24 to 2026**.....3.18

90

**Omeprazole actavis 40**

Powder for oral liq.....42.50

5 g

Midwest

Inj 40 mg ampoule with diluent – **5% DV Jan-23 to 2025**.....37.38

5

**Dr Reddy's Omeprazole**

Inj 40 mg vial – **5% DV Jan-23 to 2025**.....11.95

5

**Omezol IV**

### PANTOPRAZOLE

Tab EC 20 mg – **5% DV Dec-23 to 2025**.....1.99

90

**Panzop Relief**

Tab EC 40 mg – **5% DV Dec-23 to 2025**.....2.74

90

**Panzop Relief**

Inj 40 mg vial

## Site Protective Agents

### COLLOIDAL BISMUTH SUBCITRATE

Tab 120 mg.....14.51

50

Gastrodenol

### SUCRALFATE

Tab 1 g



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Bile and Liver Therapy

L-ORNITHINE L-ASPARTATE – **Restricted** see terms [below](#)

↓ Grans for oral liquid 3 g

→ **Restricted (RS1261)**

### Initiation

For patients with chronic hepatic encephalopathy who have not responded to treatment with, or are intolerant to lactulose, or where lactulose is contraindicated.

RIFAXIMIN – **Restricted** see terms [below](#)

↓ Tab 550 mg ..... 625.00 56 Xifaxan

→ **Restricted (RS1416)**

### Initiation

For patients with hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

## Diabetes

### Alpha Glucosidase Inhibitors

ACARBOSE

Tab 50 mg – 5% DV Dec-21 to 2024 ..... 8.95 90 **Accarb**

Tab 100 mg – 5% DV Dec-21 to 2024 ..... 15.29 90 **Accarb**

### Hyperglycaemic Agents

DIAZOXIDE – **Restricted** see terms [below](#)

↓ Cap 25 mg ..... 110.00 100 Proglicem

↓ Cap 100 mg ..... 280.00 100 Proglicem

↓ Oral liq 50 mg per ml ..... 620.00 30 ml Proglycem

→ **Restricted (RS1028)**

### Initiation

For patients with confirmed hypoglycaemia caused by hyperinsulinism.

GLUCAGON HYDROCHLORIDE

Inj 1 mg syringe kit ..... 32.00 1 Glucagen Hypokit

GLUCOSE [DEXTROSE]

Tab 1.5 g

Tab 3.1 g

Tab 4 g

Oral soln 15 g per 80 ml sachet ..... 70.00 50 HypoPak Glucose

Gel 40%

GLUCOSE WITH SUCROSE AND FRUCTOSE

Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet

### Insulin - Intermediate-Acting Preparations

INSULIN ASPART WITH INSULIN ASPART PROTAMINE

Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml,  
3 ml prefilled pen ..... 52.15 5 NovoMix 30 FlexPen

INSULIN ISOPHANE

Inj insulin human 100 u per ml, 10 ml vial

Inj insulin human 100 u per ml, 3 ml cartridge

## ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE</b>			
Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge.....	42.66	5	Humalog Mix 25
Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge.....	42.66	5	Humalog Mix 50
<b>INSULIN NEUTRAL WITH INSULIN ISOPHANE</b>			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge			
Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge			
Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge			
<b>Insulin - Long-Acting Preparations</b>			
<b>INSULIN GLARGINE</b>			
Inj 100 u per ml, 3 ml disposable pen.....	94.50	5	Lantus SoloStar
Inj 100 u per ml, 3 ml cartridge.....	94.50	5	Lantus
Inj 100 u per ml, 10 ml vial.....	63.00	1	Lantus
<b>Insulin - Rapid-Acting Preparations</b>			
<b>INSULIN ASPART</b>			
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
Inj 100 u per ml, 3 ml syringe .....	51.19	5	NovoRapid FlexPen
<b>INSULIN GLULISINE</b>			
Inj 100 u per ml, 10 ml vial.....	27.03	1	Apidra
Inj 100 u per ml, 3 ml cartridge.....	46.07	5	Apidra
Inj 100 u per ml, 3 ml disposable pen.....	46.07	5	Apidra Solostar
<b>INSULIN LISPRO</b>			
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
<b>Insulin - Short-Acting Preparations</b>			
<b>INSULIN NEUTRAL</b>			
Inj human 100 u per ml, 10 ml vial			
Inj human 100 u per ml, 3 ml cartridge			
<b>Oral Hypoglycaemic Agents</b>			
<b>GLIBENCLAMIDE</b>			
Tab 5 mg – 5% DV Jan-22 to 2024 .....	7.50	100	Daonil
<b>GLICLAZIDE</b>			
Tab 80 mg – 5% DV Feb-24 to 2026 .....	20.10	500	Glizide
<b>GLIPIZIDE</b>			
Tab 5 mg – 5% DV Mar-22 to 2024 .....	4.58	100	Minidiab

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>METFORMIN HYDROCHLORIDE</b>			
Tab immediate-release 500 mg – <b>1% DV Mar-23 to 2024</b> .....	14.74	1,000	<b>Metformin Viatris</b>
Tab immediate-release 850 mg – <b>1% DV Aug-23 to 2024</b> .....	11.28	500	Metformin Mylan <b>Metformin Viatris</b>
<i>(Metformin Mylan Tab immediate-release 850 mg to be delisted 1 January 2024)</i>			
<b>PIOGLITAZONE</b>			
Tab 15 mg – <b>5% DV Jan-22 to 2024</b> .....	6.80	90	<b>Vexazone</b>
Tab 30 mg – <b>5% DV Jan-22 to 2024</b> .....	7.30	90	<b>Vexazone</b>
Tab 45 mg – <b>5% DV Jan-22 to 2024</b> .....	12.25	90	<b>Vexazone</b>
<b>VILDAGLIPTIN</b>			
Tab 50 mg.....	35.00	60	Galvus
<b>VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE</b>			
Tab 50 mg with 1,000 mg metformin hydrochloride.....	35.00	60	Galvumet
Tab 50 mg with 850 mg metformin hydrochloride.....	35.00	60	Galvumet

**GLP-1 Agonists**

**DULAGLUTIDE – Restricted** see terms [below](#)

Note: Not to be given in combination with a funded SGLT-2 inhibitor.

↓ Inj 1.5 mg per 0.5 ml prefilled pen.....	115.23	4	Trulicity
--	--------	---	-----------

➔ **Restricted (RS1857)**

**Initiation**

Any of the following:

- 1 For continuation use; or
- 2 Patient has previously had an initial approval for an SGLT-2 inhibitor; or
- 3 All of the following:
  - 3.1 Patient has type 2 diabetes; and
  - 3.2 Any of the following:
    - 3.2.1 Patient is Māori or any Pacific ethnicity\*; or
    - 3.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)\*; or
    - 3.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator\*; or
    - 3.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult\*; or
    - 3.2.5 Patient has diabetic kidney disease (see note b)\*; and
  - 3.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.

Notes: \* Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m<sup>2</sup> in the presence of diabetes, without alternative cause.

**LIRAGLUTIDE – Restricted** see terms [below](#)

Note: Not to be given in combination with a funded SGLT-2 inhibitor or other GLP-1 agonist.

↓ Inj 6 mg per ml, 3 ml prefilled pen.....	383.72	3	Victoza
--	--------	---	---------

➔ **Restricted (RS1945)**

**Initiation**

Any of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 For continuation use; or
- 2 Patient has previously received an initial Special Authority approval for either an SGLT-2 inhibitor or GLP-1 agonist; or
- 3 All of the following:
  - 3.1 Patient has type 2 diabetes; and
  - 3.2 Any of the following:
    - 3.2.1 Patient is Māori or any Pacific ethnicity\*; or
    - 3.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)\*; or
    - 3.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator\*; or
    - 3.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult\*; or
    - 3.2.5 Patient has diabetic kidney disease (see note b)\*; and
  - 3.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.

Notes: \* Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m<sup>2</sup> in the presence of diabetes, without alternative cause.

## SGLT2 Inhibitors

➔ Restricted (RS1852)

### Initiation

Any of the following:

- 1 For continuation use; or
- 2 Patient has previously had an initial approval for a GLP-1 agonist; or
- 3 All of the following:
  - 3.1 Patient has type 2 diabetes; and
  - 3.2 Any of the following:
    - 3.2.1 Patient is Māori or any Pacific ethnicity\*; or
    - 3.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)\*; or
    - 3.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator\*; or
    - 3.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult\*; or
    - 3.2.5 Patient has diabetic kidney disease (see note b)\*; and
  - 3.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.

Notes: \* Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m<sup>2</sup> in the presence of diabetes, without alternative cause.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>EMPAGLIFLOZIN – Restricted</b> see terms <a href="#">on the previous page</a>			
Note: Not to be given in combination with a funded GLP-1 agonist.			
† Tab 10 mg .....	58.56	30	Jardiance
† Tab 25 mg .....	58.56	30	Jardiance
<b>EMPAGLIFLOZIN WITH METFORMIN HYDROCHLORIDE – Restricted</b> see terms <a href="#">on the previous page</a>			
Note: Not to be given in combination with a funded GLP-1 agonist.			
† Tab 5 mg with 1,000 mg metformin hydrochloride .....	58.56	60	Jardiamet
† Tab 5 mg with 500 mg metformin hydrochloride .....	58.56	60	Jardiamet
† Tab 12.5 mg with 1,000 mg metformin hydrochloride .....	58.56	60	Jardiamet
† Tab 12.5 mg with 500 mg metformin hydrochloride .....	58.56	60	Jardiamet

## Digestives Including Enzymes

### PANCREATIC ENZYME

Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase, 1,250 U protease))			
Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) – 5% DV Jun-22 to 2024 .....	34.93	100	<b>Creon 10000</b>
Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U) – 5% DV Jun-22 to 2024 .....	94.38	100	<b>Creon 25000</b>
Modified release granules pancreatin 60.12 mg (amylase 3,600 Ph Eur U, lipase 5,000 Ph Eur U, protease 200 Ph Eur U) .....	34.93	20 g	Creon Micro
Powder pancreatin 60.12 mg (3,600 Ph. Eur. u/amylase, 5,000 Ph. Eur. u/lipase and 200 Ph. Eur. u/protease)			

### URSODEOXYCHOLIC ACID – Restricted

 see terms [below](#)

† Cap 250 mg – 5% DV Feb-24 to 2026 .....	33.95	100	<b>Ursosan</b>
---	-------	-----	----------------

#### → Restricted (RS1824)

#### Initiation – Alagille syndrome or progressive familial intrahepatic cholestasis

Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

#### Initiation – Chronic severe drug induced cholestatic liver injury

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

#### Initiation – Primary biliary cholangitis

Both:

- 1 Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

#### Initiation – Pregnancy

Patient diagnosed with cholestasis of pregnancy.

#### Initiation – Haematological transplant

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

continued...

# ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Initiation – Total parenteral nutrition induced cholestasis

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
- 2 Liver function has not improved with modifying the TPN composition.

## Initiation – prevention of sinusoidal obstruction syndrome

Limited to 6 months treatment

Both:

- 1 The patient is enrolled in the Children's Oncology Group AALL1732 trial; and
- 2 The patient has leukaemia/lymphoma and is receiving inotuzumab ozogamicin.

## Laxatives

### Bowel-Cleansing Preparations

#### CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE

Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet

e.g. *PicoPrep*

#### MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet – 5% DV Aug-22 to 2024 .....

13.68 3  
54.72 12

**Glycoprep-O**  
**Glycoprep-O**

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet

e.g. *Glycoprep-O*

#### MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE, SODIUM CHLORIDE AND CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE

Powder for oral soln 52.9 g with ascorbic acid 6 g, potassium chloride 740 mg, sodium chloride 2.6 g and sodium sulphate 5.6 g per sachet (1) and powder for oral soln citric acid 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet (2)

e.g. *Prepkit-O*

#### MACROGOL 3350 WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE WITH/WITHOUT SODIUM SULFATE, SODIUM ASCORBATE, ASCORBIC ACID

Powd for oral soln 100g with potassium chloride 1g, sodium chloride 2g and sodium sulfate 9g per sach(1), powd for oral soln 40g with potassium chloride 1.2g and sodium chloride 3.2g per sach(1) and powd for oral soln ascorbic acid 7.54g and sodium ascorbate 48.11g per sach(1) – 5% DV Oct-23 to 2026.....

18.52 3

**Plenvu**

#### MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE

Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet.....

14.31 4

**Klean Prep**

(*Klean Prep Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet to be delisted 1 April 2024*)

## Bulk-Forming Agents

#### ISPAGHULA (PSYLLIUM) HUSK

Powder for oral soln – 5% DV Feb-24 to 2026 .....

20.00 500 g

**Konsyl-D**

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

STERCULIA WITH FRANGULA – **Restricted:** For continuation only

➔ Powder for oral soln

## Faecal Softeners

### DOCUSATE SODIUM

Tab 50 mg – **5% DV Feb-24 to 2026** ..... 3.20 100 **Coloxyl**

Tab 120 mg – **5% DV Feb-24 to 2026** ..... 4.98 100 **Coloxyl**

### DOCUSATE SODIUM WITH SENNOSIDES

Tab 50 mg with sennosides 8 mg – **5% DV Nov-22 to 2025** ..... 3.50 200 **Laxsol**

### PARAFFIN

Oral liquid 1 mg per ml

Enema 133 ml

### POLOXAMER

Oral drops 10% – **5% DV Feb-24 to 2026** ..... 4.17 30 ml **Coloxyl**

## Opioid Receptor Antagonists - Peripheral

METHYLNALTREXONE BROMIDE – **Restricted** see terms [below](#)

↓ Inj 12 mg per 0.6 ml vial ..... 36.00 1 Relistor  
246.00 7 Relistor

➔ **Restricted (RS1601)**

**Initiation – Opioid induced constipation**

Both:

- 1 The patient is receiving palliative care; and
- 2 Either:
  - 2.1 Oral and rectal treatments for opioid induced constipation are ineffective; or
  - 2.2 Oral and rectal treatments for opioid induced constipation are unable to be tolerated.

## Osmotic Laxatives

### GLYCEROL

Suppos 2.8/4.0 g – **5% DV Feb-23 to 2025** ..... 10.39 20 **Lax-suppositories  
Glycerol**

Note: DV limit applies to glycerol suppository presentations.

### LACTULOSE

Oral liq 10 g per 15 ml – **5% DV Apr-23 to 2025** ..... 3.61 500 ml **Laevolac**

### MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE

Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg

Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – **5% DV**

**Feb-24 to 2026** ..... 8.50 30 **Molaxole**

### SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE

Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – **5%**

**DV Jun-23 to 2025** ..... 35.89 50 **Micolette**

### SODIUM PHOSPHATE WITH PHOSPHORIC ACID

Oral liq 16.4% with phosphoric acid 25.14%

Enema 10% with phosphoric acid 6.58% ..... 2.50 1 **Fleet Phosphate Enema**

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Stimulant Laxatives</b>			
<b>BISACODYL</b>			
Tab 5 mg – 5% DV Jan-23 to 2025 .....	5.80	200	<b>Bisacodyl Viatris Lax-Suppositories</b>
Suppos 10 mg – 5% DV Dec-21 to 2024 .....	3.69	10	

## SENNOSIDES

Tab 7.5 mg

## SODIUM PICOSULFATE – Restricted see terms [below](#)

⚡ Oral soln 7.5 mg per ml ..... 7.40 30 ml Dulcolax SP Drop

➔ **Restricted (RS1843)**

### Initiation

Both:

- 1 The patient is a child with problematic constipation despite an adequate trial of other oral pharmacotherapies including macrogol where practicable; and
- 2 The patient would otherwise require a high-volume bowel cleansing preparation.

## Metabolic Disorder Agents

### ALGLUCOSIDASE ALFA – Restricted see terms [below](#)

⚡ Inj 50 mg vial ..... 1,142.60 1 Myozyme

➔ **Restricted (RS1793)**

### Initiation

Metabolic physician

*Re-assessment required after 12 months*

All of the following:

- 1 The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and
- 2 Any of the following:
  - 2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
  - 2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
  - 2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
  - 2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
- 3 Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
- 4 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
- 5 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

### Continuation

Metabolic physician

*Re-assessment required after 12 months*

All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
- 3 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication

continued...



	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

- and/or adjustment of infusion rates; and
- 4 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
- 5 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 6 There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
- 7 There is no evidence of new or progressive cardiomyopathy.

**ARGININE**

- Tab 1,000 mg
- Cap 500 mg
- Powder
- Inj 500 mg per ml, 10 ml vial
- Inj 600 mg per ml, 25 ml vial

**BETAINE – Restricted** see terms [below](#)

↓ Powder for oral soln.....	575.00	180 g	Cystadane
-----------------------------	--------	-------	-----------

→ **Restricted (RS1794)**

**Initiation**

Metabolic physician  
*Re-assessment required after 12 months*  
 All of the following:

- 1 The patient has a confirmed diagnosis of homocystinuria; and
- 2 Any of the following:
  - 2.1 A cystathionine beta-synthase (CBS) deficiency; or
  - 2.2 A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency; or
  - 2.3 A disorder of intracellular cobalamin metabolism; and
- 3 An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation.

**Continuation**

Metabolic physician  
*Re-assessment required after 12 months*  
 The treatment remains appropriate and the patient is benefiting from treatment.

**BIOTIN – Restricted** see terms [below](#)

- ↓ Cap 50 mg
- ↓ Cap 100 mg
- ↓ Inj 10 mg per ml, 5 ml vial

→ **Restricted (RS1330)**

Metabolic physician or metabolic disorders dietitian

**CARGLUMIC ACID – Restricted** see terms [below](#)

- ↓ Tab disp 200 mg
- **Restricted (RS1831)**

**Initiation**

Metabolic physician  
 For the acute in-patient treatment of organic acidaemias as an alternative to haemofiltration.

**COENZYME Q10 – Restricted** see terms [on the next page](#)

- ↓ Cap 120 mg
- ↓ Cap 160 mg

# ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted (RS1832)**

**Initiation**

Metabolic physician

*Re-assessment required after 6 months*

The patient has a suspected inborn error of metabolism that may respond to coenzyme Q10 supplementation.

**Continuation**

Metabolic physician

*Re-assessment required after 24 months*

Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to coenzyme Q10 supplementation; and
- and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

GALSULFASE – **Restricted** see terms [below](#)

⚡ Inj 1 mg per ml, 5 ml vial.....	2,234.00	1	Naglazyme
-----------------------------------	----------	---	-----------

➔ **Restricted (RS1795)**

**Initiation**

Metabolic physician

*Re-assessment required after 12 months*

Both:

- 1 The patient has been diagnosed with mucopolysaccharidosis VI; and
- 2 Either:
  - 2.1 Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency confirmed by either enzyme activity assay in leukocytes or skin fibroblasts; or
  - 2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.

**Continuation**

Metabolic physician

*Re-assessment required after 12 months*

All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 3 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
- 4 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

HAEM ARGINATE

Inj 25 mg per ml, 10 ml ampoule

IDURSULFASE – **Restricted** see terms [below](#)

⚡ Inj 2 mg per ml, 3 ml vial.....	4,608.30	1	Elaprase
-----------------------------------	----------	---	----------

➔ **Restricted (RS1546)**

**Initiation**

Metabolic physician

*Limited to 24 weeks treatment*

All of the following:

- 1 The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II); and
- 2 Either:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.1 Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
- 2.2 Detection of a disease causing mutation in the iduronate 2-sulfatase gene; and
- 3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant; and
- 4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
- 5 Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.

**LARONIDASE – Restricted** see terms [below](#)

↓ Inj 100 U per ml, 5 ml vial .....	1,335.16	1	Aldurazyme
-------------------------------------	----------	---	------------

→ **Restricted (RS1607)**

**Initiation**

Metabolic physician

*Limited to 24 weeks treatment*

All of the following:

- 1 The patient has been diagnosed with Hurler Syndrome (mucopolysaccharidosis I-H); and
- 2 Either:
  - 2.1 Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
  - 2.2 Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome; and
- 3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be bridging treatment to transplant; and
- 4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
- 5 Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every week.

**LEVOCARNITINE – Restricted** see terms [below](#)

- ↓ Tab 500 mg
- ↓ Cap 250 mg
- ↓ Cap 500 mg
- ↓ Oral liq 500 mg per 10 ml
- ↓ Oral soln 1,000 mg per 10 ml
- ↓ Oral soln 1,100 mg per 15 ml
- ↓ Inj 200 mg per ml, 5 ml vial

→ **Restricted (RS1035)**

Neurologist, metabolic physician or metabolic disorders dietitian

**PYRIDOXAL-5-PHOSPHATE – Restricted** see terms [below](#)

- ↓ Tab 50 mg

→ **Restricted (RS1331)**

Neurologist, metabolic physician or metabolic disorders dietitian

**RIBOFLAVIN – Restricted** see terms [below](#)

- ↓ Tab 100 mg
- ↓ Cap 100 mg

→ **Restricted (RS1833)**

**Initiation**

Metabolic physician or neurologist

*Re-assessment required after 6 months*

The patient has a suspected inborn error of metabolism that may respond to riboflavin supplementation.

continued...

# ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Continuation

Metabolic physician or neurologist

*Re-assessment required after 24 months*

Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to riboflavin supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

SAPROPTERIN DIHYDROCHLORIDE – **Restricted** see terms [below](#)

↓ Tab soluble 100 mg .....	1,452.70	30	Kuvan
----------------------------	----------	----	-------

→ **Restricted (RS1796)**

## Initiation

Metabolic physician

*Re-assessment required after 1 month*

All of the following:

- 1 Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant; and
- 2 Treatment with sapropterin is required to support management of PKU during pregnancy; and
- 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

## Continuation

Metabolic physician

*Re-assessment required after 12 months*

All of the following:

- 1 Either:
  - 1.1 Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or
  - 1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and
- 2 Any of the following:
  - 2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or
  - 2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or
  - 2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and
- 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

## SODIUM BENZOATE

Cap 500 mg

Powder

Soln 100 mg per ml

Inj 20%, 10 ml ampoule

SODIUM PHENYLBUTYRATE – **Some items restricted** see terms [on the next page](#)

Tab 500 mg

↓ Grans 483 mg per g.....	2,016.00	174 g	Pheburane
---------------------------	----------	-------	-----------

Oral liq 250 mg per ml

Inj 200 mg per ml, 10 ml ampoule

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted (RS1797)**

**Initiation**

Metabolic physician

*Re-assessment required after 12 months*

For the chronic management of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.

**Continuation**

Metabolic physician

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient is benefiting from treatment.

TALIGLUCERASE ALFA – **Restricted** see terms [below](#)

↓ Inj 200 unit vial.....	1,072.00	1	Elelyso
--------------------------	----------	---	---------

➔ **Restricted (RS1897)**

**Initiation**

Metabolic physician

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has a diagnosis of symptomatic type 1 or type 3\* Gaucher disease confirmed by the demonstration of specific deficiency of glucocerebrosidase in leukocytes or cultured skin fibroblasts, and genotypic analysis; and
- 2 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by enzyme replacement therapy (ERT) or the disease might be reasonably expected to compromise a response to ERT; and
- 3 Any of the following:
  - 3.1 Patient has haematological complications of Gaucher disease; or
  - 3.2 Patient has skeletal complications of Gaucher disease; or
  - 3.3 Patient has significant liver dysfunction or hepatomegaly attributable to Gaucher disease; or
  - 3.4 Patient has reduced vital capacity from clinically significant or progressive pulmonary disease due to Gaucher disease; or
  - 3.5 Patient is a child and has experienced growth failure with significant decrease in percentile linear growth over a 6-12 month period; and
- 4 Taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units).

Note: Indication marked with \* is an unapproved indication

**Continuation**

Metabolic physician or any relevant practitioner on the recommendation of a metabolic physician

*Re-assessment required after 3 years*

All of the following:

- 1 Patient has demonstrated a symptomatic improvement and has maintained improvements in the main symptom or symptoms for which therapy was started; and
- 2 Patient has demonstrated a clinically objective improvement or no deterioration in haemoglobin levels, platelet counts and liver and spleen size; and
- 3 RRadiological (MRI) signs of bone activity performed at two years since initiation of treatment, and five yearly thereafter, demonstrate no deterioration shown by the MRI, compared with MRI taken immediately prior to commencement of therapy or adjusted dose; and
- 4 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 5 Patient is adherent with regular treatment and taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units).

# ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

TAURINE – **Restricted** see terms [below](#)

↓ Cap 500 mg

↓ Cap 1,000 mg

↓ Powder

➔ **Restricted (RS1834)**

## Initiation

Metabolic physician

*Re-assessment required after 6 months*

The patient has a suspected specific mitochondrial disorder that may respond to taurine supplementation.

## Continuation

Metabolic physician

*Re-assessment required after 24 months*

Both:

- 1 The patient has a confirmed diagnosis of a specific mitochondrial disorder which responds to taurine supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

TRIENTINE DIHYDROCHLORIDE

Cap 300 mg

## Minerals

### Calcium

CALCIUM CARBONATE

Tab 1.25 g (500 mg elemental) – **5% DV Feb-24 to 2026** ..... 7.28      250      **Calci-Tab 500**

Tab eff 1.25 g (500 mg elemental)

Tab eff 1.75 g (1 g elemental)

### Copper

➔ **Restricted (RS1928)**

**Initiation – Moderate to severe burns**

*Limited to 3 months treatment*

Both:

- 1 Patient has been hospitalised with moderate to severe burns; and
- 2 Treatment is recommended by a National Burns Unit specialist.

COPPER – **Restricted** see terms [above](#)

† Tab 2.5 mg, chelated

COPPER CHLORIDE – **Restricted** see terms [above](#)

† Inj 0.4 mg per ml, 10 ml vial

### Fluoride

SODIUM FLUORIDE

Tab 1.1 mg (0.5 mg elemental)

### Iodine

POTASSIUM IODATE

Tab 253 mcg (150 mcg elemental iodine) – **5% DV Feb-24 to 2026** ..... 5.99      90      **NeuroTabs**

POTASSIUM IODATE WITH IODINE

Oral liq 10% with iodine 5%

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Iron</b>			
FERROUS FUMARATE			
Tab 200 mg (65 mg elemental) – <b>5% DV May-22 to 2024</b> .....	3.04	100	<b>Ferro-tab</b>
FERROUS FUMARATE WITH FOLIC ACID			
Tab 310 mg (100 mg elemental) with folic acid 350 mcg – <b>5% DV Aug-22 to 2024</b> .....	5.98	100	<b>Ferro-F-Tabs</b>
FERROUS GLUCONATE WITH ASCORBIC ACID			
Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg			
FERROUS SULFATE			
Tab long-acting 325 mg (105 mg elemental) – <b>5% DV Jan-23 to 2025</b> .....	2.55	30	<b>Ferrograd</b>
Oral liq 30 mg (6 mg elemental) per ml – <b>5% DV Jan-23 to 2025</b> .....	13.10	500 ml	<b>Ferodan</b>
FERROUS SULFATE WITH ASCORBIC ACID			
Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg			
IRON (AS FERRIC CARBOXYMALTOSE) – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 50 mg per ml, 10 ml vial.....	150.00	1	Ferinject
→ <b>Restricted (RS1417)</b>			
<b>Initiation</b>			
Treatment with oral iron has proven ineffective or is clinically inappropriate.			
IRON (AS SUCROSE)			
Inj 20 mg per ml, 5 ml ampoule.....	100.00	5	Venofer
IRON POLYMALTOSE			
Inj 50 mg per ml, 2 ml ampoule.....	34.50	5	Ferrosig
<b>Magnesium</b>			
MAGNESIUM AMINO ACID CHELATE			
Cap 750 mg (150 mg elemental)			
MAGNESIUM CHLORIDE			
Inj 1 mmol per 1 ml, 100 ml bag			
MAGNESIUM HYDROXIDE			
Tab 311 mg (130 mg elemental)			
Suspension 8%			
MAGNESIUM OXIDE			
Cap 663 mg (400 mg elemental)			
Cap 696 mg (420 mg elemental)			
MAGNESIUM OXIDE WITH MAGNESIUM ASPARTATE, MAGNESIUM AMINO ACID CHELATE AND MAGNESIUM CITRATE			
Cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium)			
MAGNESIUM SULPHATE			
Inj 100 mg per ml, 40 ml bag			
Inj 0.4 mmol per ml, 250 ml bag			
Inj 2 mmol per ml, 5 ml ampoule.....	25.53	10	Martindale
Inj 100 mg per ml, 50 ml bag			

## ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Selenium

SELENIUM – **Restricted** see terms [below](#)

⚡ Oral liq 150 mcg per 3 drops

*eg Clinicians selenium  
oral drops*

⚡ Inj 300 mcg per ml, 1 ml ampoule

➔ **Restricted** (RS1929)

**Initiation – Moderate to severe burns**

*Limited to 3 months treatment*

Both:

- 1 Patient has been hospitalised with moderate to severe burns; and
- 2 Treatment is recommended by a National Burns Unit specialist.

### Zinc

ZINC

Oral liq 5 mg per 5 drops

ZINC CHLORIDE

Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule

ZINC SULPHATE

Cap 137.4 mg (50 mg elemental).....	11.00	100	Zincaps
-------------------------------------	-------	-----	---------

## Mouth and Throat

### Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE

Soln 0.15%

Spray 0.15%

Spray 0.3%

BENZYDAMINE HYDROCHLORIDE WITH CETYLPYRIDINIUM CHLORIDE

Lozenge 3 mg with cetylpyridinium chloride

CARBOXYMETHYLCELLULOSE

Oral spray

CARMELLOSE SODIUM WITH PECTIN AND GELATINE

Paste

Powder

CHLORHEXIDINE GLUCONATE

Mouthwash 0.2%

CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE

Adhesive gel 8.7% with cetalkonium chloride 0.01%

DICHLOROBENZYL ALCOHOL WITH AMYLMETACRESOL

Lozenge 1.2 mg with amylmetacresol 0.6 mg

TRIAMCINOLONE ACETONIDE

Paste 0.1% – 5% DV Feb-24 to 2026.....	5.49	5 g	Kenalog in Orabase
--	------	-----	--------------------

### Oropharyngeal Anti-Infectives

AMPHOTERICIN B

Lozenge 10 mg.....	5.86	20	Fungilin
--------------------	------	----	----------



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MICONAZOLE			
Oral gel 20 mg per g – 5% DV Dec-21 to 2024 .....	4.74	40 g	<b>Decozol</b>
NYSTATIN			
Oral liquid 100,000 u per ml – 5% DV Feb-24 to 2026 .....	2.22	24 ml	<b>Nilstat</b>

**Other Oral Agents**

HYALURONIC ACID WITH LIDOCAINE [LIGNOCAINE]

Inj 20 mg per ml

SODIUM HYALURONATE [HYALURONIC ACID] – **Restricted** see terms [below](#)

↓ Inj 20 mg per ml, 1 ml syringe

→ **Restricted (RS1175)**

Otolaryngologist

**Vitamins**

**Multivitamin Preparations**

MULTIVITAMIN AND MINERAL SUPPLEMENT – **Restricted** see terms [below](#)

↓ Cap ..... 23.35      180      Clinicians Multivit & Mineral Boost

→ **Restricted (RS1498)**

**Initiation**

Limited to 3 months treatment

Both:

- 1 Patient was admitted to hospital with burns; and
- 2 Any of the following:
  - 2.1 Burn size is greater than 15% of total body surface area (BSA) for all types of burns; or
  - 2.2 Burn size is greater than 10% of BSA for mid-dermal or deep dermal burns; or
  - 2.3 Nutritional status prior to admission or dietary intake is poor.

MULTIVITAMIN RENAL – **Restricted** see terms [below](#)

↓ Cap ..... 6.49      30      Clinicians Renal Vit

→ **Restricted (RS1499)**

**Initiation**

Either:

- 1 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or
- 2 The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73m<sup>2</sup> body surface area (BSA).

# ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>MULTIVITAMINS</b>			
Tab (BPC cap strength) – <b>5% DV Feb-23 to 2025</b> .....	18.50	1,000	<b>Mvite</b>
↓ cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, alpha tocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg, riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 mg, cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg			<i>e.g. Vitabdeck</i>
➔ <b>Restricted (RS1620)</b>			
<b>Initiation</b>			
Any of the following:			
1 Patient has cystic fibrosis with pancreatic insufficiency; or			
2 Patient is an infant or child with liver disease or short gut syndrome; or			
3 Patient has severe malabsorption syndrome.			
↓ Powder vitamin A 3200 mcg with vitamin D 100 mcg, vitamin E 54.2 mg, vitamin C 400 mg, vitamin K1 108 mcg thiamine 3.2 mg, riboflavin 4.4 mg, niacin 41 mg, vitamin B6 3.6 mg, folic acid 600 mcg, vitamin B12 9 mcg, biotin 120 mcg, pantothenic acid 24 mg, choline 1250 mg and inositol 700 mg			<i>e.g. Paediatric Seravit</i>
➔ <b>Restricted (RS1178)</b>			
<b>Initiation</b>			
Patient has inborn errors of metabolism.			
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1)			<i>e.g. Pabrinex IV</i>
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1)			<i>e.g. Pabrinex IM</i>
Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1)			<i>e.g. Pabrinex IV</i>
<b>Vitamin A</b>			
<b>RETINOL</b>			
Tab 10,000 iu			
Cap 25,000 iu			
Oral liq 150,000 iu per ml			
Oral liq 666.7 mcg per 2 drops, 10 ml			
Oral liq 5,000 iu per drop, 30 ml			
<b>Vitamin B</b>			
<b>HYDROXOCOBALAMIN</b>			
Inj 1 mg per ml, 1 ml ampoule – <b>5% DV Nov-22 to 2024</b> .....	2.46	3	<b>Hydroxocobalamin Panpharma</b>
<b>PYRIDOXINE HYDROCHLORIDE</b>			
Tab 25 mg – <b>5% DV Feb-24 to 2026</b> .....	3.43	90	<b>Vitamin B6 25</b>
Tab 50 mg .....	23.45	500	Pyridoxine multichem
Inj 100 mg per ml, 2 ml vial			
Inj 100 mg per ml, 1 ml ampoule			
Inj 100 mg per ml, 30 ml vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>THIAMINE HYDROCHLORIDE</b>			
Tab 50 mg – <b>5% DV Apr-23 to 2025</b> .....	4.65	100	<b>Thiamine multichem</b>
Tab 100 mg			
Inj 100 mg per ml, 1 ml vial			<i>e.g. Benerva</i>
Inj 100 mg per ml, 2 ml vial			
<b>VITAMIN B COMPLEX</b>			
Tab strong, BPC .....	11.25	500	Bplex
<b>Vitamin C</b>			
<b>ASCORBIC ACID</b>			
Tab 100 mg – <b>5% DV Feb-23 to 2025</b> .....	12.50	500	<b>Cvite</b>
Tab chewable 250 mg			
<b>Vitamin D</b>			
<b>ALFACALCIDOL</b>			
Cap 0.25 mcg .....	26.32	100	One-Alpha
Cap 1 mcg .....	87.98	100	One-Alpha
Oral drops 2 mcg per ml .....	60.68	20 ml	One-Alpha
<b>CALCITRIOL</b>			
Cap 0.25 mcg – <b>5% DV Dec-22 to 2025</b> .....	7.89	100	<b>Calcitriol-AFT</b>
Cap 0.5 mcg – <b>5% DV Dec-22 to 2025</b> .....	13.68	100	<b>Calcitriol-AFT</b>
Oral liq 1 mcg per ml			
Inj 1 mcg per ml, 1 ml ampoule			
<b>COLECALCIFEROL</b>			
Cap 1.25 mg (50,000 iu) .....	2.95	12	Vit.D3
Oral liq 188 mcg per ml (7,500 iu per ml) .....	9.00	5 ml	Clinicians
		4.8 ml	Puria

(Puria Oral liq 188 mcg per ml (7,500 iu per ml) to be delisted 1 March 2024)

**Vitamin E**

ALPHA TOCOPHERYL – **Restricted** see terms [below](#)

↓ Oral liq 156 u per ml

→ **Restricted (RS1632)**

**Initiation – Cystic fibrosis**

Both:

- 1 Cystic fibrosis patient; and
- 2 Either:
  - 2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
  - 2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

**Initiation – Osteoradionecrosis**

For the treatment of osteoradionecrosis.

**Initiation – Other indications**

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

3 Either:

- 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
- 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

ALPHA TOCOPHERYL ACETATE – **Restricted** see terms [below](#)

↓ Cap 100 u

↓ Cap 500 u

↓ Oral liq 156 u per ml

→ **Restricted (RS1176)**

**Initiation – Cystic fibrosis**

Both:

- 1 Cystic fibrosis patient; and
- 2 Either:

- 2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
- 2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

**Initiation – Osteoradionecrosis**

For the treatment of osteoradionecrosis.

**Initiation – Other indications**

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and
- 3 Either:

- 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
- 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Antianaemics

### Hypoplastic and Haemolytic

EPOETIN ALFA – **Restricted** see terms [below](#)

↓ Inj 1,000 iu in 0.5 ml syringe.....	250.00	6	Binocrit
↓ inj 2,000 iu in 1 ml syringe.....	100.00	6	Binocrit
↓ Inj 3,000 iu in 0.3 ml syringe.....	150.00	6	Binocrit
↓ Inj 4,000 iu in 0.4 ml syringe.....	96.50	6	Binocrit
↓ Inj 5,000 iu in 0.5 ml syringe.....	125.00	6	Binocrit
↓ Inj 6,000 iu in 0.6 ml syringe.....	145.00	6	Binocrit
↓ Inj 8,000 iu in 0.8 ml syringe.....	175.00	6	Binocrit
↓ Inj 10,000 iu in 1 ml syringe.....	197.50	6	Binocrit
↓ Inj 40,000 iu in 1 ml syringe.....	250.00	1	Binocrit

→ **Restricted (RS1660)**

#### Initiation – chronic renal failure

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin is less than or equal to 100g/L; and
- 3 Either:
  - 3.1 Both:
    - 3.1.1 Patient does not have diabetes mellitus; and
    - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
  - 3.2 Both:
    - 3.2.1 Patient has diabetes mellitus; and
    - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
- 4 Patient is on haemodialysis or peritoneal dialysis.

#### Initiation – myelodysplasia\*

*Re-assessment required after 2 months*

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

#### Continuation – myelodysplasia\*

*Re-assessment required after 12 months*

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with epoetin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

#### Initiation – all other indications

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative.

Note: Indications marked with \* are unapproved indications

# BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## EPOETIN BETA – Restricted see terms below

Note: Epoetin beta is considered a Discretionary Variance Pharmaceutical for epoetin alfa.

- ⚡ Inj 2,000 iu in 0.3 ml syringe
- ⚡ Inj 3,000 iu in 0.3 ml syringe
- ⚡ Inj 4,000 iu in 0.3 ml syringe
- ⚡ Inj 5,000 iu in 0.3 ml syringe
- ⚡ Inj 6,000 iu in 0.3 ml syringe
- ⚡ Inj 10,000 iu in 0.6 ml syringe

➔ Restricted (RS1661)

### Initiation – chronic renal failure

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin is less than or equal to 100g/L; and
- 3 Either:
  - 3.1 Both:
    - 3.1.1 Patient does not have diabetes mellitus; and
    - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
  - 3.2 Both:
    - 3.2.1 Patient has diabetes mellitus; and
    - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
- 4 Patient is on haemodialysis or peritoneal dialysis.

### Initiation – myelodysplasia\*

Re-assessment required after 12 months

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

### Continuation – myelodysplasia\*

Re-assessment required after 2 months

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with epoetin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

### Initiation – all other indications

Haematologist.

For use in patients where blood transfusion is not a viable treatment alternative.

\*Note: Indications marked with \* are unapproved indications.

## Megaloblastic

### FOLIC ACID

Tab 0.8 mg .....	26.60	1,000	Folic Acid multichem
Tab 5 mg – 1% DV Mar-23 to 2024 .....	5.82	100	Folic Acid Mylan
			<b>Folic Acid Viatris</b>
Oral liq 50 mcg per ml .....	28.82	25 ml	Biomed
Inj 5 mg per ml, 10 ml vial			

(Folic Acid Mylan Tab 5 mg to be delisted 1 January 2024)

	Price		Per	Brand or Generic Manufacturer
	(ex man. excl. GST)	\$		

**Antifibrinolytics, Haemostatics and Local Sclerosants**

ALUMINIUM CHLORIDE – **Restricted** see terms [below](#)

↓ Topical soln 20% w/v

e.g. *Driclor*

→ **Restricted (RS1500)**

**Initiation**

For use as a haemostatis agent.

APROTININ – **Restricted** see terms [below](#)

↓ Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial

→ **Restricted (RS1332)**

**Initiation**

Cardiac anaesthetist

Either:

- 1 Paediatric patient undergoing cardiopulmonary bypass procedure; or
- 2 Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug.

ELTROMBOPAG – **Restricted** see terms [below](#)

↓ Tab 25 mg ..... 1,550.00 28 Revolade

↓ Tab 50 mg ..... 3,100.00 28 Revolade

→ **Restricted (RS1648)**

**Initiation – idiopathic thrombocytopenic purpura - post-splenectomy**

Haematologist

*Re-assessment required after 6 weeks*

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialed and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
  - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
  - 3.2 Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or
  - 3.3 Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

**Initiation – idiopathic thrombocytopenic purpura - preparation for splenectomy**

Haematologist

*Limited to 6 weeks treatment*

The patient requires eltrombopag treatment as preparation for splenectomy.

**Continuation – idiopathic thrombocytopenic purpura - post-splenectomy**

Haematologist

*Re-assessment required after 12 months*

The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre

**Initiation – idiopathic thrombocytopenic purpura contraindicated to splenectomy**

Haematologist

*Re-assessment required after 3 months*

All of the following:

- 1 Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- and
- 3 Either:
  - 3.1 Patient has immune thrombocytopenic purpura\* with a platelet count of less than or equal to 20,000 platelets per microliter; or
  - 3.2 Patient has immune thrombocytopenic purpura\* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

### Continuation – idiopathic thrombocytopenic purpura contraindicated to splenectomy

Haematologist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient's significant contraindication to splenectomy remains; and
- 2 The patient has obtained a response from treatment during the initial approval period; and
- 3 Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
- 4 Further treatment with eltrombopag is required to maintain response.

### Initiation – severe aplastic anaemia

Haematologist

*Re-assessment required after 3 months*

Both:

- 1 Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
- 2 Either:
  - 2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
  - 2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

### Continuation – severe aplastic anaemia

Haematologist

*Re-assessment required after 12 months*

Both:

- 1 The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
- 2 Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

### EMICIZUMAB – Restricted see terms [below](#)

⚠ Inj 30 mg in 1 ml vial.....	3,570.00	1	Hemlibra
⚠ Inj 60 mg in 0.4 ml vial.....	7,138.00	1	Hemlibra
⚠ Inj 105 mg in 0.7 ml vial.....	12,492.00	1	Hemlibra
⚠ Inj 150 mg in 1 ml vial.....	17,846.00	1	Hemlibra

➡ **Restricted (RS1998)**

### Initiation – Severe Haemophilia A with or without FVIII inhibitors

Haematologist

Both:

- 1 Patient has severe congenital haemophilia A with a severe bleeding phenotype (endogenous factor VIII activity less than or equal to 2%); and
- 2 Emicizumab is to be administered at a dose of no greater than 3 mg/kg weekly for 4 weeks followed by the equivalent of 1.5 mg/kg weekly.

### FERRIC SUBSULFATE

Gel 25.9%

Soln 500 ml

### POLIDOCANOL

Inj 0.5%, 30 ml vial



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>SODIUM TETRADECYL SULPHATE</b>			
Inj 3%, 2 ml ampoule			
<b>THROMBIN</b>			
Powder			
<b>TRANEXAMIC ACID</b>			
Tab 500 mg – <b>5% DV Jun-23 to 2025</b> .....	10.45	60	<b>Mercury Pharma</b>
Inj 100 mg per ml, 5 ml ampoule – <b>5% DV Dec-21 to 2024</b> .....	5.95	5	<b>Tranexamic-AFT</b>
Inj 100 mg per ml, 10 ml ampoule – <b>5% DV Dec-21 to 2024</b> .....	5.95	5	<b>Tranexamic-AFT</b>

### Anticoagulant Reversal Agents

**IDARUCIZUMAB – Restricted** see terms [below](#)

↓ Inj 50 mg per ml, 50 ml vial.....4,250.00 2 Praxbind

→ **Restricted (RS1535)**

#### Initiation

For the reversal of the anticoagulant effects of dabigatran when required in situations of life-threatening or uncontrolled bleeding, or for emergency surgery or urgent procedures.

### Blood Factors

**EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – Restricted** see terms [below](#)

↓ Inj 250 iu vial.....612.50 1 Alprolix

↓ Inj 500 iu vial.....1,225.00 1 Alprolix

↓ Inj 1,000 iu vial.....2,450.00 1 Alprolix

↓ Inj 2,000 iu vial.....4,900.00 1 Alprolix

↓ Inj 3,000 iu vial.....7,350.00 1 Alprolix

↓ Inj 4,000 iu vial.....9,800.00 1 Alprolix

→ **Restricted (RS1684)**

#### Initiation

For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

**EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – Restricted** see terms [below](#)

↓ Inj 1 mg syringe.....1,178.30 1 NovoSeven RT

↓ Inj 2 mg syringe.....2,356.60 1 NovoSeven RT

↓ Inj 5 mg syringe.....5,891.50 1 NovoSeven RT

↓ Inj 8 mg syringe.....9,426.40 1 NovoSeven RT

→ **Restricted (RS1704)**

#### Initiation

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for > 14 days predicted use. Access to funded treatment for > 14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria.

**FACTOR EIGHT INHIBITOR BYPASSING FRACTION – Restricted** see terms [below](#)

↓ Inj 500 U.....1,315.00 1 FEIBA NF

↓ Inj 1,000 U.....2,630.00 1 FEIBA NF

↓ Inj 2,500 U.....6,575.00 1 FEIBA NF

→ **Restricted (RS1705)**

#### Initiation

For patients with haemophilia. Preferred Brand of bypassing agent for > 14 days predicted use. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

## BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – Restricted</b> see terms <a href="#">below</a>			
‡ Inj 250 iu prefilled syringe.....	287.50	1	Xyntha
‡ Inj 500 iu prefilled syringe.....	575.00	1	Xyntha
‡ Inj 1,000 iu prefilled syringe.....	1,150.00	1	Xyntha
‡ Inj 2,000 iu prefilled syringe.....	2,300.00	1	Xyntha
‡ Inj 3,000 iu prefilled syringe.....	3,450.00	1	Xyntha

→ **Restricted (RS1706)**

### Initiation

For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.

**NONACOG GAMMA, [RECOMBINANT FACTOR IX] – Restricted** see terms [below](#)

‡ Inj 500 iu vial.....	435.00	1	RIXUBIS
‡ Inj 1,000 iu vial.....	870.00	1	RIXUBIS
‡ Inj 2,000 iu vial.....	1,740.00	1	RIXUBIS
‡ Inj 3,000 iu vial.....	2,610.00	1	RIXUBIS

→ **Restricted (RS1679)**

### Initiation

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

**OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – Restricted** see terms [below](#)

‡ Inj 250 iu vial.....	210.00	1	Advate
‡ Inj 500 iu vial.....	420.00	1	Advate
‡ Inj 1,000 iu vial.....	840.00	1	Advate
‡ Inj 1,500 iu vial.....	1,260.00	1	Advate
‡ Inj 2,000 iu vial.....	1,680.00	1	Advate
‡ Inj 3,000 iu vial.....	2,520.00	1	Advate

→ **Restricted (RS1707)**

### Initiation

For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

**OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) – Restricted** see terms [below](#)

‡ Inj 250 iu vial.....	237.50	1	Kogenate FS
‡ Inj 500 iu vial.....	475.00	1	Kogenate FS
‡ Inj 1,000 iu vial.....	950.00	1	Kogenate FS
‡ Inj 2,000 iu vial.....	1,900.00	1	Kogenate FS
‡ Inj 3,000 iu vial.....	2,850.00	1	Kogenate FS

→ **Restricted (RS1708)**

### Initiation

For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.

**RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] – Restricted** see terms [below](#)

‡ Inj 250 iu vial.....	300.00	1	Adynovate
‡ Inj 500 iu vial.....	600.00	1	Adynovate
‡ Inj 1,000 iu vial.....	1,200.00	1	Adynovate
‡ Inj 2,000 iu vial.....	2,400.00	1	Adynovate

→ **Restricted (RS1682)**

### Initiation

For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Vitamin K**

PHYTOMENADIONE

Inj 2 mg in 0.2 ml ampoule .....	8.00	5	Konaktion MM
Inj 10 mg per ml, 1 ml ampoule .....	9.21	5	Konaktion MM

**Antithrombotics**

**Anticoagulants**

BIVALIRUDIN – **Restricted** see terms [below](#)

↓ Inj 250 mg vial

➔ **Restricted (RS1181)**

**Initiation**

Either:

- 1 For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance; or
- 2 For use in patients undergoing endovascular procedures.

CITRATE SODIUM

- Inj 4% (200 mg per 5 ml), 5 ml ampoule
- Inj 46.7% (1.4 g per 3 ml), 3 ml syringe
- Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule

DABIGATRAN

Cap 75 mg .....	76.36	60	Pradaxa
Cap 110 mg .....	76.36	60	Pradaxa
Cap 150 mg .....	76.36	60	Pradaxa

DANAPAROID – **Restricted** see terms [below](#)

↓ Inj 750 u in 0.6 ml ampoule

➔ **Restricted (RS1182)**

**Initiation**

For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance.

DEFIBROTIDE – **Restricted** see terms [below](#)

↓ Inj 80 mg per ml, 2.5 ml ampoule

➔ **Restricted (RS1183)**

**Initiation**

Haematologist

Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities.

DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]

- Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml,  
100 ml bag

ENOXAPARIN SODIUM

Inj 20 mg in 0.2 ml syringe.....	31.28	10	Clexane
Inj 40 mg in 0.4 ml ampoule			
Inj 40 mg in 0.4 ml syringe.....	42.49	10	Clexane
Inj 60 mg in 0.6 ml syringe.....	60.67	10	Clexane
Inj 80 mg in 0.8 ml syringe.....	80.89	10	Clexane
Inj 100 mg in 1 ml syringe.....	101.30	10	Clexane
Inj 120 mg in 0.8 ml syringe.....	125.87	10	Clexane Forte
Inj 150 mg in 1 ml syringe.....	143.86	10	Clexane Forte

## BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>FONDAPARINUX SODIUM – Restricted</b> see terms <a href="#">below</a>			
↓ Inj 2.5 mg in 0.5 ml syringe			
↓ Inj 7.5 mg in 0.6 ml syringe			
➔ <b>Restricted (RS1184)</b>			
<b>Initiation</b>			
For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance.			
<b>HEPARIN SODIUM</b>			
Inj 5,000 iu per ml, 5 ml vial – <b>5% DV Jul-23 to 2025</b> .....	83.00	10	<b>Heparin Sodium Panpharma</b>
Inj 100 iu per ml, 250 ml bag			
Inj 1,000 iu per ml, 1 ml ampoule .....	245.26	50	Hospira
Inj 1,000 iu per ml, 5 ml ampoule .....	86.11	50	Pfizer
Inj 5,000 iu in 0.2 ml ampoule			
Inj 5,000 iu per ml, 1 ml ampoule .....	70.33	5	Hospira
<b>HEPARINISED SALINE</b>			
Inj 10 iu per ml, 5 ml ampoule .....	65.48	50	Pfizer
Inj 100 iu per ml, 2 ml ampoule			
Inj 100 iu per ml, 5 ml ampoule			
<b>PHENINDIONE</b>			
Tab 10 mg			
Tab 25 mg			
Tab 50 mg			
<b>PROTAMINE SULPHATE</b>			
Inj 10 mg per ml, 5 ml ampoule			
<b>RIVAROXABAN</b>			
Tab 10 mg – <b>5% DV Dec-23 to 2026</b> .....	15.60	30	<b>Xarelto</b>
Tab 15 mg – <b>5% DV Dec-23 to 2026</b> .....	14.56	28	<b>Xarelto</b>
Tab 20 mg – <b>5% DV Dec-23 to 2026</b> .....	14.56	28	<b>Xarelto</b>
<b>SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CHLORIDE</b>			
Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74.6 mcg per ml, 5,000 ml bag			
<b>WARFARIN SODIUM</b>			
Tab 1 mg .....	6.46	100	Marevan
Tab 2 mg			
Tab 3 mg .....	10.03	100	Marevan
Tab 5 mg .....	11.48	100	Marevan
<b>Antiplatelets</b>			
<b>ASPIRIN</b>			
Tab 100 mg .....	1.95	90	Ethics Aspirin EC
	14.95	990	Ethics Aspirin EC
Suppos 300 mg			
<b>CLOPIDOGREL</b>			
Tab 75 mg – <b>5% DV May-23 to 2025</b> .....	5.07	84	<b>Arrow - Clopid</b>
<b>DIPYRIDAMOLE</b>			
Tab 25 mg			
Tab long-acting 150 mg.....	13.93	60	Pytazen SR
Inj 5 mg per ml, 2 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

EPTIFIBATIDE – **Restricted** see terms [below](#)

↓ Inj 2 mg per ml, 10 ml vial.....	180.38	1	Eptifibatide Viatri Mylan
↓ Inj 750 mcg per ml, 100 ml vial.....	526.50	1	Eptifibatide Viatri

→ **Restricted (RS1759)**

**Initiation**

Any of the following:

- 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
- 2 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography; or
- 3 For use in patients undergoing intra-cranial intervention.

LYSINE ACETYLSALICYLATE [LYSINE ASPRIN] – **Restricted** see terms [below](#)

↓ Inj 500 mg			<i>e.g. Aspegic</i>
--------------	--	--	---------------------

→ **Restricted (RS1689)**

**Initiation**

Both:

- 1 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and
- 2 Administration of oral aspirin would delay the procedure.

TICAGRELOR – **Restricted** see terms [below](#)

↓ Tab 90 mg – <b>5% DV Mar-23 to 2024</b> .....	23.85	56	<b>Ticagrelor Sandoz</b>
---	-------	----	--------------------------

→ **Restricted (RS1774)**

**Initiation**

Restricted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned.

**Initiation – thrombosis prevention neurological stenting**

*Re-assessment required after 12 months*

Both:

- 1 Either:
  - 1.1 Patient has had a neurological stenting procedure\* in the last 60 days; or
  - 1.2 Patient is about to have a neurological stenting procedure performed\*; and
- 2 Either:
  - 2.1 Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor; or
  - 2.2 Either:
    - 2.2.1 Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event; or
    - 2.2.2 Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent..

**Continuation – thrombosis prevention neurological stenting**

*Re-assessment required after 12 months*

Both:

- 1 Patient is continuing to benefit from treatment; and
- 2 Treatment continues to be clinically appropriate.

**Initiation – Percutaneous coronary intervention with stent deployment**

*Limited to 12 months treatment*

All of the following:

- 1 Patient has undergone percutaneous coronary intervention; and

continued...

## BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic\*\*.

### Initiation – Stent thrombosis

Patient has experienced cardiac stent thrombosis whilst on clopidogrel.

### Initiation – Myocardial infarction

Limited to 1 week treatment

For short term use while in hospital following ST-elevated myocardial infarction.

Notes: Indications marked with \* are unapproved indications.

Note: \*\* Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment

TICLOPIDINE

Tab 250 mg

## Fibrinolytic Agents

ALTEPLASE

- Inj 2 mg vial
- Inj 10 mg vial
- Inj 50 mg vial

TENECTEPLASE

- Inj 50 mg vial

UROKINASE

- Inj 5,000 iu vial
- Inj 10,000 iu vial
- Inj 50,000 iu vial
- Inj 100,000 iu vial
- Inj 250,000 iu vial
- Inj 500,000 iu vial

## Colony-Stimulating Factors

### Drugs Used to Mobilise Stem Cells

PLERIXAFOR – Restricted see terms [below](#)

↓ Inj 20 mg per ml, 1.2 ml vial.....	8,740.00	1	Mozobil
--------------------------------------	----------	---	---------

→ Restricted (RS1536)

### Initiation – Autologous stem cell transplant

Haematologist

Limited to 3 days treatment

All of the following:

- 1 Patient is to undergo stem cell transplantation; and
- 2 Patient has not had a previous unsuccessful mobilisation attempt with plerixafor; and
- 3 Any of the following:

3.1 Both:

3.1.1 Patient is undergoing G-CSF mobilisation; and

3.1.2 Either:

3.1.2.1 Has a suboptimal peripheral blood CD34 count of less than or equal to  $10 \times 10^6/L$  on day 5 after

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
4 days of G-CSF treatment; or			
3.1.2.2 Efforts to collect > 1 × 10 <sup>6</sup> CD34 cells/kg have failed after one apheresis procedure; or			
3.2 Both:			
3.2.1 Patient is undergoing chemotherapy and G-CSF mobilisation; and			
3.2.2 Any of the following:			
3.2.2.1 Both:			
3.2.2.1.1 Has rising white blood cell counts of > 5 × 10 <sup>9</sup> /L; and			
3.2.2.1.2 Has a suboptimal peripheral blood CD34 count of less than or equal to 10 × 10 <sup>6</sup> /L; or			
3.2.2.2 Efforts to collect > 1 × 10 <sup>6</sup> CD34 cells/kg have failed after one apheresis procedure; or			
3.2.2.3 The peripheral blood CD34 cell counts are decreasing before the target has been received; or			
3.3 A previous mobilisation attempt with G-CSF or G-CSF plus chemotherapy has failed.			

### Granulocyte Colony-Stimulating Factors

FILGRASTIM – **Restricted** see terms [below](#)

↓ Inj 300 mcg in 0.5 ml prefilled syringe – 5% DV Dec-21 to 2024.....	96.22	10	<b>Nivestim</b>
↓ Inj 300 mcg in 1 ml vial.....	520.00	4	Neupogen
↓ Inj 480 mcg in 0.5 ml prefilled syringe – 5% DV Dec-21 to 2024.....	148.58	10	<b>Nivestim</b>

→ **Restricted (RS1188)**

Haematologist or oncologist

PEGFILGRASTIM – **Restricted** see terms [below](#)

↓ Inj 6 mg per 0.6 ml syringe – 5% DV Jun-23 to 2025.....	65.00	1	<b>Ziextenzo</b>
---	-------	---	------------------

→ **Restricted (RS1743)**

#### Initiation

For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 5%\*).

Note: \*Febrile neutropenia risk greater than or equal to 5% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines

## Fluids and Electrolytes

### Intravenous Administration

#### CALCIUM CHLORIDE

Inj 100 mg per ml, 10 ml vial			
Inj 100 mg per ml, 50 ml syringe			<i>e.g. Baxter</i>

#### CALCIUM GLUCONATE

Inj 10%, 10 ml ampoule			<i>e.g. Max Health</i>
------------------------	--	--	------------------------

#### COMPOUND ELECTROLYTES

Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 500 ml bag.....	57.06	18	Plasma-Lyte 148
Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 1,000 ml bag.....	29.28	12	Plasma-Lyte 148

#### COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]

Inj sodium 140 mmol/l, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, glucose 23 mmol/l (5%), 1,000 ml bag.....	227.64	12	Plasma-Lyte 148 & 5% Glucose
---	--------	----	---------------------------------

## BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION]</b>			
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml bag .....	25.20	18	Baxter
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 1,000 ml bag .....	16.92	12	Baxter
<b>GLUCOSE [DEXTROSE]</b>			
Inj 5%, 1,000 ml bag.....	16.80	10	Fresenius Kabi
Inj 5%, 100 ml bag.....	77.50	50	Fresenius Kabi
Inj 5%, 250 ml bag.....	52.50	30	Fresenius Kabi
Inj 5%, 50 ml bag.....	154.20	60	Baxter Glucose 5%
Inj 5%, 500 ml bag.....	24.00	20	Fresenius Kabi
Inj 10%, 1,000 ml bag.....	120.36	12	Baxter Glucose 10%
Inj 10%, 500 ml bag.....	118.26	18	Baxter Glucose 10%
Inj 50%, 10 ml ampoule – <b>5% DV Feb-24 to 2026</b> .....	34.75	5	<b>Biomed</b>
Inj 50%, 500 ml bag.....	362.34	18	Baxter Glucose 50%
Inj 50%, 90 ml bottle – <b>5% DV Feb-24 to 2026</b> .....	17.50	1	<b>Biomed</b>
<b>GLUCOSE WITH POTASSIUM CHLORIDE</b>			
Inj 10% glucose with 20 mmol/l potassium chloride, 500 ml bag			
<b>GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE</b>			
Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 3,000 ml bag			
Inj 10% glucose with potassium chloride 10 mmol/l and sodium chloride 15 mmol/l, 500 ml bag			
Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, 1,000 ml bag.....	218.52	12	Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 1,000 ml bag.....	171.84	12	Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.9%, 1,000 ml bag.....	303.72	12	Baxter
<b>GLUCOSE WITH SODIUM CHLORIDE</b>			
Inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag			
Inj 4% glucose and sodium chloride 0.18%, 1,000 ml bag.....	175.44	12	Baxter
Inj 5% glucose and sodium chloride 0.45%, 1,000 ml bag.....	175.32	12	Baxter
Inj 5% glucose and sodium chloride 0.9%, 1,000 ml bag.....	186.24	12	Baxter
<b>POTASSIUM CHLORIDE</b>			
Inj 75 mg (1 mmol) per ml, 10 ml ampoule			
Inj 225 mg (3 mmol) per ml, 20 ml ampoule			
<b>POTASSIUM CHLORIDE WITH SODIUM CHLORIDE</b>			
Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag ....	512.16	48	Baxter
Inj 20 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag....	175.20	12	Baxter
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag....	272.16	12	Baxter
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag .....	829.92	48	Baxter
<b>POTASSIUM DIHYDROGEN PHOSPHATE</b>			
Inj 1 mmol per ml, 10 ml ampoule .....	174.57	10	Hospira
<b>RINGER'S SOLUTION</b>			
Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, 1,000 ml bag			
<b>SODIUM ACETATE</b>			
Inj 4 mmol per ml, 20 ml ampoule			



## BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>SODIUM BICARBONATE</b>			
Inj 8.4%, 10 ml vial			
Inj 8.4%, 50 ml vial .....	22.40	1	Biomed
Inj 8.4%, 100 ml vial .....	22.95	1	Biomed
<b>SODIUM CHLORIDE</b>			
Inj 0.9%, 5 ml ampoule – 5% DV Jan-23 to 2025 .....	4.00	20	<b>Fresenius Kabi</b>
Inj 0.9%, 10 ml ampoule – 5% DV Jan-23 to 2025 .....	5.25	50	<b>Fresenius Kabi</b>
↓ Inj 0.9%, 3 ml syringe, non-sterile pack – 5% DV Mar-23 to 2025.....	12.00	30	<b>BD PosiFlush</b>
→ <b>Restricted (RS1297)</b>			
<b>Initiation</b>			
For use in flushing of in-situ vascular access devices only.			
↓ Inj 0.9%, 5 ml syringe, non-sterile pack – 5% DV Mar-23 to 2025.....	12.00	30	<b>BD PosiFlush</b>
→ <b>Restricted (RS1297)</b>			
<b>Initiation</b>			
For use in flushing of in-situ vascular access devices only.			
↓ Inj 0.9%, 10 ml syringe, non-sterile pack – 5% DV Mar-23 to 2025.....	11.70	30	<b>BD PosiFlush</b>
→ <b>Restricted (RS1297)</b>			
<b>Initiation</b>			
For use in flushing of in-situ vascular access devices only.			
Inj 0.9%, 20 ml ampoule – 5% DV Jan-23 to 2025 .....	5.00	20	<b>Fresenius Kabi</b>
Inj 23.4% (4 mmol/ml), 20 ml ampoule .....	35.50	5	Biomed
Inj 0.45%, 500 ml bag.....	76.68	18	Baxter
Inj 3%, 1,000 ml bag.....	150.72	12	Baxter
Inj 0.9%, 50 ml bag.....	118.20	60	Baxter
	147.75	75	Baxter-Viaflo
Inj 0.9%, 100 ml bag.....	84.48	48	Baxter
	105.60	60	Baxter-Viaflo
Inj 0.9%, 250 ml bag.....	48.00	24	Baxter
Inj 0.9%, 500 ml bag.....	23.94	18	Baxter
Inj 0.9%, 1,000 ml bag.....	16.32	12	Baxter
Inj 1.8%, 500 ml bottle			
<b>SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]</b>			
Inj 1 mmol per ml, 20 ml ampoule .....	53.60	5	Biomed
<b>WATER</b>			
Inj 10 ml ampoule – 5% DV Sep-23 to 2025 .....	7.60	50	<b>Multichem</b>
Inj 20 ml ampoule – 5% DV Jan-23 to 2025 .....	5.00	20	<b>Fresenius Kabi</b>
Inj 250 ml bag			
Inj 500 ml bag			
Inj, 1,000 ml bag.....	20.52	12	Baxter
<b>Oral Administration</b>			
<b>CALCIUM POLYSTYRENE SULPHONATE</b>			
Powder .....	169.85	300 g	Calcium Resonium
<b>COMPOUND ELECTROLYTES</b>			
Powder for oral soln – 5% DV Dec-22 to 2025 .....	9.53	50	<b>Electral</b>
<b>COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]</b>			
Soln with electrolytes (2 x 500 ml) .....	8.55	1,000 ml	Pedalyte - Bubblegum
<b>PHOSPHORUS</b>			
Tab eff 500 mg (16 mmol)			

## BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>POTASSIUM CHLORIDE</b>			
Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)			
Tab long-acting 600 mg (8 mmol).....	15.35	200	Span-K
Oral liq 2 mmol per ml			
<b>SODIUM BICARBONATE</b>			
Cap 840 mg.....	8.52	100	Sodibic
<b>SODIUM CHLORIDE</b>			
Tab 600 mg			
Oral liq 2 mmol/ml			
<b>SODIUM POLYSTYRENE SULPHONATE</b>			
Powder .....	84.65	454 g	Resonium A

### Plasma Volume Expanders

<b>GELATINE, SUCCINYLATED</b>			
Inj 4%, 500 ml bag.....	129.00	10	Gelofusine

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Agents Affecting the Renin-Angiotensin System

### ACE Inhibitors

#### CAPTOPRIL

↓ Oral liq 5 mg per ml .....	94.99	95 ml	Capoten
------------------------------	-------	-------	---------

➔ **Restricted (RS1263)**

#### Initiation

Any of the following:

- 1 For use in children under 12 years of age; or
- 2 For use in tube-fed patients; or
- 3 For management of rebound transient hypertension following cardiac surgery.

CILAZAPRIL – **Restricted:** For continuation only

➔ Tab 0.5 mg .....	2.69	90	Zapril
➔ Tab 2.5 mg .....	5.79	90	Zapril
➔ Tab 5 mg .....	10.05	90	Zapril

#### ENALAPRIL MALEATE

Tab 5 mg – 5% DV Feb-24 to 2025 .....	1.75	90	<b>Acetec</b>
Tab 10 mg – 5% DV Feb-24 to 2025 .....	1.97	90	<b>Acetec</b>
Tab 20 mg – 5% DV Feb-24 to 2025 .....	2.35	90	<b>Acetec</b>

#### LISINOPRIL

Tab 5 mg – 5% DV Oct-22 to 2025 .....	11.07	90	<b>Ethics Lisinopril</b> <b>Teva Lisinopril</b>
Tab 10 mg – 5% DV Oct-22 to 2025 .....	11.67	90	<b>Ethics Lisinopril</b> <b>Teva Lisinopril</b>
Tab 20 mg – 5% DV Oct-22 to 2025 .....	14.69	90	<b>Ethics Lisinopril</b> <b>Teva Lisinopril</b>

#### PERINDOPRIL

Tab 2 mg – 5% DV Jan-22 to 2024 .....	1.58	30	<b>Coversyl</b>
Tab 4 mg – 5% DV Jan-22 to 2024 .....	2.95	30	<b>Coversyl</b>
Tab 8 mg .....	5.02	30	<b>Coversyl</b>

#### QUINAPRIL

Tab 5 mg – 5% DV Feb-22 to 2024 .....	5.97	90	<b>Arrow-Quinapril 5</b>
Tab 10 mg – 5% DV Feb-22 to 2024 .....	5.18	90	<b>Arrow-Quinapril 10</b>
Tab 20 mg – 5% DV Feb-22 to 2024 .....	7.95	90	<b>Arrow-Quinapril 20</b>

#### RAMIPRIL

Cap 1.25 mg – 5% DV May-23 to 2024 .....	6.90	90	<b>Tryzan</b>
Cap 2.5 mg – 5% DV May-23 to 2024 .....	6.60	90	<b>Tryzan</b>
Cap 5 mg – 5% DV May-23 to 2024 .....	6.75	90	<b>Tryzan</b>
Cap 10 mg – 5% DV May-23 to 2024 .....	7.05	90	<b>Tryzan</b>

### ACE Inhibitors with Diuretics

QUINAPRIL WITH HYDROCHLOROTHIAZIDE – **Restricted:** For continuation only

➔ Tab 10 mg with hydrochlorothiazide 12.5 mg – 5% DV Mar-22 to 2024 .....	4.10	30	<b>Accuretic 10</b>
➔ Tab 20 mg with hydrochlorothiazide 12.5 mg – 5% DV Mar-22 to 2024 .....	5.25	30	<b>Accuretic 20</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Angiotensin II Antagonists</b>			
<b>CANDESARTAN CILEXETIL</b>			
Tab 4 mg – 5% DV Dec-21 to 2024 .....	2.00	90	<b>Candestar</b>
Tab 8 mg – 5% DV Dec-21 to 2024 .....	2.28	90	<b>Candestar</b>
Tab 16 mg – 5% DV Dec-21 to 2024 .....	3.31	90	<b>Candestar</b>
Tab 32 mg – 5% DV Dec-21 to 2024 .....	5.26	90	<b>Candestar</b>
<b>LOSARTAN POTASSIUM</b>			
Tab 12.5 mg – 5% DV Mar-24 to 2026 .....	2.00	84	<b>Losartan Actavis</b>
Tab 25 mg – 5% DV Mar-24 to 2026 .....	2.29	84	<b>Losartan Actavis</b>
Tab 50 mg – 5% DV Mar-24 to 2026 .....	2.86	84	<b>Losartan Actavis</b>
Tab 100 mg – 5% DV Mar-24 to 2026 .....	4.57	84	<b>Losartan Actavis</b>

**Angiotensin II Antagonists with Diuretics**

<b>CANDESARTAN CILEXETIL WITH HYDROCHLOROTHIAZIDE</b>			
Tab 16 mg with hydrochlorothiazide 12.5 mg .....	4.10	30	<b>APO-Candesartan HCTZ 16/12.5</b>
Tab 32 mg with hydrochlorothiazide 12.5 mg .....	5.25	30	<b>APO-Candesartan HCTZ 32/12.5</b>
<b>LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE</b>			
Tab 50 mg with hydrochlorothiazide 12.5 mg – 5% DV Jan-23 to 2025 .....	4.00	30	<b>Arrow-Losartan &amp; Hydrochlorothiazide</b>

**Angiotensin II Antagonists with Nephilysin Inhibitors**

<b>SACUBITRIL WITH VALSARTAN – Restricted see terms <a href="#">below</a></b>			
⚠ Tab 24.3 mg with valsartan 25.7 mg .....	190.00	56	<b>Entresto 24/26</b>
⚠ Tab 48.6 mg with valsartan 51.4 mg .....	190.00	56	<b>Entresto 49/51</b>
⚠ Tab 97.2 mg with valsartan 102.8 mg .....	190.00	56	<b>Entresto 97/103</b>

➔ **Restricted (RS1738)**

**Initiation**

*Re-assessment required after 12 months*

All of the following:

- 1 Patient has heart failure; and
- 2 Any of the following:
  - 2.1 Patient is in NYHA/WHO functional class II; or
  - 2.2 Patient is in NYHA/WHO functional class III; or
  - 2.3 Patient is in NYHA/WHO functional class IV; and
- 3 Either:
  - 3.1 Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; or
  - 3.2 An ECHO is not reasonably practical, and in the opinion of the treating practitioner the patient would benefit from treatment; and
- 4 Patient is receiving concomitant optimal standard chronic heart failure treatments.

**Continuation**

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient is benefiting from treatment.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Alpha-Adrenoceptor Blockers</b>			
DOXAZOSIN			
Tab 2 mg .....	17.35	500	Doxazosin Clinect
Tab 4 mg .....	20.94	500	Doxazosin Clinect
PHENOXYBENZAMINE HYDROCHLORIDE			
Cap 10 mg			
Inj 50 mg per ml, 1 ml ampoule			
Inj 50 mg per ml, 2 ml ampoule			
PHENTOLAMINE MESYLATE			
Inj 5 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 1 ml ampoule			
PRAZOSIN			
Tab 1 mg .....	5.53	100	Arrotex-Prazosin S29
Tab 2 mg .....	7.00	100	Arrotex-Prazosin S29
Tab 5 mg .....	11.70	100	Arrotex-Prazosin S29
TERAZOSIN – <b>Restricted:</b> For continuation only			
➔ Tab 1 mg			

**Antiarrhythmics**

ADENOSINE			
Inj 3 mg per ml, 2 ml vial.....	62.73	6	Adenocor
↓ Inj 3 mg per ml, 10 ml vial			
➔ <b>Restricted (RS1266)</b>			
<b>Initiation</b>			
For use in cardiac catheterisation, electrophysiology and MRI.			
AJMALINE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 5 mg per ml, 10 ml ampoule			
➔ <b>Restricted (RS1001)</b>			
Cardiologist			
AMIODARONE HYDROCHLORIDE			
Tab 100 mg – <b>5% DV Dec-22 to 2025</b> .....	3.49	30	<b>Aratac</b>
Tab 200 mg – <b>5% DV Dec-22 to 2025</b> .....	4.49	30	<b>Aratac</b>
Inj 50 mg per ml, 3 ml ampoule – <b>5% DV Dec-22 to 2025</b> .....	15.22	10	<b>Max Health</b>
ATROPINE SULPHATE			
Inj 600 mcg per ml, 1 ml ampoule – <b>5% DV Jan-22 to 2024</b> .....	15.09	10	<b>Martindale</b>
DIGOXIN			
Tab 62.5 mcg – <b>5% DV Jan-23 to 2025</b> .....	7.80	240	<b>Lanoxin PG</b>
Tab 250 mcg – <b>5% DV Jan-23 to 2025</b> .....	16.90	240	<b>Lanoxin</b>
Oral liq 50 mcg per ml			
Inj 250 mcg per ml, 2 ml vial			
DISOPYRAMIDE PHOSPHATE			
Cap 100 mg			

# CARDIOVASCULAR SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>FLECAINIDE ACETATE</b>			
Tab 50 mg – 5% DV Dec-23 to 2026 .....	19.95	60	<b>Flecainide BNM</b>
Cap long-acting 100 mg – 5% DV Aug-23 to 2026 .....	35.78	90	<b>Flecainide Controlled Release Teva</b>
Cap long-acting 200 mg – 5% DV Aug-23 to 2026 .....	54.28	90	<b>Flecainide Controlled Release Teva</b>
Inj 10 mg per ml, 15 ml ampoule .....	104.00	5	Tambocor

IVABRADINE – **Restricted** see terms [below](#)

⚡ Tab 5 mg

➔ **Restricted (RS1566)**

## Initiation

Both:

1 Patient is indicated for computed tomography coronary angiography; and

2 Either:

2.1 Patient has a heart rate of greater than 70 beats per minute while taking a maximally tolerated dose of beta blocker;  
or

2.2 Patient is unable to tolerate beta blockers.

**MEXILETINE HYDROCHLORIDE**

Cap 150 mg ..... 162.00 100 Teva

Cap 250 mg ..... 202.00 100 Teva

**PROPAFENONE HYDROCHLORIDE**

Tab 150 mg

## Antihypertensives

**MIDODRINE** – **Restricted** see terms [below](#)

⚡ Tab 2.5 mg – 5% DV Aug-23 to 2024 ..... 38.23 100 **Midodrine Medsurge**

⚡ Tab 5 mg – 5% DV Aug-23 to 2024 ..... 59.98 100 **Midodrine Medsurge**

➔ **Restricted (RS1427)**

## Initiation

Patient has disabling orthostatic hypotension not due to drugs.

## Beta-Adrenoceptor Blockers

**ATENOLOL**

Tab 50 mg – 5% DV Jun-23 to 2024 ..... 9.33 500 Mylan Atenolol

Tab 100 mg – 5% DV Jan-22 to 2024 ..... 14.20 500 Atenolol Viatris

Oral liq 5 mg per ml ..... 49.85 300 ml Atenolol-AFT

(Mylan Atenolol Tab 50 mg to be delisted 1 November 2023)

**BISOPROLOL FUMARATE**

Tab 2.5 mg ..... 1.84 90 Bisoprolol Mylan

Tab 5 mg ..... 2.55 90 Bisoprolol Mylan

1.72 30 Bosvate

Tab 10 mg ..... 3.62 90 Bisoprolol Mylan

Bisoprolol Viatris

(Bisoprolol Mylan Tab 2.5 mg to be delisted 1 November 2023)

(Bisoprolol Mylan Tab 5 mg to be delisted 1 November 2023)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>CARVEDILOL</b>			
Tab 6.25 mg .....	2.24	60	Carvedilol Sandoz
Tab 12.5 mg .....	2.30	60	Carvedilol Sandoz
Tab 25 mg .....	2.95	60	Carvedilol Sandoz
<b>CELIPROLOL – Restricted:</b> For continuation only			
➔ Tab 200 mg			
<b>ESMOLOL HYDROCHLORIDE</b>			
Inj 10 mg per ml, 10 ml vial			
<b>LABETALOL</b>			
Tab 50 mg			
Tab 100 mg – 1% DV Sep-20 to 2024 .....	14.50	100	<b>Trandate</b>
Tab 200 mg – 1% DV Sep-20 to 2024 .....	27.00	100	<b>Trandate</b>
Inj 5 mg per ml, 20 ml ampoule			
<b>METOPROLOL SUCCINATE</b>			
Tab long-acting 23.75 mg .....	1.45	30	Betaloc CR
Tab long-acting 47.5 mg .....	1.43	30	Betaloc CR
Tab long-acting 95 mg .....	2.15	30	Betaloc CR
Tab long-acting 190 mg .....	4.27	30	Betaloc CR
<b>METOPROLOL TARTRATE</b>			
Tab 50 mg – 1% DV Mar-22 to 2024 .....	5.66	100	<b>IPCA-Metoprolol</b>
Tab 100 mg – 1% DV Mar-22 to 2024 .....	7.55	60	<b>IPCA-Metoprolol</b>
Tab long-acting 200 mg .....	23.40	28	Slow-Lopresor
Inj 1 mg per ml, 5 ml vial .....	26.50	5	Metoprolol IV Mylan Metoprolol IV Viatrix
<b>NADOLOL</b>			
Tab 40 mg – 1% DV Mar-22 to 2024 .....	19.19	100	<b>Nadolol BNM</b>
Tab 80 mg – 1% DV Mar-22 to 2024 .....	30.39	100	<b>Nadolol BNM</b>
<b>PROPRANOLOL</b>			
Tab 10 mg – 1% DV Mar-22 to 2024 .....	7.04	100	<b>Drofate</b>
Tab 40 mg – 1% DV Mar-22 to 2024 .....	8.75	100	<b>IPCA-Propranolol</b>
Cap long-acting 160 mg .....	18.17	100	Cardinol LA
Oral liq 4 mg per ml			
Inj 1 mg per ml, 1 ml ampoule			
<b>SOTALOL</b>			
Tab 80 mg – 5% DV Jan-23 to 2025 .....	37.50	500	<b>Mylan</b>
Tab 160 mg – 5% DV Jan-23 to 2025 .....	14.00	100	<b>Mylan</b>

## Calcium Channel Blockers

### Dihydropyridine Calcium Channel Blockers

<b>AMLODIPINE</b>			
Tab 2.5 mg – 5% DV Feb-24 to 2026 .....	1.45	90	<b>Vasorex</b>
Tab 5 mg – 5% DV Feb-24 to 2026 .....	1.21	90	<b>Vasorex</b>
Tab 10 mg – 5% DV Feb-24 to 2026 .....	1.31	90	<b>Vasorex</b>
<b>FELODIPINE</b>			
Tab long-acting 2.5 mg .....	1.45	30	Plendil ER
Tab long-acting 5 mg – 5% DV Jan-22 to 2024 .....	4.07	90	<b>Felo 5 ER</b>
Tab long-acting 10 mg – 5% DV Jan-22 to 2024 .....	4.32	90	<b>Felo 10 ER</b>

# CARDIOVASCULAR SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ISRADIPINE</b>			
Tab 2.5 mg			
Cap 2.5 mg			
<b>NICARDIPINE HYDROCHLORIDE – Restricted</b> see terms <a href="#">below</a>			
‡ Inj 2.5 mg per ml, 10 ml vial			
→ <b>Restricted (RS1699)</b>			
<b>Initiation</b>			
Anaesthetist, intensivist, cardiologist or paediatric cardiologist			
Any of the following:			
1 Patient has hypertension requiring urgent treatment with an intravenous agent; or			
2 Patient has excessive ventricular afterload; or			
3 Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass.			
<b>NIFEDIPINE</b>			
Tab long-acting 10 mg.....	19.42	56	Tensipine MR10
Tab long-acting 20 mg.....	17.72	100	Nyefax Retard
Tab long-acting 30 mg.....	34.10	100	Mylan (24 hr release)
	4.78	14	Mylan Italy (24 hr release)
Tab long-acting 60 mg.....	52.81	100	Mylan (24 hr release)
Cap 5 mg			
<i>(Mylan (24 hr release) Tab long-acting 30 mg to be delisted 1 February 2024)</i>			
<b>NIMODIPINE</b>			
Tab 30 mg – 5% DV Dec-22 to 2025.....	350.00	100	<b>Nimotop</b>
Inj 200 mcg per ml, 50 ml vial.....	337.50	5	Nimotop
<b>Other Calcium Channel Blockers</b>			
<b>DILTIAZEM HYDROCHLORIDE</b>			
Tab 30 mg			
Cap long-acting 120 mg – 5% DV Jun-23 to 2025.....	65.35	500	<b>Diltiazem CD Clinect</b>
Cap long-acting 180 mg – 1% DV Mar-22 to 2024.....	7.00	30	<b>Cardizem CD</b>
Cap long-acting 240 mg – 1% DV Mar-22 to 2024.....	9.30	30	<b>Cardizem CD</b>
Inj 5 mg per ml, 5 ml vial			
<b>PERHEXILINE MALEATE</b>			
Tab 100 mg.....	62.90	100	Pexsig
<b>VERAPAMIL HYDROCHLORIDE</b>			
Tab 40 mg.....	7.01	100	Isoptin
Tab 80 mg.....	11.74	100	Isoptin
Tab long-acting 120 mg.....	36.02	100	Isoptin SR
Tab long-acting 240 mg.....	15.12	30	Isoptin SR
Inj 2.5 mg per ml, 2 ml ampoule.....	25.00	5	Isoptin
<b>Centrally-Acting Agents</b>			
<b>CLONIDINE</b>			
Patch 2.5 mg, 100 mcg per day – 5% DV Feb-24 to 2026.....	11.70	4	<b>Mylan</b>
Patch 5 mg, 200 mcg per day – 5% DV Feb-24 to 2026.....	12.80	4	<b>Mylan</b>
Patch 7.5 mg, 300 mcg per day – 5% DV Feb-24 to 2026.....	17.90	4	<b>Mylan</b>

‡ Item restricted (see → above); † Item restricted (see → below)

e.g. *Brand* indicates brand example only. It is not a contracted product.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>CLONIDINE HYDROCHLORIDE</b>			
Tab 25 mcg – <b>5% DV Nov-22 to 2025</b> .....	29.32	112	<b>Clonidine Teva</b>
Tab 150 mcg – <b>5% DV Jan-22 to 2024</b> .....	37.07	100	<b>Catapres</b>
Inj 150 mcg per ml, 1 ml ampoule – <b>5% DV Jan-22 to 2024</b> .....	29.68	10	<b>Medsurge</b>
<b>METHYLDOPA</b>			
Tab 250 mg .....	15.10	100	Methyldopa Mylan

**Diuretics**

**Loop Diuretics**

<b>BUMETANIDE</b>			
Tab 1 mg .....	16.36	100	Burinex
Inj 500 mcg per ml, 4 ml vial			
<b>FUROSEMIDE [FRUSEMIDE]</b>			
Tab 40 mg – <b>1% DV Mar-21 to 2024</b> .....	8.00	1,000	<b>IPCA-Frusemide</b>
Tab 500 mg .....	25.00	50	Urex Forte
Oral liq 10 mg per ml .....	11.20	30 ml	Lasix
Inj 10 mg per ml, 2 ml ampoule – <b>5% DV Jan-23 to 2025</b> .....	2.40	5	<b>Furosemide-Baxter</b>
Inj 10 mg per ml, 25 ml ampoule .....	60.65	6	Lasix

**Osmotic Diuretics**

<b>MANNITOL</b>			
Inj 10%, 1,000 ml bag .....	802.56	12	Baxter
Inj 20%, 500 ml bag .....	1,178.10	18	Baxter

**Potassium Sparing Combination Diuretics**

<b>AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE</b>			
Tab 5 mg with furosemide 40 mg			
<b>AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE</b>			
Tab 5 mg with hydrochlorothiazide 50 mg			

**Potassium Sparing Diuretics**

<b>AMILORIDE HYDROCHLORIDE</b>			
Tab 5 mg			
Oral liq 1 mg per ml .....	32.10	25 ml	Biomed
<b>EPLERENONE – Restricted see terms below</b>			
↓ Tab 25 mg – <b>5% DV Jun-22 to 2024</b> .....	18.50	30	<b>Inspira</b>
↓ Tab 50 mg – <b>5% DV Jun-22 to 2024</b> .....	25.00	30	<b>Inspira</b>

➔ **Restricted (RS1640)**

**Initiation**

Both:

- 1 Patient has heart failure with ejection fraction less than 40%; and
- 2 Either:
  - 2.1 Patient is intolerant to optimal dosing of spironolactone; or
  - 2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>SPIRONOLACTONE</b>			
Tab 25 mg – 5% DV Sep-22 to 2025 .....	3.68	100	<b>Spiractin</b>
Tab 100 mg – 5% DV Sep-22 to 2025 .....	10.65	100	<b>Spiractin</b>
Oral liq 5 mg per ml .....	33.00	25 ml	Biomed

## Thiazide and Related Diuretics

<b>BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]</b>			
Tab 2.5 mg – 5% DV Mar-24 to 2026 .....	51.50	500	<b>Arrow-Bendrofluaizide</b>
Tab 5 mg – 5% DV Mar-24 to 2026 .....	61.00	500	<b>Arrow-Bendrofluaizide</b>
<b>CHLOROTHIAZIDE</b>			
Oral liq 50 mg per ml .....	27.82	25 ml	Biomed
<b>CHLORTALIDONE [CHLORTHALIDONE]</b>			
Tab 25 mg – 5% DV Apr-23 to 2025 .....	6.95	50	<b>Hygroton</b>
<b>INDAPAMIDE</b>			
Tab 2.5 mg – 5% DV Feb-24 to 2026 .....	16.00	90	<b>Dapa-Tabs</b>
<b>METOLAZONE</b>			
Tab 5 mg			

## Vasopressin receptor antagonists

<b>TOLVAPTAN – Restricted</b> see terms <a href="#">below</a>			
↓ Tab 15 mg .....	873.50	28	Jinarc
↓ Tab 30 mg .....	873.50	28	Jinarc
↓ Tab 45 mg + 15 mg .....	1,747.00	56	Jinarc
↓ Tab 60 mg + 30 mg .....	1,747.00	56	Jinarc
↓ Tab 90 mg + 30 mg .....	1,747.00	56	Jinarc

➔ **Restricted (RS1930)**

### Initiation – autosomal dominant polycystic kidney disease

Renal physician or any relevant practitioner on the recommendation of a renal physician

*Re-assessment required after 12 months*

All of the following:

- 1 Patient has a confirmed diagnosis of autosomal dominant polycystic kidney disease; and
- 2 Patient has an estimated glomerular filtration rate (eGFR) of greater than or equal to 25 mL/min/1.73 m<sup>2</sup> at treatment initiation; and
- 3 Either:
  - 3.1 Patient's disease is rapidly progressing, with a decline in eGFR of greater than or equal to 5 mL/min/1.73 m<sup>2</sup> within one-year; or
  - 3.2 Patient's disease is rapidly progressing, with an average decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m<sup>2</sup> per year over a five-year period.

### Continuation – autosomal dominant polycystic kidney disease

Renal physician or any relevant practitioner on the recommendation of a renal physician

*Re-assessment required after 12 months*

Both:

- 1 Patient has not developed end-stage renal disease, defined as an eGFR of less than 15 mL/min/1.73 m<sup>2</sup>; and
- 2 Patient has not undergone a kidney transplant.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Lipid-Modifying Agents

### Fibrates

#### BEZAFIBRATE

Tab 200 mg – 5% DV Feb-22 to 2024	19.46	90	<b>Bezalip</b>
Tab long-acting 400 mg – 5% DV Feb-22 to 2024	21.21	30	<b>Bezalip Retard</b>

### HMG CoA Reductase Inhibitors (Statins)

#### ATORVASTATIN

Tab 10 mg – 5% DV Dec-21 to 2024	6.16	500	<b>Lorstat</b>
Tab 20 mg – 5% DV Dec-21 to 2024	9.24	500	<b>Lorstat</b>
Tab 40 mg – 5% DV Dec-21 to 2024	14.92	500	<b>Lorstat</b>
Tab 80 mg – 5% DV Dec-21 to 2024	26.54	500	<b>Lorstat</b>

#### PRAVASTATIN

Tab 10 mg			
Tab 20 mg	2.11	28	Pravastatin Mylan Pravastatin Viatris
Tab 40 mg	3.61	28	Pravastatin Mylan

(Pravastatin Mylan Tab 20 mg to be delisted 1 January 2024)

#### ROSUVASTATIN – Restricted see terms [below](#)

↓ Tab 5 mg – 5% DV Oct-24 to 2026	1.29	30	<b>Rosuvastatin Viatris</b>
↓ Tab 10 mg – 5% DV Oct-24 to 2026	1.69	30	<b>Rosuvastatin Viatris</b>
↓ Tab 20 mg – 5% DV Apr-24 to 2026	2.71	30	<b>Rosuvastatin Viatris</b>
↓ Tab 40 mg – 5% DV Apr-24 to 2026	4.55	30	<b>Rosuvastatin Viatris</b>

→ Restricted (RS1868)

#### Initiation – cardiovascular disease risk

Either:

- 1 Both:
  - 1.1 Patient is considered to be at risk of cardiovascular disease; and
  - 1.2 Patient is Māori or any Pacific ethnicity; or
- 2 Both:
  - 2.1 Patient has a calculated risk of cardiovascular disease of at least 15% over 5 years; and
  - 2.2 LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

#### Initiation – familial hypercholesterolemia

Both:

- 1 Patient has familial hypercholesterolemia (defined as a Dutch Lipid Criteria score greater than or equal to 6); and
- 2 LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

#### Initiation – established cardiovascular disease

Both:

- 1 Any of the following:
  - 1.1 Patient has proven coronary artery disease (CAD); or
  - 1.2 Patient has proven peripheral artery disease (PAD); or
  - 1.3 Patient has experienced an ischaemic stroke; and
- 2 LDL cholesterol has not reduced to less than 1.4 mmol/litre with treatment with the maximum tolerated dose of atorvastatin

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

and/or simvastatin.

## Initiation – recurrent major cardiovascular events

Both:

- 1 Patient has experienced a recurrent major cardiovascular event (defined as myocardial infarction, ischaemic stroke, coronary revascularisation, hospitalisation for unstable angina) in the last 2 years; and
- 2 LDL cholesterol has not reduced to less than 1.0 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

## SIMVASTATIN

Tab 10 mg – 5% DV Mar-24 to 2026 .....	1.68	90	<b>Simvastatin Mylan</b> Simvastatin Viatriis
Tab 20 mg – 5% DV Mar-24 to 2026 .....	2.54	90	<b>Simvastatin Mylan</b> Simvastatin Viatriis
Tab 40 mg – 5% DV Mar-24 to 2026 .....	4.11	90	<b>Simvastatin Mylan</b> Simvastatin Viatriis
Tab 80 mg – 5% DV Mar-24 to 2026 .....	8.81	90	<b>Simvastatin Mylan</b> Simvastatin Viatriis

## Resins

### CHOLESTYRAMINE

Powder for oral liq 4 g

### COLESTIPOL HYDROCHLORIDE

Grans for oral liq 5 g

### COLESTYRAMINE

Powder for oral suspension 4 g sachet .....	61.50	50	Colestyramine - Mylan
---	-------	----	-----------------------

## Selective Cholesterol Absorption Inhibitors

### EZETIMIBE – **Restricted** see terms [below](#)

⚡ Tab 10 mg – 5% DV Dec-23 to 2026 .....	1.76	30	<b>Ezetimibe Sandoz</b>
--	------	----	-------------------------

➔ **Restricted (RS1005)**

### Initiation

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
  - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
  - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
  - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

### EZETIMIBE WITH SIMVASTATIN – **Restricted** see terms [below](#)

⚡ Tab 10 mg with simvastatin 10 mg .....	5.15	30	Zimybe
⚡ Tab 10 mg with simvastatin 20 mg .....	6.15	30	Zimybe
⚡ Tab 10 mg with simvastatin 40 mg .....	7.15	30	Zimybe
⚡ Tab 10 mg with simvastatin 80 mg .....	8.15	30	Zimybe

➔ **Restricted (RS1006)**

### Initiation

All of the following:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

## Other Lipid-Modifying Agents

ACIPIMOX

Cap 250 mg

## Nitrates

GLYCERYL TRINITRATE

Inj 1 mg per ml, 5 ml ampoule			
Inj 1 mg per ml, 10 ml ampoule			
Inj 1 mg per ml, 50 ml vial			
Inj 5 mg per ml, 10 ml ampoule	118.00	5	Hospira
Oral pump spray, 400 mcg per dose	7.48	250 dose	Nitrolingual Pump Spray
Patch 25 mg, 5 mg per day	15.73	30	Nitroderm TTS 5
Patch 50 mg, 10 mg per day	18.62	30	Nitroderm TTS 10

ISOSORBIDE MONONITRATE

Tab 20 mg – 5% DV Feb-24 to 2026	22.49	100	<b>Ismo 20</b>
Tab long-acting 40 mg – 5% DV Feb-24 to 2026	9.80	30	<b>Ismo 40 Retard</b>
Tab long-acting 60 mg – 5% DV Feb-24 to 2026	13.50	90	<b>Duride</b>

## Other Cardiac Agents

 LEVOSIMENDAN – **Restricted** see terms [below](#)

- ↓ Inj 2.5 mg per ml, 5 ml vial
- ↓ Inj 2.5 mg per ml, 10 ml vial

 → **Restricted (RS1007)**
**Initiation – Heart transplant**

Either:

- 1 For use as a bridge to heart transplant, in patients who have been accepted for transplant; or
- 2 For the treatment of heart failure following heart transplant.

**Initiation – Heart failure**

Cardiologist or intensivist

For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.

## Sympathomimetics

ADRENALINE

Inj 1 in 1,000, 1 ml ampoule	4.98	5	Aspen Adrenaline
	12.65		DBL Adrenaline
Inj 1 in 1,000, 30 ml vial			
Inj 1 in 10,000, 10 ml ampoule	49.00	10	Aspen Adrenaline
	27.00	5	Hospira
Inj 1 in 10,000, 10 ml syringe			

DOBUTAMINE

Inj 12.5 mg per ml, 20 ml ampoule – 5% DV Dec-21 to 2024	61.13	5	<b>Dobutamine-hameln</b>
--	-------	---	--------------------------

## CARDIOVASCULAR SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>DOPAMINE HYDROCHLORIDE</b>			
Inj 40 mg per ml, 5 ml ampoule – 5% DV Jan-22 to 2024 .....	38.65	10	<b>Max Health Ltd</b>
<b>EPHEDRINE</b>			
Inj 3 mg per ml, 10 ml syringe			
Inj 30 mg per ml, 1 ml ampoule – 5% DV Feb-24 to 2026 .....	34.31	10	<b>Max Health</b>
<b>ISOPRENALINE [ISOPROTERENOL]</b>			
Inj 200 mcg per ml, 1 ml ampoule			
Inj 200 mcg per ml, 5 ml ampoule			
<b>METARAMINOL</b>			
Inj 0.5 mg per ml, 10 ml syringe			
Inj 0.5 mg per ml, 20 ml syringe			
Inj 0.5 mg per ml, 5 ml syringe			
Inj 1 mg per ml, 1 ml ampoule			
Inj 1 mg per ml, 10 ml syringe			
Inj 10 mg per ml, 1 ml ampoule – 5% DV Feb-24 to 2026 .....	53.00	10	<b>Torbay</b>
<b>NORADRENALINE</b>			
Inj 0.06 mg per ml, 100 ml bag			
Inj 0.06 mg per ml, 50 ml syringe			
Inj 0.1 mg per ml, 100 ml bag			
Inj 0.1 mg per ml, 50 ml syringe			
Inj 0.12 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 50 ml syringe			
Inj 0.16 mg per ml, 50 ml syringe			
Inj 1 mg per ml, 100 ml bag			
Inj 1 mg per ml, 4 ml ampoule – 5% DV Feb-24 to 2025 .....	45.00	10	<b>Noradrenaline BNM</b>
<b>PHENYLEPHRINE HYDROCHLORIDE</b>			
Inj 10 mg per ml, 1 ml ampoule .....	163.38	25	<b>Neosynephrine HCL</b>

### Vasodilators

ALPROSTADIL – **Restricted** see terms [below](#)

⚡ Inj 10 mcg vial

⚡ Inj 20 mcg vial

➡ **Restricted (RS1992)**

#### Initiation

Both:

- 1 Patient has erectile dysfunction; and
- 2 Patient is to receive a penile Doppler ultrasonography.

ALPROSTADIL HYDROCHLORIDE

Inj 500 mcg per ml, 1 ml ampoule .....2,030.33 5 Prostin VR

DIAZOXIDE

Inj 15 mg per ml, 20 ml ampoule

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>HYDRALAZINE HYDROCHLORIDE</b>			
↓ Tab 25 mg			
➔ <b>Restricted (RS1008)</b>			
<b>Initiation</b>			
Either:			
1 For the treatment of refractory hypertension; or			
2 For the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.			
Inj 20 mg ampoule .....	25.90	5	Apresoline
<b>MILRINONE</b>			
Inj 1 mg per ml, 10 ml ampoule – 5% DV Dec-21 to 2024 .....	71.00	10	Milrinone-Baxter
<b>MINOXIDIL</b>			
Tab 10 mg .....	78.40	100	Loniten
<b>NICORANDIL</b>			
Tab 10 mg .....	25.57	60	Ikorel
Tab 20 mg .....	32.28	60	Ikorel
<b>PAPAVERINE HYDROCHLORIDE</b>			
Inj 30 mg per ml, 1 ml vial			
Inj 12 mg per ml, 10 ml ampoule .....	257.12	5	Hospira
<b>PENTOXIFYLLINE [OXPENTIFYLLINE]</b>			
Tab 400 mg			
<b>SODIUM NITROPRUSSIDE</b>			
Inj 50 mg vial			

**Endothelin Receptor Antagonists**

<b>AMBRISENTAN – Restricted</b> see terms <a href="#">below</a>			
↓ Tab 5 mg – 5% DV Dec-23 to 2026 .....	1,550.00	30	Ambrisentan Mylan
	200.00		<b>Ambrisentan Viatris</b>
↓ Tab 10 mg – 5% DV Dec-23 to 2026 .....	200.00	30	<b>Ambrisentan Viatris</b>
	1,550.00		Mylan

(Ambrisentan Mylan Tab 5 mg to be delisted 1 December 2023)

(Mylan Tab 10 mg to be delisted 1 December 2023)

➔ **Restricted (RS1981)**

**Initiation – PAH monotherapy**

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Limited to 6 months treatment

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:

4.1 All of the following:

- 4.1.1 PAH has been confirmed by right heart catheterisation; and
- 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
- 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units ( $\text{dyn s cm}^{-5}$ ); and

4.1.5 Any of the following:

4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or

4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool\*\*; or

4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or

4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or

4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and

5 Both:

5.1 Ambrisentan is to be used as PAH monotherapy; and

5.2 Any of the following:

5.2.1 Patient has experienced intolerable side effects with both sildenafil and bosentan; or

5.2.2 Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); or

5.2.3 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease.

## Initiation – PAH dual therapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Limited to 6 months treatment

All of the following:

1 Patient has pulmonary arterial hypertension (PAH); and

2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and

3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and

4 Any of the following:

4.1 All of the following:

4.1.1 PAH has been confirmed by right heart catheterisation; and

4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and

4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and

4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units ( $\text{dyn s cm}^{-5}$ ); and

4.1.5 Any of the following:

4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or

4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool\*\*; or

4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or

4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or

4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and

5 All of the following:

continued...



Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 5.1 Ambrisentan is to be used as PAH dual therapy; and
- 5.2 Either:
  - 5.2.1 Patient has tried a PAH monotherapy (sildenafil or bosentan) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool\*\*;
  - 5.2.2 Patient has tried PAH dual therapy including bosentan and has experienced intolerable side effects on bosentan; and
- 5.3 Both:
  - 5.3.1 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy; and
  - 5.3.2 Patient has an absolute or relative contraindication to bosentan (eg due to current use of a combined oral contraceptive or liver disease).

**Initiation – PAH triple therapy**

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

*Limited to 6 months treatment*

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
  - 4.1 All of the following:
    - 4.1.1 PAH has been confirmed by right heart catheterisation; and
    - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
    - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
    - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units ( $\text{dyn s cm}^{-5}$ ); and
    - 4.1.5 Any of the following:
      - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
      - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool\*\*;
      - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
  - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
  - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
  - 5.1 Ambrisentan is to be used as PAH triple therapy; and
  - 5.2 Any of the following:
    - 5.2.1 Patient is on the lung transplant list; or
    - 5.2.2 Both:
      - 5.2.2.1 Patient is presenting in NYHA/WHO functional class IV; and
      - 5.2.2.2 Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); or
    - 5.2.3 Both:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 5.2.3.1 Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool\*\*; and
- 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

## Continuation

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

*Re-assessment required after 2 years*

The patient is continuing to derive benefit from ambrisentan treatment according to a validated PAH risk stratification tool\*\*.

Notes: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

\*\* the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

BOSENTAN – **Restricted** see terms [below](#)

⚡ Tab 62.5 mg – 5% DV Dec-21 to 2024	119.85	60	<b>Bosentan Dr Reddy's</b>
⚡ Tab 125 mg – 5% DV Dec-21 to 2024	119.85	60	<b>Bosentan Dr Reddy's</b>

➡ **Restricted (RS1982)**

## Initiation – PAH monotherapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

*Limited to 6 months treatment*

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)\*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
  - 4.1 All of the following:
    - 4.1.1 PAH has been confirmed by right heart catheterisation; and
    - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
    - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
    - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm<sup>-5</sup>); and
    - 4.1.5 Any of the following:
      - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
      - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool\*\*; or
      - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
  - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
  - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
  - 5.1 Bosentan is to be used as PAH monotherapy; and
  - 5.2 Any of the following:

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
------------------------------------	-------------------------------------

continued...

- 5.2.1 Patient has experienced intolerable side effects on sildenafil; or
- 5.2.2 Patient has an absolute contraindication to sildenafil; or
- 5.2.3 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease.

**Initiation – PAH dual therapy**

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

*Limited to 6 months treatment*

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)\*; and
  - 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
  - 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
  - 4 Any of the following:
    - 4.1 All of the following:
      - 4.1.1 PAH has been confirmed by right heart catheterisation; and
      - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
      - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
      - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s  $cm^{-5}$ ); and
      - 4.1.5 Any of the following:
        - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † ; or
        - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool\*\*; or
        - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
  - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
  - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
  - 5.1 Bosentan is to be used as part of PAH dual therapy; and
  - 5.2 Either:
    - 5.2.1 Patient has tried a PAH monotherapy (sildenafil) for at least three months and has experienced an inadequate therapeutic response to treatment according to a validated risk stratification tool\*\*; or
    - 5.2.2 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would likely benefit from initial dual therapy.

**Initiation – PAH triple therapy**

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

*Limited to 6 months treatment*

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)\*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
  - 4.1 All of the following:
    - 4.1.1 PAH has been confirmed by right heart catheterisation; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
  - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
  - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units ( $\text{dyn s cm}^{-5}$ ); and
  - 4.1.5 Any of the following:
    - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
    - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool\*\*; or
    - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
  - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
  - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
- 5.1 Bosentan is to be used as part of PAH triple therapy; and
  - 5.2 Any of the following:
    - 5.2.1 Patient is on the lung transplant list; or
    - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or
    - 5.2.3 Both:
      - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool\*\*; and
      - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

## Continuation

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

*Re-assessment required after 2 years*

Patient is continuing to derive benefit from bosentan treatment according to a validated PAH risk stratification tool\*\*.

Notes: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

\*\* the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

## Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – **Restricted** see terms [below](#)

⚡ Tab 25 mg – 5% DV Jan-22 to 2024 .....	0.85	4	<b>Vedafil</b>
⚡ Tab 50 mg – 5% DV Jan-22 to 2024 .....	1.70	4	<b>Vedafil</b>
⚡ Tab 100 mg – 5% DV Jan-22 to 2024 .....	10.20	12	<b>Vedafil</b>
⚡ Inj 0.8 mg per ml, 12.5 ml vial			

➔ **Restricted (RS1983)**

**Initiation – tablets Raynaud's Phenomenon**

All of the following:

- 1 Patient has Raynaud's phenomenon; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
------------------------------------	-------------------------------------

continued...

- ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

**Initiation – tablets Pulmonary arterial hypertension**

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)\*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
  - 4.1 All of the following:
    - 4.1.1 PAH is confirmed by right heart catheterisation; and
    - 4.1.2 A mean pulmonary artery pressure (PAPm) of greater than 20 mmHg; and
    - 4.1.3 A pulmonary capillary wedge pressure (PCWP) that is less than or equal to 15 mmHg; and
    - 4.1.4 Pulmonary vascular resistance (PVR) of at least 2 Wood Units or at least 160 International Units (dyn s  $cm^{-5}$ ); and
    - 4.1.5 Any of the following:
      - 4.1.5.1 PAH is non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
      - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool\*\*; or
      - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
  - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
  - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures.

**Initiation – tablets other conditions**

Any of the following:

- 1 For use in weaning patients from inhaled nitric oxide; or
- 2 For perioperative use in cardiac surgery patients; or
- 3 For use in intensive care as an alternative to nitric oxide; or
- 4 For use in the treatment of erectile dysfunction secondary to spinal cord injury in patients being treated in a spinal unit.

**Initiation – injection**

Both:

- 1 For use in the treatment of pulmonary hypertension in infants or children being treated in paediatric intensive care units and neonatal intensive care units when the enteral route is not accessible; and
- 2 Any of the following:
  - 2.1 For perioperative use following cardiac surgery; or
  - 2.2 For use in persistent pulmonary hypertension of the newborn (PPHN); or
  - 2.3 For use in congenital diaphragmatic hernia.

Notes: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

\*\* the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Prostacyclin Analogues

EPOPROSTENOL – **Restricted** see terms [below](#)

⚡ Inj 500 mcg vial.....	36.61	1	Veletri
⚡ Inj 1.5 mg vial.....	73.21	1	Veletri

→ **Restricted** (RS1984)

### Initiation – PAH dual therapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

*Limited to 6 months treatment*

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV; and
- 4 Any of the following:
  - 4.1 All of the following:
    - 4.1.1 PAH has been confirmed by right heart catheterisation; and
    - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
    - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
    - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units ( $\text{dyn s cm}^{-5}$ ); and
    - 4.1.5 Any of the following:
      - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
      - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool\*\*; or
      - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
  - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
  - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 All of the following:
  - 5.1 Epoprostenol is to be used as part of PAH dual therapy with either sildenafil or an endothelin receptor antagonist; and
  - 5.2 Patient is presenting in NYHA/WHO functional class IV; and
  - 5.3 Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool.

### Initiation – PAH triple therapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

*Limited to 6 months treatment*

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV; and
- 4 Any of the following:
  - 4.1 All of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 4.1.1 PAH has been confirmed by right heart catheterisation; and
- 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
- 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
- 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn  $cm^{-5}$ ); and
- 4.1.5 Any of the following:
  - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † ; or
  - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool\*\*; or
  - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
  - 5.1 Epoprostenol is to be used as PAH triple therapy; and
  - 5.2 Any of the following:
    - 5.2.1 Patient is on the lung transplant list; or
    - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or
    - 5.2.3 Both:
      - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool; and
      - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

**Continuation**

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

*Re-assessment required after 2 years*

Patient is continuing to derive benefit from iloprost treatment according to a validated PAH risk stratification tool.

Notes: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

\*\* the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

**ILOPROST**

Inj 50 mcg in 0.5 ml ampoule.....	380.00	5	Ilomedin
↓ Nebuliser soln 10 mcg per ml, 2 ml – 5% DV Mar-23 to 2025 .....	185.03	30	<b>Vebulis</b>

➔ **Restricted (RS1985)**

**Initiation – PAH monotherapy**

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

*Limited to 6 months treatment*

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
  - 4.1 All of the following:
    - 4.1.1 PAH has been confirmed by right heart catheterisation; and
    - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
    - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
    - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s  $cm^{-5}$ ); and
    - 4.1.5 Any of the following:
      - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † ; or
      - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool\*\*; or
      - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
  - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
  - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
- 5 Both:
  - 5.1 Iloprost is to be used as PAH monotherapy; and
  - 5.2 Either:
    - 5.2.1 Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan); or
    - 5.2.2 Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists.

## Initiation – PAH dual therapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Limited to 6 months treatment

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
  - 4.1 All of the following:
    - 4.1.1 PAH has been confirmed by right heart catheterisation; and
    - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
    - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
    - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s  $cm^{-5}$ ); and
    - 4.1.5 Any of the following:
      - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † ; or
      - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool\*\*; or

continued...



Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
------------------------------------	-------------------------------------

continued...

- 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
- 5 All of the following:
  - 5.1 Iloprost is to be used as PAH dual therapy with either sildenafil or an endothelin receptor antagonist; and
  - 5.2 Either:
    - 5.2.1 Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil; or
    - 5.2.2 Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist; and
  - 5.3 Either:
    - 5.3.1 Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool\*\*; or
    - 5.3.2 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy.

**Initiation – PAH triple therapy**

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

*Limited to 6 months treatment*

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
  - 4.1 All of the following:
    - 4.1.1 PAH has been confirmed by right heart catheterisation; and
    - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
    - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
    - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn  $cm^{-5}$ ); and
    - 4.1.5 Any of the following:
      - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † ; or
      - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool\*\*; or
      - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
  - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
  - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
- 5 Both:
  - 5.1 Iloprost is to be used as PAH triple therapy; and
  - 5.2 Any of the following:
    - 5.2.1 Patient is on the lung transplant list; or
    - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

### 5.2.3 Both:

- 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool\*\*; and
- 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

### Continuation

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

*Re-assessment required after 2 years*

Patient is continuing to derive benefit from iloprost treatment according to a validated PAH risk stratification tool.

Notes: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

\*\* the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Anti-Infective Preparations

### Antibacterials

HYDROGEN PEROXIDE			
Crn 1%.....	8.56	10 g	Crystaderm
Soln 3% (10 vol)			
MAFENIDE ACETATE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Powder 50 g sachet			
➔ <b>Restricted (RS1299)</b>			
<b>Initiation</b>			
For the treatment of burns patients.			
MUPIROCIN			
Oint 2%			
SODIUM FUSIDATE [FUSIDIC ACID]			
Crn 2% – <b>5% DV Dec-21 to 2024</b> .....	1.59	5 g	<b>Foban</b>
Oint 2% – <b>5% DV Dec-21 to 2024</b> .....	1.59	5 g	<b>Foban</b>
SULFADIAZINE SILVER			
Crn 1%.....	10.80	50 g	Flamazine

### Antifungals

AMOROLFINE			
Nail soln 5% – <b>5% DV Feb-24 to 2026</b> .....	21.87	5 ml	<b>MycoNail</b>
CICLOPIROX OLAMINE			
Nail soln 8%			
➔ Soln 1% – <b>Restricted:</b> For continuation only			
CLOTRIMAZOLE			
Crn 1% – <b>5% DV Apr-23 to 2025</b> .....	1.10	20 g	<b>Clomazol</b>
➔ Soln 1% – <b>Restricted:</b> For continuation only			
ECONAZOLE NITRATE			
➔ Crn 1% – <b>Restricted:</b> For continuation only			
Foaming soln 1%			
KETOCONAZOLE			
Shampoo 2%.....	3.23	100 ml	Sebizole
METRONIDAZOLE			
Gel 0.75%			
MICONAZOLE NITRATE			
Crn 2%.....	0.81	15 g	Multichem
➔ Lotn 2% – <b>Restricted:</b> For continuation only			
Tinc 2%			
NYSTATIN			
Crn 100,000 u per g			

### Antiparasitics

DIMETHICONE			
Lotn 4% – <b>5% DV Dec-22 to 2025</b> .....	4.25	200 ml	<b>healthE Dimethicone 4% Lotion</b>

## DERMATOLOGICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MALATHION [MALDISON] Lotn 0.5% Shampoo 1%			
PERMETHRIN Crm 5%.....	5.75	30 g	Lyderm
Lotn 5% – 5% DV Feb-24 to 2026 .....	4.28	30 ml	<b>A-Scabies</b>
<i>(Lyderm Crm 5% to be delisted 1 February 2024)</i>			
PHENOTHRIN Shampoo 0.5%			

### Antiacne Preparations

ADAPALENE Crm 0.1% Gel 0.1%			
BENZOYL PEROXIDE Soln 5%			
ISOTRETINOIN Cap 5 mg – 5% DV Mar-22 to 2024 .....	11.26	60	<b>Oratane</b>
Cap 10 mg – 5% DV Mar-22 to 2024 .....	18.75	120	<b>Oratane</b>
Cap 20 mg – 5% DV Mar-22 to 2024 .....	26.73	120	<b>Oratane</b>
TRETINOIN Crm 0.05% – 5% DV Jan-22 to 2024 .....	15.57	50 g	<b>ReTrieve</b>

### Antipruritic Preparations

CALAMINE Crm, aqueous, BP – 5% DV May-22 to 2024 .....	1.08 3.45	100 g	<b>Calamine-AFT</b> healthE Calamine Aqueous
CROTAMITON Crm 10% – 5% DV Dec-21 to 2024 .....	3.29	20 g	<b>Itch-Soothe</b>

### Barrier Creams and Emollients

#### Barrier Creams

DIMETHICONE Crm 5% tube – 5% DV Dec-22 to 2025 .....	1.47	100 g	<b>healthE Dimethicone</b> 5%
Crm 5% pump bottle – 5% DV Dec-22 to 2025 .....	4.30	500 ml	<b>healthE Dimethicone</b> 5%
Crm 10% pump bottle.....	4.52	500 ml	healthE Dimethicone 10%
ZINC Crm			<i>e.g. Zinc Cream (Orion-) ;Zinc Cream (PSM)</i>
Oint Paste			<i>e.g. Zinc oxide (PSM)</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ZINC AND CASTOR OIL</b>			
Crn.....	1.63	20 g	Orion
Oint – <b>5% DV Nov-23 to 2025</b> .....	4.65	500 g	Boucher
	4.25		<b>Evvara</b>
Note: DV limit applies to the pack sizes of greater than 30 g.			
Oint, BP .....	1.26	20 g	healthE
Note: DV limit applies to the pack sizes of 30 g or less.			
<i>(Boucher Oint to be delisted 1 November 2023)</i>			
<b>ZINC WITH WOOL FAT</b>			
Crn zinc 15.25% with wool fat 4%			<i>e.g. Sudocrem</i>
<b>Emollients</b>			
<b>AQUEOUS CREAM</b>			
Crn 100 g			
Note: DV limit applies to the pack sizes of 100 g or less.			
Crn 500 g – <b>5% DV Jul-22 to 2024</b> .....	1.73	500 g	<b>GEM Aqueous Cream</b>
Note: DV limit applies to the pack sizes of greater than 100 g.			
<b>CETOMACROGOL</b>			
Crn BP, 500 g – <b>5% DV May-22 to 2024</b> .....	1.99	500 g	<b>Cetomacrogol-AFT</b>
Crn BP, 100 g			
<b>CETOMACROGOL WITH GLYCEROL</b>			
Crn 90% with glycerol 10%, .....	1.65	100 g	healthE
Note: DV limit applies to the pack sizes of 100 g or less.			
Crn 90% with glycerol 10% – <b>5% DV Jul-23 to 2025</b> .....	2.13	500 ml	<b>Evvara</b>
	3.50	1,000 ml	<b>Evvara</b>
Note: DV limit applies to the pack sizes of greater than 100 g.			
<b>EMULSIFYING OINTMENT</b>			
Oint BP – <b>5% DV Feb-24 to 2026</b> .....	2.30	100 g	<b>Jaychem</b>
Note: DV limit applies to pack sizes of less than 200 g.			
Oint BP, 500 g .....	3.40	500 g	Emulsifying Ointment ADE
Note: DV limit applies to pack sizes of greater than 200 g.			
<b>GLYCEROL WITH PARAFFIN</b>			
Crn glycerol 10% with white soft paraffin 5% and liquid paraffin 10%			<i>e.g. QV cream</i>
<b>OIL IN WATER EMULSION</b>			
Crn, 500 g – <b>5% DV Sep-22 to 2025</b> .....	2.04	500 g	<b>Fatty Cream AFT</b>
Note: DV limit applies to the pack sizes of greater than 100 g.			
Crn, 100 g – <b>5% DV Aug-22 to 2024</b> .....	1.59	1	<b>healthE Fatty Cream</b>
Note: DV limit applies to the pack sizes of 100 g or less.			
<b>PARAFFIN</b>			
Oint liquid paraffin 50% with white soft paraffin 50% – <b>5% DV May-23 to 2025</b> .....	1.84	100 g	<b>White Soft Liquid Paraffin AFT</b>
Note: DV limit applies to the pack sizes of 100 g or less.			
White soft.....	0.79	10 g	healthE
Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.			
White soft.....	4.99	450 g	healthE
Yellow soft			
Lotn liquid paraffin 85%			<i>e.g QV Bath Oil</i>

## DERMATOLOGICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PARAFFIN WITH WOOL FAT</b>			
Lotn liquid paraffin 15.9% with wool fat 0.6%			<i>e.g. AlphaKeri;BK ;DP; Hydroderm Lotn</i>
Lotn liquid paraffin 91.7% with wool fat 3%			<i>e.g. Alpha Keri Bath Oil</i>
<b>UREA</b>			
Crm 10%.....	1.37	100 g	healthE Urea Cream
<b>WOOL FAT</b>			
Crm			
<b>Corticosteroids</b>			
<b>BETAMETHASONE DIPROPIONATE</b>			
Crm 0.05%.....	36.00	50 g	Diprosone
Note: DV limit applies to the pack sizes of greater than 30 g.			
Oint 0.05%.....	36.00	50 g	Diprosone
Note: DV limit applies to the pack sizes of greater than 30 g.			
<b>BETAMETHASONE VALERATE</b>			
Crm 0.1% – 5% DV Jan-22 to 2024.....	4.53	50 g	<b>Beta Cream</b>
Oint 0.1% – 5% DV Jan-22 to 2024.....	5.84	50 g	<b>Beta Ointment</b>
Lotn 0.1% – 5% DV Mar-22 to 2024.....	25.00	50 ml	<b>Betnovate</b>
<b>CLOBETASOL PROPIONATE</b>			
Crm 0.05% – 5% DV Jan-23 to 2025.....	2.40	30 g	<b>Dermol</b>
Oint 0.05% – 5% DV Jan-23 to 2025.....	2.33	30 g	<b>Dermol</b>
<b>CLOBETASONE BUTYRATE</b>			
Crm 0.05%			
<b>DIFLUCORTOLONE VALERATE – Restricted:</b> For continuation only			
➔ Crm 0.1%			
➔ Fatty oint 0.1%			
<b>HYDROCORTISONE</b>			
Crm 1%, 30 g – 5% DV Apr-23 to 2025.....	1.78	30 g	<b>Ethics</b>
Note: DV limit applies to the pack sizes of less than or equal to 100 g.			
Crm 1%, 500 g – 5% DV Aug-23 to 2025.....	20.40	500 g	<b>Noumed</b>
Note: DV limit applies to the pack sizes of greater than 100 g.			
<b>HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN</b>			
Lotn 1% with paraffin liquid 15.9% and lanolin 0.6%.....	10.57	250 ml	DP Lotn HC
<b>HYDROCORTISONE BUTYRATE</b>			
Crm 0.1%.....	4.85	100 g	Locoid Lipocream
Oint 0.1% – 5% DV Dec-21 to 2024.....	10.28	100 g	<b>Locoid</b>
Milky emul 0.1% – 5% DV Dec-21 to 2024.....	12.33	100 ml	<b>Locoid Crelo</b>
<b>METHYLPREDNISOLONE ACEPONATE</b>			
Crm 0.1% – 5% DV Feb-24 to 2026.....	4.95	15 g	<b>Advantan</b>
Oint 0.1% – 5% DV Feb-24 to 2026.....	4.95	15 g	<b>Advantan</b>
<b>MOMETASONE FUROATE</b>			
Crm 0.1% – 5% DV Feb-22 to 2024.....	1.95	15 g	<b>Elocon Alcohol Free</b>
	3.10	50 g	<b>Elocon Alcohol Free</b>
Oint 0.1% – 5% DV Feb-22 to 2024.....	1.95	15 g	<b>Elocon</b>
	2.90	50 g	<b>Elocon</b>
Lotn 0.1% – 5% DV Feb-22 to 2024.....	4.50	30 ml	<b>Elocon</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TRIAMCINOLONE ACETONIDE			
Crn 0.02% – 5% DV Feb-24 to 2026 .....	6.49	100 g	<b>Aristocort</b>
Oint 0.02% – 5% DV Feb-24 to 2026.....	6.54	100 g	<b>Aristocort</b>

### Corticosteroids with Anti-Infective Agents

BETAMETHASONE VALERATE WITH CLIOQUINOL – **Restricted** see terms [below](#)

↓ Crn 0.1% with clioquinol 3%

→ **Restricted (RS1125)**

#### Initiation

Either:

- 1 For the treatment of intertrigo; or
- 2 For continuation use.

BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSIDIC ACID]

Crn 0.1% with sodium fusidate (fusidic acid) 2%

HYDROCORTISONE WITH MICONAZOLE

Crn 1% with miconazole nitrate 2% – 5% DV Dec-21 to 2024 ..... 1.89 15 g **Micreme H**

HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN

Oint 1% with natamycin 1% and neomycin sulphate 0.5%..... 3.35 15 g Pimafucort

TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GRAMICIDIN AND NYSTATIN

Crn 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g

### Psoriasis and Eczema Preparations

ACITRETIN

Cap 10 mg ..... 17.86 60 Novatretin  
Cap 25 mg ..... 41.36 60 Novatretin

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Foam spray 500 mcg with calcipotriol 50 mcg per g ..... 59.95 60 g Enstilar  
Gel 500 mcg with calcipotriol 50 mcg per g – 5% DV Dec-21 to 2024 ..... 39.35 60 g **Daivobet**  
Oint 500 mcg with calcipotriol 50 mcg per g – 5% DV Dec-21 to 2024 ..... 15.90 30 g **Daivobet**

CALCIPOTRIOL

Oint 50 mcg per g ..... 40.00 120 g Daivonex

COAL TAR WITH SALICYLIC ACID AND SULPHUR

Oint 12% with salicylic acid 2% and sulphur 4%

METHOXSALEN [8-METHOXYPORALEN]

Tab 10 mg  
Lotn 1.2%

PIMECROLIMUS – **Restricted** see terms [below](#)

↓ Crn 1% – 5% DV Feb-24 to 2026 ..... 33.00 15 g **Elidel**

→ **Restricted (RS1781)**

#### Initiation

Dermatologist, paediatrician or ophthalmologist

Both:

- 1 Patient has atopic dermatitis on the eyelid; and
- 2 Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy, documented allergy to topical corticosteroids, cataracts, glaucoma, or raised intraocular pressure.

## DERMATOLOGICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCENIN</b>			
Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – <b>5% DV</b> <b>Feb-24 to 2026</b> .....	5.41	500 ml	<b>Pinetarsol</b>
<b>POTASSIUM PERMANGANATE</b>			
Tab 400 mg Crystals			
<b>TACROLIMUS</b>			
↓ Oint 0.1% – <b>5% DV Dec-23 to 2026</b> .....	33.00	30 g	<b>Zematop</b>
→ <b>Restricted (RS1859)</b>			
<b>Initiation</b>			
Dermatologist or paediatrician			
Both:			
1 Patient has atopic dermatitis on the face; and			
2 Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy or documented allergy to topical corticosteroids.			

### Scalp Preparations

<b>BETAMETHASONE VALERATE</b>			
Scalp app 0.1% – <b>5% DV Jan-22 to 2024</b> .....	9.84	100 ml	<b>Beta Scalp</b>
<b>CLOBETASOL PROPIONATE</b>			
Scalp app 0.05% – <b>5% DV Jan-23 to 2025</b> .....	6.26	30 ml	<b>Dermol</b>
<b>HYDROCORTISONE BUTYRATE</b>			
Scalp lotn 0.1% – <b>5% DV Dec-21 to 2024</b> .....	6.57	100 ml	<b>Locoid</b>

### Wart Preparations

<b>PODOPHYLLOTOXIN</b>			
Soln 0.5% .....	33.60	3.5 ml	Condyline
<b>SILVER NITRATE</b>			
Sticks with applicator			

### Other Skin Preparations

<b>DIPHEMANIL METILSULFATE</b>			
Powder 2%			
<b>IMIQUIMOD</b>			
Crn 5%, 250 mg sachet .....	21.72	24	Perrigo
<b>SUNSCREEN, PROPRIETARY</b>			
Lotn – <b>5% DV Apr-23 to 2025</b> .....	6.50	200 g	<b>Marine Blue Lotion SPF 50+</b>

### Antineoplastics

<b>FLUOROURACIL SODIUM</b>			
Crn 5% – <b>5% DV Dec-21 to 2024</b> .....	6.95	20 g	<b>Efudix</b>
<b>METHYL AMINOLEVULINATE HYDROCHLORIDE – Restricted</b> see terms <a href="#">below</a>			
↓ Crn 16%			
→ <b>Restricted (RS1127)</b>			
Dermatologist or plastic surgeon			



Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

**Wound Management Products**

CALCIUM GLUCONATE  
Gel 2.5%

*e.g. Orion*

# GENITO-URINARY SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Anti-Infective Agents

### ACETIC ACID

Soln 3%

Soln 5%

### ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID

Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator

### CHLORHEXIDINE GLUCONATE

Crm 1%

Lotn 1%

### CLOTRIMAZOLE

Vaginal crm 1% with applicator – 5% DV Apr-23 to 2025 ..... 3.50

35 g

**Clomazol**

Vaginal crm 2% with applicator – 5% DV Apr-23 to 2025 ..... 3.85

20 g

**Clomazol**

### MICONAZOLE NITRATE

Vaginal crm 2% with applicator ..... 6.89

40 g

Micreme

### NYSTATIN

Vaginal crm 100,000 u per 5 g with applicator(s) – 5% DV Feb-24 to 2026 ..... 5.70

75 g

**Nilstat**

## Contraceptives

### Antiandrogen Oral Contraceptives

#### CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL

Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets – 5% DV

Feb-24 to 2026 ..... 5.08

168

**Ginet**

### Combined Oral Contraceptives

#### ETHINYLOESTRADIOL WITH DESOGESTREL

Tab 20 mcg with desogestrel 150 mcg

Tab 30 mcg with desogestrel 150 mcg

#### ETHINYLOESTRADIOL WITH LEVONORGESTREL

Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – 5% DV

Aug-23 to 2025 ..... 1.50

84

**Lo-Oralcon 20 ED**

Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – 5% DV

Aug-23 to 2025 ..... 1.50

84

**Oralcon 30 ED**

Tab 20 mcg with levonorgestrel 100 mcg

Tab 30 mcg with levonorgestrel 150 mcg

#### ETHINYLOESTRADIOL WITH NORETHISTERONE

Tab 35 mcg with norethisterone 1 mg

Tab 35 mcg with norethisterone 1 mg and 7 inert tab ..... 12.25

84

**Brevinor 1/28**

Tab 35 mcg with norethisterone 500 mcg

#### NORETHISTERONE WITH MESTRANOL

Tab 1 mg with mestranol 50 mcg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Contraceptive Devices**

INTRA-UTERINE DEVICE

IUD 29.1 mm length x 23.2 mm width – 5% DV Apr-23 to 2025	29.80	1	Choice TT380 Short
IUD 33.6 mm length x 29.9 mm width – 5% DV Apr-23 to 2025	29.80	1	Choice TT380 Standard
IUD 35.5 mm length x 19.6 mm width – 5% DV Apr-23 to 2025	33.00	1	Choice Load 375

**Emergency Contraception**

LEVONORGESTREL

Tab 1.5 mg – 5% DV Jun-23 to 2025	1.75	1	Levonorgestrel BNM
-----------------------------------	------	---	--------------------

**Progestogen-Only Contraceptives**

LEVONORGESTREL

Tab 30 mcg	16.50	84	Microlut
Subdermal implant (2 x 75 mg rods) – 5% DV Dec-23 to 2026	106.92	1	Jadelle
Intra-uterine device 52 mg	269.50	1	Mirena
Intra-uterine device 13.5 mg	215.60	1	Jaydess

MEDROXYPROGESTERONE ACETATE

Inj 150 mg per ml, 1 ml syringe	9.18	1	Depo-Provera
---------------------------------	------	---	--------------

NORETHISTERONE

Tab 350 mcg – 5% DV Mar-22 to 2024	12.25	84	Noriday 28
------------------------------------	-------	----	------------

**Obstetric Preparations**

**Antiprogestogens**

MIFEPRISTONE

Tab 200 mg			
------------	--	--	--

**Oxytocics**

CARBOPROST TROMETAMOL

Inj 250 mcg per ml, 1 ml ampoule			
----------------------------------	--	--	--

DINOPROSTONE

Pessaries 10 mg			
Vaginal gel 1 mg in 3 g	65.39	1	Prostin E2
Vaginal gel 2 mg in 3 g	82.33	1	Prostin E2

ERGOMETRINE MALEATE

Inj 500 mcg per ml, 1 ml ampoule	160.00	5	DBL Ergometrine
----------------------------------	--------	---	-----------------

OXYTOCIN

Inj 5 iu per ml, 1 ml ampoule – 5% DV Jun-23 to 2025	4.98	5	Oxytocin BNM
Inj 10 iu per ml, 1 ml ampoule – 5% DV Jun-23 to 2025	5.98	5	Oxytocin BNM

OXYTOCIN WITH ERGOMETRINE MALEATE

Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 5% DV Dec-22 to 2025	32.40	5	Syntometrine
---	-------	---	--------------

**Tocolytics**

PROGESTERONE

Cap 100 mg – 5% DV May-23 to 2025	14.85	30	Utrogestan
-----------------------------------	-------	----	------------

## GENITO-URINARY SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

TERBUTALINE – **Restricted** see terms [below](#)

⚡ Inj 500 mcg ampoule

➔ **Restricted (RS1130)**

Obstetrician

### Oestrogens

OESTRIOL

Crm 1 mg per g with applicator – 5% DV Feb-24 to 2026 ..... 6.95 15 g **Ovestin**

Pessaries 500 mcg – 5% DV Feb-24 to 2026 ..... 7.55 15 **Ovestin**

### Urologicals

#### 5-Alpha Reductase Inhibitors

FINASTERIDE – **Restricted** see terms [below](#)

⚡ Tab 5 mg – 5% DV Dec-23 to 2026 ..... 4.79 100 **Ricit**

➔ **Restricted (RS1131)**

**Initiation**

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 Either:
  - 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
  - 2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

#### Alpha-1A Adrenoceptor Blockers

TAMSULOSIN HYDROCHLORIDE – **Restricted** see terms [below](#)

⚡ Cap 400 mcg – 5% DV Jan-23 to 2025 ..... 22.31 100 **Tamsulosin-Rex**

➔ **Restricted (RS1132)**

**Initiation**

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

### Urinary Alkalisers

POTASSIUM CITRATE – **Restricted** see terms [below](#)

⚡ Oral liq 3 mmol per ml ..... 31.80 200 ml **Biomed**

➔ **Restricted (RS1133)**

**Initiation**

Both:

- 1 The patient has recurrent calcium oxalate urolithiasis; and
- 2 The patient has had more than two renal calculi in the two years prior to the application.

SODIUM CITRO-TARTRATE

Grans eff 4 g sachets – 5% DV Feb-24 to 2026 ..... 3.50 28 **Ural**

### Urinary Antispasmodics

OXYBUTYNIN

Tab 5 mg ..... 5.42 100 **Alchemy Oxybutynin**

Oral liq 5 mg per 5 ml

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>SOLIFENACIN SUCCINATE</b>			
Tab 5 mg – <b>5% DV Jun-23 to 2024</b> .....	2.05	30	Solifenacin Mylan <b>Solifenacin Viatris</b>
Tab 10 mg – <b>5% DV Jun-23 to 2024</b> .....	3.72	30	Solifenacin Mylan <b>Solifenacin Viatris</b>
<i>(Solifenacin Mylan Tab 5 mg to be delisted 1 December 2023)</i>			
<i>(Solifenacin Mylan Tab 10 mg to be delisted 1 December 2023)</i>			

## HORMONE PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Anabolic Agents

#### OXANDROLONE

↓ Tab 2.5 mg

→ **Restricted (RS1302)**

#### Initiation

For the treatment of burns patients.

### Androgen Agonists and Antagonists

#### CYPROTERONE ACETATE

Tab 50 mg – 5% DV Jan-22 to 2024 ..... 14.37 50 **Siterone**

Tab 100 mg – 5% DV Jan-22 to 2024 ..... 28.03 50 **Siterone**

#### TESTOSTERONE

Patch 5 mg per day ..... 225.00 30 **Androderm**

#### TESTOSTERONE CIPIONATE

Inj 100 mg per ml, 10 ml vial..... 85.00 1 **Depo-Testosterone**

#### TESTOSTERONE ESTERS

Inj testosterone decanoate 100 mg, testosterone isocarproate 60 mg,  
testosterone phenylpropionate 60 mg and testosterone propionate  
30 mg per ml, 1 ml ampoule

#### TESTOSTERONE UNDECANOATE

→ Cap 40 mg – **Restricted:** For continuation only..... 21.00 60 **Andriol Testocaps**

Inj 250 mg per ml, 4 ml vial..... 86.00 1 **Reandron 1000**

### Calcium Homeostasis

#### CALCITONIN

Inj 100 iu per ml, 1 ml ampoule ..... 121.00 5 **Miacalcic**

#### CINACALCET – **Restricted** see terms [below](#)

↓ Tab 30 mg – 5% DV Apr-22 to 2024 ..... 42.06 28 **Cinacalef Devatis**

↓ Tab 60 mg – 5% DV Apr-22 to 2024 ..... 84.12 28 **Cinacalef Devatis**

→ **Restricted (RS1931)**

#### Initiation – parathyroid carcinoma or calciphylaxis

Nephrologist or endocrinologist

*Re-assessment required after 6 months*

Either:

1 All of the following:

- 1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
- 1.2 The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
- 1.3 The patient is symptomatic; or

2 All of the following:

- 2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriopathy); and
- 2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L); and
- 2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

thiosulfate.

### Continuation – parathyroid carcinoma or calciphylaxis

Nephrologist or endocrinologist

Both:

- 1 The patient's serum calcium level has fallen to < 3mmol/L; and
- 2 The patient has experienced clinically significant symptom improvement.

Note: This does not include parathyroid adenomas unless these have become malignant.

### Initiation – primary hyperparathyroidism

All of the following:

- 1 Patient has primary hyperparathyroidism; and
- 2 Either:
  - 2.1 Patient has hypercalcaemia of more than 3 mmol/L with or without symptoms; or
  - 2.2 Patient has hypercalcaemia of more than 2.85 mmol/L with symptoms; and
- 3 Surgery is not feasible or has failed; and
- 4 Patient has other comorbidities, severe bone pain, or calciphylaxis.

### Initiation – secondary or tertiary hyperparathyroidism

*Re-assessment required after 6 months*

All of the following:

- 1 Either:
  - 1.1 Patient has tertiary hyperparathyroidism and markedly elevated parathyroid hormone (PTH) with hypercalcaemia; or
  - 1.2 Patient has symptomatic secondary hyperparathyroidism and elevated PTH; and
- 2 Patient is on renal replacement therapy; and
- 3 Any of the following:
  - 3.1 Residual parathyroid tissue has not been localised despite repeat unsuccessful parathyroid explorations; or
  - 3.2 Parathyroid tissue is surgically inaccessible; or
  - 3.3 Parathyroid surgery is not feasible.

### Continuation – secondary or tertiary hyperparathyroidism

*Re-assessment required after 12 months*

Either:

- 1 The patient has had a kidney transplant, and following a treatment free interval of at least 12 weeks a clinically acceptable parathyroid hormone (PTH) level to support ongoing cessation of treatment has not been reached; or
- 2 The patient has not received a kidney transplant and trial of withdrawal of cinacalcet is clinically inappropriate.

### ZOLEDRONIC ACID

Inj 4 mg per 5 ml, vial – <b>5% DV Jun-23 to 2024</b> .....	18.00	1	Zoledronic acid Mylan <b>Zoledronic acid Viatriis</b>
---	-------	---	--

*(Zoledronic acid Mylan Inj 4 mg per 5 ml, vial to be delisted 1 November 2023)*

## Corticosteroids

### BETAMETHASONE

- Tab 500 mcg
- Inj 4 mg per ml, 1 ml ampoule

### BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE

- Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule

### DEXAMETHASONE

Tab 0.5 mg – <b>5% DV Jan-22 to 2024</b> .....	1.50	30	<b>Dexamethsone</b>
Tab 4 mg – <b>5% DV Jan-22 to 2024</b> .....	2.65	30	<b>Dexamethsone</b>
Oral liq 1 mg per ml .....	49.50	25 ml	Biomed

## HORMONE PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>DEXAMETHASONE PHOSPHATE</b>			
Inj 4 mg per ml, 1 ml ampoule – 5% DV Feb-23 to 2025	7.86	10	<b>Hameln</b>
Inj 4 mg per ml, 2 ml ampoule – 5% DV Feb-23 to 2025	13.10	10	<b>Hameln</b>
<b>FLUDROCORTISONE ACETATE</b>			
Tab 100 mcg – 5% DV Dec-22 to 2025	11.46	100	<b>Florinef</b>
<b>HYDROCORTISONE</b>			
Tab 5 mg	8.10	100	Douglas
Tab 20 mg	20.32	100	Douglas
Inj 100 mg vial – 5% DV Nov-21 to 2024	4.38	1	<b>Solu-Cortef</b>
<b>METHYLPREDNISOLONE (AS SODIUM SUCCINATE)</b>			
Tab 4 mg	112.00	100	Medrol
Tab 100 mg	223.10	20	Medrol
Inj 40 mg vial	22.30	1	Solu-Medrol Act-O-Vial
Inj 125 mg vial	34.10	1	Solu-Medrol Act-O-Vial
Inj 500 mg vial	26.88	1	Solu-Medrol Act-O-Vial
Inj 1 g vial	32.84	1	Solu-Medrol
<b>METHYLPREDNISOLONE ACETATE</b>			
Inj 40 mg per ml, 1 ml vial	47.06	5	Depo-Medrol
<b>PREDNISOLONE</b>			
Oral liq 5 mg per ml – 5% DV Dec-21 to 2024	6.00	30 ml	<b>Redipred</b>
Enema 200 mcg per ml, 100 ml			
<b>PREDNISONE</b>			
Tab 1 mg	18.58	500	Prednisone Clinect
Tab 2.5 mg	21.04	500	Prednisone Clinect
Tab 5 mg	19.30	500	Prednisone Clinect
Tab 20 mg	50.51	500	Prednisone Clinect
<b>TRIAMCINOLONE ACETONIDE</b>			
Inj 10 mg per ml, 1 ml ampoule – 10% DV Feb-24 to 2026	21.42	5	<b>Kenacort-A 10</b>
Inj 40 mg per ml, 1 ml ampoule – 5% DV Feb-24 to 2026	52.63	5	<b>Kenacort-A 40</b>
<b>TRIAMCINOLONE HEXACETONIDE</b>			
Inj 20 mg per ml, 1 ml vial			

## Hormone Replacement Therapy

### Oestrogens

<b>OESTRADIOL</b>			
Tab 1 mg			
Patch 25 mcg per day	6.12	8	Estradot
Patch 50 mcg per day	7.04	8	Estradot
Patch 75 mcg per day	7.91	8	Estradot
Patch 100 mcg per day	7.91	8	Estradot
<b>OESTRADIOL VALERATE</b>			
Tab 1 mg	12.36	84	Progynova
Tab 2 mg	12.36	84	Progynova
<b>OESTROGENS (CONJUGATED EQUINE)</b>			
Tab 300 mcg			
Tab 625 mcg			

↑ Item restricted (see → above); ↓ Item restricted (see → below)

e.g. *Brand* indicates brand example only. It is not a contracted product.



	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

## Progestogen and Oestrogen Combined Preparations

### OESTRADIOL WITH NORETHISTERONE ACETATE

Tab 1 mg with 0.5 mg norethisterone acetate

Tab 2 mg with 1 mg norethisterone acetate

Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestradiol (12) and tab 1 mg oestradiol (6)

### OESTROGENS WITH MEDROXYPROGESTERONE ACETATE

Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone acetate

Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate

## Progestogens

### MEDROXYPROGESTERONE ACETATE

Tab 2.5 mg ..... 4.69 30 Provera

Tab 5 mg ..... 17.50 100 Provera

Tab 10 mg ..... 8.94 30 Provera

## Other Endocrine Agents

### CABERGOLINE – **Restricted** see terms [below](#)

↓ Tab 0.5 mg ..... 4.43 2 Dostinex

17.94 8 Dostinex

→ **Restricted (RS1855)**

### Initiation

Any of the following:

- 1 Inhibition of lactation; or
- 2 Patient has hyperprolactinemia; or
- 3 Patient has acromegaly.

Note: Indication marked with \* is an unapproved indication.

### CLOMIFENE CITRATE

Tab 50 mg ..... 29.84 10 Mylan Clomiphen

### GESTRINONE

Cap 2.5 mg

### METYRAPONE

Cap 250 mg

### PENTAGASTRIN

Inj 250 mcg per ml, 2 ml ampoule

## Other Oestrogen Preparations

### OESTRADIOL

Implant 50 mg

### OESTRIOL

Tab 2 mg – **5% DV Feb-24 to 2026** ..... 7.70 30 **Ovestin**

## Other Progestogen Preparations

### MEDROXYPROGESTERONE

Tab 100 mg ..... 116.15 100 Provera HD

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

## HORMONE PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
NORETHISTERONE			
Tab 5 mg .....	5.49	30	Primolut N

### Pituitary and Hypothalamic Hormones and Analogues

#### CORTICORELIN (OVINE)

Inj 100 mcg vial

#### THYROTROPIN ALFA

Inj 900 mcg vial

### Adrenocorticotrophic Hormones

#### TETRACOSACTIDE [TETRACOSACTRIN]

Inj 250 mcg per ml, 1 ml ampoule .....	86.25	1	Synacthen
Inj 1 mg per ml, 1 ml ampoule .....	690.00	1	Synacthen Depot

### GnRH Agonists and Antagonists

#### BUSERELIN

Inj 1 mg per ml, 5.5 ml vial

#### GONADORELIN

Inj 100 mcg vial

#### GOSERELIN

Implant 3.6 mg, syringe .....	65.68	1	Teva
Implant 10.8 mg, syringe .....	122.37	1	Teva

#### LEUPRORELIN ACETATE

Inj 3.75 mg prefilled dual chamber syringe.....	221.60	1	Lucrin Depot 1-month
Inj 11.25 mg prefilled dual chamber syringe.....	591.68	1	Lucrin Depot 3-month

### Gonadotrophins

#### CHORIOGONADOTROPIN ALFA

Inj 250 mcg in 0.5 ml syringe

### Growth Hormone

#### SOMATROPIN – Restricted see terms [below](#)

⚠ Inj 5 mg cartridge – 5% DV Jan-22 to 2024 .....	69.75	1	Omnitrope
⚠ Inj 10 mg cartridge – 5% DV Jan-22 to 2024 .....	69.75	1	Omnitrope
⚠ Inj 15 mg cartridge – 5% DV Jan-22 to 2024 .....	139.50	1	Omnitrope

➔ Restricted (RS1826)

#### Initiation – growth hormone deficiency in children

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

Either:

- 1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

2 All of the following:

- 2.1 Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
- 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
- 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
- 2.5 Appropriate imaging of the pituitary gland has been obtained.

**Continuation – growth hormone deficiency in children**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

**Initiation – Turner syndrome**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

**Continuation – Turner syndrome**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 Height velocity greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
- 3 A current bone age is 14 years or under; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

**Initiation – short stature without growth hormone deficiency**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and

continued...

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

### Continuation – short stature without growth hormone deficiency

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 Current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

### Initiation – short stature due to chronic renal insufficiency

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of an endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:
  - 6.1 The patient has a GFR less than or equal to 30 ml/min/1.73 m<sup>2</sup> as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l × 40 = corrected GFR (ml/min/1.73 m<sup>2</sup>)) in a child who may or may not be receiving dialysis; or
  - 6.2 The patient has received a renal transplant and has received < 5mg/ m<sup>2</sup> /day of prednisone or equivalent for at least 6 months.

### Continuation – short stature due to chronic renal insufficiency

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of an endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

continued...

Price	Brand or
(ex man. excl. GST)	Generic
\$	Manufacturer
Per	

continued...

### **Initiation – Prader-Willi syndrome**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient is aged six months or older; and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 5 Either:
  - 5.1 Both:
    - 5.1.1 The patient is aged two years or older; and
    - 5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
  - 5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

### **Continuation – Prader-Willi syndrome**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

### **Initiation – adults and adolescents**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak

continued...

## HORMONE PREPARATIONS

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

### Continuation – adults and adolescents

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

Any of the following:

- 1 All of the following:
  - 1.1 The patient has been treated with somatropin for < 12 months; and
  - 1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
  - 1.3 Serum IGF-I levels have increased to within  $\pm 1SD$  of the mean of the normal range for age and sex; and
  - 1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or
- 2 All of the following:
  - 2.1 The patient has been treated with somatropin for more than 12 months; and
  - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
  - 2.3 Serum IGF-I levels have continued to be maintained within  $\pm 1SD$  of the mean of the normal range for age and sex (other than for obvious external factors); and
  - 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients; or
- 3 All of the following:
  - 3.1 The patient has had a Special Authority approval for somatropin for childhood deficiency in children and no longer meets the renewal criteria under this indication; and
  - 3.2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
  - 3.3 The patient has severe growth hormone deficiency (see notes); and
  - 3.4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
  - 3.5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

## Thyroid and Antithyroid Preparations

### CARBIMAZOLE

Tab 5 mg – 5% DV Sep-22 to 2025 ..... 7.56      100      Neo-Mercazole

### IODINE

Soln BP 50 mg per ml

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>LEVOTHYROXINE</b>			
Tab 25 mcg			
Tab 50 mcg			
Tab 100 mcg			
<b>LIOTHYRONINE SODIUM</b>			
↓ Tab 20 mcg			
➔ <b>Restricted (RS1301)</b>			
<b>Initiation</b>			
For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receive radioiodine therapy.			
Inj 20 mcg vial			
Inj 100 mcg vial			
<b>POTASSIUM IODATE</b>			
Tab 170 mg			
<b>POTASSIUM PERCHLORATE</b>			
Cap 200 mg			
<b>PROPYLTHIOURACIL – Restricted see terms below</b>			
↓ Tab 50 mg .....	35.00	100	PTU
➔ <b>Restricted (RS1276)</b>			
<b>Initiation</b>			
Both:			
1 The patient has hyperthyroidism; and			
2 The patient is intolerant of carbimazole or carbimazole is contraindicated.			
<b>PROTIRELIN</b>			
Inj 100 mcg per ml, 2 ml ampoule			

## Vasopressin Agents

<b>ARGIPRESSIN [VASOPRESSIN]</b>			
Inj 20 u per ml, 1 ml ampoule			
<b>DESMOPRESSIN</b>			
Wafer 120 mcg .....	47.00	30	Minirin Melt
<b>DESMOPRESSIN ACETATE</b>			
Tab 100 mcg.....	25.00	30	Minirin
Tab 200 mcg.....	54.45	30	Minirin
Nasal spray 10 mcg per dose – <b>5% DV Feb-24 to 2026</b> .....	34.95	6 ml	<b>Desmopressin-PH&amp;T</b>
Inj 4 mcg per ml, 1 ml ampoule			
Inj 15 mcg per ml, 1 ml ampoule			
Nasal drops 100 mcg per ml			
<b>TERLIPRESSIN</b>			
Inj 1 mg per 8.5 ml ampoule .....	215.00	5	Glypressin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Antibacterials</b>			
<b>Aminoglycosides</b>			
AMIKACIN – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 5 mg per ml, 10 ml syringe			
⚡ Inj 5 mg per ml, 5 ml syringe .....	21.43	1	Biomed
⚡ Inj 15 mg per ml, 5 ml syringe			
⚡ Inj 250 mg per ml, 2 ml vial – <b>5% DV Dec-21 to 2024</b> .....	199.95	5	<b>DBL Amikacin</b>
➔ <b>Restricted (RS1041)</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
GENTAMICIN SULPHATE			
Inj 10 mg per ml, 1 ml ampoule .....	95.00	5	DBL Gentamicin
Inj 40 mg per ml, 2 ml ampoule .....	18.38	10	Pfizer
PAROMOMYCIN – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Cap 250 mg .....	126.00	16	Humatin
➔ <b>Restricted (RS1603)</b>			
Clinical microbiologist, infectious disease specialist or gastroenterologist			
STREPTOMYCIN SULPHATE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 400 mg per ml, 2.5 ml ampoule			
➔ <b>Restricted (RS1043)</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
TOBRAMYCIN			
⚡ Powder			
➔ <b>Restricted (RS1475)</b>			
<b>Initiation</b>			
For addition to orthopaedic bone cement.			
⚡ Inj 40 mg per ml, 2 ml vial – <b>5% DV Jul-23 to 2024</b> .....	18.50	5	Tobramycin Mylan <b>Viatrix</b>
➔ <b>Restricted (RS1044)</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
⚡ Inj 100 mg per ml, 5 ml vial			
➔ <b>Restricted (RS1044)</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
⚡ Solution for inhalation 60 mg per ml, 5 ml – <b>5% DV Dec-23 to 2026</b> .....	395.00	56 dose	<b>Tobramycin BNM</b>
➔ <b>Restricted (RS1435)</b>			
<b>Initiation</b>			
Patient has cystic fibrosis.			
<i>(Tobramycin Mylan Inj 40 mg per ml, 2 ml vial to be delisted 1 January 2024)</i>			
<b>Carbapenems</b>			
ERTAPENEM – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 1 g vial .....	70.00	1	Invanz
➔ <b>Restricted (RS1045)</b>			
Clinical microbiologist or infectious disease specialist			
IMIPENEM WITH CILASTATIN – <b>Restricted</b> see terms <a href="#">on the next page</a>			
⚡ Inj 500 mg with 500 mg cilastatin vial .....	60.00	1	Imipenem+Cilastatin RBX



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**➔ Restricted (RS1046)**

Clinical microbiologist or infectious disease specialist

**MEROPENEM – Restricted** see terms [below](#)

↓ Inj 500 mg vial .....	33.92	10	Meropenem-AFT
↓ Inj 1 g vial .....	45.04	10	Meropenem-AFT

**➔ Restricted (RS1047)**

Clinical microbiologist or infectious disease specialist

**Cephalosporins and Cephamycins - 1st Generation**
**CEFALEXIN**

Cap 250 mg – <b>5% DV Apr-23 to 2025</b> .....	3.85	20	<b>Cephalexin ABM</b>
Cap 500 mg – <b>5% DV Apr-23 to 2025</b> .....	5.85	20	<b>Cephalexin ABM</b>
Grans for oral liq 25 mg per ml – <b>5% DV Jan-23 to 2025</b> .....	7.88	100 ml	<b>Flynn</b>
Grans for oral liq 50 mg per ml – <b>5% DV Jan-23 to 2025</b> .....	11.75	100 ml	Cefalexin Sandoz
	10.38		<b>Flynn</b>

**CEFAZOLIN**

Inj 500 mg vial – <b>5% DV Mar-24 to 2026</b> .....	3.39	5	<b>Cefazolin-AFT</b>
Inj 1 g vial – <b>5% DV Mar-24 to 2026</b> .....	3.59	5	<b>Cefazolin-AFT</b>
Inj 2 g vial – <b>5% DV Mar-24 to 2026</b> .....	7.09	5	<b>Cefazolin-AFT</b>

**Cephalosporins and Cephamycins - 2nd Generation**
**CEFACLOR**

Cap 250 mg – <b>5% DV Apr-23 to 2025</b> .....	25.85	100	<b>Ranbaxy-Cefaclor</b>
Grans for oral liq 25 mg per ml – <b>5% DV Apr-23 to 2025</b> .....	3.75	100 ml	<b>Ranbaxy-Cefaclor</b>

**CEFOXITIN**

Inj 1 g vial

**CEFUROXIME**

Tab 250 mg			
Inj 750 mg vial .....	8.59	10	Cefuroxime-AFT
Inj 1.5 g vial .....	13.69	10	Cefuroxime-AFT

**Cephalosporins and Cephamycins - 3rd Generation**
**CEFOTAXIME**

Inj 500 mg vial .....	1.90	1	Cefotaxime Sandoz
Inj 1 g vial – <b>5% DV Dec-23 to 2026</b> .....	38.98	10	<b>DBL Cefotaxime</b>

**CEFTAZIDIME – Restricted** see terms [below](#)

↓ Inj 1 g vial – <b>5% DV Dec-23 to 2026</b> .....	25.80	10	<b>Ceftazidime Kabi</b>
	2.69	1	Ceftazidime-AFT

*(Ceftazidime-AFT Inj 1 g vial to be delisted 1 December 2023)*
**➔ Restricted (RS1048)**

Clinical microbiologist, infectious disease specialist or respiratory specialist

**CEFTRIAXONE**

Inj 500 mg vial – <b>5% DV Apr-23 to 2025</b> .....	0.79	1	<b>Ceftriaxone-AFT</b>
Inj 1 g vial – <b>5% DV Apr-23 to 2025</b> .....	3.59	5	<b>Ceftriaxone-AFT</b>
Inj 2 g vial – <b>5% DV Aug-23 to 2025</b> .....	7.85	5	<b>Ceftriaxone-AFT</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Cephalosporins and Cephamycins - 4th Generation

CEFEPIME – **Restricted** see terms [below](#)

⚡ Inj 1 g vial – 5% DV Jan-22 to 2024	35.00	10	Cefepime Kabi
⚡ Inj 2 g vial – 5% DV Jan-22 to 2024	55.00	10	Cefepime Kabi

➔ **Restricted** (RS1049)

Clinical microbiologist or infectious disease specialist

## Cephalosporins and Cephamycins - 5th Generation

CEFTAROLINE FOSAMIL – **Restricted** see terms [below](#)

⚡ Inj 600 mg vial	1,834.25	10	Zinforo
-------------------	----------	----	---------

➔ **Restricted** (RS1446)

**Initiation – multi-resistant organism salvage therapy**

Clinical microbiologist or infectious disease specialist

Either:

- 1 for patients where alternative therapies have failed; or
- 2 for patients who have a contraindication or hypersensitivity to standard current therapies.

## Macrolides

AZITHROMYCIN – **Restricted** see terms [below](#)

⚡ Tab 250 mg			
⚡ Tab 500 mg – 1% DV Dec-21 to 2024	2.57	2	Zithromax
⚡ Grans for oral liq 200 mg per 5 ml (40 mg per ml)	16.97	15 ml	Zithromax

➔ **Restricted** (RS1598)

**Initiation – bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections**

Any of the following:

- 1 Patient has received a lung transplant, stem cell transplant or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome\*; or
- 2 Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome\*; or
- 3 Patient has cystic fibrosis and has chronic infection with *Pseudomonas aeruginosa* or *Pseudomonas* related gram negative organisms\*; or
- 4 Patient has an atypical *Mycobacterium* infection.

Note: Indications marked with \* are unapproved indications

**Initiation – non-cystic fibrosis bronchiectasis\***

Respiratory specialist or paediatrician

*Re-assessment required after 12 months*

All of the following:

- 1 For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis\*; and
- 2 Patient is aged 18 and under; and
- 3 Either:
  - 3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
  - 3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

Note: Indications marked with \* are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

**Continuation – non-cystic fibrosis bronchiectasis\***

Respiratory specialist or paediatrician

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
- 2 Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and
- 3 The patient will not receive more than a total of 24 months' azithromycin cumulative treatment (see note).

Note: Indications marked with \* are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

**Initiation – other indications**

*Re-assessment required after 5 days*

For any other condition.

**Continuation – other indications**

*Re-assessment required after 5 days*

For any other condition.

CLARITHROMYCIN – **Restricted** see terms [below](#)

↓ Tab 250 mg – 1% DV Feb-22 to 2024 .....	8.53	14	<b>Klacid</b>
↓ Tab 500 mg – 1% DV Feb-22 to 2024 .....	14.58	14	<b>Klacid</b>
↓ Grans for oral liq 50 mg per ml .....	192.00	50 ml	Klacid
↓ Inj 500 mg vial .....	9.87	1	Martindale

➔ **Restricted (RS1709)**

**Initiation – Tab 250 mg and oral liquid**

Any of the following:

- 1 Atypical mycobacterial infection; or
- 2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or
- 3 Helicobacter pylori eradication; or
- 4 Prophylaxis of infective endocarditis associated with surgical or dental procedures if amoxicillin is contra-indicated.

**Initiation – Tab 500 mg**

Helicobacter pylori eradication.

**Initiation – Infusion**

Any of the following:

- 1 Atypical mycobacterial infection; or
- 2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or
- 3 Community-acquired pneumonia.

ERYTHROMYCIN (AS ETHYLSUCCINATE)

Tab 400 mg .....	16.95	100	E-Mycin
Grans for oral liq 200 mg per 5 ml .....	5.00	100 ml	E-Mycin
Grans for oral liq 400 mg per 5 ml .....	6.77	100 ml	E-Mycin

ERYTHROMYCIN (AS LACTOBIONATE)

Inj 1 g vial – 5% DV Dec-22 to 2025 .....	10.00	1	<b>Erythrocin IV</b>
---	-------	---	----------------------

ERYTHROMYCIN (AS STEARATE) – **Restricted:** For continuation only

➔ Tab 250 mg

➔ Tab 500 mg

ROXITHROMYCIN – **Some items restricted** see terms [on the next page](#)

↓ Tab dispersible 50 mg			
Tab 150 mg – 5% DV Aug-23 to 2026 .....	13.19	50	<b>Arrow-Roxithromycin</b>
Tab 300 mg – 5% DV Aug-23 to 2026 .....	25.00	50	<b>Arrow-Roxithromycin</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔ Restricted (RS1569)</b>			
<b>Initiation</b>			
Only for use in patients under 12 years of age.			
<b>Penicillins</b>			
<b>AMOXICILLIN</b>			
Cap 250 mg.....	43.45	500	Alphamox
Cap 500 mg.....	66.44	500	Alphamox
Grans for oral liq 125 mg per 5 ml – 5% DV Feb-24 to 2026.....	2.22	100 ml	<b>Alphamox 125</b>
Grans for oral liq 250 mg per 5 ml – 5% DV Feb-24 to 2026.....	2.81	100 ml	<b>Alphamox 250</b>
Inj 250 mg vial.....	15.97	10	Ibiamox
Inj 500 mg vial.....	17.43	10	Ibiamox
Inj 1 g vial.....	21.64	10	Ibiamox
<b>AMOXICILLIN WITH CLAVULANIC ACID</b>			
Tab 500 mg with clavulanic acid 125 mg – 5% DV Feb-24 to 2026.....	1.59	10	<b>Curam Duo 500/125</b>
Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml.....	6.50	100 ml	Augmentin
Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml.....	2.20	100 ml	Curam
Inj 500 mg with clavulanic acid 100 mg vial – 5% DV Dec-21 to 2024.....	17.50	10	<b>Amoxiclav multichem</b>
Inj 1,000 mg with clavulanic acid 200 mg vial – 5% DV Dec-21 to 2024.....	26.90	10	<b>Amoxiclav multichem</b>
<b>BENZATHINE BENZYL PENICILLIN</b>			
Inj 900 mg (1.2 million units) in 2.3 ml syringe.....	375.97	10	Bicillin LA
<b>BENZYL PENICILLIN SODIUM [PENICILLIN G]</b>			
Inj 600 mg (1 million units) vial – 5% DV Feb-24 to 2026.....	16.50	10	<b>Sandoz</b>
<b>FLUCLOXACILLIN</b>			
Cap 250 mg – 5% DV May-22 to 2024.....	15.79	250	<b>Flucloxacillin-AFT</b>
Cap 500 mg – 5% DV May-22 to 2024.....	52.99	500	<b>Flucloxacillin-AFT</b>
Grans for oral liq 25 mg per ml – 5% DV Jan-22 to 2024.....	3.29	100 ml	<b>AFT</b>
Grans for oral liq 50 mg per ml – 5% DV Jan-22 to 2024.....	3.68	100 ml	<b>AFT</b>
Inj 250 mg vial.....	17.56	10	Flucloxin
Inj 500 mg vial.....	18.78	10	Flucloxin
Inj 1 g vial – 5% DV Feb-24 to 2026.....	6.00	5	<b>Flucil</b>
<b>PHENOXYMETHYL PENICILLIN [PENICILLIN V]</b>			
Cap 250 mg – 5% DV Jan-22 to 2024.....	3.84	50	<b>Cilicaine VK</b>
Cap 500 mg – 5% DV Jan-22 to 2024.....	6.86	50	<b>Cilicaine VK</b>
Grans for oral liq 125 mg per 5 ml – 5% DV Jan-23 to 2025.....	3.40	100 ml	<b>AFT</b>
Grans for oral liq 250 mg per 5 ml – 5% DV Jan-23 to 2025.....	4.24	100 ml	<b>AFT</b>
<b>PIPERACILLIN WITH TAZOBACTAM – Restricted see terms below</b>			
⚠ Inj 4 g with tazobactam 0.5 g vial – 5% DV Feb-23 to 2025.....	3.59	1	<b>PipTaz-AFT</b>
<b>➔ Restricted (RS1053)</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
<b>PROCAINE PENICILLIN</b>			
Inj 1.5 g in 3.4 ml syringe			
<b>TICARCILLIN WITH CLAVULANIC ACID – Restricted see terms below</b>			
⚠ Inj 3 g with clavulanic acid 0.1 mg vial			
<b>➔ Restricted (RS1054)</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Quinolones</b>			
CIPROFLOXACIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 250 mg .....	2.42	28	Cipflox
↓ Tab 500 mg .....	3.40	28	Cipflox
↓ Tab 750 mg .....	5.95	28	Cipflox
↓ Oral liq 50 mg per ml			
↓ Oral liq 100 mg per ml			
↓ Inj 2 mg per ml, 100 ml bag			
↓ Inj 2 mg per ml, 100 ml bottle .....	125.00	10	Ciprofloxacin Kabi
→ <b>Restricted (RS1055)</b>			
Clinical microbiologist or infectious disease specialist			
MOXIFLOXACIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 400 mg .....	42.00	5	Avelox
↓ Inj 1.6 mg per ml, 250 ml bottle – <b>5% DV Feb-24 to 2026</b> .....	39.00	1	<b>Moxifloxacin Kabi</b>
	413.40	10	<b>Moxifloxacin Kabi</b>
<i>(Moxifloxacin Kabi Inj 1.6 mg per ml, 250 ml bottle to be delisted 1 February 2024)</i>			
→ <b>Restricted (RS1644)</b>			
<b>Initiation – Mycobacterium infection</b>			
Infectious disease specialist, clinical microbiologist or respiratory specialist			
Any of the following:			
1 Both:			
1.1 Active tuberculosis; and			
1.2 Any of the following:			
1.2.1 Documented resistance to one or more first-line medications; or			
1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or			
1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or			
1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or			
1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications;			
or			
2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated; or			
3 Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.			
<b>Initiation – Pneumonia</b>			
Infectious disease specialist or clinical microbiologist			
Either:			
1 Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or			
2 Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.			
<b>Initiation – Penetrating eye injury</b>			
Ophthalmologist			
Five days treatment for patients requiring prophylaxis following a penetrating eye injury.			
<b>Initiation – Mycoplasma genitalium</b>			
All of the following:			
1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium and is symptomatic; and			
2 Either:			
2.1 Has tried and failed to clear infection using azithromycin; or			
2.2 Has laboratory confirmed azithromycin resistance; and			
3 Treatment is only for 7 days.			
NORFLOXACIN			
Tab 400 mg .....	245.00	100	Arrow-Norfloxacin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Tetracyclines</b>			
DEMECLOCYCLINE HYDROCHLORIDE			
Tab 150 mg			
Cap 150 mg			
Cap 300 mg			
DOXYCYCLINE			
➔ Tab 50 mg – <b>Restricted:</b> For continuation only			
Tab 100 mg .....	64.43	500	Doxine
Inj 5 mg per ml, 20 ml vial			
MINOCYCLINE			
Tab 50 mg			
➔ Cap 100 mg – <b>Restricted:</b> For continuation only			
TETRACYCLINE			
Tab 250 mg .....	58.20	28	Accord
Cap 500 mg			
TIGECYCLINE – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 50 mg vial			
➔ <b>Restricted (RS1059)</b>			
Clinical microbiologist or infectious disease specialist			
<b>Other Antibacterials</b>			
AZTREONAM – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 1 g vial .....	364.92	10	Azactam
➔ <b>Restricted (RS1277)</b>			
Clinical microbiologist or infectious disease specialist			
CHLORAMPHENICOL – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 1 g vial			
➔ <b>Restricted (RS1277)</b>			
Clinical microbiologist or infectious disease specialist			
CLINDAMYCIN – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Cap 150 mg .....	5.30	24	Dalacin C
⚡ Oral liq 15 mg per ml			
⚡ Inj 150 mg per ml, 4 ml ampoule – 5% DV Aug-23 to 2025 .....	35.10	10	Hameln
➔ <b>Restricted (RS1061)</b>			
Clinical microbiologist or infectious disease specialist			
COLISTIN SULPHOMETHATE [COLESTIMETHATE] – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 150 mg per ml, 1 ml vial.....	65.00	1	Colistin-Link
➔ <b>Restricted (RS1062)</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
DAPTOMYCIN – <b>Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 500 mg vial – 5% DV Jan-24 to 2025 .....	243.52	1	Cubicin
	115.36		<b>Daptomycin Dr Reddy's</b>
<i>(Cubicin Inj 500 mg vial to be delisted 1 January 2024)</i>			
➔ <b>Restricted (RS1063)</b>			
Clinical microbiologist or infectious disease specialist			
FOSFOMYCIN – <b>Restricted</b> see terms <a href="#">on the next page</a>			
⚡ Powder for oral solution, 3 g sachet			<i>e.g. UroFos</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔ <b>Restricted (RS1315)</b>			
Clinical microbiologist or infectious disease specialist			
LINCOMYCIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 300 mg per ml, 2 ml vial			
➔ <b>Restricted (RS1065)</b>			
Clinical microbiologist or infectious disease specialist			
LINEZOLID – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 600 mg – <b>5% DV Dec-21 to 2024</b> .....	276.89	10	<b>Zyvox</b>
↓ Oral liq 20 mg per ml .....	1,879.00	150 ml	Zyvox
↓ Inj 2 mg per ml, 300 ml bottle – <b>5% DV Dec-21 to 2024</b> .....	155.00	10	<b>Linezolid Kabi</b>
➔ <b>Restricted (RS1066)</b>			
Clinical microbiologist or infectious disease specialist			
METHENAMINE (HEXAMINE) HIPPURATE			
Tab 1 g – <b>5% DV Feb-23 to 2025</b> .....	19.95	100	<b>Hiprex</b>
NITROFURANTOIN			
Tab 50 mg – <b>5% DV Dec-22 to 2024</b> .....	22.20	100	<b>Nifuran</b>
Tab 100 mg – <b>5% DV Dec-22 to 2024</b> .....	37.50	100	<b>Nifuran</b>
Cap modified-release 100 mg – <b>5% DV Dec-23 to 2026</b> .....	81.20	100	<b>Macrobid</b>
PIVMECILLINAM – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 200 mg			
➔ <b>Restricted (RS1322)</b>			
Clinical microbiologist or infectious disease specialist			
SODIUM FUSIDATE [FUSIDIC ACID] – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 250 mg .....	135.70	36	Fucidin
➔ <b>Restricted (RS1064)</b>			
Clinical microbiologist or infectious disease specialist			
SULPHADIAZINE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 500 mg			
➔ <b>Restricted (RS1067)</b>			
Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist			
TEICOPLANIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 400 mg vial – <b>5% DV Jun-22 to 2024</b> .....	49.95	1	<b>Targocid</b>
➔ <b>Restricted (RS1068)</b>			
Clinical microbiologist or infectious disease specialist			
TRIMETHOPRIM			
Tab 100 mg			
Tab 300 mg – <b>5% DV Jan-22 to 2024</b> .....	18.55	50	<b>TMP</b>
TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]			
Tab 80 mg with sulphamethoxazole 400 mg – <b>5% DV Jan-22 to 2024</b> .....	64.80	500	<b>Trisul</b>
Oral liq 8 mg with sulphamethoxazole 40 mg per ml .....	2.97	100 ml	Deprim
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule			
VANCOMYCIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 500 mg vial – <b>5% DV Feb-24 to 2026</b> .....	3.38	1	<b>Mylan</b>
➔ <b>Restricted (RS1069)</b>			
Clinical microbiologist or infectious disease specialist			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Antifungals

### Imidazoles

#### KETOCONAZOLE

↓ Tab 200 mg

→ **Restricted (RS1410)**

Oncologist

### Polyene Antimycotics

#### AMPHOTERICIN B

↓ Inj (liposomal) 50 mg vial.....	3,450.00	10	AmBisome
-----------------------------------	----------	----	----------

→ **Restricted (RS1071)**

#### Initiation

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

Either:

- 1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
- 2 Both:
  - 2.1 Possible invasive fungal infection; and
  - 2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

↓ Inj 50 mg vial

→ **Restricted (RS1316)**

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

#### NYSTATIN

Tab 500,000 u .....	17.09	50	Nilstat
Cap 500,000 u .....	15.47	50	Nilstat

### Triazoles

#### FLUCONAZOLE – **Restricted** see terms [below](#)

↓ Cap 50 mg – <b>5% DV Dec-23 to 2026</b> .....	4.10	28	<b>Mylan</b>
↓ Cap 150 mg – <b>5% DV Dec-23 to 2026</b> .....	0.45	1	<b>Mylan</b>
↓ Cap 200 mg – <b>5% DV Dec-23 to 2026</b> .....	8.90	28	<b>Mylan</b>
↓ Oral liquid 50 mg per 5 ml .....	129.02	35 ml	Diflucan
↓ Inj 2 mg per ml, 50 ml vial.....	3.11	1	Fluconazole-Baxter
↓ Inj 2 mg per ml, 100 ml vial.....	3.83	1	Fluconazole-Baxter

→ **Restricted (RS1072)**

Consultant

#### ITRACONAZOLE – **Restricted** see terms [below](#)

↓ Cap 100 mg.....	6.83	15	Itrazole
↓ Oral liquid 10 mg per ml			

→ **Restricted (RS1073)**

Clinical immunologist, clinical microbiologist, dermatologist or infectious disease specialist

#### POSACONAZOLE – **Restricted** see terms [on the next page](#)

↓ Tab modified-release 100 mg – <b>5% DV Apr-23 to 2025</b> .....	206.00	24	<b>Posaconazole Juno</b>
↓ Oral liq 40 mg per ml – <b>5% DV May-23 to 2025</b> .....	342.51	105 ml	<b>Devatis</b>



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted (RS1074)**

**Initiation**

Haematologist or infectious disease specialist

*Re-assessment required after 6 weeks*

Both:

- 1 Either:
  - 1.1 Patient has acute myeloid leukaemia; or
  - 1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and
- 2 Patient is to be treated with high dose remission induction therapy or re-induction therapy.

**Continuation**

Haematologist or infectious disease specialist

*Re-assessment required after 6 weeks*

Both:

- 1 Patient has previously received posaconazole prophylaxis during remission induction therapy; and
- 2 Any of the following:
  - 2.1 Patient is to be treated with high dose remission re-induction therapy; or
  - 2.2 Patient is to be treated with high dose consolidation therapy; or
  - 2.3 Patient is receiving a high risk stem cell transplant.

VORICONAZOLE – **Restricted** see terms [below](#)

↓ Tab 50 mg .....	91.00	56	Vttack
↓ Tab 200 mg .....	350.00	56	Vttack
↓ Powder for oral suspension 40 mg per ml .....	1,523.22	70 ml	Vfend
↓ Inj 200 mg vial – <b>5% DV Aug-23 to 2025</b> .....	19.85	1	<b>AFT</b>

➔ **Restricted (RS1075)**

**Initiation – Proven or probable aspergillus infection**

Clinical microbiologist, haematologist or infectious disease specialist

Both:

- 1 Patient is immunocompromised; and
- 2 Patient has proven or probable invasive aspergillus infection.

**Initiation – Possible aspergillus infection**

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient has possible invasive aspergillus infection; and
- 3 A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

**Initiation – Resistant candidiasis infections and other moulds**

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

- 1 Patient is immunocompromised; and
- 2 Either:
  - 2.1 Patient has fluconazole resistant candidiasis; or
  - 2.2 Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp; and
- 3 A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.

**Other Antifungals**

CASPOFUNGIN – **Restricted** see terms [on the next page](#)

↓ Inj 50 mg vial – <b>5% DV Apr-23 to 2025</b> .....	110.00	1	<b>Alchemy Caspofungin</b>
↓ Inj 70 mg vial – <b>5% DV Apr-23 to 2025</b> .....	135.00	1	<b>Alchemy Caspofungin</b>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted (RS1076)**

**Initiation**

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist  
Either:

- 1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
- 2 Both:
  - 2.1 Possible invasive fungal infection; and
  - 2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

FLUCYTOSINE – **Restricted** see terms [below](#)

⚡ Tab 500 mg

⚡ Cap 500 mg

➔ **Restricted (RS1279)**

Clinical microbiologist or infectious disease specialist

TERBINAFINE

Tab 250 mg – 5% DV Feb-24 to 2026 .....	8.97	84	Deolate
---	------	----	---------

## Antimycobacterials

### Antileprotics

CLOFAZIMINE – **Restricted** see terms [below](#)

⚡ Cap 50 mg

➔ **Restricted (RS1077)**

Clinical microbiologist, dermatologist or infectious disease specialist

DAPSONE – **Restricted** see terms [below](#)

⚡ Tab 25 mg .....	268.50	100	Dapsone
-------------------	--------	-----	---------

⚡ Tab 100 mg .....	329.50	100	Dapsone
--------------------	--------	-----	---------

➔ **Restricted (RS1078)**

Clinical microbiologist, dermatologist or infectious disease specialist

### Antituberculotics

BEDAQUILINE – **Restricted** see terms [below](#)

⚡ Tab 100 mg .....	3,084.51	24	Sirturo
--------------------	----------	----	---------

	24,162.00	188	Sirturo
--	-----------	-----	---------

➔ **Restricted (RS1977)**

**Initiation – multi-drug resistant tuberculosis**

*Limited to 6 months treatment*

- Both:
- 1 The person has multi-drug resistant tuberculosis (MDR-TB); and
  - 2 Manatū Hauora - Ministry of Health's Tuberculosis Clinical Network has reviewed the individual case and recommends bedaquiline as part of the treatment regimen.

CYCLOSERINE – **Restricted** see terms [below](#)

⚡ Cap 250 mg

➔ **Restricted (RS1079)**

Clinical microbiologist, infectious disease specialist or respiratory specialist

ETHAMBUTOL HYDROCHLORIDE – **Restricted** see terms [on the next page](#)

⚡ Tab 100 mg

⚡ Tab 400 mg .....	49.34	56	Myambutol
--------------------	-------	----	-----------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔ Restricted (RS1080)</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
ISONIAZID – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 100 mg – 5% DV Jan-22 to 2024 .....	23.00	100	<b>PSM</b>
<b>➔ Restricted (RS1281)</b>			
Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician			
ISONIAZID WITH RIFAMPICIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 100 mg with rifampicin 150 mg.....	89.82	100	Rifinah
↓ Tab 150 mg with rifampicin 300 mg – 5% DV Jan-22 to 2024.....	179.13	100	<b>Rifinah</b>
<b>➔ Restricted (RS1282)</b>			
Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician			
PARA-AMINOSALICYLIC ACID – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Grans for oral liq 4 g.....	280.00	30	Paser
<b>➔ Restricted (RS1083)</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
PROTIONAMIDE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 250 mg .....	305.00	100	Peteha
<b>➔ Restricted (RS1084)</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
PYRAZINAMIDE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 500 mg			
<b>➔ Restricted (RS1085)</b>			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
RIFABUTIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Cap 150 mg.....	353.71	30	Mycobutin
<b>➔ Restricted (RS1086)</b>			
Clinical microbiologist, gastroenterologist, infectious disease specialist or respiratory specialist			
RIFAMPICIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Cap 150 mg – 5% DV Dec-23 to 2026.....	58.54	100	<b>Rifadin</b>
↓ Cap 300 mg – 5% DV Dec-23 to 2026.....	122.06	100	<b>Rifadin</b>
↓ Oral liq 100 mg per 5 ml – 5% DV Dec-23 to 2026.....	12.60	60 ml	<b>Rifadin</b>
↓ Inj 600 mg vial – 5% DV Dec-23 to 2026.....	134.98	1	<b>Rifadin</b>
<b>➔ Restricted (RS1087)</b>			
Clinical microbiologist, dermatologist, internal medicine physician, paediatrician or public health physician			

## Antiparasitics

### Anthelmintics

<b>ALBENDAZOLE – Restricted</b> see terms <a href="#">below</a>			
↓ Tab 200 mg			
↓ Tab 400 mg			
<b>➔ Restricted (RS1088)</b>			
Clinical microbiologist or infectious disease specialist			
IVERMECTIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 3 mg.....	17.20	4	Stromectol
<b>➔ Restricted (RS1283)</b>			
Clinical microbiologist, dermatologist or infectious disease specialist			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>MEBENDAZOLE</b>			
Tab 100 mg – 5% DV Jan-22 to 2024 .....	7.97	6	<b>Vermox</b>
Oral liq 100 mg per 5 ml			
<b>PRAZIQUANTEL</b>			
Tab 600 mg			
<b>Antiprotozoals</b>			
<b>ARTEMETHER WITH LUMEFANTRINE – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 20 mg with lumefantrine 120 mg			
➡ <b>Restricted (RS1090)</b>			
Clinical microbiologist or infectious disease specialist			
<b>ARTESUNATE – Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 60 mg vial			
➡ <b>Restricted (RS1091)</b>			
Clinical microbiologist or infectious disease specialist			
<b>ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 62.5 mg with proguanil hydrochloride 25 mg.....	25.00	12	Malarone Junior
⚡ Tab 250 mg with proguanil hydrochloride 100 mg.....	64.00	12	Malarone
➡ <b>Restricted (RS1092)</b>			
Clinical microbiologist or infectious disease specialist			
<b>CHLOROQUINE PHOSPHATE – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 250 mg			
➡ <b>Restricted (RS1093)</b>			
Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist			
<b>MEFLOQUINE – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 250 mg			
➡ <b>Restricted (RS1094)</b>			
Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist			
<b>METRONIDAZOLE</b>			
Tab 200 mg .....	33.15	250	Metrogyl
Tab 400 mg .....	5.23	21	Metrogyl
Oral liq benzoate 200 mg per 5 ml .....	25.00	100 ml	Flagyl-S
Inj 5 mg per ml, 100 ml bag – 5% DV Dec-23 to 2026.....	18.00	10	<b>Baxter</b>
Suppos 500 mg .....	24.48	10	Flagyl
<b>NITAZOXANIDE – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 500 mg .....	1,680.00	30	Alinia
⚡ Oral liq 100 mg per 5 ml			
➡ <b>Restricted (RS1095)</b>			
Clinical microbiologist or infectious disease specialist			
<b>ORNIDAZOLE</b>			
Tab 500 mg – 5% DV Dec-21 to 2024 .....	36.16	10	<b>Arrow-Ornidazole</b>
<b>PENTAMIDINE ISETHIONATE – Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 300 mg vial .....	216.00	5	Pentacarinat
➡ <b>Restricted (RS1096)</b>			
Clinical microbiologist or infectious disease specialist			
<b>PRIMAQUINE – Restricted</b> see terms <a href="#">on the next page</a>			
⚡ Tab 15 mg			
⚡ Tab 7.5 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔ <b>Restricted (RS1097)</b> Clinical microbiologist or infectious disease specialist			
PYRIMETHAMINE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 25 mg			
➔ <b>Restricted (RS1098)</b> Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist			
QUININE DIHYDROCHLORIDE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 60 mg per ml, 10 ml ampoule			
↓ Inj 300 mg per ml, 2 ml vial			
➔ <b>Restricted (RS1099)</b> Clinical microbiologist or infectious disease specialist			
SODIUM STIBOGLUCONATE – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Inj 100 mg per ml, 1 ml vial			
➔ <b>Restricted (RS1100)</b> Clinical microbiologist or infectious disease specialist			
SPIRAMYCIN – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Tab 500 mg			
➔ <b>Restricted (RS1101)</b> Maternal-foetal medicine specialist			

## Antiretrovirals

### Non-Nucleoside Reverse Transcriptase Inhibitors

#### ➔ **Restricted (RS1898)**

##### **Initiation – Confirmed HIV**

Patient has confirmed HIV infection.

##### **Initiation – Prevention of maternal transmission**

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

##### **Initiation – Post-exposure prophylaxis following exposure to HIV**

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
  - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashm.org.au/hiv/hiv-management/pep/>).

##### **Initiation – Percutaneous exposure**

Patient has percutaneous exposure to blood known to be HIV positive.

##### EFAVIRENZ – **Restricted** see terms [above](#)

↑ Tab 200 mg .....	190.15	90	Stocrin
↑ Tab 600 mg .....	63.38	30	Stocrin
↑ Oral liq 30 mg per ml			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ETRAVIRINE – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 200 mg .....	770.00	60	Intelence
NEVIRAPINE – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 200 mg – 5% DV Jan-22 to 2024 .....	84.00	60	<b>Nevirapine Alphapharm</b> Nevirapine Viatrix
† Oral suspension 10 mg per ml.....	203.55	240 ml	Viramune Suspension

## Nucleoside Reverse Transcriptase Inhibitors

➔ **Restricted (RS1899)**

### Initiation – Confirmed HIV

Patient has confirmed HIV infection.

### Initiation – Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

### Initiation – Post-exposure prophylaxis following exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
  - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashm.org.au/hiv/hiv-management/pep/>).

### Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

ABACAVIR SULPHATE – **Restricted** see terms [above](#)

† Tab 300 mg .....	180.00	60	Ziagen
† Oral liq 20 mg per ml .....	256.31	240 ml	Ziagen

ABACAVIR SULPHATE WITH LAMIVUDINE – **Restricted** see terms [above](#)

† Tab 600 mg with lamivudine 300 mg – 5% DV May-23 to 2025 .....	29.50	30	<b>Abacavir/lamivudine</b> Viatrix
--	-------	----	---------------------------------------

EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL – **Restricted** see terms [above](#)

† Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate).....	106.88	30	Mylan Viatrix
--	--------	----	------------------

(Mylan Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) to be delisted 1 December 2023)

EMTRICITABINE – **Restricted** see terms [above](#)

† Cap 200 mg .....	307.20	30	Emtriva
--------------------	--------	----	---------

LAMIVUDINE – **Restricted** see terms [above](#)

† Tab 150 mg – 5% DV Feb-24 to 2026 .....	84.50	60	Lamivudine Alphapharm
	98.00		<b>Lamivudine Viatrix</b>

† Oral liq 10 mg per ml

(Lamivudine Alphapharm Tab 150 mg to be delisted 1 November 2023)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>STAVUDINE – Restricted</b> see terms <a href="#">on the previous page</a>			
† Cap 30 mg			
† Cap 40 mg			
† Powder for oral soln 1 mg per ml			
<b>ZIDOVUDINE [AZT] – Restricted</b> see terms <a href="#">on the previous page</a>			
† Cap 100 mg	152.25	100	Retrovir
† Oral liq 10 mg per ml	30.45	200 ml	Retrovir
† Inj 10 mg per ml, 20 ml vial	750.00	5	Retrovir IV
<b>ZIDOVUDINE [AZT] WITH LAMIVUDINE – Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 300 mg with lamivudine 150 mg	92.40	60	Alphapharm Lamivudine/Zidovudine Viatrix

## Protease Inhibitors

### → Restricted (RS1900)

#### Initiation – Confirmed HIV

Patient has confirmed HIV infection.

#### Initiation – Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

#### Initiation – Post-exposure prophylaxis following exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
  - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashm.org.au/hiv/hiv-management/pep/>).

#### Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

#### ATAZANAVIR SULPHATE – Restricted

 see terms [above](#)

† Cap 150 mg – <b>5% DV May-23 to 2025</b>	85.00	60	<b>Atazanavir Mylan</b>
† Cap 200 mg – <b>5% DV May-23 to 2025</b>	110.00	60	<b>Atazanavir Mylan</b>

#### DARUNAVIR – Restricted

 see terms [above](#)

† Tab 400 mg – <b>5% DV Feb-24 to 2026</b>	132.00	60	Darunavir Mylan
	150.00		<b>Darunavir Viatrix</b>
† Tab 600 mg – <b>5% DV Feb-24 to 2026</b>	225.00	60	<b>Darunavir Viatrix</b>

(Darunavir Mylan Tab 400 mg to be delisted 1 January 2024)

#### INDINAVIR – Restricted

 see terms [above](#)

- † Cap 200 mg
- † Cap 400 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>LOPINAVIR WITH RITONAVIR – Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 100 mg with ritonavir 25 mg – 5% DV Feb-22 to 2024 .....	150.00	60	<b>Lopinavir/Ritonavir Mylan</b>
† Tab 200 mg with ritonavir 50 mg – 5% DV Feb-22 to 2024 .....	295.00	120	<b>Lopinavir/Ritonavir Mylan</b>
<b>RITONAVIR – Restricted</b> see terms <a href="#">on the previous page</a>			
† Tab 100 mg .....	43.31	30	Norvir

## Strand Transfer Inhibitors

### ➔ Restricted (RS1901)

#### Initiation – Confirmed HIV

Patient has confirmed HIV infection.

#### Initiation – Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

#### Initiation – Post-exposure prophylaxis following exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
  - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashm.org.au/hiv/hiv-management/pep/>).

#### Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

#### DOLUTEGRAVIR – Restricted

 see terms [above](#)

† Tab 50 mg .....	1,090.00	30	Tivicay
-------------------	----------	----	---------

#### RALTEGRAVIR POTASSIUM – Restricted

 see terms [above](#)

† Tab 400 mg .....	1,090.00	60	ISENTRESS
† Tab 600 mg .....	1,090.00	60	ISENTRESS HD

## Antivirals

### Hepatitis B

<b>ENTECAVIR</b>			
Tab 0.5 mg – 5% DV Mar-24 to 2026 .....	12.04	30	<b>Entecavir (Rex)</b>
	52.00		Entecavir Sandoz

(Entecavir Sandoz Tab 0.5 mg to be delisted 1 March 2024)

#### LAMIVUDINE

Tab 100 mg – 5% DV Feb-24 to 2026 .....	12.06	28	<b>Zetlam</b>
Oral liq 5 mg per ml .....	270.00	240 ml	Zeffix



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>TENOFOVIR DISOPROXIL</b>			
Tab 245 mg (300 mg as a maleate) – <b>5% DV Sep-23 to 2025</b> .....	15.00	30	Tenofovir Disoproxil Mylan <b>Tenofovir Disoproxil Viatriis</b>

(Tenofovir Disoproxil Mylan Tab 245 mg (300 mg as a maleate) to be delisted 1 February 2024)

## Hepatitis C

### GLECAPREVIR WITH PIBRENTASVIR

Note: the supply of treatment is via Pharmac's approved direct distribution supply. Further details can be found on Pharmac's website <https://www.pharmac.govt.nz/maviret>.

Tab 100 mg with pibrentasvir 40 mg .....	24,750.00	84	Maviret
--	-----------	----	---------

### LEDIPASVIR WITH SOFOSBUVIR – **Restricted** see terms [below](#)

↓ Tab 90 mg with sofosbuvir 400 mg .....	24,363.46	28	Harvoni
--	-----------	----	---------

→ **Restricted (RS1528)**

Note: Only for use in patients with approval by the Hepatitis C Treatment Panel (HepCTP). Applications will be considered by HepCTP at its regular meetings and approved subject to eligibility according to the Access Criteria (set out in Section B of the Pharmaceutical Schedule).

## Herpesviridae

### ACICLOVIR

Tab dispersible 200 mg – <b>5% DV Mar-23 to 2025</b> .....	1.78	25	<b>Lovir</b>
Tab dispersible 400 mg – <b>5% DV Apr-23 to 2025</b> .....	5.81	56	<b>Lovir</b>
Tab dispersible 800 mg – <b>5% DV Apr-23 to 2025</b> .....	6.46	35	<b>Lovir</b>
Inj 250 mg vial – <b>5% DV Jan-22 to 2024</b> .....	10.00	5	<b>Aciclovir-Baxter</b>

### CIDOFOVIR – **Restricted** see terms [below](#)

↓ Inj 75 mg per ml, 5 ml vial			
-------------------------------	--	--	--

→ **Restricted (RS1108)**

Clinical microbiologist, infectious disease specialist, otolaryngologist or oral surgeon

### FOSCARNET SODIUM – **Restricted** see terms [below](#)

↓ Inj 24 mg per ml, 250 ml bottle			
-----------------------------------	--	--	--

→ **Restricted (RS1109)**

Clinical microbiologist or infectious disease specialist

### GANCICLOVIR – **Restricted** see terms [below](#)

↓ Inj 500 mg vial .....	380.00	5	Cymevene
-------------------------	--------	---	----------

→ **Restricted (RS1110)**

Clinical microbiologist or infectious disease specialist

### VALACICLOVIR

Tab 500 mg – <b>5% DV Jan-22 to 2024</b> .....	6.50	30	<b>Vaconvir</b>
Tab 1,000 mg – <b>5% DV Jan-22 to 2024</b> .....	13.76	30	<b>Vaconvir</b>

### VALGANCICLOVIR – **Restricted** see terms [below](#)

↓ Tab 450 mg – <b>5% DV Sep-23 to 2024</b> .....	132.00	60	Valganciclovir Mylan <b>Valganciclovir Viatriis</b>
--	--------	----	--

(Valganciclovir Mylan Tab 450 mg to be delisted 1 February 2024)

→ **Restricted (RS1799)**

### Initiation – Transplant cytomegalovirus prophylaxis

Re-assessment required after 3 months

Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Continuation – Transplant cytomegalovirus prophylaxis

*Re-assessment required after 3 months*

Either:

- 1 Both:
  - 1.1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
  - 1.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or
- 2 Both:
  - 2.1 Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy for CMV prophylaxis; and
  - 2.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone.

## Initiation – Lung transplant cytomegalovirus prophylaxis

Relevant specialist

*Limited to 12 months treatment*

All of the following:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
  - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
  - 2.2 The recipient is cytomegalovirus positive; and
- 3 Patient has a high risk of CMV disease.

## Initiation – Cytomegalovirus in immunocompromised patients

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
  - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
  - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
  - 2.3 Patient has cytomegalovirus retinitis.

## HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL – **Restricted** see terms [below](#)

↓ Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) – <b>5% DV Jun-23 to 2025</b> .....	15.45	30	Tenofovir Disoproxil Emtricitabine Mylan <b>Tenofovir Disoproxil          Emtricitabine Viatr</b>
--	-------	----	---

*(Tenofovir Disoproxil Emtricitabine Mylan Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) to be delisted 1 November 2023)*

➔ **Restricted (RS1902)**

### Initiation – Confirmed HIV

Patient has confirmed HIV infection.

### Initiation – Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

### Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
  - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
  - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
  - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation – Percutaneous exposure**

Patient has percutaneous exposure to blood known to be HIV positive.

**Initiation – Pre-exposure prophylaxis**

*Re-assessment required after 24 months*

Both:

- 1 Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion; and
- 2 The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines (<https://ashm.org.au/HIV/PrEP/>)

**Continuation – Pre-exposure prophylaxis**

*Re-assessment required after 24 months*

Both:

- 1 Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion; and
- 2 The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines (<https://ashm.org.au/HIV/PrEP/>)

**Influenza**

**OSELTAMIVIR – Restricted** see terms [below](#)

Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

- ↓ Tab 75 mg
- ↓ Powder for oral suspension 6 mg per ml

➔ **Restricted (RS1307)**

**Initiation**

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a Te Whatu Ora Hospital approved infections control plan.

**ZANAMIVIR**

Note: The restriction on the use of zanamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

- ↓ Powder for inhalation 5 mg.....37.38 20 dose Relenza Rotadisk

➔ **Restricted (RS1369)**

**Initiation**

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a Te Whatu Ora Hospital approved infections control plan.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## COVID-19 Treatments

MOLNUIPIRAVIR – **Restricted** see terms [below](#)

⚡ Cap 200 mg.....0.00 40 Lagevrio

➔ **Restricted (RS1893)**

### Initiation

Only if patient meets access criteria (as per <https://pharmac.govt.nz/covid-oral-antivirals>). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability.

NIRMATRELVIR WITH RITONAVIR – **Restricted** see terms [below](#)

⚡ Tab 150 mg with ritonavir 100 mg.....0.00 30 Paxlovid

➔ **Restricted (RS1894)**

### Initiation

Only if patient meets access criteria (as per <https://pharmac.govt.nz/covid-oral-antivirals>). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability.

REMEDSIVIR – **Restricted** see terms [below](#)

Note: Remdesivir to be provided to Te Whatu Ora Hospitals at a cost of \$0.00 as stock has been purchased directly by Pharmac.

⚡ Inj 100 mg vial.....760.57 1 Veklury

➔ **Restricted (RS1912)**

### Initiation – Treatment of mild to moderate COVID-19

Only if patient meets access criteria (as per <https://pharmac.govt.nz/covid-oral-antivirals>). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability.

### Initiation – COVID-19 in hospitalised patients

*Therapy limited to 5 doses*

All of the following:

- 1 Patient is hospitalised with confirmed (or probable) symptomatic COVID-19; and
- 2 Patient is considered to be at high risk of progression to severe disease; and
- 3 Patient's symptoms started within the last 7 days; and
- 4 Patient does not require, or is not expected to require, mechanical ventilation; and
- 5 Not to be used in conjunction with other funded COVID-19 antiviral treatments; and
- 6 Treatment not to exceed five days.

## Immune Modulators

INTERFERON ALFA-2B

Inj 18 m iu, 1.2 ml multidose pen

Inj 30 m iu, 1.2 ml multidose pen

Inj 60 m iu, 1.2 ml multidose pen

INTERFERON GAMMA – **Restricted** see terms [below](#)

⚡ Inj 100 mcg in 0.5 ml vial

➔ **Restricted (RS1113)**

### Initiation

Patient has chronic granulomatous disease and requires interferon gamma.

PEGYLATED INTERFERON ALFA-2A – **Restricted** see terms [below](#)

⚡ Inj 180 mcg prefilled syringe.....500.00 4 Pegasys

➔ **Restricted (RS1827)**

**Initiation – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver**

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

**transplant**

*Limited to 48 weeks treatment*

Any of the following:

- 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
- 2 Patient has chronic hepatitis C and is co-infected with HIV; or
- 3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.

Notes: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

**Continuation – Chronic hepatitis C - genotype 1 infection**

Gastroenterologist, infectious disease specialist or general physician

*Re-assessment required after 48 weeks*

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:
  - 3.1 Patient has responder relapsed; or
  - 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir.

**Initiation – Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior**

Gastroenterologist, infectious disease specialist or general physician

*Limited to 48 weeks treatment*

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
  - 3.1 Patient has responder relapsed; or
  - 3.2 Patient was a partial responder; or
  - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir.

**Initiation – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV**

*Limited to 6 months treatment*

Patient has chronic hepatitis C, genotype 2 or 3 infection.

**Initiation – Hepatitis B**

Gastroenterologist, infectious disease specialist or general physician

*Limited to 48 weeks treatment*

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log<sub>10</sub> IU/ml; and
- 5 Either:
  - 5.1 HBeAg positive; or
  - 5.2 Serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (greater than or equal to Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon.

### **Initiation – myeloproliferative disorder or cutaneous T cell lymphoma**

*Re-assessment required after 12 months*

Any of the following:

- 1 Patient has a cutaneous T cell lymphoma\*; or
- 2 All of the following:
  - 2.1 Patient has a myeloproliferative disorder\*; and
  - 2.2 Patient is intolerant of hydroxyurea; and
  - 2.3 Treatment with anagrelide and busulfan is not clinically appropriate; or
- 3 Both:
  - 3.1 Patient has a myeloproliferative disorder; and
  - 3.2 Patient is pregnant, planning pregnancy or lactating.

### **Continuation – myeloproliferative disorder or cutaneous T cell lymphoma**

*Re-assessment required after 12 months*

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment; and
- 3 Either:
  - 3.1 Patient has a cutaneous T cell lymphoma\*; or
  - 3.2 Both:
    - 3.2.1 Patient has a myeloproliferative disorder\*; and
    - 3.2.2 Either:
      - 3.2.2.1 Remains intolerant of hydroxyurea and treatment with anagrelide and busulfan remains clinically inappropriate; or
      - 3.2.2.2 Patient is pregnant, planning pregnancy or lactating.

Note: Indications marked with \* are unapproved indications

### **Initiation – ocular surface squamous neoplasia**

Ophthalmologist

*Re-assessment required after 12 months*

Patient has ocular surface squamous neoplasia\*.

### **Continuation – ocular surface squamous neoplasia**

Ophthalmologist

*Re-assessment required after 12 months*

The treatment remains appropriate and patient is benefitting from treatment.

Note: Indications marked with \* are unapproved indications

### **Initiation – post-allogenic bone marrow transplant**

*Re-assessment required after 3 months*

Patient has received an allogenic bone marrow transplant\* and has evidence of disease relapse.

### **Continuation – post-allogenic bone marrow transplant**

*Re-assessment required after 3 months*

Patient is responding and ongoing treatment remains appropriate.

Note: Indications marked with \* are unapproved indications

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Anticholinesterases

EDROPHONIUM CHLORIDE – **Restricted** see terms [below](#)

↓ Inj 10 mg per ml, 15 ml vial

↓ Inj 10 mg per ml, 1 ml ampoule

➔ **Restricted (RS1015)**

#### Initiation

For the diagnosis of myasthenia gravis.

NEOSTIGMINE METILSULFATE

Inj 2.5 mg per ml, 1 ml ampoule – <b>5% DV Mar-22 to 2024</b> .....	33.81	10	<b>Max Health</b>
---	-------	----	-------------------

NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BROMIDE

Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule – <b>5% DV Dec-21 to 2024</b> .....	26.13	10	<b>Max Health</b>
---	-------	----	-------------------

PYRIDOSTIGMINE BROMIDE

Tab 60 mg .....	50.28	100	Mestinon
-----------------	-------	-----	----------

### Antirheumatoid Agents

HYDROXYCHLOROQUINE – **Restricted** see terms [below](#)

↓ Tab 200 mg .....	8.78	100	Plaquenil
--------------------	------	-----	-----------

➔ **Restricted (RS1776)**

#### Initiation

Any of the following:

- 1 Rheumatoid arthritis; or
- 2 Systemic or discoid lupus erythematosus; or
- 3 Malaria treatment or suppression; or
- 4 Relevant dermatological conditions (cutaneous forms of lupus and lichen planus, cutaneous vasculitides and mucosal ulceration); or
- 5 Sarcoidosis (pulmonary and non-pulmonary).

LEFLUNOMIDE

Tab 10 mg – <b>5% DV Dec-23 to 2026</b> .....	6.00	30	<b>Arava</b>
---	------	----	--------------

Tab 20 mg – <b>5% DV Dec-23 to 2026</b> .....	6.00	30	<b>Arava</b>
---	------	----	--------------

PENICILLAMINE

Tab 125 mg .....	67.23	100	D-Penaminate
------------------	-------	-----	--------------

Tab 250 mg .....	110.12	100	D-Penaminate
------------------	--------	-----	--------------

SODIUM AUROTHIOMALATE

Inj 10 mg in 0.5 ml ampoule

Inj 20 mg in 0.5 ml ampoule

Inj 50 mg in 0.5 ml ampoule

### Drugs Affecting Bone Metabolism

#### Bisphosphonates

ALENDRONATE SODIUM

Tab 70 mg .....	2.44	4	Fosamax
-----------------	------	---	---------

ALENDRONATE SODIUM WITH COLECALCIFEROL

Tab 70 mg with colecalciferol 5,600 iu .....	1.51	4	Fosamax Plus
--	------	---	--------------

# MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PAMIDRONATE DISODIUM</b>			
Inj 3 mg per ml, 10 ml vial.....	32.49	1	Pamisol
Inj 6 mg per ml, 10 ml vial.....	88.11	1	Pamisol
Inj 9 mg per ml, 10 ml vial.....	94.34	1	Pamisol
<b>RISEDRONATE SODIUM</b>			
Tab 35 mg – 5% DV Jun-23 to 2025 .....	2.50	4	<b>Risedronate Sandoz</b>
<b>ZOLEDRONIC ACID</b>			
Inj 5 mg per 100 ml, bag – 5% DV Jun-23 to 2025.....	22.53	100 ml	<b>Zoledronic Acid Viatrix</b>

## Other Drugs Affecting Bone Metabolism

DENOSUMAB – **Restricted** see terms [below](#)

↓ Inj 60 mg prefilled syringe.....326.00 1 Prolia

➔ **Restricted (RS1665)**

### Initiation

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 Either:
  - 2.1 The patient is female and postmenopausal; or
  - 2.2 The patient is male or non-binary; and
- 3 Any of the following:
  - 3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
  - 3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
  - 3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
  - 3.4 Documented T-Score less than or equal to -3.0 (see Note); or
  - 3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
  - 3.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 4 Zoledronic acid is contraindicated because the patient's creatinine clearance is less than 35 mL/min; and
- 5 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes); and
- 6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

continued...



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- e) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialed so that the patient achieves the minimum requirement of 12 months' continuous therapy.

**RALOXIFENE – Restricted** see terms [below](#)

↓ Tab 60 mg .....	53.76	28	Evista
-------------------	-------	----	--------

→ **Restricted (RS1666)**

**Initiation**

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score greater than or equal to -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

**TERIPARATIDE – Restricted** see terms [below](#)

↓ Inj 250 mcg per ml, 2.4 ml cartridge .....	490.00	1	Forteo
--	--------	---	--------

→ **Restricted (RS1143)**

**Initiation**

Limited to 18 months treatment

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and

continued...

# MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this restriction are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

## Enzymes

### HYALURONIDASE

Inj 1,500 iu ampoule

## Hyperuricaemia and Antigout

### ALLOPURINOL

Tab 100 mg .....	11.47	500	DP-Allopurinol
Tab 300 mg .....	28.57	500	DP-Allopurinol

### BENZBROMARONE – **Restricted:** For continuation only

➔ Tab 50 mg			
➔ Tab 100 mg .....	45.00	100	Benzbromaron AL 100

### COLCHICINE

Tab 500 mcg – <b>5% DV Sep-22 to 2025</b> .....	6.00	100	<b>Colgout</b>
---	------	-----	----------------

### FEBUXOSTAT – **Restricted** see terms [below](#)

⚡ Tab 80 mg .....	20.00	28	Febuxostat multichem
⚡ Tab 120 mg .....	20.00	28	Febuxostat multichem

➔ **Restricted (RS1844)**

### Initiation – Gout

Both:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
  - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
  - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
  - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); or
  - 2.4 The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

**Initiation – Tumour lysis syndrome**

Haematologist or oncologist

*Re-assessment required after 6 weeks*

Both:

- 1 Patient is scheduled to receive cancer therapy carrying an intermediate or high risk of tumour lysis syndrome; and
- 2 Patient has a documented history of allopurinol intolerance.

**Continuation – Tumour lysis syndrome**

Haematologist or oncologist

*Re-assessment required after 6 weeks*

The treatment remains appropriate and patient is benefitting from treatment.

**PROBENECID**

Tab 500 mg

**RASBURICASE – Restricted** see terms [below](#)

↓ Inj 1.5 mg vial

➔ **Restricted (RS1016)**

Haematologist

**Muscle Relaxants and Related Agents**

**ATRACURIUM BESYLATE**

Inj 10 mg per ml, 2.5 ml ampoule .....	10.00	5	Tracrium
Inj 10 mg per ml, 5 ml ampoule .....	12.50	5	Tracrium

**BACLOFEN**

Tab 10 mg .....	4.20	100	Pacifen
Oral liq 1 mg per ml			
Inj 0.05 mg per ml, 1 ml ampoule .....	11.55	1	Lioresal Intrathecal
Inj 2 mg per ml, 5 ml ampoule – <b>5% DV Dec-21 to 2024</b> .....	306.82	5	<b>Medsurge</b>

**CLOSTRIDIUM BOTULINUM TYPE A TOXIN**

Inj 100 u vial .....	467.50	1	Botox
Inj 300 u vial .....	388.50	1	Dysport
Inj 500 u vial .....	1,295.00	2	Dysport

**DANTROLENE**

Cap 25 mg .....	112.13	100	Dantrium
Cap 50 mg .....	77.00	100	Dantrium
Inj 20 mg vial .....	994.56	6	Dantrium IV

**MIVACURIUM CHLORIDE**

Inj 2 mg per ml, 10 ml ampoule

**ORPHENADRINE CITRATE**

Tab 100 mg – <b>5% DV Jan-22 to 2024</b> .....	20.76	100	<b>Norflex</b>
--	-------	-----	----------------

**PANCURONIUM BROMIDE**

Inj 2 mg per ml, 2 ml ampoule

**ROCURONIUM BROMIDE**

Inj 10 mg per ml, 5 ml ampoule – <b>5% DV Jan-23 to 2025</b> .....	37.06	10	<b>Hameln</b>
--	-------	----	---------------

**SUXAMETHONIUM CHLORIDE**

Inj 50 mg per ml, 2 ml ampoule – <b>5% DV Feb-24 to 2026</b> .....	35.40	10	<b>Martindale</b>
--	-------	----	-------------------

**VECURONIUM BROMIDE**

Inj 10 mg vial

# MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Reversers of Neuromuscular Blockade

SUGAMMADEX – **Restricted** see terms [below](#)

⚡ Inj 100 mg per ml, 2 ml vial – 5% DV Aug-22 to 2024.....	384.00	10	Sugammadex BNM
⚡ Inj 100 mg per ml, 5 ml vial – 5% DV Aug-22 to 2024.....	960.00	10	Sugammadex BNM

➔ **Restricted (RS1370)**

### Initiation

Any of the following:

- 1 Patient requires reversal of profound neuromuscular blockade following rapid sequence induction that has been undertaken using rocuronium (i.e. suxamethonium is contraindicated or undesirable); or
- 2 Severe neuromuscular degenerative disease where the use of neuromuscular blockade is required; or
- 3 Patient has an unexpectedly difficult airway that cannot be intubated and requires a rapid reversal of anaesthesia and neuromuscular blockade; or
- 4 The duration of the patient's surgery is unexpectedly short; or
- 5 Neostigmine or a neostigmine/anticholinergic combination is contraindicated (for example the patient has ischaemic heart disease, morbid obesity or COPD); or
- 6 Patient has a partial residual block after conventional reversal.

## Non-Steroidal Anti-Inflammatory Drugs

CELECOXIB

Cap 100 mg – 5% DV Nov-22 to 2025 .....	3.45	60	Celecoxib Pfizer
Cap 200 mg – 5% DV Nov-22 to 2025 .....	3.20	30	Celecoxib Pfizer

DICLOFENAC SODIUM

Tab EC 25 mg – 5% DV Jan-22 to 2024 .....	1.99	50	Diclofenac Sandoz
Tab 50 mg dispersible .....	1.50	20	Voltaren D
Tab EC 50 mg – 5% DV Jan-22 to 2024 .....	1.99	50	Diclofenac Sandoz
Tab long-acting 75 mg.....	19.60	100	Voltaren SR
Inj 25 mg per ml, 3 ml ampoule .....	13.20	5	Voltaren
Suppos 12.5 mg .....	2.04	10	Voltaren
Suppos 25 mg .....	2.44	10	Voltaren
Suppos 50 mg .....	4.22	10	Voltaren
Suppos 100 mg .....	7.00	10	Voltaren

ETORICOXIB – **Restricted** see terms [below](#)

- ⚡ Tab 30 mg
- ⚡ Tab 60 mg
- ⚡ Tab 90 mg
- ⚡ Tab 120 mg

➔ **Restricted (RS1592)**

### Initiation

For in-vivo investigation of allergy only.

IBUPROFEN

Tab 200 mg - 1,000 tablet pack – 1% DV Feb-21 to 2024.....	21.40	1,000	Relieve
Tab 200 mg - 20 tablet pack.....	1.35	20	Relieve
➔ Tab 400 mg – <b>Restricted:</b> For continuation only			
➔ Tab 600 mg – <b>Restricted:</b> For continuation only			
Tab long-acting 800 mg – 5% DV Jan-22 to 2024.....	3.05	30	Brufen SR
Oral liq 20 mg per ml – 5% DV Apr-22 to 2024 .....	2.25	200 ml	Ethics
Inj 5 mg per ml, 2 ml ampoule			
Inj 10 mg per ml, 2 ml vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>INDOMETACIN [INDOMETHACIN]</b>			
Cap 25 mg			
Cap 50 mg			
Cap long-acting 75 mg			
Inj 1 mg vial			
Suppos 100 mg			
<b>KETOPROFEN</b>			
Cap long-acting 200 mg .....	12.07	28	Oruvail SR
<b>MEFENAMIC ACID – Restricted:</b> For continuation only			
➔ Cap 250 mg			
<b>NAPROXEN</b>			
Tab 250 mg – 5% DV Jan-22 to 2024 .....	32.69	500	<b>Noflam 250</b>
Tab 500 mg – 5% DV Jan-22 to 2024 .....	28.71	250	<b>Noflam 500</b>
Tab long-acting 750 mg – 5% DV Jan-22 to 2024 .....	6.47	28	<b>Naprosyn SR 750</b>
Tab long-acting 1 g – 5% DV Jan-22 to 2024 .....	8.62	28	<b>Naprosyn SR 1000</b>
<b>PARECOXIB</b>			
Inj 40 mg vial .....	100.00	10	Dynastat
<b>SULINDAC</b>			
Tab 100 mg			
Tab 200 mg			
<b>TENOXICAM</b>			
Tab 20 mg – 5% DV Jan-23 to 2025 .....	18.50	100	<b>Tilcotil</b>
Inj 20 mg vial .....	9.95	1	<b>AFT</b>

**Topical Products for Joint and Muscular Pain**

CAPSAICIN – **Restricted** see terms [below](#)

⚠ Crm 0.025%.....9.75 45 g Zostrix

➔ **Restricted (RS1309)**

**Initiation**

Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Agents for Parkinsonism and Related Disorders

### Agents for Essential Tremor, Chorea and Related Disorders

RILUZOLE – **Restricted** see terms [below](#)

↓ Tab 50 mg – <b>5% DV Dec-21 to 2024</b> .....	130.00	56	<b>Rilutek</b>
→ <b>Restricted (RS1351)</b>			

#### Initiation

Neurologist or respiratory specialist

*Re-assessment required after 6 months*

All of the following:

- 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
  - 5.1 The patient is ambulatory; or
  - 5.2 The patient is able to use upper limbs; or
  - 5.3 The patient is able to swallow.

#### Continuation

*Re-assessment required after 18 months*

All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and
- 3 Any of the following:
  - 3.1 The patient is ambulatory; or
  - 3.2 The patient is able to use upper limbs; or
  - 3.3 The patient is able to swallow.

TETRABENAZINE

Tab 25 mg – <b>5% DV Apr-23 to 2025</b> .....	106.59	112	<b>Motetis</b>
---	--------	-----	----------------

### Anticholinergics

BENZATROPINE MESYLATE

Tab 2 mg .....	9.59	60	Benztrop
Inj 1 mg per ml, 2 ml ampoule .....	95.00	5	Phebra

PROCYCLIDINE HYDROCHLORIDE

Tab 5 mg

### Dopamine Agonists and Related Agents

AMANTADINE HYDROCHLORIDE

Cap 100 mg .....	38.24	60	Symmetrel
------------------	-------	----	-----------

APOMORPHINE HYDROCHLORIDE

Inj 10 mg per ml, 2 ml ampoule .....	59.50	5	Movapo
Inj 10 mg per ml, 5 ml ampoule .....	121.84	5	Movapo

BROMOCRIPTINE

Cap 5 mg

ENTACAPONE

Tab 200 mg – <b>5% DV Apr-22 to 2024</b> .....	18.04	100	<b>Comtan</b>
--	-------	-----	---------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>LEVODOPA WITH BENSERAZIDE</b>			
Tab dispersible 50 mg with benserazide 12.5 mg .....	13.25	100	Madopar Rapid
Cap 50 mg with benserazide 12.5 mg .....	13.75	100	Madopar 62.5
Cap 100 mg with benserazide 25 mg .....	15.80	100	Madopar 125
Cap long-acting 100 mg with benserazide 25 mg .....	22.85	100	Madopar HBS
Cap 200 mg with benserazide 50 mg .....	26.25	100	Madopar 250
<b>LEVODOPA WITH CARBIDOPA</b>			
Tab 100 mg with carbidopa 25 mg .....	21.11	100	Sinemet
Tab long-acting 100 mg with carbidopa 25 mg .....			
Tab long-acting 200 mg with carbidopa 50 mg .....	43.65	100	Sinemet CR
Tab 250 mg with carbidopa 25 mg .....	38.39	100	Sinemet
<b>PRAMIPEXOLE HYDROCHLORIDE</b>			
Tab 0.25 mg – <b>5% DV Dec-22 to 2025</b> .....	5.51	100	<b>Ramipex</b>
Tab 1 mg – <b>5% DV Dec-22 to 2025</b> .....	18.66	100	<b>Ramipex</b>
<b>RASAGILINE</b>			
Tab 1mg – <b>1% DV Jan-22 to 2024</b> .....	53.50	30	<b>Azilect</b>
<b>ROPINIROLE HYDROCHLORIDE</b>			
Tab 0.25 mg – <b>5% DV Jan-23 to 2025</b> .....	4.05	84	<b>Ropin</b>
Tab 1 mg – <b>5% DV Jan-23 to 2025</b> .....	4.95	84	<b>Ropin</b>
Tab 2 mg – <b>5% DV Jan-23 to 2025</b> .....	6.48	84	<b>Ropin</b>
Tab 5 mg – <b>5% DV Jan-23 to 2025</b> .....	14.50	84	<b>Ropin</b>
<b>SELEGILINE HYDROCHLORIDE – Restricted: For continuation only</b>			
➔ Tab 5 mg			
<b>TOLCAPONE</b>			
Tab 100 mg .....	152.38	100	Tasmar

**Anaesthetics**

**General Anaesthetics**

<b>DESFLURANE</b>			
Soln for inhalation 100%, 240 ml bottle .....	1,350.00	6	Suprane
<b>DEXMEDETOMIDINE</b>			
Inj 100 mcg per ml, 2 ml vial .....	97.88	5	Dexmedetomidine-Teva
<b>ETOMIDATE</b>			
Inj 2 mg per ml, 10 ml ampoule			
<b>ISOFLURANE</b>			
Soln for inhalation 100%, 250 ml bottle .....	2,730.00	6	Aerrane
<b>KETAMINE</b>			
Inj 1 mg per ml, 100 ml bag .....	135.00	5	Biomed
Inj 10 mg per ml, 10 ml syringe .....	70.00	5	Biomed
Inj 100 mg per ml, 2 ml vial .....	31.50	5	Ketalar
<b>METHOHEXITAL SODIUM</b>			
Inj 10 mg per ml, 50 ml vial			
<b>PROPOFOL</b>			
Inj 10 mg per ml, 20 ml ampoule – <b>5% DV Jan-23 to 2025</b> .....	4.35	5	<b>Fresofol 1% MCT/LCT</b>
Inj 10 mg per ml, 50 ml vial – <b>5% DV Jan-23 to 2025</b> .....	19.50	10	<b>Fresofol 1% MCT/LCT</b>
Inj 10 mg per ml, 100 ml vial – <b>5% DV Jan-23 to 2025</b> .....	39.00	10	<b>Fresofol 1% MCT/LCT</b>

## NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SEVOFLURANE			
Soln for inhalation 100%, 250 ml bottle .....	930.00	6	Baxter
THIOPENTAL [THIOPENTONE] SODIUM			
Inj 500 mg ampoule			
<b>Local Anaesthetics</b>			
ARTICAINE HYDROCHLORIDE			
Inj 1%			
ARTICAINE HYDROCHLORIDE WITH ADRENALINE			
Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge			
Inj 4% with adrenaline 1:100,000, 1.8 ml dental cartridge			
Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge			
Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge			
Inj 4% with adrenaline 1:200,000 1.8 ml dental cartridge			
Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge			
BENZOCAINE			
Gel 20%			
BENZOCAINE WITH TETRACAINE HYDROCHLORIDE			
Gel 18% with tetracaine hydrochloride 2%			<i>e.g. ZAP Topical Anaesthetic Gel</i>
BUPIVACAINE HYDROCHLORIDE			
Inj 5 mg per ml, 4 ml ampoule – <b>5% DV Feb-24 to 2026</b> .....	62.50	5	<b>Marcain Isobaric</b>
Inj 2.5 mg per ml, 20 ml ampoule			
Inj 2.5 mg per ml, 20 ml ampoule sterile pack – <b>5% DV Feb-24 to 2026</b> .....	28.00	5	<b>Marcain</b>
Inj 5 mg per ml, 10 ml ampoule sterile pack .....	16.20	5	Marcain
Inj 5 mg per ml, 20 ml ampoule			
Inj 5 mg per ml, 20 ml ampoule sterile pack .....	16.56	5	Marcain
Inj 1.25 mg per ml, 100 ml bag			
Inj 1.25 mg per ml, 200 ml bag			
Inj 2.5 mg per ml, 100 ml bag .....	150.00	5	Marcain
Inj 2.5 mg per ml, 200 ml bag			
Inj 1.25 mg per ml, 500 ml bag			
BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE			
Inj 2.5 mg per ml with adrenaline 1:200,000, 10 ml ampoule			
Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial .....	94.50	5	Marcain with Adrenaline
Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial .....	80.50	5	Marcain with Adrenaline
BUPIVACAINE HYDROCHLORIDE WITH FENTANYL			
Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag			
Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag .....	160.00	5	Biomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag – <b>5% DV Jan-23 to 2025</b> .....	122.50	5	<b>Bupafen</b>
Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag – <b>5% DV Jan-23 to 2025</b> .....	127.50	5	<b>Bupafen</b>
Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe .....	36.00	5	Biomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe .....	52.50	5	Biomed
BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE			
Inj 0.5% with glucose 8%, 4 ml ampoule – <b>5% DV Sep-22 to 2025</b> .....	26.67	5	<b>Marcain Heavy</b>



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>COCAINE HYDROCHLORIDE</b>			
Paste 5%			
Soln 15%, 2 ml syringe			
Soln 4%, 2 ml syringe.....	28.76	1	Biomed
<b>COCAINE HYDROCHLORIDE WITH ADRENALINE</b>			
Paste 15% with adrenaline 0.06%			
Paste 25% with adrenaline 0.06%			
<b>ETHYL CHLORIDE</b>			
Spray 100%			
<b>LIDOCAINE [LIGNOCAINE]</b>			
Crn 4%.....	5.40	5 g	LMX4
	27.00	30 g	LMX4
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE</b>			
Gel 2%.....	4.87	20 g	Orion
Soln 4%			
Spray 10% – <b>5% DV Jan-23 to 2025</b> .....	78.95	50 ml	<b>Xylocaine</b>
Oral (gel) soln 2%.....	44.00	200 ml	Mucosoothie
Inj 1%, 20 ml ampoule, sterile pack			
Inj 2%, 20 ml ampoule, sterile pack			
Inj 1%, 5 ml ampoule.....	9.50	25	Lidocaine-Baxter
Inj 1%, 20 ml vial.....	6.85	5	Lidocaine-Baxter
Inj 2%, 5 ml ampoule.....	9.00	25	Lidocaine-Baxter
Inj 2%, 20 ml vial.....	7.15	5	Lidocaine-Baxter
Gel 2%, 11 ml urethral syringe – <b>5% DV Jan-23 to 2025</b> .....	59.50	10	<b>Instillagel Lido</b>
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE</b>			
Inj 1% with adreanline 1:100,000, 20 ml vial			
Inj 1% with adrenaline 1:100,000, 5 ml ampoule – <b>5% DV Jan-23 to 2025</b> .....	32.00	10	<b>Xylocaine</b>
Inj 1% with adrenaline 1:200,000, 20 ml vial.....	50.00	5	Xylocaine
Inj 2% with adrenaline 1:100,000, 1.7 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge			
Inj 2% with adrenaline 1:200,000, 20 ml vial.....	60.00	5	Xylocaine
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE</b>			
Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe.....	18.75	1	Topicaine
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINE</b>			
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe.....	103.32	10	Pfizer
<i>(Pfizer Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe to be delisted 1 November 2023)</i>			
<b>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRINE HYDROCHLORIDE</b>			
Nasal spray 5% with phenylephrine hydrochloride 0.5%			
<b>LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE</b>			
Crn 2.5% with prilocaine 2.5%.....	45.00	30 g	EMLA
Patch 25 mcg with prilocaine 25 mcg.....	115.00	20	EMLA
Crn 2.5% with prilocaine 2.5%, 5 g.....	45.00	5	EMLA
<b>MEPIVACAINE HYDROCHLORIDE</b>			
Inj 3%, 1.8 ml dental cartridge.....	43.60	50	Scandonest 3%
Inj 3%, 2.2 ml dental cartridge.....	43.60	50	Scandonest 3%

## NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>MEPIVACAINE HYDROCHLORIDE WITH ADRENALINE</b>			
Inj 2% with adrenaline 1:100,000, 1.8 ml dental cartridge			
Inj 2% with adrenaline 1:100,000, 2.2 ml dental cartridge			
<b>PRILOCAINE HYDROCHLORIDE</b>			
Inj 0.5%, 50 ml vial .....	100.00	5	Citanest
Inj 2%, 5 ml ampoule			
<b>PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN</b>			
Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge			
Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge			
<b>ROPIVACAINE HYDROCHLORIDE</b>			
Inj 2 mg per ml, 10 ml ampoule – 5% DV Feb-24 to 2026 .....	9.80	5	Ropivacaine Kabi
Inj 2 mg per ml, 20 ml ampoule – 5% DV Feb-24 to 2026 .....	10.25	5	Ropivacaine Kabi
Inj 2 mg per ml, 100 ml bag – 5% DV Feb-24 to 2026 .....	32.85	5	Ropivacaine Kabi
Inj 2 mg per ml, 200 ml bag – 5% DV Feb-24 to 2026 .....	43.40	5	Ropivacaine Kabi
Inj 7.5 mg per ml, 10 ml ampoule – 5% DV Feb-24 to 2026 .....	11.00	5	Ropivacaine Kabi
Inj 7.5 mg per ml, 20 ml ampoule – 5% DV Feb-24 to 2026 .....	13.50	5	Ropivacaine Kabi
Inj 10 mg per ml, 10 ml ampoule – 5% DV Feb-24 to 2026 .....	11.75	5	Ropivacaine Kabi
Inj 10 mg per ml, 20 ml ampoule – 5% DV Feb-24 to 2026 .....	17.60	5	Ropivacaine Kabi
<b>ROPIVACAINE HYDROCHLORIDE WITH FENTANYL</b>			
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag .....	198.50	5	Naropin
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag .....	270.00	5	Naropin
<i>(Naropin Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag to be delisted 1 July 2024)</i>			
<i>(Naropin Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag to be delisted 1 July 2024)</i>			
<b>TETRACAINE [AMETHOCAINE] HYDROCHLORIDE</b>			
Gel 4%			

## Analgesics

### Non-Opioid Analgesics

<b>ASPIRIN</b>			
Tab dispersible 300 mg .....	4.50	100	Ethics Aspirin
<b>CAPSAICIN – Restricted</b> see terms <a href="#">below</a>			
⚡ Crm 0.075% .....	11.95	45 g	Zostrix HP
➔ <b>Restricted (RS1145)</b>			
<b>Initiation</b>			
For post-herpetic neuralgia or diabetic peripheral neuropathy.			
<b>METHOXYFLURANE – Restricted</b> see terms <a href="#">below</a>			
⚡ Soln for inhalation 99.9%, 3 ml bottle			
➔ <b>Restricted (RS1292)</b>			
<b>Initiation</b>			
Both:			
1 Patient is undergoing a painful procedure with an expected duration of less than one hour; and			
2 Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane.			
<b>NEFOPAM HYDROCHLORIDE</b>			
Tab 30 mg			

↑ Item restricted (see ➔ above); ⚡ Item restricted (see ➔ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PARACETAMOL – Some items restricted</b> see terms <a href="#">below</a>			
Tab soluble 500 mg			
Tab 500 mg - blister pack - 1,000 tablet pack – 1% DV Feb-22 to 2024	19.75	1,000	<b>Pacimol</b>
Tab 500 mg - blister pack - 12 tablet pack			
Tab 500 mg - blister pack - 20 tablet pack			
Tab 500 mg - bottle pack – 1% DV Feb-22 to 2024	17.92	1,000	<b>Noumed Paracetamol</b>
Oral liq 120 mg per 5 ml – 20% DV Jun-23 to 2025	10.50	200 ml	Avallon
	3.98		<b>Paracetamol (Ethics)</b>
Oral liq 250 mg per 5 ml – 20% DV Apr-23 to 2025	3.35	200 ml	<b>Pamol</b>
↓ Inj 10 mg per ml, 100 ml vial	8.90	10	Paracetamol Kabi
Suppos 25 mg			
Suppos 50 mg			
Suppos 125 mg – 5% DV Feb-24 to 2026	4.29	10	<b>Gacet</b>
Suppos 250 mg – 5% DV Feb-24 to 2026	5.39	10	<b>Gacet</b>
Suppos 500 mg – 5% DV Feb-24 to 2026	16.55	50	<b>Gacet</b>

→ **Restricted (RS1146)**

**Initiation**

Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours.

**SUCROSE**

Oral liq 25% ..... 13.00 25 ml Biomed

↓ Oral liq 66.7% (preservative free)

→ **Restricted (RS1763)**

**Initiation**

For use in neonatal patients only.

**Opioid Analgesics**

**ALFENTANIL**

Inj 0.5 mg per ml, 2 ml ampoule – 5% DV Feb-24 to 2026 ..... 24.75 10 Hameln  
8.99 5 **Medsurge**

*(Hameln Inj 0.5 mg per ml, 2 ml ampoule to be delisted 1 February 2024)*

**CODEINE PHOSPHATE**

Tab 15 mg – 5% DV May-23 to 2025 ..... 5.92 100 **Noumed**

Tab 30 mg – 5% DV Apr-23 to 2025 ..... 6.98 100 Aspen

Tab 60 mg – 5% DV Apr-23 to 2025 ..... 13.89 100 **Noumed**

Tab 60 mg – 5% DV Apr-23 to 2025 ..... 13.89 100 **Noumed**

**DIHYDROCODEINE TARTRATE**

Tab long-acting 60 mg – 5% DV Dec-22 to 2025 ..... 8.60 60 **DHC Continus**

# NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>FENTANYL</b>			
Inj 10 mcg per ml, 10 ml syringe			
Inj 50 mcg per ml, 2 ml ampoule – 5% DV Apr-22 to 2024	3.75	10	<b>Boucher and Muir</b>
Inj 10 mcg per ml, 50 ml bag	210.00	10	Biomed
Inj 10 mcg per ml, 50 ml syringe	165.00	10	Biomed
Inj 50 mcg per ml, 10 ml ampoule – 5% DV Apr-22 to 2024	9.41	10	<b>Boucher and Muir</b>
Inj 10 mcg per ml, 100 ml bag – 5% DV Feb-24 to 2026	114.25	5	<b>Biomed</b>
Inj 20 mcg per ml, 50 ml syringe	26.50	1	Biomed
Inj 20 mcg per ml, 100 ml bag			
Patch 12.5 mcg per hour – 5% DV Jan-22 to 2024	6.99	5	<b>Fentanyl Sandoz</b>
Patch 25 mcg per hour – 5% DV Jan-22 to 2024	7.99	5	<b>Fentanyl Sandoz</b>
Patch 50 mcg per hour – 5% DV Jan-22 to 2024	9.49	5	<b>Fentanyl Sandoz</b>
Patch 75 mcg per hour – 5% DV Jan-22 to 2024	17.99	5	<b>Fentanyl Sandoz</b>
Patch 100 mcg per hour – 5% DV Jan-22 to 2024	18.59	5	<b>Fentanyl Sandoz</b>
<b>METHADONE HYDROCHLORIDE</b>			
Tab 5 mg – 5% DV Feb-23 to 2025	1.45	10	<b>Methadone BNM</b>
Oral liq 2 mg per ml – 5% DV Jan-22 to 2024	6.40	200 ml	<b>Biodone</b>
Oral liq 5 mg per ml – 5% DV Jan-22 to 2024	6.40	200 ml	<b>Biodone Forte</b>
Oral liq 10 mg per ml – 5% DV Jan-22 to 2024	7.50	200 ml	<b>Biodone Extra Forte</b>
Inj 10 mg per ml, 1 ml vial	68.90	10	AFT
<b>MORPHINE HYDROCHLORIDE</b>			
Oral liq 1 mg per ml	11.98	200 ml	RA-Morph
Oral liq 2 mg per ml	16.24	200 ml	RA-Morph
Oral liq 5 mg per ml	19.44	200 ml	RA-Morph
Oral liq 10 mg per ml	27.74	200 ml	RA-Morph
<b>MORPHINE SULPHATE</b>			
Tab immediate-release 10 mg	2.80	10	Sevredol
Tab immediate-release 20 mg	5.52	10	Sevredol
Cap long-acting 10 mg – 5% DV Apr-23 to 2025	3.00	10	<b>m-Eslon</b>
Cap long-acting 30 mg – 5% DV Apr-23 to 2025	4.30	10	<b>m-Eslon</b>
Cap long-acting 60 mg – 5% DV Apr-23 to 2025	9.00	10	<b>m-Eslon</b>
Cap long-acting 100 mg – 5% DV Apr-23 to 2025	10.50	10	<b>m-Eslon</b>
Inj 1 mg per ml, 100 ml bag – 5% DV Feb-24 to 2026	114.25	5	<b>Biomed</b>
Inj 1 mg per ml, 10 ml syringe – 5% DV Feb-24 to 2026	27.25	5	<b>Biomed</b>
Inj 1 mg per ml, 50 ml syringe – 5% DV Feb-24 to 2026	63.75	5	<b>Biomed</b>
Inj 1 mg per ml, 2 ml syringe			
Inj 2 mg per ml, 30 ml syringe	135.00	10	Biomed
Inj 5 mg per ml, 1 ml ampoule – 5% DV Mar-23 to 2025	5.38	5	<b>Medsurge</b>
Inj 10 mg per ml, 1 ml ampoule – 5% DV Mar-23 to 2025	4.68	5	<b>Medsurge</b>
Inj 10 mg per ml, 100 mg cassette			
Inj 10 mg per ml, 100 ml bag			
Inj 15 mg per ml, 1 ml ampoule – 5% DV Mar-23 to 2025	5.53	5	<b>Medsurge</b>
Inj 30 mg per ml, 1 ml ampoule – 5% DV Mar-23 to 2025	6.28	5	<b>Medsurge</b>
Inj 200 mcg in 0.4 ml syringe			
Inj 300 mcg in 0.3 ml syringe			
<b>MORPHINE TARTRATE</b>			
Inj 80 mg per ml, 1.5 ml ampoule			

↑ Item restricted (see → above); ↓ Item restricted (see → below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>OXYCODONE HYDROCHLORIDE</b>			
Tab controlled-release 5 mg – <b>5% DV Jun-22 to 2024</b> .....	2.69	20	<b>Oxycodone Sandoz</b>
Tab controlled-release 10 mg – <b>5% DV Jun-22 to 2024</b> .....	2.69	20	<b>Oxycodone Sandoz</b>
Tab controlled-release 20 mg – <b>5% DV Jun-22 to 2024</b> .....	3.49	20	<b>Oxycodone Sandoz</b>
Tab controlled-release 40 mg – <b>5% DV Jun-22 to 2024</b> .....	5.49	20	<b>Oxycodone Sandoz</b>
Tab controlled-release 80 mg – <b>5% DV Jun-22 to 2024</b> .....	12.99	20	<b>Oxycodone Sandoz</b>
Cap immediate-release 5 mg – <b>5% DV Dec-21 to 2024</b> .....	1.88	20	<b>OxyNorm</b>
Cap immediate-release 10 mg – <b>5% DV Dec-21 to 2024</b> .....	3.32	20	<b>OxyNorm</b>
Cap immediate-release 20 mg – <b>5% DV Dec-21 to 2024</b> .....	5.23	20	<b>OxyNorm</b>
Oral liq 5 mg per 5 ml – <b>5% DV Sep-21 to 2024</b> .....	11.20	250 ml	<b>OxyNorm</b>
Inj 1 mg per ml, 100 ml bag			
Inj 10 mg per ml, 1 ml ampoule – <b>5% DV Jul-22 to 2024</b> .....	5.82	5	<b>Hameln</b>
Inj 10 mg per ml, 2 ml ampoule – <b>5% DV Jul-22 to 2024</b> .....	11.49	5	<b>Hameln</b>
Inj 50 mg per ml, 1 ml ampoule – <b>5% DV Jul-22 to 2024</b> .....	22.92	5	<b>Hameln</b>
<b>PARACETAMOL WITH CODEINE</b>			
Tab paracetamol 500 mg with codeine phosphate 8 mg – <b>5% DV Jan-23 to 2025</b> .....	27.50	1,000	<b>Paracetamol + Codeine (Relieve)</b>
<b>PETHIDINE HYDROCHLORIDE</b>			
Tab 50 mg – <b>5% DV Aug-23 to 2025</b> .....	8.68	10	<b>Noumed Pethidine</b>
Inj 5 mg per ml, 10 ml syringe			
Inj 5 mg per ml, 100 ml bag			
Inj 10 mg per ml, 100 ml bag			
Inj 10 mg per ml, 50 ml syringe			
Inj 50 mg per ml, 1 ml ampoule .....	29.88	5	<b>DBL Pethidine Hydrochloride</b>
Inj 50 mg per ml, 2 ml ampoule .....	30.72	5	<b>DBL Pethidine Hydrochloride</b>
<b>REMIFENTANIL</b>			
Inj 1 mg vial – <b>5% DV Feb-24 to 2026</b> .....	14.95	5	<b>Remifentanil-AFT</b>
Inj 2 mg vial – <b>5% DV Feb-24 to 2026</b> .....	20.95	5	<b>Remifentanil-AFT</b>
<b>TRAMADOL HYDROCHLORIDE</b>			
Tab sustained-release 100 mg .....	1.95	20	<b>Tramal SR 100</b>
Tab sustained-release 150 mg .....	2.95	20	<b>Tramal SR 150</b>
Tab sustained-release 200 mg .....	3.80	20	<b>Tramal SR 200</b>
Cap 50 mg – <b>5% DV Jan-24 to 2026</b> .....	3.33	100	<b>Arrow-Tramadol</b>
Oral soln 10 mg per ml			
Inj 10 mg per ml, 100 ml bag			
Inj 50 mg per ml, 1 ml ampoule .....	10.00	5	<b>Tramal 50</b>
Inj 50 mg per ml, 2 ml ampoule .....	9.00	5	<b>Tramal 100</b>

**Antidepressants**

**Cyclic and Related Agents**

<b>AMITRIPTYLINE</b>			
Tab 10 mg – <b>5% DV Mar-24 to 2026</b> .....	2.99	100	<b>Arrow-Amitriptyline</b>
Tab 25 mg – <b>5% DV Mar-24 to 2026</b> .....	1.99	100	<b>Arrow-Amitriptyline</b>
Tab 50 mg – <b>5% DV Mar-24 to 2026</b> .....	3.14	100	<b>Arrow-Amitriptyline</b>
<b>CLOMIPRAMINE HYDROCHLORIDE</b>			
Tab 10 mg – <b>1% DV Feb-22 to 2024</b> .....	10.17	30	<b>Clomipramine Teva</b>
Tab 25 mg – <b>1% DV Feb-22 to 2024</b> .....	11.99	30	<b>Clomipramine Teva</b>

Products with Hospital Supply Status (HSS) are in **bold**  
 Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

## NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Restricted:</b> For continuation only			
➔ Tab 75 mg .....	3.85	30	Dosulepin Viatris
➔ Cap 25 mg .....	7.83	50	Dosulepin Mylan Dosulepin Viatris
<b>DOXEPIN HYDROCHLORIDE – Restricted:</b> For continuation only			
➔ Cap 10 mg			
➔ Cap 25 mg			
➔ Cap 50 mg			
<b>IMIPRAMINE HYDROCHLORIDE</b>			
Tab 10 mg .....	5.48	50	Tofranil
	6.58	60	Tofranil
Tab 25 mg .....	8.80	50	Tofranil
<b>MAPROTIline HYDROCHLORIDE – Restricted:</b> For continuation only			
➔ Tab 25 mg			
➔ Tab 75 mg			
<b>MIANSERIN HYDROCHLORIDE – Restricted:</b> For continuation only			
➔ Tab 30 mg			
<b>NORTRIPTYLINE HYDROCHLORIDE</b>			
Tab 10 mg – 5% DV May-23 to 2025 .....	2.46	100	<b>Norpress</b>
Tab 25 mg – 5% DV May-23 to 2025 .....	6.29	180	<b>Norpress</b>
<b>Monoamine-Oxidase Inhibitors - Non-Selective</b>			
<b>PHENELZINE SULPHATE</b>			
Tab 15 mg			
<b>TRANLYCYPROMINE SULPHATE</b>			
Tab 10 mg			
<b>Monoamine-Oxidase Type A Inhibitors</b>			
<b>MOCLOBEMIDE</b>			
Tab 150 mg – 5% DV Jan-22 to 2024 .....	11.80	60	<b>Aurorix</b>
Tab 300 mg – 5% DV Jan-22 to 2024 .....	19.25	60	<b>Aurorix</b>
<b>Other Antidepressants</b>			
<b>MIRTAZAPINE</b>			
Tab 30 mg – 1% DV Jan-22 to 2024 .....	2.60	28	<b>Noumed</b>
Tab 45 mg – 1% DV Jan-22 to 2024 .....	3.45	28	<b>Noumed</b>
<b>VENLAFAXINE</b>			
Cap 37.5 mg .....	8.29	84	Enlafax XR
Cap 75 mg .....	10.32	84	Enlafax XR
Cap 150 mg .....	13.95	84	Enlafax XR
<b>Selective Serotonin Reuptake Inhibitors</b>			
<b>CITALOPRAM HYDROBROMIDE</b>			
Tab 20 mg – 5% DV Mar-23 to 2025 .....	2.86	84	<b>Celapram</b>
<b>ESCITALOPRAM</b>			
Tab 10 mg .....	1.07	28	Escitalopram (Ethics)
Tab 20 mg .....	1.92	28	Escitalopram (Ethics)

↑ Item restricted (see ➔ above); ↓ Item restricted (see ➔ below)  
e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>FLUOXETINE HYDROCHLORIDE</b>			
Tab dispersible 20 mg, scored – 5% DV Feb-23 to 2025 .....	2.50	28	<b>Fluox</b>
Cap 20 mg – 5% DV Jun-23 to 2025 .....	3.13	90	<b>Arrow-Fluoxetine</b>
<b>PAROXETINE</b>			
Tab 20 mg – 5% DV Jan-23 to 2025 .....	4.11	90	<b>Loxamine</b>
<b>SERTRALINE</b>			
Tab 50 mg – 5% DV Apr-23 to 2025 .....	0.99	30	<b>Setrona</b>
Tab 100 mg – 5% DV Apr-23 to 2025 .....	1.74	30	<b>Setrona</b>

**Antiepilepsy Drugs**

**Agents for the Control of Status Epilepticus**

<b>CLONAZEPAM</b>			
Inj 1 mg per ml, 1 ml ampoule			
<b>DIAZEPAM</b>			
Inj 5 mg per ml, 2 ml ampoule .....	27.92	5	Hospira
Rectal tubes 5 mg – 5% DV Feb-23 to 2025 .....	54.58	5	<b>Stesolid</b>
Rectal tubes 10 mg			
<b>LORAZEPAM</b>			
Inj 2 mg vial			
Inj 4 mg per ml, 1 ml vial			
<b>PARALDEHYDE</b>			
Soln 97%			
Inj 5 ml ampoule			
<b>PHENYTOIN SODIUM</b>			
Inj 50 mg per ml, 2 ml ampoule .....	104.58	5	Hospira
Inj 50 mg per ml, 5 ml ampoule .....	154.01	5	Hospira

**Control of Epilepsy**

<b>CARBAMAZEPINE</b>			
Tab 200 mg .....	14.53	100	Tegretol
Tab long-acting 200 mg .....	16.98	100	Tegretol CR
Tab 400 mg .....	34.58	100	Tegretol
Tab long-acting 400 mg .....	39.17	100	Tegretol CR
Oral liq 20 mg per ml .....	26.37	250 ml	Tegretol
<b>CLOBAZAM</b>			
Tab 10 mg			
<b>CLONAZEPAM</b>			
Oral drops 2.5 mg per ml			
<b>ETHOSUXIMIDE</b>			
Cap 250 mg .....	140.88	100	Zarontin
Oral liq 50 mg per ml .....	56.35	200 ml	Zarontin
<b>GABAPENTIN</b>			
Note: Gabapentin not to be given in combination with pregabalin			
Cap 100 mg – 1% DV Feb-22 to 2024 .....	6.45	100	<b>Nupentin</b>
Cap 300 mg – 1% DV Feb-22 to 2024 .....	8.45	100	<b>Nupentin</b>
Cap 400 mg – 1% DV Feb-22 to 2024 .....	10.26	100	<b>Nupentin</b>

# NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>LACOSAMIDE – Restricted</b> see terms <a href="#">below</a>			
↓ Tab 50 mg .....	25.04	14	Vimpat
↓ Tab 100 mg .....	50.06	14	Vimpat
	200.24	56	Vimpat
↓ Tab 150 mg .....	75.10	14	Vimpat
	300.40	56	Vimpat
↓ Tab 200 mg .....	400.55	56	Vimpat
↓ Inj 10 mg per ml, 20 ml vial			
→ <b>Restricted (RS1988)</b>			
<b>Initiation</b>			
<i>Re-assessment required after 15 months</i>			
Both:			
1 Patient has focal epilepsy; and			
2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam, and any two of carbamazepine, lamotrigine, and phenytoin sodium (see Note).			
Note: Those of childbearing potential are not required to trial phenytoin sodium, sodium valproate, or topiramate. Those who can father children are not required to trial sodium valproate.			
<b>Continuation</b>			
Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment.			
<b>LAMOTRIGINE</b>			
Tab dispersible 2 mg .....	55.00	30	Lamictal
Tab dispersible 5 mg .....	50.00	30	Lamictal
Tab dispersible 25 mg .....	4.20	56	Logem
Tab dispersible 50 mg .....	5.11	56	Logem
Tab dispersible 100 mg .....	6.75	56	Logem
<b>LEVETIRACETAM</b>			
Tab 250 mg .....	5.84	60	Everet
Tab 500 mg .....	10.51	60	Everet
Tab 750 mg .....	16.71	60	Everet
Tab 1,000 mg .....	21.82	60	Everet
Oral liq 100 mg per ml .....	44.78	300 ml	Levetiracetam-AFT
Inj 100 mg per ml, 5 ml vial .....	38.95	10	Levetiracetam-AFT
<b>PHENOBARBITONE</b>			
Tab 15 mg .....	40.00	500	PSM
Tab 30 mg – <b>5% DV Dec-23 to 2025</b> .....	398.50	500	<b>Noumed</b>
			<b>Phenobarbitone</b>
	40.00		PSM
<i>(PSM Tab 30 mg to be delisted 1 December 2023)</i>			
<b>PHENYTOIN</b>			
Tab 50 mg .....			
<b>PHENYTOIN SODIUM</b>			
Cap 30 mg .....			
Cap 100 mg .....			
Oral liq 6 mg per ml .....			



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PREGABALIN</b>			
Note: Pregabalin not to be given in combination with gabapentin			
Cap 25 mg.....	2.25	56	Pregabalin Pfizer
Cap 75 mg.....	2.65	56	Pregabalin Pfizer
Cap 150 mg.....	4.01	56	Pregabalin Pfizer
Cap 300 mg.....	7.38	56	Pregabalin Pfizer
<b>PRIMIDONE</b>			
Tab 250 mg			
<b>SODIUM VALPROATE</b>			
Tab 100 mg			
Tab EC 200 mg			
Tab EC 500 mg			
Oral liq 40 mg per ml			
Inj 100 mg per ml, 4 ml vial.....	9.98	1	Epilim IV
<b>STIRIPENTOL – Restricted see terms <a href="#">below</a></b>			
↓ Cap 250 mg.....	509.29	60	Diacomit
↓ Powder for oral liq 250 mg sachet.....	509.29	60	Diacomit
<b>→ Restricted (RS1989)</b>			
<b>Initiation</b>			
Paediatric neurologist			
<i>Re-assessment required after 6 months</i>			
Both:			
1 Patient has confirmed diagnosis of Dravet syndrome; and			
2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.			
Note: Those of childbearing potential are not required to trial sodium valproate or topiramate. Those who can father children are not required to trial sodium valproate.			
<b>Continuation</b>			
Paediatric neurologist			
Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.			
<b>TOPIRAMATE</b>			
Tab 25 mg.....	11.07	60	Arrow-Topiramate
	26.04		Topamax
	11.07		Topiramate Actavis
Tab 50 mg.....	18.81	60	Arrow-Topiramate
	44.26		Topamax
	18.81		Topiramate Actavis
Tab 100 mg.....	31.99	60	Arrow-Topiramate
	75.25		Topamax
	31.99		Topiramate Actavis
Tab 200 mg.....	55.19	60	Arrow-Topiramate
	129.85		Topamax
	55.19		Topiramate Actavis
Cap sprinkle 15 mg.....	20.84	60	Topamax
Cap sprinkle 25 mg.....	26.04	60	Topamax
<b>VIGABATRIN – Restricted see terms <a href="#">on the next page</a></b>			
↓ Tab 500 mg			
↓ Powder for oral soln 500 mg per sachet.....	71.58	60	Sabril

# NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## ➔ Restricted (RS1865)

### Initiation

Re-assessment required after 15 months

Both:

- 1 Any of the following:
  - 1.1 Patient has infantile spasms; or
  - 1.2 Both:
    - 1.2.1 Patient has epilepsy; and
    - 1.2.2 Either:
      - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
      - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; or
  - 1.3 Patient has tuberous sclerosis complex; and
- 2 Either:
  - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
  - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

### Continuation

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
- 2 Either:
  - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
  - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

## Antimigraine Preparations

### Acute Migraine Treatment

#### DIHYDROERGOTAMINE MESYLATE

Inj 1 mg per ml, 1 ml ampoule

#### METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL

Tab 5 mg with paracetamol 500 mg

#### RIZATRIPTAN

Tab orodispersible 10 mg – 5% DV Feb-24 to 2026 ..... 4.84      30      Rizamelt

#### SUMATRIPTAN

Tab 50 mg – 1% DV Feb-22 to 2024 ..... 14.41      90      Sumagran

Tab 100 mg – 1% DV Feb-22 to 2024 ..... 22.68      90      Sumagran

Inj 12 mg per ml, 0.5 ml prefilled pen ..... 34.00      2      Imigran

### Prophylaxis of Migraine

#### PIZOTIFEN

Tab 500 mcg ..... 23.21      100      Sandomigran

## Antinausea and Vertigo Agents

APREPITANT – Restricted see terms [on the next page](#)

⚡ Cap 2 × 80 mg and 1 × 125 mg – 5% DV Dec-21 to 2024 ..... 30.00      3      Emend Tri-Pack

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔ Restricted (RS1154)</b>			
<b>Initiation</b>			
Patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.			
<b>BETAHISTINE DIHYDROCHLORIDE</b>			
Tab 16 mg – 5% DV Dec-23 to 2026 .....	3.70	100	<b>Serc</b>
<b>CYCLIZINE HYDROCHLORIDE</b>			
Tab 50 mg – 5% DV Dec-21 to 2024 .....	0.49	10	<b>Nausicalm</b>
<b>CYCLIZINE LACTATE</b>			
Inj 50 mg per ml, 1 ml ampoule – 5% DV Dec-22 to 2025 .....	16.36	10	<b>Hameln</b>
<b>DOMPERIDONE</b>			
Tab 10 mg – 5% DV Jun-23 to 2025 .....	4.00	100	<b>Domperidone Viatris</b>
<b>DROPERIDOL</b>			
Inj 2.5 mg per ml, 1 ml ampoule – 5% DV Mar-23 to 2025 .....	43.85	10	<b>Droperidol Panpharma</b>
<b>GRANISETRON</b>			
Inj 1 mg per ml, 3 ml ampoule – 5% DV Feb-24 to 2026 .....	1.20	1	<b>Deva</b>
<b>HYOSCINE HYDROBROMIDE</b>			
Inj 400 mcg per ml, 1 ml ampoule			
↓ Patch 1.5 mg .....	17.70	2	<b>Scopoderm TTS</b>
<b>➔ Restricted (RS1155)</b>			
<b>Initiation</b>			
Any of the following:			
1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or			
2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective; or			
3 For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT3 antagonist have proven ineffective, are not tolerated or are contraindicated.			
<b>METOCLOPRAMIDE HYDROCHLORIDE</b>			
Tab 10 mg – 5% DV Mar-24 to 2026 .....	1.57	100	<b>Metoclopramide Actavis 10</b>
Oral liq 5 mg per 5 ml			
Inj 5 mg per ml, 2 ml ampoule – 5% DV Dec-22 to 2025 .....	7.00	10	<b>Baxter</b>
<b>ONDANSETRON</b>			
Tab 4 mg – 5% DV Aug-23 to 2025 .....	2.27	50	<b>Periset</b>
Tab dispersible 4 mg – 5% DV Mar-24 to 2026 .....	0.76	10	<b>Ondansetron ODT-DRLA Periset ODT</b>
	0.56		
Tab 8 mg – 5% DV Aug-23 to 2025 .....	4.10	50	<b>Periset</b>
Tab dispersible 8 mg – 5% DV Mar-24 to 2026 .....	1.13	10	<b>Ondansetron ODT-DRLA Periset ODT</b>
	0.90		
Inj 2 mg per ml, 2 ml ampoule – 5% DV Mar-23 to 2025 .....	1.42	5	<b>Ondansetron-AFT</b>
Inj 2 mg per ml, 4 ml ampoule – 5% DV Mar-23 to 2025 .....	2.20	5	<b>Ondansetron Kabi Ondansetron-AFT</b>
	1.89		

*(Ondansetron ODT-DRLA Tab dispersible 4 mg to be delisted 1 March 2024)*

*(Ondansetron ODT-DRLA Tab dispersible 8 mg to be delisted 1 March 2024)*

# NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PROCHLORPERAZINE</b>			
Tab buccal 3 mg			
Tab 5 mg – 5% DV Mar-24 to 2026	25.00	250	<b>Nausafix</b>
Inj 12.5 mg per ml, 1 ml ampoule			
Suppos 25 mg			
<b>TROPISETRON</b>			
Inj 1 mg per ml, 2 ml ampoule			
Inj 1 mg per ml, 5 ml ampoule			
<b>Antipsychotic Agents</b>			
<b>General</b>			
<b>AMISULPRIDE</b>			
Tab 100 mg	7.21	30	Sulprix
Tab 200 mg	20.94	60	Sulprix
Tab 400 mg	38.71	60	Sulprix
Oral liq 100 mg per ml			
<b>ARIPIPRAZOLE</b>			
Tab 5 mg – 5% DV Oct-22 to 2025	10.50	30	<b>Aripiprazole Sandoz</b>
Tab 10 mg – 5% DV Oct-22 to 2025	10.50	30	<b>Aripiprazole Sandoz</b>
Tab 15 mg – 5% DV Oct-22 to 2025	10.50	30	<b>Aripiprazole Sandoz</b>
Tab 20 mg – 5% DV Oct-22 to 2025	10.50	30	<b>Aripiprazole Sandoz</b>
Tab 30 mg – 5% DV Oct-22 to 2025	10.50	30	<b>Aripiprazole Sandoz</b>
<b>CHLORPROMAZINE HYDROCHLORIDE</b>			
Tab 10 mg	14.83	100	Largactil
Tab 25 mg	15.62	100	Largactil
Tab 100 mg	36.73	100	Largactil
Oral liq 10 mg per ml			
Oral liq 20 mg per ml			
Inj 25 mg per ml, 2 ml ampoule	30.79	10	Largactil
<i>(Largactil Tab 10 mg to be delisted 1 April 2024)</i>			
<b>CLOZAPINE</b>			
Tab 25 mg	6.69	50	Clopine
	13.37	100	Clopine
	6.69	50	Clozaril
	13.37	100	Clozaril
Tab 50 mg	8.67	50	Clopine
	17.33	100	Clopine
Tab 100 mg	17.33	50	Clopine
	34.65	100	Clopine
	17.33	50	Clozaril
	34.65	100	Clozaril
Tab 200 mg	34.65	50	Clopine
	69.30	100	Clopine
Oral liq 50 mg per ml	67.62	100 ml	Versacloz
<b>HALOPERIDOL</b>			
Tab 500 mcg	6.23	100	Serenace
Tab 1.5 mg	9.43	100	Serenace
Tab 5 mg	29.72	100	Serenace
Oral liq 2 mg per ml	23.84	100 ml	Serenace
Inj 5 mg per ml, 1ml ampoule	21.55	10	Serenace

↑ Item restricted (see → above); ↓ Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>LEVOMEPRMAZINE</b>			
Tab 25 mg .....	16.10	100	Nozinan
Tab 100 mg .....	41.75	100	Nozinan
<b>LEVOMEPRMAZINE HYDROCHLORIDE</b>			
Inj 25 mg per ml, 1 ml ampoule – <b>5% DV Apr-23 to 2025</b> .....	24.48	10	<b>Wockhardt</b>
<b>LITHIUM CARBONATE</b>			
Tab long-acting 400 mg – <b>5% DV Sep-21 to 2024</b> .....	72.00	100	<b>Priadel</b>
Cap 250 mg .....	22.36	100	Douglas
<b>OLANZAPINE</b>			
Tab 2.5 mg .....	1.35	28	Zypine
Tab 5 mg .....	1.58	28	Zypine
Tab orodispersible 5 mg – <b>5% DV Feb-24 to 2026</b> .....	2.42	28	<b>Zypine ODT</b>
Tab 10 mg .....	2.01	28	Zypine
Tab orodispersible 10 mg – <b>5% DV Feb-24 to 2026</b> .....	2.89	28	<b>Zypine ODT</b>
Inj 10 mg vial			
<b>PERICYAZINE</b>			
Tab 2.5 mg			
Tab 10 mg			
<b>QUETIAPINE</b>			
Tab 25 mg – <b>5% DV Feb-24 to 2026</b> .....	2.36	90	<b>Quetapel</b>
Tab 100 mg – <b>5% DV Feb-24 to 2026</b> .....	6.40	90	<b>Quetapel</b>
Tab 200 mg – <b>5% DV Feb-24 to 2026</b> .....	10.97	90	<b>Quetapel</b>
Tab 300 mg – <b>5% DV Feb-24 to 2026</b> .....	15.83	90	<b>Quetapel</b>
<b>RISPERIDONE</b>			
Tab 0.5 mg – <b>5% DV Mar-24 to 2026</b> .....	2.17	60	<b>Risperidone (Teva)</b>
Tab 1 mg – <b>5% DV Mar-24 to 2026</b> .....	2.44	60	<b>Risperidone (Teva)</b>
Tab 2 mg – <b>5% DV Mar-24 to 2026</b> .....	2.72	60	<b>Risperidone (Teva)</b>
Tab 3 mg – <b>5% DV Mar-24 to 2026</b> .....	4.50	60	<b>Risperidone (Teva)</b>
Tab 4 mg – <b>5% DV Mar-24 to 2026</b> .....	6.25	60	<b>Risperidone (Teva)</b>
Oral liq 1 mg per ml – <b>5% DV Mar-24 to 2026</b> .....	10.29	30 ml	<b>Risperon</b>
<b>ZIPRASIDONE</b>			
Cap 20 mg .....	17.90	60	Zusdone
Cap 40 mg .....	27.41	60	Zusdone
Cap 60 mg .....	38.39	60	Zusdone
Cap 80 mg .....	46.55	60	Zusdone
<b>ZUCLOPENTHIXOL ACETATE</b>			
Inj 50 mg per ml, 1 ml ampoule			
Inj 50 mg per ml, 2 ml ampoule			
<b>ZUCLOPENTHIXOL HYDROCHLORIDE</b>			
Tab 10 mg .....	31.45	100	Clopixol

**Depot Injections**

<b>FLUPENTHIXOL DECANOATE</b>			
Inj 20 mg per ml, 1 ml ampoule .....	13.14	5	Fluanxol
Inj 20 mg per ml, 2 ml ampoule .....	20.90	5	Fluanxol
Inj 100 mg per ml, 1 ml ampoule .....	40.87	5	Fluanxol
<b>HALOPERIDOL DECANOATE</b>			
Inj 50 mg per ml, 1 ml ampoule .....	28.39	5	Haldol
Inj 100 mg per ml, 1 ml ampoule .....	55.90	5	Haldol Concentrate

Products with Hospital Supply Status (HSS) are in **bold**  
 Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>OLANZAPINE – Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 210 mg vial .....	252.00	1	Zyprexa Relprevv
⚡ Inj 300 mg vial .....	414.00	1	Zyprexa Relprevv
⚡ Inj 405 mg vial .....	504.00	1	Zyprexa Relprevv

➔ **Restricted (RS1379)**

### Initiation

*Re-assessment required after 12 months*

Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
- 2 All of the following:
  - 2.1 The patient has schizophrenia; and
  - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
  - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

### Continuation

*Re-assessment required after 12 months*

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

**PALIPERIDONE – Restricted** see terms [below](#)

⚡ Inj 25 mg syringe .....	194.25	1	Invega Sustenna
⚡ Inj 50 mg syringe .....	271.95	1	Invega Sustenna
⚡ Inj 75 mg syringe .....	357.42	1	Invega Sustenna
⚡ Inj 100 mg syringe .....	435.12	1	Invega Sustenna
⚡ Inj 150 mg syringe .....	435.12	1	Invega Sustenna

➔ **Restricted (RS1381)**

### Initiation

*Re-assessment required after 12 months*

Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
  - 2.1 The patient has schizophrenia or other psychotic disorder; and
  - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
  - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

### Continuation

*Re-assessment required after 12 months*

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

**PALIPERIDONE PALMITATE – Restricted** see terms [below](#)

⚡ Inj 175 mg syringe .....	815.85	1	Invega Trinza
⚡ Inj 263 mg syringe .....	1,072.26	1	Invega Trinza
⚡ Inj 350 mg syringe .....	1,305.36	1	Invega Trinza
⚡ Inj 525 mg syringe .....	1,305.36	1	Invega Trinza

➔ **Restricted (RS1932)**

### Initiation

*Re-assessment required after 12 months*

Both:

- 1 The patient has schizophrenia; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2 The patient has had an initial Special Authority approval for paliperidone once-monthly depot injection.

**Continuation**

*Re-assessment required after 12 months*

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PIPOTHIAZINE PALMITATE – **Restricted:** For continuation only

➔ Inj 50 mg per ml, 1 ml ampoule

➔ Inj 50 mg per ml, 2 ml ampoule

RISPERIDONE – **Restricted** see terms [below](#)

↓ Inj 25 mg vial .....	135.98	1	Risperdal Consta
↓ Inj 37.5 mg vial .....	178.71	1	Risperdal Consta
↓ Inj 50 mg vial .....	217.56	1	Risperdal Consta

➔ **Restricted (RS1380)**

**Initiation**

*Re-assessment required after 12 months*

Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
  - 2.1 The patient has schizophrenia or other psychotic disorder; and
  - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
  - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

**Continuation**

*Re-assessment required after 12 months*

The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

ZUCLOPENTHIXOL DECANOATE

Inj 200 mg per ml, 1 ml ampoule .....	19.80	5	Clopixol
Inj 500 mg per ml, 1 ml ampoule .....			<i>e.g. Clopixol Conc</i>

**Anxiolytics**

BUSPIRONE HYDROCHLORIDE

Tab 5 mg – <b>5% DV May-22 to 2024</b> .....	18.50	100	<b>Buspirone Viatris</b>
Tab 10 mg – <b>5% DV May-22 to 2024</b> .....	12.50	100	<b>Buspirone Viatris</b>

CLONAZEPAM

Tab 500 mcg .....	5.64	100	Paxam
Tab 2 mg .....	10.78	100	Paxam

DIAZEPAM

Tab 2 mg – <b>5% DV Mar-24 to 2026</b> .....	95.00	500	<b>Arrow-Diazepam</b>
Tab 5 mg – <b>5% DV Mar-24 to 2026</b> .....	115.00	500	<b>Arrow-Diazepam</b>

LORAZEPAM

Tab 1 mg – <b>5% DV Dec-21 to 2024</b> .....	9.72	250	<b>Ativan</b>
Tab 2.5 mg – <b>5% DV Dec-21 to 2024</b> .....	12.50	100	<b>Ativan</b>

OXAZEPAM

Tab 10 mg			
Tab 15 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Multiple Sclerosis Treatments**

➔ **Restricted (RS1993)**

**Initiation – Multiple Sclerosis - dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab and teriflunomide**

Any relevant practitioner

*Re-assessment required after 12 months*

Either:

- 1 All of the following:
  - 1.1 Diagnosis of multiple sclerosis (MS) meets the McDonald 2017 diagnostic criteria for MS and has been confirmed by a neurologist; and
  - 1.2 Patients has an EDSS score between 0 – 6.0; and
  - 1.3 Patient has had at least one significant attack of MS in the previous 12 months or two significant attacks in the past 24 months; and
  - 1.4 All of the following:
    - 1.4.1 Each significant attack must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the attack, but the neurologist/physician must be satisfied that the clinical features were characteristic); and
    - 1.4.2 Each significant attack is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s); and
    - 1.4.3 Each significant attack has lasted at least one week and has started at least one month after the onset of a previous attack (where relevant); and
    - 1.4.4 Each significant attack can be distinguished from the effects of general fatigue; and is not associated with a fever (T> 37.5°C); and
    - 1.4.5 Either:
      - 1.4.5.1 Each significant attack is severe enough to change either the EDSS or at least one of the Kurtze Functional System scores by at least 1 point; or
      - 1.4.5.2 Each significant attack is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte’s symptom); and
  - 1.5 Evidence of new inflammatory activity on an MRI scan within the past 24 months; and
  - 1.6 Any of the following:
    - 1.6.1 A sign of that new inflammatory activity on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing lesion; or
    - 1.6.2 A sign of that new inflammatory activity is a lesion showing diffusion restriction; or
    - 1.6.3 A sign of that new inflammatory is a T2 lesion with associated local swelling; or
    - 1.6.4 A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent attack that occurred within the last 2 years; or
    - 1.6.5 A sign of that new inflammatory activity is new T2 lesions compared with a previous MRI scan; or
- 2 Patient has an active approval for ocrelizumab and does not have primary progressive MS.

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

**Continuation – Multiple Sclerosis - dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab and teriflunomide**

Any relevant practitioner

Patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use unilateral or bilateral aids at any time in the last six months (ie the patient has walked 100 metres or more with or without aids in the last six months).

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

**DIMETHYL FUMARATE – Restricted** see terms [above](#)

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

† Cap 120 mg.....	520.00	14	Tecfidera
† Cap 240 mg.....	2,000.00	56	Tecfidera

† Item restricted (see ➔ above); ‡ Item restricted (see ➔ below)

e.g. Brand indicates brand example only. It is not a contracted product.



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>FINGOLIMOD – Restricted</b> see terms <a href="#">on the previous page</a>			
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.			
† Cap 0.5 mg.....	2,200.00	28	Gilenya
<b>GLATIRAMER ACETATE – Restricted</b> see terms <a href="#">on the previous page</a>			
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.			
† Inj 40 mg prefilled syringe – 5% DV Oct-22 to 2025.....	1,137.48	12	<b>Copaxone</b>
<b>INTERFERON BETA-1-ALPHA – Restricted</b> see terms <a href="#">on the previous page</a>			
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.			
† Inj 6 million iu in 0.5 ml pen injector.....	1,170.00	4	Avonex Pen
† Inj 6 million iu in 0.5 ml syringe.....	1,170.00	4	Avonex
<b>INTERFERON BETA-1-BETA – Restricted</b> see terms <a href="#">on the previous page</a>			
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.			
† Inj 8 million iu per ml, 1 ml vial			
<b>NATALIZUMAB – Restricted</b> see terms <a href="#">on the previous page</a>			
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.			
† Inj 20 mg per ml, 15 ml vial.....	1,750.00	1	Tysabri
<b>TERIFLUNOMIDE – Restricted</b> see terms <a href="#">on the previous page</a>			
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.			
† Tab 14 mg .....	659.90	28	Aubagio

**Multiple Sclerosis Treatments - Other**

<b>OCRELIZUMAB – Restricted</b> see terms <a href="#">below</a>			
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.			
† Inj 30 mg per ml, 10 ml vial.....	9,346.00	1	Ocrevus

➔ **Restricted (RS1997)**

**Initiation – Multiple Sclerosis - ocrelizumab**

Any relevant practitioner

*Re-assessment required after 12 months*

Either:

- 1 All of the following:
  - 1.1 Diagnosis of multiple sclerosis (MS) meets the McDonald 2017 diagnostic criteria for MS and has been confirmed by a neurologist; and
  - 1.2 Patients has an EDSS score between 0 – 6.0; and
  - 1.3 Patient has had at least one significant attack of MS in the previous 12 months or two significant attacks in the past 24 months; and
  - 1.4 All of the following:
    - 1.4.1 Each significant attack must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the attack, but the neurologist/physician must be satisfied that the clinical features were characteristic); and
    - 1.4.2 Each significant attack is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s); and
    - 1.4.3 Each significant attack has lasted at least one week and has started at least one month after the onset of a previous attack (where relevant); and
    - 1.4.4 Each significant attack can be distinguished from the effects of general fatigue; and is not associated with a fever (T> 37.5°C); and
    - 1.4.5 Either:
      - 1.4.5.1 Each significant attack is severe enough to change either the EDSS or at least one of the Kurtze

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- Functional System scores by at least 1 point; or
- 1.4.5.2 Each significant attack is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom); and
- 1.5 Evidence of new inflammatory activity on an MRI scan within the past 24 months; and
- 1.6 Any of the following:
- 1.6.1 A sign of that new inflammatory activity on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing lesion; or
  - 1.6.2 A sign of that new inflammatory activity is a lesion showing diffusion restriction; or
  - 1.6.3 A sign of that new inflammatory is a T2 lesion with associated local swelling; or
  - 1.6.4 A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent attack that occurred within the last 2 years; or
  - 1.6.5 A sign of that new inflammatory activity is new T2 lesions compared with a previous MRI scan; or
- 2 Patient has an active Special Authority approval for either dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab or teriflunomide.

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

### Continuation – Multiple Sclerosis - ocrelizumab

Any relevant practitioner

Patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use unilateral or bilateral aids at any time in the last six months (ie the patient has walked 100 metres or more with or without aids in the last six months).

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

### Initiation – Primary Progressive Multiple Sclerosis

Any relevant practitioner

*Re-assessment required after 12 months*

All of the following:

- 1 Diagnosis of primary progressive multiple sclerosis (PPMS) meets the 2017 McDonald criteria and has been confirmed by a neurologist; and
- 2 Patient has an EDSS 2.0 (score equal to or greater than 2 on pyramidal functions) to EDSS 6.5; and
- 3 Patient has no history of relapsing remitting multiple sclerosis.

### Continuation – Primary Progressive Multiple Sclerosis

Any relevant practitioner

Patient has had an EDSS score of 2.0 to 6.5 (inclusive) at any time in the last six months (ie patient has walked 20 metres with bilateral assistance/aids, without rest in the last six months).

## Sedatives and Hypnotics

### CHLORAL HYDRATE

Oral liq 100 mg per ml

Oral liq 200 mg per ml

LORMETAZEPAM – **Restricted:** For continuation only

➔ Tab 1 mg

MELATONIN – **Restricted** see terms [below](#)

⚡ Tab modified-release 2 mg – 5% DV Apr-22 to 2024 ..... 11.50      30      **Vigisom**

⚡ Tab 3 mg

Note: Only for use in compounding an oral liquid formulation, for in-hospital use only.

➔ **Restricted (RS1576)**

### Initiation – insomnia secondary to neurodevelopmental disorder

Psychiatrist, paediatrician, neurologist or respiratory specialist

*Re-assessment required after 12 months*

All of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder); and
- 2 Behavioural and environmental approaches have been tried or are inappropriate; and
- 3 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and
- 4 Patient is aged 18 years or under.

**Continuation – insomnia secondary to neurodevelopmental disorder**

Psychiatrist, paediatrician, neurologist or respiratory specialist

*Re-assessment required after 12 months*

All of the following:

- 1 Patient is aged 18 years or under; and
- 2 Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined); and
- 3 Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia; and
- 4 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day.

**Initiation – insomnia where benzodiazepines and zopiclone are contraindicated**

Both:

- 1 Patient has insomnia and benzodiazepines and zopiclone are contraindicated; and
- 2 For in-hospital use only.

**MIDAZOLAM**

Tab 7.5 mg

Oral liq 2 mg per ml

Inj 1 mg per ml, 5 ml ampoule – 5% DV Jan-22 to 2024 ..... 3.95

Inj 5 mg per ml, 3 ml ampoule – 5% DV Jan-22 to 2024 ..... 3.52

10

5

**Mylan Midazolam**  
Midazolam Viatris  
**Mylan Midazolam**

**PHENOBARBITONE**

Inj 130 mg per ml, 1 ml vial

Inj 200 mg per ml, 1 ml ampoule

**TEMAZEPAM**

Tab 10 mg – 5% DV Feb-24 to 2026 ..... 1.40

25

**Normison**

**TRIAZOLAM – Restricted:** For continuation only

➔ Tab 125 mcg

➔ Tab 250 mcg

**ZOPICLONE**

Tab 7.5 mg

**Spinal Muscular Atrophy**

**NUSINERSEN – Restricted** see terms [below](#)

↓ Inj 12 mg per 5 ml vial ..... 120,000.00

1

**Spinraza**

➔ **Restricted (RS1938)**

**Initiation**

*Re-assessment required after 12 months*

All of the following:

- 1 Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation; and
- 2 Patient is 18 years of age or under; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

3 Either:

3.1 Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age; or

3.2 Both:

3.2.1 Patient is pre-symptomatic; and

3.2.2 Patient has three or less copies of SMN2.

## Continuation

*Re-assessment required after 12 months*

All of the following:

- 1 There has been demonstrated maintenance of motor milestone function since treatment initiation; and
- 2 Patient does not require invasive permanent ventilation (at least 16 hours per day), in the absence of a potentially reversible cause while being treated with nusinersen; and
- 3 Nusinersen not to be administered in combination other SMA disease modifying treatments or gene therapy.

RISDIPLAM – **Restricted** see terms [below](#)

Note: the supply of risdiplam is via Pharmac's approved direct distribution supply. Further details can be found on Pharmac's website <https://pharmac.govt.nz/risdiplam>

↓ Powder for oral soln 750 mcg per ml, 60 mg per bottle..... 14,100.00 80 ml Evrysdi

→ **Restricted (RS1954)**

## Initiation

*Re-assessment required after 12 months*

All of the following:

- 1 Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation; and
- 2 Patient is 18 years of age or under; and
- 3 Either:
  - 3.1 Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age; or
  - 3.2 Both:
    - 3.2.1 Patient is pre-symptomatic; and
    - 3.2.2 Patient has three or less copies of SMN2.

## Continuation

*Re-assessment required after 12 months*

All of the following:

- 1 There has been demonstrated maintenance of motor milestone function since treatment initiation; and
- 2 Patient does not require invasive permanent ventilation (at least 16 hours per day), in the absence of a potentially reversible cause while being treated with risdiplam; and
- 3 Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Stimulants / ADHD Treatments**

<b>ATOMOXETINE</b>			
Cap 10 mg.....	18.41	28	APO-Atomoxetine Generic Partners
Cap 18 mg.....	27.06	28	APO-Atomoxetine Generic Partners
Cap 25 mg.....	29.22	28	APO-Atomoxetine Generic Partners
Cap 40 mg.....	29.22	28	APO-Atomoxetine Generic Partners
Cap 60 mg.....	46.51	28	APO-Atomoxetine Generic Partners
Cap 80 mg.....	56.45	28	APO-Atomoxetine Generic Partners
Cap 100 mg.....	58.48	28	APO-Atomoxetine Generic Partners

**CAFFEINE**

Tab 100 mg			
<b>DEXAMFETAMINE SULFATE – Restricted</b> see terms <a href="#">below</a>			
↓ Tab 5 mg – 5% DV Jan-22 to 2024 .....	28.50	100	Aspen
	21.00		<b>PSM</b>

➔ **Restricted (RS1169)**

**Initiation – ADHD**  
 Paediatrician or psychiatrist  
 Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

**Initiation – Narcolepsy**  
 Neurologist or respiratory specialist  
*Re-assessment required after 24 months*  
 Patient suffers from narcolepsy.

**Continuation – Narcolepsy**  
 Neurologist or respiratory specialist  
*Re-assessment required after 24 months*  
 The treatment remains appropriate and the patient is benefiting from treatment.

# NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>METHYLPHENIDATE HYDROCHLORIDE – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab extended-release 18 mg.....	58.96 7.75	30	Concerta Methylphenidate ER - Teva
⚡ Tab extended-release 27 mg.....	65.44 11.45	30	Concerta Methylphenidate ER - Teva
⚡ Tab extended-release 36 mg.....	71.93 15.50	30	Concerta Methylphenidate ER - Teva
⚡ Tab extended-release 54 mg.....	86.24 22.25	30	Concerta Methylphenidate ER - Teva
⚡ Tab immediate-release 5 mg.....	3.20	30	Rubifen
⚡ Tab immediate-release 10 mg.....	3.00	30	Ritalin Rubifen
⚡ Tab immediate-release 20 mg.....	7.85	30	Rubifen
⚡ Tab sustained-release 20 mg.....	10.95	30	Rubifen SR
⚡ Cap modified-release 10 mg.....	15.60	30	Ritalin LA
⚡ Cap modified-release 20 mg.....	20.40	30	Ritalin LA
⚡ Cap modified-release 30 mg.....	25.52	30	Ritalin LA
⚡ Cap modified-release 40 mg.....	30.60	30	Ritalin LA

## ➔ Restricted (RS1294)

### Initiation – ADHD (immediate-release and sustained-release formulations)

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

### Initiation – Narcolepsy (immediate-release and sustained-release formulations)

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

Patient suffers from narcolepsy.

### Continuation – Narcolepsy (immediate-release and sustained-release formulations)

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

The treatment remains appropriate and the patient is benefiting from treatment.

### Initiation – Extended-release and modified-release formulations

Paediatrician or psychiatrist

Both:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Either:
  - 2.1 Patient is taking a currently listed formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
  - 2.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

## MODAFINIL – Restricted

 see terms [below](#)

⚡ Tab 100 mg – 5% DV Mar-22 to 2024 .....29.13      60      **Modavigil**

## ➔ Restricted (RS1803)

### Initiation – Narcolepsy

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

All of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Either:
  - 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
  - 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
- 3 Either:
  - 3.1 An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
  - 3.2 Methylphenidate and dexamphetamine are contraindicated.

**Continuation – Narcolepsy**

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

The treatment remains appropriate and the patient is benefiting from treatment.

**Treatments for Dementia**

<b>DONEPEZIL HYDROCHLORIDE</b>			
Tab 5 mg .....	4.34	90	Donepezil-Rex
Tab 10 mg .....	6.64	90	Donepezil-Rex
<b>RIVASTIGMINE – Restricted</b> see terms <a href="#">below</a>			
↓ Patch 4.6 mg per 24 hour – 5% DV Feb-22 to 2024.....	38.00	30	<b>Rivastigmine Patch BNM 5</b>
↓ Patch 9.5 mg per 24 hour – 5% DV Feb-22 to 2024.....	38.00	30	<b>Rivastigmine Patch BNM 10</b>

➔ **Restricted (RS1436)**

**Initiation**

*Re-assessment required after 6 months*

Both:

- 1 The patient has been diagnosed with dementia; and
- 2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

**Continuation**

*Re-assessment required after 12 months*

Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

**Treatments for Substance Dependence**

<b>BUPRENORPHINE WITH NALOXONE – Restricted</b> see terms <a href="#">below</a>			
↓ Tab 2 mg with naloxone 0.5 mg – 5% DV Dec-22 to 2025.....	11.76	28	<b>Buprenorphine Naloxone BNM</b>
↓ Tab 8 mg with naloxone 2 mg – 5% DV Dec-22 to 2025.....	34.00	28	<b>Buprenorphine Naloxone BNM</b>

➔ **Restricted (RS1172)**

**Initiation – Detoxification**

All of the following:

- 1 Patient is opioid dependent; and

continued...

# NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and			
3 Prescriber works in an opioid treatment service approved by the Ministry of Health.			
<b>Initiation – Maintenance treatment</b>			
All of the following:			
1 Patient is opioid dependent; and			
2 Patient will not be receiving methadone; and			
3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and			
4 Prescriber works in an opioid treatment service approved by the Ministry of Health.			
<b>BUPROPION HYDROCHLORIDE</b>			
Tab modified-release 150 mg.....	11.00	30	Zyban
<b>DISULFIRAM</b>			
Tab 200 mg – 5% DV Nov-21 to 2024.....	236.40	100	<b>Antabuse</b>
<b>NALTREXONE HYDROCHLORIDE – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 50 mg – 5% DV Dec-23 to 2026.....	83.33	30	<b>Naltrexond</b>
	77.77	28	Naltrexone AOP
➔ <b>Restricted (RS1173)</b>			
<b>Initiation – Alcohol dependence</b>			
Both:			
1 Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and			
2 Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.			
<b>Initiation – Constipation</b>			
For the treatment of opioid-induced constipation.			
<b>NICOTINE – Some items restricted</b> see terms <a href="#">below</a>			
Patch 7 mg per 24 hours .....	19.14	28	Habitrol
Patch 14 mg per 24 hours .....	21.05	28	Habitrol
Patch 21 mg per 24 hours .....	24.12	28	Habitrol
⚡ Oral spray 1 mg per dose			<i>e.g. Nicorette QuickMist Mouth Spray</i>
Lozenge 1 mg.....	19.76	216	Habitrol
Lozenge 2 mg.....	21.65	216	Habitrol
⚡ Soln for inhalation 15 mg cartridge			<i>e.g. Nicorette Inhalator</i>
Gum 2 mg.....	21.42	204	Habitrol (Fruit)
			Habitrol (Mint)
Gum 4 mg.....	24.17	204	Habitrol (Fruit)
			Habitrol (Mint)
➔ <b>Restricted (RS1873)</b>			
<b>Initiation</b>			
Any of the following:			
1 For perioperative use in patients who have a 'nil by mouth' instruction; or			
2 For use within mental health inpatient units; or			
3 Patient would be admitted to a mental health inpatient unit, but is unable to due to COVID-19 self-isolation requirement; or			
4 For acute use in agitated patients who are unable to leave the hospital facilities.			
<b>VARENICLINE – Restricted</b> see terms <a href="#">on the next page</a>			
⚡ Tab 0.5 mg × 11 and 1 mg × 42 – 5% DV Jan-22 to 2024 .....	16.67	53	<b>Varenicline Pfizer</b>
⚡ Tab 1 mg – 5% DV Jan-22 to 2024 .....	17.62	56	<b>Varenicline Pfizer</b>



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted (RS1702)**

**Initiation**

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
  - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
  - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not had a Special Authority for varenicline approved in the last 6 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Chemotherapeutic Agents**

**Alkylating Agents**

**BENDAMUSTINE HYDROCHLORIDE – Restricted** see terms [below](#)

⚠ Inj 25 mg vial – 5% DV Sep-21 to 2024.....	77.00	1	<b>Ribomustin</b>
⚠ Inj 100 mg vial – 5% DV Sep-21 to 2024 .....	308.00	1	<b>Ribomustin</b>

➡ **Restricted (RS1917)**

**Initiation – treatment naive CLL**

All of the following:

- 1 The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is chemotherapy treatment naive; and
- 3 The patient is unable to tolerate toxicity of full-dose FCR; and
- 4 Patient has ECOG performance status 0-2; and
- 5 Patient has a Cumulative Illness Rating Scale (CIRS) score of < 6; and
- 6 Bendamustine is to be administered at a maximum dose of 100 mg/m<sup>2</sup> on days 1 and 2 every 4 weeks for a maximum of 6 cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

**Initiation – Indolent, Low-grade lymphomas**

*Re-assessment required after 9 months*

All of the following:

- 1 The patient has indolent low grade NHL requiring treatment; and
- 2 Patient has a WHO performance status of 0-2; and
- 3 Any of the following:
  - 3.1 Both:
    - 3.1.1 Patient is treatment naive; and
    - 3.1.2 Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+); or
  - 3.2 Both:
    - 3.2.1 Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen; and
    - 3.2.2 Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles; or
  - 3.3 All of the following:
    - 3.3.1 The patient has not received prior bendamustine therapy; and
    - 3.3.2 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
    - 3.3.3 Patient has had a rituximab treatment-free interval of 12 months or more; or
- 3.4 Bendamustine is to be administered as monotherapy for a maximum of 6 cycles in rituximab refractory patients.

**Continuation – Indolent, Low-grade lymphomas**

*Re-assessment required after 9 months*

Either:

- 1 Both:
  - 1.1 Patient is refractory to or has relapsed within 12 months of rituximab in combination with bendamustine; and
  - 1.2 Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles; or
- 2 Both:
  - 2.1 Patients have not received a bendamustine regimen within the last 12 months; and
  - 2.2 Either:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
2.2.1 Both:			
2.2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and			
2.2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or			
2.2.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.			
Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.			
<b>Initiation – Hodgkin's lymphoma*</b>			
Relevant specialist or medical practitioner on the recommendation of a relevant specialist			
<i>Limited to 6 months treatment</i>			
All of the following:			
1 Patient has Hodgkin's lymphoma requiring treatment; and			
2 Patient has a ECOG performance status of 0-2; and			
3 Patient has received one prior line of chemotherapy; and			
4 Patient's disease relapsed or was refractory following prior chemotherapy; and			
5 Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m <sup>2</sup> twice per cycle, for a maximum of four cycles.			
Note: Indications marked with * are unapproved indications.			
<b>BUSULFAN</b>			
Tab 2 mg .....	89.25	100	Myleran
Inj 6 mg per ml, 10 ml ampoule			
<b>CARMUSTINE</b>			
Inj 100 mg vial – <b>5% DV Sep-22 to 2025</b> .....	710.00	1	<b>BiCNU</b>
<b>CHLORAMBUCIL</b>			
Tab 2 mg			
<b>CYCLOPHOSPHAMIDE</b>			
Tab 50 mg – <b>5% DV Jan-22 to 2024</b> .....	145.00	50	<b>Cyclonex</b>
Inj 1 g vial – <b>5% DV Dec-21 to 2024</b> .....	35.65	1	<b>Endoxan</b>
Inj 2 g vial – <b>5% DV Dec-21 to 2024</b> .....	71.25	1	<b>Endoxan</b>
<b>IFOSFAMIDE</b>			
Inj 1 g vial .....	96.00	1	Holoxan
Inj 2 g vial .....	180.00	1	Holoxan
<b>LOMUSTINE</b>			
Cap 10 mg .....	132.59	20	Ceenu
Cap 40 mg .....	399.15	20	Ceenu
<b>MELPHALAN</b>			
Tab 2 mg			
Inj 50 mg vial – <b>5% DV Dec-23 to 2026</b> .....	48.25	1	<b>Melpha</b>
<b>THIOTEPA</b>			
Inj 15 mg vial			
Inj 100 mg vial			

**Anthracyclines and Other Cytotoxic Antibiotics**

<b>BLEOMYCIN SULPHATE</b>			
Inj 15,000 iu vial.....	185.16	1	DBL Bleomycin Sulfate
<b>DACTINOMYCIN [ACTINOMYCIN D]</b>			
Inj 0.5 mg vial .....	255.00	1	Cosmegen

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>DAUNORUBICIN</b>			
Inj 2 mg per ml, 10 ml vial.....	171.93	1	Pfizer
Inj 20 mg vial .....	1,495.00	10	Daunorubicin Zentiva
<b>DOXORUBICIN HYDROCHLORIDE</b>			
Inj 2 mg per ml, 5 ml vial			
Inj 2 mg per ml, 25 ml vial.....	11.50	1	Doxorubicin Ebewe
Inj 50 mg vial			
Inj 2 mg per ml, 50 ml vial.....	23.00	1	Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial – 5% DV Jan-22 to 2024.....	69.99	1	<b>Doxorubicin Ebewe</b>
<b>EPIRUBICIN HYDROCHLORIDE</b>			
Inj 2 mg per ml, 5 ml vial.....			
Inj 2 mg per ml, 25 ml vial.....	30.00	1	Epirubicin Ebewe
Inj 2 mg per ml, 100 ml vial – 5% DV Jan-22 to 2024.....	99.99	1	<b>Epirubicin Ebewe</b>
<b>IDARUBICIN HYDROCHLORIDE</b>			
Inj 5 mg vial .....			
Inj 10 mg vial .....	109.74	1	Zavedos
	233.64	1	Zavedos
<b>MITOMYCIN C</b>			
Inj 5 mg vial			
Inj 20 mg vial .....	1,250.00	1	Teva
<b>MITOZANTRONE</b>			
Inj 2 mg per ml, 10 ml vial.....			
	97.50	1	Mitozantrone Ebewe

### Antimetabolites

AZACITIDINE – **Restricted** see terms [below](#)

⚠ Inj 100 mg vial – 5% DV Dec-21 to 2024 .....75.06 1 **Azacitidine Dr Reddy's**

➡ **Restricted (RS1904)**

#### Initiation

Haematologist

*Re-assessment required after 12 months*

All of the following:

- 1 Any of the following:
  - 1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
  - 1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
  - 1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
- 2 The patient has performance status (WHO/ECOG) grade 0-2; and
- 3 The patient has an estimated life expectancy of at least 3 months.

#### Continuation

Haematologist or medical practitioner on the recommendation of a haematologist

*Re-assessment required after 12 months*

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>CAPECITABINE</b>			
Tab 150 mg – 5% DV Jan-24 to 2025 .....	9.80	60	<b>Capecitabine Viatris</b>
	10.00		Capercit
Tab 500 mg – 5% DV Jan-24 to 2025 .....	46.50	120	<b>Capecitabine Viatris</b>
	49.00		Capercit
<i>(Capercit Tab 150 mg to be delisted 1 January 2024)</i>			
<i>(Capercit Tab 500 mg to be delisted 1 January 2024)</i>			
<b>CLADRIBINE</b>			
Inj 2 mg per ml, 5 ml vial			
Inj 1 mg per ml, 10 ml vial.....	749.96	1	Leustatin
<b>CYTARABINE</b>			
Inj 20 mg per ml, 5 ml vial.....	472.00	5	Pfizer
Inj 100 mg per ml, 20 ml vial.....	48.80	1	Pfizer
<b>FLUDARABINE PHOSPHATE</b>			
Tab 10 mg .....	412.00	20	Fludara Oral
Inj 50 mg vial – 5% DV Jan-23 to 2025 .....	634.00	5	<b>Fludarabine Ebewe</b>
<b>FLUOROURACIL</b>			
Inj 50 mg per ml, 20 ml vial – 5% DV Feb-22 to 2024 .....	10.51	1	<b>Fluorouracil Accord</b>
Inj 50 mg per ml, 100 ml vial – 5% DV Feb-22 to 2024 .....	29.44	1	<b>Fluorouracil Accord</b>
<b>GEMCITABINE</b>			
Inj 10 mg per ml, 100 ml vial.....	15.89	1	Gemcitabine Ebewe
<b>MERCAPTOPURINE</b>			
Tab 50 mg – 5% DV Dec-22 to 2025 .....	25.90	25	<b>Puri-nethol</b>
↓ Oral suspension 20 mg per ml.....	428.00	100 ml	Allmercap
➔ <b>Restricted (RS1635)</b>			
<b>Initiation</b>			
Paediatric haematologist or paediatric oncologist			
<i>Re-assessment required after 12 months</i>			
The patient requires a total dose of less than one full 50 mg tablet per day.			
<b>Continuation</b>			
Paediatric haematologist or paediatric oncologist			
<i>Re-assessment required after 12 months</i>			
The patient requires a total dose of less than one full 50 mg tablet per day.			
<b>METHOTREXATE</b>			
Tab 2.5 mg – 5% DV Jan-22 to 2024 .....	9.98	90	<b>Trexate</b>
Tab 10 mg – 5% DV Jan-22 to 2024 .....	33.71	90	<b>Trexate</b>
Inj 2.5 mg per ml, 2 ml vial			
Inj 7.5 mg prefilled syringe.....	14.61	1	Methotrexate Sandoz
Inj 10 mg prefilled syringe.....	14.66	1	Methotrexate Sandoz
Inj 15 mg prefilled syringe.....	14.77	1	Methotrexate Sandoz
Inj 20 mg prefilled syringe.....	14.88	1	Methotrexate Sandoz
Inj 25 mg prefilled syringe.....	14.99	1	Methotrexate Sandoz
Inj 30 mg prefilled syringe.....	15.09	1	Methotrexate Sandoz
Inj 25 mg per ml, 2 ml vial.....	30.00	5	Methotrexate DBL
			Onco-Vial
Inj 25 mg per ml, 20 ml vial.....	45.00	1	DBL Methotrexate
			Onco-Vial
Inj 100 mg per ml, 10 ml vial.....	25.00	1	Methotrexate Ebewe
Inj 100 mg per ml, 50 ml vial – 5% DV Dec-23 to 2026 .....	67.99	1	<b>Methotrexate Ebewe</b>

# ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PEMETREXED – Restricted</b> see terms <a href="#">below</a>			
⚡ Inj 100 mg vial .....	60.89	1	Juno Pemetrexed
⚡ Inj 500 mg vial .....	217.77	1	Juno Pemetrexed
➔ <b>Restricted (RS1596)</b>			
<b>Initiation – Mesothelioma</b>			
<i>Re-assessment required after 8 months</i>			
Both:			
1 Patient has been diagnosed with mesothelioma; and			
2 Pemetrexed to be administered at a dose of 500 mg/m <sup>2</sup> every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.			
<b>Continuation – Mesothelioma</b>			
<i>Re-assessment required after 8 months</i>			
All of the following:			
1 No evidence of disease progression; and			
2 The treatment remains appropriate and the patient is benefitting from treatment; and			
3 Pemetrexed to be administered at a dose of 500mg/m <sup>2</sup> every 21 days for a maximum of 6 cycles.			
<b>Initiation – Non small cell lung cancer</b>			
<i>Re-assessment required after 8 months</i>			
Both:			
1 Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and			
2 Either:			
2.1 Both:			
2.1.1 Patient has chemotherapy-naïve disease; and			
2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m <sup>2</sup> every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles; or			
2.2 All of the following:			
2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and			
2.2.2 Patient has not received prior funded treatment with pemetrexed; and			
2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m <sup>2</sup> every 21 days for a maximum of 6 cycles.			
<b>Continuation – Non small cell lung cancer</b>			
<i>Re-assessment required after 8 months</i>			
All of the following:			
1 No evidence of disease progression; and			
2 The treatment remains appropriate and the patient is benefitting from treatment; and			
3 Pemetrexed is to be administered at a dose of 500mg/m <sup>2</sup> every 21 days.			
<b>THIOGUANINE</b>			
Tab 40 mg			
<b>Other Cytotoxic Agents</b>			
<b>AMSACRINE</b>			
Inj 50 mg per ml, 1.5 ml ampoule			
Inj 75 mg			
<b>ANAGRELIDE HYDROCHLORIDE</b>			
Cap 0.5 mg			
<b>ARSENIC TRIOXIDE</b>			
Inj 1 mg per ml, 10 ml vial.....	4,817.00	10	Phenasen
<b>BORTEZOMIB – Restricted</b> see terms <a href="#">on the next page</a>			
⚡ Inj 3.5 mg vial – 5% DV May-23 to 2025.....	74.93	1	<b>DBL Bortezomib</b>

↑ Item restricted (see ➔ above); ⚡ Item restricted (see ➔ below)  
e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>➔ Restricted (RS1725)</b>			
<b>Initiation – multiple myeloma/amyloidosis</b>			
Either:			
1 The patient has symptomatic multiple myeloma; or			
2 The patient has symptomatic systemic AL amyloidosis.			
<b>DACARBAZINE</b>			
Inj 200 mg vial .....	72.11	1	DBL Dacarbazine
<b>ETOPOSIDE</b>			
Cap 50 mg .....	340.73	20	Vepesid
Cap 100 mg .....	340.73	10	Vepesid
Inj 20 mg per ml, 5 ml vial.....	7.90	1	Rex Medical
<b>ETOPOSIDE (AS PHOSPHATE)</b>			
Inj 100 mg vial .....	40.00	1	Etopophos
<b>HYDROXYUREA [HYDROXYCARBAMIDE]</b>			
Cap 500 mg – <b>5% DV Dec-23 to 2026</b> .....	20.72	100	<b>Devatis</b>
<b>IBRUTINIB – Restricted see terms below</b>			
↓ Tab 140 mg .....	3,217.00	30	Imbruvica
↓ Tab 420 mg .....	9,652.00	30	Imbruvica
<b>➔ Restricted (RS1933)</b>			
<b>Initiation – chronic lymphocytic leukaemia (CLL)</b>			
<i>Re-assessment required after 6 months</i>			
All of the following:			
1 Patient has chronic lymphocytic leukaemia (CLL) requiring therapy; and			
2 Patient has not previously received funded ibrutinib; and			
3 Ibrutinib is to be used as monotherapy; and			
4 Any of the following:			
4.1 Both:			
4.1.1 There is documentation confirming that patient has 17p deletion or TP53 mutation; and			
4.1.2 Patient has experienced intolerable side effects with venetoclax monotherapy; or			
4.2 All of the following:			
4.2.1 Patient has received at least one prior immunochemotherapy for CLL; and			
4.2.2 Patient's CLL has relapsed within 36 months of previous treatment; and			
4.2.3 Patient has experienced intolerable side effects with venetoclax in combination with rituximab regimen; or			
4.3 Patient's CLL is refractory to or has relapsed within 36 months of a venetoclax regimen.			
<b>Continuation – chronic lymphocytic leukaemia (CLL)</b>			
<i>Re-assessment required after 12 months</i>			
Both:			
1 No evidence of clinical disease progression; and			
2 The treatment remains appropriate and the patient is benefitting from treatment.			
Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL) and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.			
<b>IRINOTECAN HYDROCHLORIDE</b>			
Inj 20 mg per ml, 5 ml vial – <b>5% DV Mar-22 to 2024</b> .....	52.57	1	<b>Accord</b>

# ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>LENALIDOMIDE – Restricted</b> see terms <a href="#">below</a>			
⚡ Cap 5 mg.....	5,122.76	28	Revlimid
⚡ Cap 10 mg.....	4,655.25	21	Revlimid
	6,207.00	28	Revlimid
⚡ Cap 15 mg.....	5,429.39	21	Revlimid
	7,239.18	28	Revlimid
⚡ Cap 25 mg.....	7,627.00	21	Revlimid

➔ **Restricted (RS1836)**

## Initiation – Relapsed/refractory disease

Haematologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
- 2 Patient has not previously been treated with lenalidomide; and
- 3 Either:
  - 3.1 Lenalidomide to be used as third line\* treatment for multiple myeloma; or
  - 3.2 Both:
    - 3.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
    - 3.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and
- 4 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

## Continuation – Relapsed/refractory disease

Haematologist

*Re-assessment required after 6 months*

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

## Initiation – Maintenance following first-line autologous stem cell transplant (SCT)

Haematologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has newly diagnosed symptomatic multiple myeloma and has undergone first-line treatment that included an autologous stem cell transplantation; and
- 2 Patient has at least a stable disease response in the first 100 days after transplantation; and
- 3 Lenalidomide maintenance is to be commenced within 6 months of transplantation; and
- 4 Lenalidomide to be administered at a maximum dose of 15 mg/day.

## Continuation – Maintenance following first-line autologous stem cell transplant (SCT)

Haematologist

*Re-assessment required after 6 months*

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with \* is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

## OLAPARIB – Restricted

 see terms [on the next page](#)

⚡ Tab 100 mg.....	3,701.00	56	Lynparza
⚡ Tab 150 mg.....	3,701.00	56	Lynparza



	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

➔ **Restricted (RS1925)**

**Initiation – Ovarian cancer**

Medical oncologist

*Re-assessment required after 12 months*

All of the following:

- 1 Patient has a high-grade serous\* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and
- 3 Either:
  - 3.1 All of the following:
    - 3.1.1 Patient has newly diagnosed, advanced disease; and
    - 3.1.2 Patient has received one line\*\* of previous treatment with platinum-based chemotherapy; and
    - 3.1.3 Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen; or
  - 3.2 All of the following:
    - 3.2.1 Patient has received at least two lines\*\* of previous treatment with platinum-based chemotherapy; and
    - 3.2.2 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line\*\* of platinum-based chemotherapy; and
    - 3.2.3 Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen; and
    - 3.2.4 Patient has not previously received funded olaparib treatment; and
- 4 Treatment will be commenced within 12 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and
- 5 Treatment to be administered as maintenance treatment; and
- 6 Treatment not to be administered in combination with other chemotherapy.

**Continuation – Ovarian cancer**

Medical oncologist

*Re-assessment required after 12 months*

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from treatment; and
- 2 Either:
  - 2.1 No evidence of progressive disease; or
  - 2.2 Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinician's opinion; and
- 3 Treatment to be administered as maintenance treatment; and
- 4 Treatment not to be administered in combination with other chemotherapy; and
- 5 Either:
  - 5.1 Both:
    - 5.1.1 Patient has received one line\*\* of previous treatment with platinum-based chemotherapy; and
    - 5.1.2 Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years; or
  - 5.2 Patient has received at least two lines\*\* of previous treatment with platinum-based chemotherapy.

Notes: \*Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

\*\*A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

**PEGASPARGASE – Restricted** see terms [on the next page](#)

↓ Inj 750 iu per ml, 5 ml vial.....	3,455.00	1	Oncaspar LYO
-------------------------------------	----------	---	--------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted (RS1788)**

**Initiation – Newly diagnosed ALL**

Limited to 12 months treatment

Both:

- 1 The patient has newly diagnosed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol.

**Initiation – Relapsed ALL**

Limited to 12 months treatment

Both:

- 1 The patient has relapsed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol.

**Initiation – Lymphoma**

Limited to 12 months treatment

Patient has lymphoma requiring L-asparaginase containing protocol (e.g. SMILE).

**PENTOSTATIN [DEOXYCOFORMYCIN]**

Inj 10 mg vial

**PROCARBAZINE HYDROCHLORIDE**

Cap 50 mg .....	980.00	50	Natulan
-----------------	--------	----	---------

**TEMOZOLOMIDE – Restricted see terms below**

⚡ Cap 5 mg .....	9.13	5	Temaccord
⚡ Cap 20 mg .....	16.38	5	Temaccord
⚡ Cap 100 mg .....	35.98	5	Temaccord
⚡ Cap 140 mg .....	50.12	5	Temaccord
⚡ Cap 250 mg .....	86.34	5	Temaccord

➔ **Restricted (RS1994)**

**Initiation – gliomas**

Re-assessment required after 12 months

Patient has a glioma.

**Continuation – gliomas**

Re-assessment required after 12 months

Treatment remains appropriate and patient is benefitting from treatment.

**Initiation – Neuroendocrine tumours**

Re-assessment required after 9 months

All of the following:

- 1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour\*; and
- 2 Temozolomide is to be given in combination with capecitabine; and
- 3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m<sup>2</sup> per day; and
- 4 Temozolomide to be discontinued at disease progression.

**Continuation – Neuroendocrine tumours**

Re-assessment required after 6 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

**Initiation – ewing's sarcoma**

Re-assessment required after 9 months

Patient has relapse or refractory Ewing's sarcoma.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

**Continuation – ewing's sarcoma**

*Re-assessment required after 6 months*

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a \* is an unapproved indication. Temozolomide is not funded for the treatment of relapsed high grade glioma.

THALIDOMIDE – **Restricted** see terms [below](#)

↓ Cap 50 mg.....	378.00	28	Thalomid
↓ Cap 100 mg.....	756.00	28	Thalomid

→ **Restricted (RS1192)**

**Initiation**

*Re-assessment required after 12 months*

Any of the following:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis\*; or
- 3 The patient has erythema nodosum leprosum.

**Continuation**

Patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen

Indication marked with \* is an unapproved indication

TRETINOIN

Cap 10 mg.....	479.50	100	Vesanoid
----------------	--------	-----	----------

VENETOCLAX – **Restricted** see terms [below](#)

↓ Tab 14 x 10 mg, 7 x 50 mg, 21 x 100 mg.....	1,771.86	42	Venclexta
↓ Tab 10 mg.....	13.68	2	Venclexta
	95.78	14	Venclexta
↓ Tab 50 mg.....	239.44	7	Venclexta
↓ Tab 100 mg.....	8,209.41	120	Venclexta

*(Venclexta Tab 10 mg to be delisted 1 December 2023)*

→ **Restricted (RS1713)**

**Initiation – relapsed/refractory chronic lymphocytic leukaemia**

Haematologist

*Re-assessment required after 7 months*

All of the following:

- 1 Patient has chronic lymphocytic leukaemia requiring treatment; and
- 2 Patient has received at least one prior therapy for chronic lymphocytic leukaemia; and
- 3 Patient has not previously received funded venetoclax; and
- 4 The patient's disease has relapsed within 36 months of previous treatment; and
- 5 Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax; and
- 6 Patient has an ECOG performance status of 0-2.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Continuation – relapsed/refractory chronic lymphocytic leukaemia

Haematologist

*Re-assessment required after 6 months*

Both:

- 1 Treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment; and
- 2 Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity.

## Initiation – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation\*

Haematologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has previously untreated chronic lymphocytic leukaemia; and
- 2 There is documentation confirming that patient has 17p deletion by FISH testing or TP53 mutation by sequencing; and
- 3 Patient has an ECOG performance status of 0-2.

## Continuation – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation\*

Haematologist

*Re-assessment required after 6 months*

The treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL)\* and B-cell prolymphocytic leukaemia (B-PLL)\*. Indications marked with \* are unapproved indications.

## Platinum Compounds

### CARBOPLATIN

Inj 10 mg per ml, 45 ml vial.....45.20      1      Carboplatin Ebewe

### CISPLATIN

Inj 1 mg per ml, 100 ml vial – 5% DV Mar-22 to 2024 .....29.66      1      **DBL Cisplatin**

### OXALIPLATIN

Inj 5 mg per ml, 20 ml vial – 5% DV Oct-23 to 2024.....33.35      1      **Alchemy Oxaliplatin**

## Protein-Tyrosine Kinase Inhibitors

### ALECTINIB – Restricted see terms [below](#)

↓ Cap 150 mg.....7,935.00      224      Alecensa

➔ **Restricted (RS1712)**

#### Initiation

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-small cell lung cancer; and
- 2 There is documentation confirming that the patient has an ALK tyrosine kinase gene rearrangement using an appropriate ALK test; and
- 3 Patient has an ECOG performance score of 0-2.

#### Continuation

*Re-assessment required after 6 months*

Both:

- 1 No evidence of progressive disease according to RECIST criteria; and
- 2 The patient is benefitting from and tolerating treatment.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>DASATINIB – Restricted</b> see terms <a href="#">below</a>			
↓ Tab 20 mg .....	3,774.06	60	Sprycel
↓ Tab 50 mg .....	6,214.20	60	Sprycel
↓ Tab 70 mg .....	7,692.58	60	Sprycel

→ **Restricted (RS1685)**

**Initiation**

Haematologist or any relevant practitioner on the recommendation of a haematologist

*Re-assessment required after 6 months*

Any of the following:

- 1 Both:
  - 1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and
  - 1.2 Maximum dose of 140 mg/day; or
- 2 Both:
  - 2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and
  - 2.2 Maximum dose of 140 mg/day; or
- 3 All of the following:
  - 3.1 The patient has a diagnosis of CML in chronic phase; and
  - 3.2 Maximum dose of 100 mg/day; and
  - 3.3 Any of the following:
    - 3.3.1 Patient has documented treatment failure\* with imatinib; or
    - 3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
    - 3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or
    - 3.3.4 Patients is enrolled in the KISS study\*\* and requires dasatinib treatment according to the study protocol.

**Continuation**

Haematologist or any relevant practitioner on the recommendation of a haematologist

*Re-assessment required after 6 months*

All of the following:

- 1 Lack of treatment failure while on dasatinib\*; and
- 2 Dasatinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML.

Note: \*treatment failure for CML as defined by Leukaemia Net Guidelines. \*\*Kinase-Inhibition Study with Sprycel Start-up  
<https://www.cancertrialsnz.ac.nz/kiss/>

**ERLOTINIB – Restricted** see terms [below](#)

↓ Tab 100 mg .....	329.70	30	Alchemy
↓ Tab 150 mg .....	569.70	30	Alchemy

→ **Restricted (RS1885)**

**Initiation**

*Re-assessment required after 4 months*

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
- 3 Either:
  - 3.1 Patient is treatment naive; or
  - 3.2 Both:
    - 3.2.1 The patient has discontinued gefitinib due to intolerance; and
    - 3.2.2 The cancer did not progress while on gefitinib; and
- 4 Erlotinib is to be given for a maximum of 3 months.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Continuation

*Re-assessment required after 6 months*

Both:

- 1 Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
- 2 Erlotinib is to be given for a maximum of 3 months.

## Continuation – pandemic circumstances

*Re-assessment required after 6 months*

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Erlotinib to be discontinued at progression; and
- 3 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

GEFITINIB – **Restricted** see terms [below](#)

↓ Tab 250 mg .....918.00      30      Iressa

→ **Restricted (RS1887)**

## Initiation

*Re-assessment required after 4 months*

All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 Either:
  - 2.1 Patient is treatment naive; or
  - 2.2 Both:
    - 2.2.1 The patient has discontinued erlotinib due to intolerance; and
    - 2.2.2 The cancer did not progress whilst on erlotinib; and
- 3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
- 4 Gefitinib is to be given for a maximum of 3 months.

## Continuation

*Re-assessment required after 6 months*

Both:

- 1 Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
- 2 Gefitinib is to be given for a maximum of 3 months.

## Continuation – pandemic circumstances

*Re-assessment required after 6 months*

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Gefitinib to be discontinued at progression; and
- 3 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

## IMATINIB MESILATE

The Glivec brand of imatinib mesilate (supplied by Novartis) is fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST only, see SA1460 in Section B of the Pharmaceutical Schedule

↓ Tab 100 mg .....2,400.00      60      Glivec

→ **Restricted (RS1402)**

## Initiation

*Re-assessment required after 12 months*

Both:

- 1 Patient has diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2 Maximum dose of 400 mg/day.

**Continuation**

*Re-assessment required after 12 months*

Adequate clinical response to treatment with imatinib (prescriber determined).

Note: The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

Cap 100 mg – 5% DV Dec-23 to 2026.....	44.93	60	<b>Imatinib-Rex</b>
Cap 400 mg – 5% DV Dec-23 to 2026.....	69.76	30	<b>Imatinib-Rex</b>

(Glivec Tab 100 mg to be delisted 1 December 2023)

LAPATINIB – **Restricted** see terms [below](#)

↓ Tab 250 mg .....	1,899.00	70	Tykerb
--------------------	----------	----	--------

→ **Restricted (RS1828)**

**Initiation**

For continuation use only.

**Continuation**

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
- 3 Lapatinib not to be given in combination with trastuzumab; and
- 4 Lapatinib to be discontinued at disease progression.

NILOTINIB – **Restricted** see terms [below](#)

↓ Cap 150 mg .....	4,680.00	120	Tasigna
↓ Cap 200 mg .....	6,532.00	120	Tasigna

→ **Restricted (RS1437)**

**Initiation**

Haematologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
- 2 Either:
  - 2.1 Patient has documented CML treatment failure\* with imatinib; or
  - 2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: \*treatment failure as defined by Leukaemia Net Guidelines.

**Continuation**

Haematologist

*Re-assessment required after 6 months*

All of the following:

- 1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
- 2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

PALBOCICLIB – **Restricted** see terms [on the next page](#)

↓ Tab 75 mg .....	4,000.00	21	Ibrance
↓ Tab 100 mg .....	4,000.00	21	Ibrance
↓ Tab 125 mg .....	4,000.00	21	Ibrance

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted (RS1731)**

**Initiation**

Medical oncologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has unresectable locally advanced or metastatic breast cancer; and
- 2 There is documentation confirming disease is hormone-receptor positive and HER2-negative; and
- 3 Patient has an ECOG performance score of 0-2; and
- 4 Either:
  - second or subsequent line setting
  - 4.1 Disease has relapsed or progressed during prior endocrine therapy; or
  - 4.2 Both:
    - first line setting
    - 4.2.1 Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
    - 4.2.2 Either:
      - 4.2.2.1 Patient has not received prior systemic treatment for metastatic disease; or
      - 4.2.2.2 All of the following:
        - 4.2.2.2.1 Patient commenced treatment with palbociclib in combination with an endocrine agent prior to 1 April 2020; and
        - 4.2.2.2.2 Patient has not received prior systemic endocrine treatment for metastatic disease; and
        - 4.2.2.2.3 There is no evidence of progressive disease; and
- 5 Treatment must be used in combination with an endocrine partner.

**Continuation**

Medical oncologist

*Re-assessment required after 12 months*

All of the following:

- 1 Treatment must be used in combination with an endocrine partner; and
- 2 No evidence of progressive disease; and
- 3 The treatment remains appropriate and the patient is benefitting from treatment.

PAZOPANIB – **Restricted** see terms [below](#)

⚡ Tab 200 mg .....	1,334.70	30	Votrient
⚡ Tab 400 mg .....	2,669.40	30	Votrient

➔ **Restricted (RS1198)**

**Initiation**

*Re-assessment required after 3 months*

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
  - 2.1 The patient is treatment naive; or
  - 2.2 The patient has only received prior cytokine treatment; or
  - 2.3 Both:
    - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
    - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 All of the following:
  - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and

continued...



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 5.2 Haemoglobin level < lower limit of normal; and
- 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
- 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
- 5.5 Karnofsky performance score of less than or equal to 70; and
- 5.6 2 or more sites of organ metastasis.

**Continuation**

*Re-assessment required after 3 months*

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

**RUXOLITINIB – Restricted** see terms [below](#)

↓ Tab 5 mg .....	2,500.00	56	Jakavi
↓ Tab 10 mg .....	5,000.00	56	Jakavi
↓ Tab 15 mg .....	5,000.00	56	Jakavi
↓ Tab 20 mg .....	5,000.00	56	Jakavi

→ **Restricted (RS1726)**

**Initiation**

Haematologist

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
- 2 Either:
  - 2.1 A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; or
  - 2.2 Both:
    - 2.2.1 A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
    - 2.2.2 Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy; and
- 3 A maximum dose of 20 mg twice daily is to be given.

**Continuation**

Relevant specialist or medical practitioner on the recommendation of a Relevant specialist

*Re-assessment required after 12 months*

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 A maximum dose of 20 mg twice daily is to be given.

**SUNITINIB – Restricted** see terms [below](#)

↓ Cap 12.5 mg – 5% DV Jul-22 to 2024 .....	208.38	28	<b>Sunitinib Pfizer</b>
↓ Cap 25 mg – 5% DV Jul-22 to 2024 .....	416.77	28	<b>Sunitinib Pfizer</b>
↓ Cap 50 mg – 5% DV Jul-22 to 2024 .....	694.62	28	<b>Sunitinib Pfizer</b>

→ **Restricted (RS1886)**

**Initiation – RCC**

*Re-assessment required after 3 months*

All of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
  - 2.1 The patient is treatment naive; or
  - 2.2 The patient has only received prior cytokine treatment; or
  - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
  - 2.4 Both:
    - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
    - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 All of the following:
  - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
  - 5.2 Haemoglobin level < lower limit of normal; and
  - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
  - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
  - 5.5 Karnofsky performance score of less than or equal to 70; and
  - 5.6 2 or more sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Notes: RCC - Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

## Continuation – RCC

*Re-assessment required after 3 months*

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

## Initiation – GIST

*Re-assessment required after 3 months*

Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
  - 2.1 The patient's disease has progressed following treatment with imatinib; or
  - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

## Continuation – GIST

*Re-assessment required after 6 months*

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
  - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
  - 1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non-measurable disease); or
  - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

continued...

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

continued...

**Continuation – GIST pandemic circumstances**

*Re-assessment required after 6 months*

All of the following:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 3 Sunitinib is to be discontinued at progression; and
- 4 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

Note: GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

**Taxanes**

**DOCETAXEL**

Inj 10 mg per ml, 8 ml vial – 5% DV Dec-23 to 2026 .....	24.91	1	<b>DBL Docetaxel</b>
--	-------	---	----------------------

**PACLITAXEL**

Inj 6 mg per ml, 5 ml vial.....	47.30	5	Paclitaxel Ebewe
Inj 6 mg per ml, 16.7 ml vial.....	24.00	1	Paclitaxel Ebewe
Inj 6 mg per ml, 25 ml vial.....	26.69	1	Paclitaxel Ebewe
Inj 6 mg per ml, 50 ml vial.....	44.00	1	Paclitaxel Ebewe

**Treatment of Cytotoxic-Induced Side Effects**

**CALCIUM FOLINATE**

Tab 15 mg .....	135.33	10	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 5 ml ampoule .....	18.25	5	Calcium Folate Ebewe
Inj 10 mg per ml, 5 ml vial.....	7.28	1	Calcium Folate Sandoz
Inj 10 mg per ml, 10 ml vial.....	9.49	1	Calcium Folate Sandoz
Inj 10 mg per ml, 30 ml vial.....	22.51	1	Calcium Folate Ebewe
Inj 10 mg per ml, 35 ml vial.....	25.14	1	Calcium Folate Sandoz
Inj 10 mg per ml, 100 ml vial.....	72.00	1	Calcium Folate Sandoz

**DEXRAZOXANE – Restricted** see terms [below](#)

↓ Inj 500 mg			<i>e.g. Cardioxane</i>
--------------	--	--	------------------------

➔ **Restricted (RS1695)**

**Initiation**

Medical oncologist, paediatric oncologist, haematologist or paediatric haematologist

All of the following:

- 1 Patient is to receive treatment with high dose anthracycline given with curative intent; and
- 2 Based on current treatment plan, patient's cumulative lifetime dose of anthracycline will exceed 250mg/m2 doxorubicin equivalent or greater; and
- 3 Dextrazoxane to be administered only whilst on anthracycline treatment; and
- 4 Either:
  - 4.1 Treatment to be used as a cardioprotectant for a child or young adult; or
  - 4.2 Treatment to be used as a cardioprotectant for secondary malignancy.

**MESNA**

Tab 400 mg .....	314.00	50	Uromitexan
Tab 600 mg .....	448.50	50	Uromitexan
Inj 100 mg per ml, 4 ml ampoule .....	177.45	15	Uromitexan
Inj 100 mg per ml, 10 ml ampoule .....	407.40	15	Uromitexan

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Vinca Alkaloids</b>			
VINBLASTINE SULPHATE			
Inj 1 mg per ml, 10 ml vial.....	270.37	5	Hospira
VINCRIStINE SULPHATE			
Inj 1 mg per ml, 1 ml vial.....	74.52	5	DBL Vincristine Sulfate
Inj 1 mg per ml, 2 ml vial.....	102.73	5	DBL Vincristine Sulfate
VINORELBINE			
Cap 20 mg – 5% DV Oct-23 to 2025 .....	30.00	1	<b>Vinorelbine Te Arai</b>
Cap 30 mg – 5% DV Oct-23 to 2025 .....	40.00	1	<b>Vinorelbine Te Arai</b>
Cap 80 mg – 5% DV Oct-23 to 2025 .....	60.00	1	<b>Vinorelbine Te Arai</b>
Inj 10 mg per ml, 1 ml vial.....	12.00	1	Navelbine
Inj 10 mg per ml, 5 ml vial.....	56.00	1	Navelbine
<i>(Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 October 2024)</i>			
<i>(Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 October 2024)</i>			

## Endocrine Therapy

ABIRATERONE ACETATE – **Restricted** see terms [below](#)

⚠ Tab 250 mg ..... 4,276.19 120 Zytiga

➡ **Restricted (RS1888)**

### Initiation

Medical oncologist, radiation oncologist or urologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has prostate cancer; and
- 2 Patient has metastases; and
- 3 Patient's disease is castration resistant; and
- 4 Either:

4.1 All of the following:

- 4.1.1 Patient is symptomatic; and
- 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
- 4.1.3 Patient has ECOG performance score of 0-1; and
- 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or

4.2 All of the following:

- 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
- 4.2.2 Patient has ECOG performance score of 0-2; and
- 4.2.3 Patient has not had prior treatment with abiraterone.

### Continuation

Medical oncologist, radiation oncologist or urologist

*Re-assessment required after 6 months*

All of the following:

- 1 Significant decrease in serum PSA from baseline; and
- 2 No evidence of clinical disease progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The treatment remains appropriate and the patient is benefiting from treatment.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

**Continuation – pandemic circumstances**

*Re-assessment required after 6 months*

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Abiraterone acetate to be discontinued at progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

**BICALUTAMIDE**

Tab 50 mg – 5% DV Dec-23 to 2026 ..... 4.18 28 **Binarex**

**FLUTAMIDE**

Tab 250 mg ..... 119.50 100 Flutamin

**FULVESTRANT – Restricted** see terms [below](#)

↓ Inj 50 mg per ml, 5 ml prefilled syringe..... 1,068.00 2 Faslodex

→ **Restricted (RS1732)**

**Initiation**

Medical oncologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has oestrogen-receptor positive locally advanced or metastatic breast cancer; and
- 2 Patient has disease progression following prior treatment with an aromatase inhibitor or tamoxifen for their locally advanced or metastatic disease; and
- 3 Treatment to be given at a dose of 500 mg monthly following loading doses; and
- 4 Treatment to be discontinued at disease progression.

**Continuation**

Medical oncologist

*Re-assessment required after 6 months*

All of the following:

- 1 Treatment remains appropriate and patient is benefitting from treatment; and
- 2 Treatment to be given at a dose of 500 mg monthly; and
- 3 No evidence of disease progression.

**OCTREOTIDE – Some items restricted** see terms [below](#)

Inj 50 mcg per ml, 1 ml ampoule – 5% DV Jun-22 to 2024 ..... 27.58 5 **Max Health**

Inj 100 mcg per ml, 1 ml ampoule – 5% DV Jun-22 to 2024 ..... 32.71 5 **Max Health**

Inj 500 mcg per ml, 1 ml ampoule – 5% DV Jun-22 to 2024 ..... 113.10 5 **Max Health**

↓ Inj depot 10 mg prefilled syringe – 5% DV Mar-22 to 2024 ..... 439.97 1 **Octreotide Depot Teva**

↓ Inj depot 20 mg prefilled syringe – 5% DV Mar-22 to 2024 ..... 647.03 1 **Octreotide Depot Teva**

↓ Inj depot 30 mg prefilled syringe – 5% DV Mar-22 to 2024 ..... 718.55 1 **Octreotide Depot Teva**

→ **Restricted (RS1889)**

**Initiation – Malignant bowel obstruction**

All of the following:

- 1 The patient has nausea\* and vomiting\* due to malignant bowel obstruction\*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with \* are unapproved indications

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Initiation – acromegaly

*Re-assessment required after 3 months*

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
  - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
  - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
  - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

## Continuation – acromegaly

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

## Initiation – Other indications

Any of the following:

- 1 VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
  - 2.1 Gastrinoma; and
  - 2.2 Either:
    - 2.2.1 Patient has failed surgery; or
    - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 3 Both:
  - 3.1 Insulinomas; and
  - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
  - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
  - 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: restriction applies only to the long-acting formulations of octreotide

## Initiation – pre-operative acromegaly

*Limited to 12 months treatment*

All of the following:

- 1 Patient has acromegaly; and
- 2 Patient has a large pituitary tumour, greater than 10 mm at its widest; and
- 3 Patient is scheduled to undergo pituitary surgery in the next six months.

Note: Indications marked with \* are unapproved indications

## Continuation – Acromegaly - pandemic circumstances

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has acromegaly; and
- 2 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 3 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>TAMOXIFEN CITRATE</b>			
Tab 10 mg – 5% DV Dec-23 to 2026 .....	15.00	60	<b>Tamoxifen Sandoz</b>
Tab 20 mg – 5% DV Dec-23 to 2026 .....	5.32	60	<b>Tamoxifen Sandoz</b>

**Aromatase Inhibitors**

<b>ANASTROZOLE</b>			
Tab 1 mg – 5% DV Dec-23 to 2026 .....	4.39	30	<b>Anatrole</b>
<b>EXEMESTANE</b>			
Tab 25 mg – 5% DV Nov-23 to 2026 .....	9.86	30	<b>Pfizer Exemestane</b>
<b>LETROZOLE</b>			
Tab 2.5 mg – 5% DV Jan-22 to 2024 .....	5.84	30	<b>Letrole</b>

**Imaging Agents**

<b>AMINOLEVULINIC ACID HYDROCHLORIDE – Restricted see terms below</b>			
↓ Powder for oral soln, 30 mg per ml, 1.5 g vial .....	4,400.00	1	Gliolan
	44,000.00	10	Gliolan

→ **Restricted (RS1565)**

**Initiation – high grade malignant glioma**

All of the following:

- 1 Patient has newly diagnosed, untreated, glioblastoma multiforme; and
- 2 Treatment to be used as adjuvant to fluorescence-guided resection; and
- 3 Patient's tumour is amenable to complete resection.

**Immunosuppressants**

**Calcineurin Inhibitors**

<b>CICLOSPORIN</b>			
Cap 25 mg .....	44.63	50	Neoral
Cap 50 mg .....	88.91	50	Neoral
Cap 100 mg .....	177.81	50	Neoral
Oral liq 100 mg per ml .....	198.13	50 ml	Neoral
Inj 50 mg per ml, 5 ml ampoule .....	276.30	10	Sandimmun
<b>TACROLIMUS – Restricted see terms below</b>			
↓ Cap 0.5 mg .....	49.60	100	Tacrolimus Sandoz
↓ Cap 0.75 mg .....	99.30	100	Tacrolimus Sandoz
↓ Cap 1 mg .....	84.30	100	Tacrolimus Sandoz
↓ Cap 5 mg .....	248.20	50	Tacrolimus Sandoz
↓ Inj 5 mg per ml, 1 ml ampoule			

→ **Restricted (RS1990)**

**Initiation – organ transplant recipients**

Any specialist

For use in organ transplant recipients.

**Initiation – non-transplant indications\***

Any specialist

Both:

- 1 Patient requires long-term systemic immunosuppression; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2 Either:

- 2.1 Ciclosporin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response; or
- 2.2 Patient is a child with nephrotic syndrome\*.

Note: Indications marked with \* are unapproved indications

**Fusion Proteins**

ETANERCEPT – **Restricted** see terms [below](#)

⚡ Inj 25 mg autoinjector – 5% DV Feb-21 to 2024	690.00	4	<b>Enbrel</b>
⚡ Inj 25 mg vial – 5% DV Sep-19 to 2024	690.00	4	<b>Enbrel</b>
⚡ Inj 50 mg autoinjector – 5% DV Sep-19 to 2024	1,050.00	4	<b>Enbrel</b>
⚡ Inj 50 mg syringe – 5% DV Sep-19 to 2024	1,050.00	4	<b>Enbrel</b>

➔ **Restricted** (RS1879)

**Initiation – polyarticular course juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 6 months*

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and
- 1.2 Either:
  - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
  - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for polyarticular course JIA; or

2 All of the following:

- 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
- 2.3 Any of the following:
  - 2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
  - 2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
  - 2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

**Continuation – polyarticular course juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 6 months*

Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
  - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

continued...



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

**Initiation – oligoarticular course juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 6 months*

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for oligoarticular course juvenile idiopathic arthritis (JIA); and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for oligoarticular course JIA; or

2 All of the following:

2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and

2.3 Any of the following:

2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or

2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose); or

2.3.3 High disease activity (cJADAS10 score greater than 4) after a 6-month trial of methotrexate.

**Continuation – oligoarticular course juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 6 months*

Both:

1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

**Initiation – Arthritis - rheumatoid**

Rheumatologist

*Re-assessment required after 6 months*

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects; or

1.2.2 The patient has received insufficient benefit to meet the renewal criteria for rheumatoid arthritis; or

2 All of the following:

2.1 Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and

2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.3 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
- 2.4 Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated); and
- 2.5 Either:
  - 2.5.1 Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin; or
  - 2.5.2 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate; and
- 2.6 Either:
  - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
  - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

### Continuation – Arthritis - rheumatoid

Any relevant practitioner

*Re-assessment required after 2 years*

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

### Initiation – ankylosing spondylitis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
    - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
  - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
  - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
  - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
  - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
  - 2.5 Either:
    - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

continued...

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

continued...

2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

**Continuation – ankylosing spondylitis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

**Initiation – psoriatic arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for adalimumab or secukinumab for psoriatic arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab or secukinumab; or
    - 1.2.2 The patient has received insufficient benefit from adalimumab or secukinumab to meet the renewal criteria for adalimumab or secukinumab for psoriatic arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
  - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
  - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
  - 2.4 Either:
    - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
    - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2.5 Any of the following:

- 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
- 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

### Continuation – psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Both:

1 Either:

- 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

### Initiation – severe chronic plaque psoriasis, prior TNF use

Dermatologist

*Limited to 4 months treatment*

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
- 2 Either:
  - 2.1 The patient has experienced intolerable side effects from adalimumab; or
  - 2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and
- 3 Patient must be reassessed for continuation after 3 doses.

### Initiation – severe chronic plaque psoriasis, treatment-naive

Dermatologist

*Limited to 4 months treatment*

All of the following:

- 1 Either:
  - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
  - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

**Continuation – severe chronic plaque psoriasis**

Dermatologist

*Re-assessment required after 6 months*

Both:

1 Either:

1.1 Both:

1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

1.1.2 Either:

1.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or

1.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or

1.2 Both:

1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and

1.2.2 Either:

1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or

1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

**Initiation – pyoderma gangrenosum**

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum\*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.

Note: Indications marked with \* are unapproved indications.

**Continuation – pyoderma gangrenosum**

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

**Initiation – adult-onset Still's disease**

Rheumatologist

*Re-assessment required after 6 months*

Either:

1 Both:

1.1 Either:

1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or

1.1.2 The patient has been started on tocilizumab for AOSD in a Te Whatu Ora Hospital; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
- 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2 All of the following:

- 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
- 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
- 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

### Continuation – adult-onset Still's disease

Rheumatologist

*Re-assessment required after 6 months*

The patient has a sustained improvement in inflammatory markers and functional status.

### Initiation – undifferentiated spondyloarthritis

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis\* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day (or maximum tolerated dose); and
- 4 Patient has tried and not responded to at least three months of leflunomide at a dose of up to 20 mg daily (or maximum tolerated dose); and
- 5 Any of the following:
  - 5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour measured no more than one month prior to the date of this application; or
  - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with \* are unapproved indications.

### Continuation – undifferentiated spondyloarthritis

Rheumatologist or medical practitioner on the recommendation of a Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Either:
  - 1.1 Applicant is a rheumatologist; or
  - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg dose every 7 days.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Monoclonal Antibodies

ABCIXIMAB – **Restricted** see terms [below](#)

↓ Inj 2 mg per ml, 5 ml vial

→ **Restricted (RS1202)**

### Initiation

Either:

- 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
- 2 For use in patients undergoing intra-cranial intervention.

ADALIMUMAB (AMGEVITA) – **Restricted** see terms [below](#)

↓ Inj 20 mg per 0.4 ml prefilled syringe – 5% DV Oct-22 to 31 Jul 2026.....	190.00	1	<b>Amgevita</b>
↓ Inj 40 mg per 0.8 ml prefilled pen – 5% DV Oct-22 to 31 Jul 2026.....	375.00	2	<b>Amgevita</b>
↓ Inj 40 mg per 0.8 ml prefilled syringe – 5% DV Oct-22 to 31 Jul 2026.....	375.00	2	<b>Amgevita</b>

→ **Restricted (RS1940)**

### Initiation – Behcet's disease - severe

Any relevant practitioner

Both:

- 1 The patient has severe Behcet's disease\* that is significantly impacting the patient's quality of life; and
- 2 Either:
  - 2.1 The patient has severe ocular, neurological, and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s); or
  - 2.2 The patient has severe gastrointestinal, rheumatological and/or mucocutaneous symptoms and has not responded adequately to two or more treatments appropriate for the particular symptom(s).

Note: Indications marked with \* are unapproved indications.

### Initiation – Hidradenitis suppurativa

Dermatologist

*Re-assessment required after 4 months*

All of the following:

- 1 Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
- 2 Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has demonstrated intolerance to or has contraindications for systemic antibiotics; and
- 3 Patient has 3 or more active lesions; and
- 4 The patient has a DLQI of 10 or more and the assessment is no more than 1 month old at time of application.

### Continuation – Hidradenitis suppurativa

Any relevant practitioner

*Re-assessment required after 2 years*

Both:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a DLQI improvement of 4 or more from baseline.

### Initiation – Plaque psoriasis - severe chronic

Dermatologist

*Re-assessment required after 4 months*

Either:

- 1 Both:
  - 1.1 Patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
  - 1.2 Either:
    - 1.2.1 Patient has experienced intolerable side effects; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
  - 2.1 Either:
    - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
    - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
  - 2.2 Patient has tried, but had an inadequate response to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
  - 2.3 A PASI assessment or (DLQI) assessment has been completed for at least the most recent prior treatment course but no longer than 1 month following cessation of each prior treatment course and is no more than 1 month old at the time of application.

## Continuation – Plaque psoriasis - severe chronic

Any relevant practitioner

*Re-assessment required after 2 years*

Either:

- 1 Both:
  - 1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
  - 1.2 Either:
    - 1.2.1 The patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
    - 1.2.2 The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value; or
- 2 Both:
  - 2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
  - 2.2 Either:
    - 2.2.1 The patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
    - 2.2.2 The patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value.

## Initiation – pyoderma gangrenosum

Dermatologist

Both:

- 1 Patient has pyoderma gangrenosum\*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response.

Note: Indications marked with \* are unapproved indications.

## Initiation – Crohn's disease - adults

Any relevant practitioner

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
  - 2.1 Patient has a CDAI score of greater than or equal to 300 or HBI score of greater than or equal to 10; or
  - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or

continued...



Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
- 2.4 Patient has an ileostomy or colostomy and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

**Continuation – Crohn's disease - adults**

Any relevant practitioner

*Re-assessment required after 2 years*

Any of the following:

- 1 CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced 3 points, from when the patient was initiated on adalimumab; or
- 2 CDAI score is 150 or less, or HBI is 4 or less; or
- 3 The patient has demonstrated an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed.

**Initiation – Crohn's disease - children**

Any relevant practitioner

*Re-assessment required after 6 months*

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Either:
  - 2.1 Patient has a PCDAI score of greater than or equal to 30; or
  - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

**Continuation – Crohn's disease - children**

Any relevant practitioner

*Re-assessment required after 2 years*

Any of the following:

- 1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
- 2 PCDAI score is 15 or less; or
- 3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed.

**Initiation – Crohn's disease - fistulising**

Any relevant practitioner

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Any of the following:
  - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
  - 2.2 Patient has one or more rectovaginal fistula(e); or
  - 2.3 Patient has complex peri-anal fistula; and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application.

**Continuation – Crohn's disease - fistulising**

Any relevant practitioner

*Re-assessment required after 2 years*

Either:

- 1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Initiation – Ocular inflammation - chronic

Any relevant practitioner

*Re-assessment required after 4 months*

Either:

- 1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; or
- 2 Both:
  - 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
  - 2.2 Any of the following:
    - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
    - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
    - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

## Continuation – Ocular inflammation - chronic

Any relevant practitioner

*Re-assessment required after 2 years*

Any of the following:

- 1 The patient has had a good clinical response following 12 weeks' initial treatment; or
- 2 Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

## Initiation – Ocular inflammation - severe

Any relevant practitioner

*Re-assessment required after 4 months*

Either:

- 1 Patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; or
- 2 Both:
  - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
  - 2.2 Any of the following:
    - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
    - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
    - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

## Continuation – Ocular inflammation - severe

Any relevant practitioner

*Re-assessment required after 2 years*

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 3 Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

**Initiation – ankylosing spondylitis**

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 Patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects; or
    - 1.2.2 The patient has received insufficient benefit to meet the renewal criteria for ankylosing spondylitis; or
- 2 All of the following:
  - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
  - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
  - 2.3 Patient has bilateral sacroiliitis demonstrated by radiology imaging; and
  - 2.4 Patient has not responded adequately to treatment with two or more NSAIDs, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
  - 2.5 Either:
    - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following BASMI measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
    - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender; and
  - 2.6 A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment and is no more than 1 month old at the time of application.

**Continuation – ankylosing spondylitis**

Any relevant practitioner

*Re-assessment required after 2 years*

For applications where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less.

**Initiation – Arthritis - oligoarticular course juvenile idiopathic**

Named specialist or rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for etanercept for oligoarticular course juvenile idiopathic arthritis (JIA); and
  - 1.2 Either:
    - 1.2.1 Patient has experienced intolerable side effects; or
    - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for oligoarticular course JIA; or
- 2 All of the following:
  - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
  - 2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and
  - 2.3 Either:
    - 2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose).

### **Continuation – Arthritis - oligoarticular course juvenile idiopathic**

Any relevant practitioner

*Re-assessment required after 2 years*

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

### **Initiation – Arthritis - polyarticular course juvenile idiopathic**

Named specialist or rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 Patient has had an initial Special Authority approval for etanercept for polyarticular course juvenile idiopathic arthritis (JIA); and
  - 1.2 Either:
    - 1.2.1 Patient has experienced intolerable side effects; or
    - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for polyarticular course JIA; or
- 2 All of the following:
  - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
  - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
  - 2.3 Any of the following:
    - 2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
    - 2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
    - 2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

### **Continuation – Arthritis - polyarticular course juvenile idiopathic**

Any relevant practitioner

*Re-assessment required after 2 years*

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

### **Initiation – Arthritis - psoriatic**

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 Patient has had an initial Special Authority approval for etanercept or secukinumab for psoriatic arthritis; and
  - 1.2 Either:
    - 1.2.1 Patient has experienced intolerable side effects; or
    - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for psoriatic arthritis; or

continued...

	Price		Brand or Generic Manufacturer
	(ex man. \$)	excl. GST) Per	

continued...

2 All of the following:

- 2.1 Patient has had active psoriatic arthritis for six months duration or longer; and
- 2.2 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
- 2.3 Patient has tried and not responded to at least three months of sulfasalazine or leflunomide at maximum tolerated doses (unless contraindicated); and
- 2.4 Either:
  - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
  - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
  - 2.5.1 Patient has CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 2.5.2 Patient has an elevated ESR greater than 25 mm per hour; or
  - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Continuation – Arthritis – psoriatic**

Any relevant practitioner

*Re-assessment required after 2 years*

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in swollen joint count from baseline and a clinically significant response in the opinion of the physician; or
- 2 Patient demonstrates at least a continuing 30% improvement in swollen joint count from baseline and a clinically significant response in the opinion of the treating physician.

**Initiation – Arthritis - rheumatoid**

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects; or
    - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
  - 2.1 Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
  - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
  - 2.3 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
  - 2.4 Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated); and
  - 2.5 Either:
    - 2.5.1 Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin; or
    - 2.5.2 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

leflunomide alone or in combination with methotrexate; and

2.6 Either:

- 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
- 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

## Continuation – Arthritis - rheumatoid

Any relevant practitioner

*Re-assessment required after 2 years*

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

## Initiation – Still's disease - adult-onset (AOSD)

Rheumatologist

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for etanercept and/or tocilizumab for (AOSD); and
  - 1.2 Either:
    - 1.2.1 Patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
    - 1.2.2 Patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab; or
- 2 All of the following:
  - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria; and
  - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, NSAIDs and methotrexate; and
  - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

## Initiation – ulcerative colitis

Any relevant practitioner

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Either:
  - 2.1 Patient's SCCAI score is greater than or equal to 4; or
  - 2.2 Patient's PUCAI score is greater than or equal to 20; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and systemic corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

## Continuation – ulcerative colitis

Any relevant practitioner

*Re-assessment required after 2 years*

Either:

- 1 The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on biologic therapy; or
- 2 The PUCAI score has reduced by 10 points or more from the PUCAI score when the patient was initiated on biologic therapy.

continued...

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

**Initiation – undifferentiated spondyloarthritis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis\* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has tried and not responded to at least three months of each of methotrexate, sulphasalazine and leflunomide, at maximum tolerated doses (unless contraindicated); and
- 3 Any of the following:
  - 3.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 3.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
  - 3.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with \* are unapproved indications.

**Continuation – undifferentiated spondyloarthritis**

Any relevant practitioner

*Re-assessment required after 2 years*

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response in the opinion of the treating physician.

**Initiation – inflammatory bowel arthritis – axial**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has axial inflammatory pain for six months or more; and
- 3 Patient is unable to take NSAIDs; and
- 4 Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI; and
- 5 Patient has not responded adequately to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist; and
- 6 A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment.

**Continuation – inflammatory bowel arthritis – axial**

Any relevant practitioner

*Re-assessment required after 2 years*

Where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less.

**Initiation – inflammatory bowel arthritis – peripheral**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 3 Patient has tried and not experienced a response to at least three months of methotrexate, or azathioprine at a maximum tolerated dose (unless contraindicated); and
- 4 Patient has tried and not experienced a response to at least three months of sulphasalazine at a maximum tolerated dose (unless contraindicated); and
- 5 Any of the following:
  - 5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 5.2 Patient has an ESR greater than 25 mm per hour; or
  - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

### Continuation – inflammatory bowel arthritis – peripheral

Any relevant practitioner

*Re-assessment required after 2 years*

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 Patient demonstrates at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician.

ADALIMUMAB (HUMIRA - ALTERNATIVE BRAND) – **Restricted** see terms [below](#)

‡ Inj 20 mg per 0.2 ml prefilled syringe.....	1,599.96	2	Humira
‡ Inj 40 mg per 0.4 ml prefilled syringe.....	1,599.96	2	Humira
‡ Inj 40 mg per 0.4 ml prefilled pen .....	1,599.96	2	HumiraPen
‡ Inj 40 mg per 0.8 ml pen.....	1,599.96	2	HumiraPen
‡ Inj 40 mg per 0.8 ml syringe .....	1,599.96	2	Humira

*(HumiraPen Inj 40 mg per 0.8 ml pen to be delisted 1 March 2024)*

*(Humira Inj 40 mg per 0.8 ml syringe to be delisted 1 March 2024)*

➔ **Restricted (RS1922)**

### Initiation – Behcet’s disease – severe

Any relevant practitioner

*Re-assessment required after 6 months*

All of the following:

- 1 Either:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

### Continuation – Behcet’s disease – severe

Any relevant practitioner

*Re-assessment required after 6 months*

Both:

- 1 The patient has had a good clinical response to treatment with measurably improved quality of life; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

continued...



Price			Brand or
(ex man.	excl. GST)	Per	Generic
\$			Manufacturer

continued...

**Initiation – Hidradenitis suppurativa**

Dermatologist or Practitioner on the recommendation of a dermatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Either:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 7 days. Fortnightly dosing has been considered.

**Continuation – Hidradenitis suppurativa**

Dermatologist or Practitioner on the recommendation of a dermatologist

*Re-assessment required after 6 months*

All of the following:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
- 3 Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

**Initiation – Psoriasis - severe chronic plaque**

Dermatologist or Practitioner on the recommendation of a dermatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Either:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Continuation – Psoriasis - severe chronic plaque**

Dermatologist or Practitioner on the recommendation of a dermatologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 Both:
    - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
    - 1.1.2 Either:
      - 1.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
      - 1.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
  - 1.2 Both:

continued...

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

- 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
- 1.2.2 Either:
  - 1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
  - 1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

### Initiation – Pyoderma gangrenosum

Dermatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Either:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 A maximum of 8 doses.

### Continuation – Pyoderma gangrenosum

Dermatologist

*Re-assessment required after 6 months*

Both:

- 1 The patient has demonstrated clinical improvement and continues to require treatment; and
- 2 A maximum of 8 doses.

### Initiation – Crohn's disease - adult

Gastroenterologist or Practitioner on the recommendation of a gastroenterologist

*Re-assessment required after 6 months*

All of the following:

- 1 Any of the following:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
  - 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

### Continuation – Crohn's disease - adult

Gastroenterologist or Practitioner on the recommendation of a gastroenterologist

*Re-assessment required after 6 months*

Both:

- 1 Any of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
  - 1.2 CDAI score is 150 or less; or
  - 1.3 The patient has demonstrated an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – Crohn’s disease - children**

Gastroenterologist or Practitioner on the recommendation of a gastroenterologist

*Re-assessment required after 6 months*

All of the following:

- 1 Any of the following:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
  - 1.3 Patient has Crohn’s and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Continuation – Crohn’s disease - children**

Gastroenterologist or Practitioner on the recommendation of a gastroenterologist

*Re-assessment required after 6 months*

Both:

- 1 Any of the following:
  - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
  - 1.2 PCDAI score is 15 or less; or
  - 1.3 The patient has demonstrated an adequate response to treatment, but PCDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – Crohn’s disease - fistulising**

Gastroenterologist or Practitioner on the recommendation of a gastroenterologist

*Re-assessment required after 6 months*

All of the following:

- 1 Any of the following:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
  - 1.3 Patient has Crohn’s and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Continuation – Crohn’s disease - fistulising**

Gastroenterologist or Practitioner on the recommendation of a gastroenterologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or

continued...

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

continued...

- 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain; and

- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

### **Initiation – Ocular inflammation – chronic**

Any relevant practitioner

*Re-assessment required after 12 months*

All of the following:

- 1 Any of the following:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
  - 1.3 Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

### **Continuation – Ocular inflammation – chronic**

Any relevant practitioner

*Re-assessment required after 12 months*

Both:

- 1 Any of the following:
  - 1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
  - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
  - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

### **Initiation – Ocular inflammation – severe**

Any relevant practitioner

*Re-assessment required after 12 months*

All of the following:

- 1 Any of the following:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
  - 1.3 Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

### **Continuation – Ocular inflammation – severe**

Any relevant practitioner

*Re-assessment required after 12 months*

Both:

- 1 Any of the following:
  - 1.1 The patient has had a good clinical response following 3 initial doses; or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
  - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – ankylosing spondylitis**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Either:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita); and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Continuation – ankylosing spondylitis**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

Both:

- 1 Treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – Arthritis – oligoarticular course juvenile idiopathic**

Named specialist or rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Either:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

**Continuation – Arthritis – oligoarticular course juvenile idiopathic**

Named specialist or rheumatologist

*Re-assessment required after 6 months*

For patients that demonstrate at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

**Initiation – Arthritis – polyarticular course juvenile idiopathic**

Named specialist or rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Either:

continued...

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

continued...

- 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
- 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

### Continuation – Arthritis - polyarticular course juvenile idiopathic

Named specialist or rheumatologist

*Re-assessment required after 6 months*

For patients that demonstrate at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

### Initiation – Arthritis - psoriatic

Named specialist or rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Either:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

### Continuation – Arthritis - psoriatic

Named specialist or rheumatologist

*Re-assessment required after 6 months*

Both:

- 1 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

### Initiation – Arthritis – rheumatoid

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Either:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Either:
  - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
  - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

**Continuation – Arthritis – rheumatoid**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

Both:

- 1 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 2 Either:
  - 2.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
  - 2.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

**Initiation – Still's disease – adult-onset (AOSD)**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Either:
  - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
  - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

**Continuation – Still's disease – adult-onset (AOSD)**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

the patient has demonstrated a sustained improvement in inflammatory markers and functional status.

**AFLIBERCEPT – Restricted** see terms [below](#)

↓ Inj 40 mg per ml, 0.1 ml vial.....1,250.00      1      Eylea

➔ **Restricted (RS1872)**

**Initiation – Wet Age Related Macular Degeneration**

Ophthalmologist or nurse practitioner

*Re-assessment required after 3 months*

Either:

- 1 All of the following:
  - 1.1 Any of the following:
    - 1.1.1 Wet age-related macular degeneration (wet AMD); or
    - 1.1.2 Polypoidal choroidal vasculopathy; or
    - 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
  - 1.2 Either:
    - 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
    - 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
  - 1.3 There is no structural damage to the central fovea of the treated eye; and
  - 1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or
- 2 Either:
  - 2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.2 Patient has previously\* (\*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

### Continuation – Wet Age Related Macular Degeneration

Ophthalmologist or nurse practitioner

*Re-assessment required after 12 months*

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 3 There is no structural damage to the central fovea of the treated eye.

### Initiation – Diabetic Macular Oedema

Ophthalmologist or nurse practitioner

*Re-assessment required after 4 months*

All of the following:

- 1 Patient has centre involving diabetic macular oedema (DMO); and
- 2 Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
- 3 Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
- 4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
- 5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

### Continuation – Diabetic Macular Oedema

Ophthalmologist or nurse practitioner

*Re-assessment required after 12 months*

All of the following:

- 1 There is stability or two lines of Snellen visual acuity gain; and
- 2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
- 3 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
- 5 After each consecutive 12 months treatment with aflibercept, patient has retrialled with at least one injection of bevacizumab and had no response.

**BASILIXIMAB – Restricted** see terms [below](#)

⚡ Inj 20 mg vial .....	2,560.00	1	Simulect
------------------------	----------	---	----------

➔ **Restricted (RS1203)**

#### Initiation

For use in solid organ transplants.

**BENRALIZUMAB – Restricted** see terms [below](#)

⚡ Inj 30 mg per ml, 1 ml prefilled pen .....	3,539.00	1	Fasenra
--	----------	---	---------

➔ **Restricted (RS1920)**

### Initiation – Severe eosinophilic asthma

Respiratory physician or clinical immunologist

*Re-assessment required after 12 months*

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and

continued...



Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 4 Patient has a blood eosinophil count of greater than  $0.5 \times 10^9$  cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long-acting beta-2 agonist, or budesonide/formoterol as part of the anti-inflammatory reliever therapy plus maintenance regimen, unless contraindicated or not tolerated; and
- 6 Either:
  - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
  - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
- 7 Treatment is not to be used in combination with subsidised mepolizumab; and
- 8 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment; and
- 9 Either:
  - 9.1 Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma; or
  - 9.2 Both:
    - 9.2.1 Patient was refractory or intolerant to previous anti-IL5 biological therapy; and
    - 9.2.2 Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment.

**Continuation – Severe eosinophilic asthma**

Respiratory physician or clinical immunologist

*Re-assessment required after 2 years*

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 Either:
  - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with benralizumab; or
  - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

BEVACIZUMAB – **Restricted** see terms [below](#)

↓ Inj 25 mg per ml, 4 ml vial

↓ Inj 25 mg per ml, 16 ml vial

→ **Restricted (RS1691)**

**Initiation – Recurrent Respiratory Papillomatosis**

Otolaryngologist

*Re-assessment required after 12 months*

All of the following:

- 1 Maximum of 6 doses; and
- 2 The patient has recurrent respiratory papillomatosis; and
- 3 The treatment is for intra-lesional administration.

**Continuation – Recurrent Respiratory Papillomatosis**

Otolaryngologist

*Re-assessment required after 12 months*

All of the following:

- 1 Maximum of 6 doses; and
- 2 The treatment is for intra-lesional administration; and
- 3 There has been a reduction in surgical treatments or disease regrowth as a result of treatment.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Initiation – ocular conditions

Either:

- 1 Ocular neovascularisation; or
- 2 Exudative ocular angiopathy.

## CASIRIVIMAB AND IMDEVIMAB – Restricted see terms [below](#)

† Inj 120 mg per ml casirivimab, 11.1 ml vial (1) and inj 120 mg per ml imdevimab, 11.1 ml vial (1).....	0.00	1	Ronapreve
--	------	---	-----------

### → Restricted (RS1874)

## Initiation – Treatment of profoundly immunocompromised patients

Limited to 2 weeks treatment

All of the following:

- 1 Patient has confirmed (or probable) COVID-19; and
- 2 The patient is in the community (treated as an outpatient) with mild to moderate disease severity\*; and
- 3 Patient is profoundly immunocompromised\*\* and is at risk of not having mounted an adequate response to vaccination against COVID-19 or is unvaccinated; and
- 4 Patient's symptoms started within the last 10 days; and
- 5 Patient is not receiving high flow oxygen or assisted/mechanical ventilation; and
- 6 Casirivimab and imdevimab is to be administered at a maximum dose of no greater than 2,400 mg.

Notes: \* Mild to moderate disease severity as described on the [Ministry of Health Website](#)

\*\* Examples include B-cell depletive illnesses or patients receiving treatment that is B-Cell depleting.

## Initiation – mild to moderate COVID-19-hospitalised patients

Any relevant practitioner

Limited to 2 weeks treatment

All of the following:

- 1 Patient has confirmed (or probable) COVID-19; and
- 2 Patient is an in-patient in hospital with mild to moderate disease severity\*; and
- 3 Patient's symptoms started within the last 10 days; and
- 4 Patient is not receiving high flow oxygen or assisted/mechanical ventilation; and
- 5 Any of the following:
  - 5.1 Age > 50; or
  - 5.2 BMI > 30; or
  - 5.3 Patient is Māori or Pacific ethnicity; or
  - 5.4 Patient is at increased risk of severe illness from COVID-19, excluding pregnancy, as described on the Ministry of Health website (see Notes); and
- 6 Either:
  - 6.1 Patient is unvaccinated; or
  - 6.2 Patient is seronegative where serology testing is readily available or strongly suspected to be seronegative where serology testing is not available; and
- 7 Casirivimab and imdevimab is to be administered at a maximum dose of no greater than 2,400 mg.

Notes: \* Mild to moderate disease severity as described on the [Ministry of Health Website](#)

\*\* (<https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-information-specific-audiences/covid-19-advice-higher-risk-people>)

## CETUXIMAB – Restricted see terms [below](#)

† Inj 5 mg per ml, 20 ml vial.....	364.00	1	Erbitux
‡ Inj 5 mg per ml, 100 ml vial.....	1,820.00	1	Erbitux

### → Restricted (RS1613)

## Initiation

Medical oncologist

All of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck; and
- 2 Patient is contraindicated to, or is intolerant of, cisplatin; and
- 3 Patient has good performance status; and
- 4 To be administered in combination with radiation therapy.

**GEMTUZUMAB OZOGAMICIN – Restricted** see terms [below](#)

↓ Inj 5 mg vial .....	12,973.00	1	Mylotarg
-----------------------	-----------	---	----------

→ **Restricted (RS1923)**

**Initiation**

All of the following:

- 1 Patient has not received prior chemotherapy for this condition; and
- 2 Patient has de novo CD33-positive acute myeloid leukaemia; and
- 3 Patient does not have acute promyelocytic leukaemia; and
- 4 Gemtuzumab ozogamicin will be used in combination with standard anthracycline and cytarabine (AraC); and
- 5 Patient is being treated with curative intent; and
- 6 Patient's disease risk has been assessed by cytogenetic testing to be good or intermediate; and
- 7 Patient must be considered eligible for standard intensive remission induction chemotherapy with standard anthracycline and cytarabine (AraC); and
- 8 Gemtuzumab ozogamicin to be funded for one course only (one dose at 3 mg per m<sup>2</sup> body surface area or up to 2 vials of 5 mg as separate doses).

Note: Acute myeloid leukaemia excludes acute promyelocytic leukaemia and acute myeloid leukaemia that is secondary to another haematological disorder (eg myelodysplasia or myeloproliferative disorder).

**INFLIXIMAB – Restricted** see terms [below](#)

↓ Inj 100 mg – 5% DV Sep-20 to 2025 .....	428.00	1	<b>Remicade</b>
---	--------	---	-----------------

→ **Restricted (RS1941)**

**Initiation – Graft vs host disease**

Patient has steroid-refractory acute graft vs. host disease of the gut.

**Initiation – rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 4 months*

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
  - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
  - 2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
- 3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

**Continuation – rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

### Initiation – ankylosing spondylitis

Rheumatologist

*Re-assessment required after 3 months*

Both:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and

2 Either:

2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or

2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

### Continuation – ankylosing spondylitis

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and

2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

### Initiation – psoriatic arthritis

Rheumatologist

*Re-assessment required after 4 months*

Both:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis; and

2 Either:

2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept and/or secukinumab; or

2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept and/or secukinumab, the patient did not meet the renewal criteria for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis.

### Continuation – psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Both:

1 Either:

1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and

2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

### Initiation – severe ocular inflammation

*Re-assessment required after 4 months*

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and

1.2 Either:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or

2 Both:

- 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
- 2.2 Any of the following:
  - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
  - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
  - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

**Continuation – severe ocular inflammation**

*Re-assessment required after 12 months*

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

**Initiation – chronic ocular inflammation**

*Re-assessment required after 4 months*

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and
- 1.2 Either:
  - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
  - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation; or

2 Both:

- 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2.2 Any of the following:
  - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
  - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at therapeutic dose; or
  - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

**Continuation – chronic ocular inflammation**

*Re-assessment required after 12 months*

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

- 3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

### Initiation – Pulmonary sarcoidosis

Both:

- 1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
- 2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

### Initiation – Crohn's disease (adults)

Any relevant practitioner

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has active Crohn's disease; and
- 2 Any of the following:
  - 2.1 Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10; or
  - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
  - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
  - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

### Continuation – Crohn's disease (adults)

Any relevant practitioner

*Re-assessment required after 2 years*

Both:

- 1 Any of the following:
  - 1.1 CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced by 3 points, from when the patient was initiated on infliximab; or
  - 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
  - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score and/or HBI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

### Initiation – Crohn's disease (children)

Any relevant practitioner

*Re-assessment required after 6 months*

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Either:
  - 2.1 Patient has a PCDAI score of greater than or equal to 30; or
  - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

continued...

Price		Brand or
(ex man.	excl. GST)	Generic
\$	Per	Manufacturer

continued...

**Continuation – Crohn's disease (children)**

Any relevant practitioner

*Re-assessment required after 2 years*

Both:

- 1 Any of the following:
  - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
  - 1.2 PCDAI score is 15 or less; or
  - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

**Initiation – fistulising Crohn's disease**

Gastroenterologist

*Re-assessment required after 6 months*

Both:

- 1 Patient has confirmed Crohn's disease; and
- 2 Any of the following:
  - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
  - 2.2 Patient has one or more rectovaginal fistula(e); or
  - 2.3 Patient has complete peri-anal fistula.

**Continuation – fistulising Crohn's disease**

Any relevant practitioner

*Re-assessment required after 2 years*

Both:

- 1 Either:
  - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
  - 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

**Initiation – acute fulminant ulcerative colitis**

Gastroenterologist

*Limited to 6 weeks treatment*

Both:

- 1 Patient has acute, fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

**Continuation – fulminant ulcerative colitis**

Any relevant practitioner

*Re-assessment required after 2 years*

Both:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Initiation – ulcerative colitis

Any relevant practitioner

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Either:
  - 2.1 Patients SCCAI is greater than or equal to 4; or
  - 2.2 Patients PUCAI score is greater than or equal to 20; and
- 3 Patient has experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and systemic corticosteroids.

## Continuation – ulcerative colitis

Any relevant practitioner

*Re-assessment required after 2 years*

Both:

- 1 Either:
  - 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
  - 1.2 The PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

## Initiation – plaque psoriasis

Dermatologist

*Re-assessment required after 3 doses*

Either:

- 1 Both:
  - 1.1 Patient has had an initial Special Authority approval for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis; and
  - 1.2 Either:
    - 1.2.1 Patient has experienced intolerable side effects from adalimumab, etanercept or secukinumab; or
    - 1.2.2 Patient has received insufficient benefit from adalimumab, etanercept or secukinumab to meet the renewal criteria for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis; or
- 2 All of the following:
  - 2.1 Either:
    - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
    - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
  - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
  - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
  - 2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

continued...



	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation – plaque psoriasis**

Dermatologist

*Re-assessment required after 3 doses*

Both:

- 1 Either:
  - 1.1 Both:
    - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
    - 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
  - 1.2 Both:
    - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
    - 1.2.2 Either:
      - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
      - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

**Initiation – neurosarcoidosis**

Neurologist

*Re-assessment required after 18 months*

All of the following:

- 1 Biopsy consistent with diagnosis of neurosarcoidosis; and
- 2 Patient has CNS involvement; and
- 3 Patient has steroid-refractory disease; and
- 4 Either:
  - 4.1 IV cyclophosphamide has been tried; or
  - 4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

**Continuation – neurosarcoidosis**

Neurologist

*Re-assessment required after 18 months*

Either:

- 1 A withdrawal period has been tried and the patient has relapsed; or
- 2 All of the following:
  - 2.1 A withdrawal period has been considered but would not be clinically appropriate; and
  - 2.2 There has been a marked reduction in prednisone dose; and
  - 2.3 Either:
    - 2.3.1 There has been an improvement in MRI appearances; or
    - 2.3.2 Marked improvement in other symptomology.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Initiation – severe Behcet's disease

*Re-assessment required after 4 months*

All of the following:

- 1 The patient has severe Behcet's disease which is significantly impacting the patient's quality of life (see Notes); and
- 2 Either:
  - 2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or
  - 2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and
- 3 The patient is experiencing significant loss of quality of life.

Notes:

- a) Behcet's disease diagnosed according to the International Study Group for Behcet's Disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al J Rheumatol. 2004;31:931-7.
- b) Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

## Continuation – severe Behcet's disease

*Re-assessment required after 6 months*

Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

## Initiation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum\*;
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.

Note: Indications marked with \* are unapproved indications.

## Continuation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

## Initiation – Inflammatory bowel arthritis (axial)

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has had axial inflammatory pain for six months or more; and
- 3 Patient is unable to take NSAIDs; and
- 4 Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI; and
- 5 Patient has not experienced an adequate response to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist; and
- 6 Patient has a BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

previous pharmacological treatment .

**Continuation – Inflammatory bowel arthritis (axial)**

*Re-assessment required after 2 years*

Where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10-point scale, or an improvement in BASDAI of 50%, whichever is less.

**Initiation – Inflammatory bowel arthritis (peripheral)**

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn’s disease; and
- 2 Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular; and
- 3 Patient has tried and not experienced a response to at least three months of methotrexate or azathioprine at a maximum tolerated dose (unless contraindicated); and
- 4 Patient has tried and not experienced a response to at least three months of sulfasalazine at a maximum tolerated dose (unless contraindicated); and
- 5 Any of the following:
  - 5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 5.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
  - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Continuation – Inflammatory bowel arthritis (peripheral)**

*Re-assessment required after 2 years*

Either:

- 1 Following initial treatment, patient has experienced at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 Patient has experienced at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician.

MEPOLIZUMAB – **Restricted** see terms [below](#)

⚡ Inj 100 mg prefilled pen .....	1,638.00	1	Nucala
⚡ Inj 100 mg vial .....	1,638.00	1	Nucala

*(Nucala Inj 100 mg vial to be delisted 1 August 2024)*

➡ **Restricted (RS1918)**

**Initiation – Severe eosinophilic asthma**

Respiratory physician or clinical immunologist

*Re-assessment required after 12 months*

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than  $0.5 \times 10^9$  cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the single maintenance and reliever therapy regimen, unless contraindicated or not tolerated; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

6 Either:

- 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
- 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and

7 Treatment is not to be used in combination with subsidised benralizumab; and

8 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment; and

9 Either:

- 9.1 Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma; and
- 9.2 Both:
  - 9.2.1 Patient was refractory or intolerant to previous anti-IL5 biological therapy; and
  - 9.2.2 Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment.

## Continuation – Severe eosinophilic asthma

Respiratory physician or clinical immunologist

*Re-assessment required after 2 years*

Both:

1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and

2 Either:

- 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with mepolizumab; or
- 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

OBINUTUZUMAB – **Restricted** see terms [below](#)

↓ Inj 25 mg per ml, 40 ml vial.....	5,910.00	1	Gazyva
-------------------------------------	----------	---	--------

→ **Restricted (RS1919)**

### Initiation

Haematologist

*Limited to 6 months treatment*

All of the following:

- 1 The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is obinutuzumab treatment naive; and
- 3 The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
- 4 Patient has adequate neutrophil and platelet counts\* unless the cytopenias are a consequence of marrow infiltration by CLL; and
- 5 Patient has good performance status; and
- 6 Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

\* greater than or equal to  $1.5 \times 10^9/L$  and platelets greater than or equal to  $75 \times 10^9/L$

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

**Initiation – follicular / marginal zone lymphoma**

*Re-assessment required after 9 months*

All of the following:

- 1 Either:
  - 1.1 Patient has follicular lymphoma; or
  - 1.2 Patient has marginal zone lymphoma; and
- 2 Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen\*; and
- 3 Patient has an ECOG performance status of 0-2; and
- 4 Patient has been previously treated with no more than four chemotherapy regimens; and
- 5 Obinutuzumab to be administered at a maximum dose of 1000 mg for a maximum of 6 cycles in combination with chemotherapy\*.

Note: \* includes unapproved indications

**Continuation – follicular / marginal zone lymphoma**

*Re-assessment required after 24 months*

All of the following:

- 1 Patient has no evidence of disease progression following obinutuzumab induction therapy; and
- 2 Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and
- 3 Obinutuzumab to be discontinued at disease progression.

OMALIZUMAB – **Restricted** see terms [below](#)

↓ Inj 150 mg prefilled syringe.....	450.00	1	Xolair
↓ Inj 150 mg vial .....	450.00	1	Xolair

→ **Restricted (RS1652)**

**Initiation – severe asthma**

Clinical immunologist or respiratory specialist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient must be aged 6 years or older ; and
- 2 Patient has a diagnosis of severe asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
- 5 Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Either:
  - 6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
  - 6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less; and
- 8 Baseline measurements of the patient’s asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

**Continuation – severe asthma**

Respiratory specialist

*Re-assessment required after 6 months*

Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

### Initiation – severe chronic spontaneous urticaria

Clinical immunologist or dermatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Either:
  - 2.1 Both:
    - 2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
    - 2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; and
- 3 Any of the following:
  - 3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
  - 3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
  - 3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and
- 4 Either:
  - 4.1 Treatment to be stopped if inadequate response\* following 4 doses; or
  - 4.2 Complete response\* to 6 doses of omalizumab.

### Continuation – severe chronic spontaneous urticaria

Clinical immunologist or dermatologist

*Re-assessment required after 6 months*

Either:

- 1 Patient has previously had a complete response\* to 6 doses of omalizumab; or
- 2 Both:
  - 2.1 Patient has previously had a complete response\* to 6 doses of omalizumab; and
  - 2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: \*Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

**PALIVIZUMAB – Restricted** see terms [below](#)

⚠ Inj 100 mg per ml, 1 ml vial.....	1,700.00	1	Synagis
-------------------------------------	----------	---	---------

*(Synagis Inj 100 mg per ml, 1 ml vial to be delisted 1 January 2024)*

➡ **Restricted (RS1907)**

### Initiation – RSV prophylaxis for the 2022/2023 RSV seasons, in the context of COVID-19

Paediatrician

*Re-assessment required after 6 months*

Either:

- 1 Infant was born in the last 2 years and has severe lung, airway, neurological or neuromuscular disease that requires ongoing, life-sustaining community ventilation; or
- 2 Both:
  - 2.1 Infant was born in the last 12 months; and
  - 2.2 Any of the following:
    - 2.2.1 Patient was born at less than 28 weeks gestation; or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

2.2.2 Both:

2.2.2.1 Patient was born at less than 32 weeks gestation; and

2.2.2.2 Either:

2.2.2.2.1 Patient has chronic lung disease; or

2.2.2.2.2 Patient is Māori or any Pacific ethnicity; or

2.2.3 Both:

2.2.3.1 Patient has haemodynamically significant heart disease; and

2.2.3.2 Any of the following:

2.2.3.2.1 Patient has unoperated simple congenital heart disease with significant left to right shunt (see note a); or

2.2.3.2.2 Patient has unoperated or surgically palliated complex congenital heart disease; or

2.2.3.2.3 Patient has severe pulmonary hypertension (see note b); or

2.2.3.2.4 Patient has moderate or severe LV failure (see note c).

Notes:

- a) Patient requires/will require heart failure medication, and/or patient has significant pulmonary hypertension, and/or patient will require surgical palliation/definitive repair within the next 3 months.
- b) Mean pulmonary artery pressure more than 25 mmHg.
- c) LV Ejection Fraction less than 40%.

**Continuation – RSV prophylaxis for the 2022/2023 RSV seasons, in the context of COVID-19**

Paediatrician

*Re-assessment required after 6 months*

Patient still meets initial criteria.

PERTUZUMAB – **Restricted** see terms [below](#)

↓ Inj 30 mg per ml, 14 ml vial.....3,927.00      1      Perjeta

➔ **Restricted (RS1995)**

**Initiation**

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
  - 2.1 Patient is chemotherapy treatment naive; or
  - 2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
- 3 The patient has good performance status (ECOG grade 0-1); and
- 4 Pertuzumab to be administered in combination with trastuzumab; and
- 5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
- 6 Pertuzumab to be discontinued at disease progression.

**Continuation**

*Re-assessment required after 12 months*

Either:

- 1 Both:
  - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  - 1.2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab; or

continued...

# ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

2 All of the following:

- 2.1 Patient has previously discontinued treatment with pertuzumab and trastuzumab for reasons other than severe toxicity or disease progression; and
- 2.2 Patient has signs of disease progression; and
- 2.3 Disease has not progressed during previous treatment with pertuzumab and trastuzumab.

**RANIBIZUMAB – Restricted** see terms [below](#)

⚡ Inj 10 mg per ml, 0.23 ml vial

⚡ Inj 10 mg per ml, 0.3 ml vial

➔ **Restricted (RS1870)**

**Initiation – Wet Age Related Macular Degeneration**

Ophthalmologist or nurse practitioner

*Re-assessment required after 3 months*

Either:

1 All of the following:

1.1 Any of the following:

- 1.1.1 Wet age-related macular degeneration (wet AMD); or
- 1.1.2 Polypoidal choroidal vasculopathy; or
- 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and

1.2 Either:

- 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
- 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and

1.3 There is no structural damage to the central fovea of the treated eye; and

1.4 Patient has not previously been treated with aflibercept for longer than 3 months; or

2 Patient has current approval to use aflibercept for treatment of wAMD and was found to be intolerant to aflibercept within 3 months.

**Continuation – Wet Age Related Macular Degeneration**

Ophthalmologist or nurse practitioner

*Re-assessment required after 12 months*

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 3 There is no structural damage to the central fovea of the treated eye.

**RITUXIMAB (MABTHERA) – Restricted** see terms [below](#)

⚡ Inj 10 mg per ml, 10 ml vial..... 1,075.50

⚡ Inj 10 mg per ml, 50 ml vial..... 2,688.30

2 Mabthera

1 Mabthera

➔ **Restricted (RS1785)**

**Initiation – rheumatoid arthritis - prior TNF inhibitor use**

Rheumatologist

*Limited to 4 months treatment*

All of the following:

1 Both:

- 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and

1.2 Either:

continued...



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
- 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and

2 Either:

- 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

**Initiation – rheumatoid arthritis - TNF inhibitors contraindicated**

Rheumatologist

*Limited to 4 months treatment*

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
  - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
  - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
  - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 6 Either:
  - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
  - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
  - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
- 8 Either:
  - 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

**Continuation – rheumatoid arthritis - re-treatment in 'partial responders' to rituximab**

Rheumatologist

*Re-assessment required after 4 months*

All of the following:

- 1 Any of the following:
  - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
  - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

### Continuation – rheumatoid arthritis - re-treatment in 'responders' to rituximab

Rheumatologist

*Re-assessment required after 4 months*

All of the following:

- 1 Either:
  - 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
  - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
  - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

RITUXIMAB (RIXIMYO) – **Restricted** see terms [below](#)

⚡ Inj 10 mg per ml, 10 ml vial.....	275.33	2	Riximyo
⚡ Inj 10 mg per ml, 50 ml vial.....	688.20	1	Riximyo

➔ **Restricted (RS1973)**

### Initiation – haemophilia with inhibitors

Haematologist

Any of the following:

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

### Continuation – haemophilia with inhibitors

Haematologist

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

### Initiation – post-transplant

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder\*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with \* are unapproved indications.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

**Continuation – post-transplant**

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder\*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with \* are unapproved indications.

**Initiation – indolent, low-grade lymphomas or hairy cell leukaemia\***

*Re-assessment required after 9 months*

Either:

- 1 Both:
  - 1.1 The patient has indolent low grade NHL or hairy cell leukaemia\* with relapsed disease following prior chemotherapy; and
  - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
  - 2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia\* requiring first-line systemic chemotherapy; and
  - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. \*Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

**Continuation – indolent, low-grade lymphomas or hairy cell leukaemia\***

*Re-assessment required after 12 months*

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia\* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. \*Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

**Initiation – aggressive CD20 positive NHL**

Either:

- 1 All of the following:
  - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
  - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
  - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
  - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
  - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

**Continuation – aggressive CD20 positive NHL**

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

**Initiation – Chronic lymphocytic leukaemia**

*Re-assessment required after 12 months*

All of the following:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 Any of the following:
  - 2.1 The patient is rituximab treatment naive; or
  - 2.2 Either:
    - 2.2.1 The patient is chemotherapy treatment naive; or
    - 2.2.2 Both:
      - 2.2.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
      - 2.2.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; or
  - 2.3 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; and
- 3 The patient has good performance status; and
- 4 Either:
  - 4.1 The patient does not have chromosome 17p deletion CLL; or
  - 4.2 Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia; and
- 5 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles; and
- 6 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

### Continuation – Chronic lymphocytic leukaemia

*Re-assessment required after 12 months*

Both:

- 1 Either:
  - 1.1 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; or
  - 1.2 All of the following:
    - 1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
    - 1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
    - 1.2.3 The patient does not have chromosome 17p deletion CLL; and
    - 1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and
- 2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

### Initiation – severe cold haemagglutinin disease (CHAD)

Haematologist

*Re-assessment required after 8 weeks*

All of the following:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has cold haemagglutinin disease\*; and
- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Note: Indications marked with \* are unapproved indications.

**Continuation – severe cold haemagglutinin disease (CHAD)**

Haematologist

*Re-assessment required after 8 weeks*

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m<sup>2</sup> weekly for 4 weeks) is now planned; or
- 2 All of the following:
  - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease\*; and
  - 2.2 An initial response lasting at least 12 months was demonstrated; and
  - 2.3 Patient now requires repeat treatment.

Note: Indications marked with \* are unapproved indications.

**Initiation – warm autoimmune haemolytic anaemia (warm AIHA)**

Haematologist

*Re-assessment required after 8 weeks*

All of the following:

- 1 Patient has warm autoimmune haemolytic anaemia\*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Note: Indications marked with \* are unapproved indications.

**Continuation – warm autoimmune haemolytic anaemia (warm AIHA)**

Haematologist

*Re-assessment required after 8 weeks*

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m<sup>2</sup> weekly for 4 weeks) is now planned; or
- 2 All of the following:
  - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia\*; and
  - 2.2 An initial response lasting at least 12 months was demonstrated; and
  - 2.3 Patient now requires repeat treatment.

Note: Indications marked with \* are unapproved indications.

**Initiation – immune thrombocytopenic purpura (ITP)**

Haematologist

*Re-assessment required after 8 weeks*

All of the following:

- 1 Either:
  - 1.1 Patient has immune thrombocytopenic purpura\* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
  - 1.2 Patient has immune thrombocytopenic purpura\* with a platelet count of 20,000 to 30,000 platelets per microlitre

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

and significant mucocutaneous bleeding; and

2 Any of the following:

- 2.1 Treatment with steroids and splenectomy have been ineffective; or
- 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
- 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy); and

3 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Note: Indications marked with \* are unapproved indications.

### Continuation – immune thrombocytopenic purpura (ITP)

Haematologist

*Re-assessment required after 8 weeks*

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m<sup>2</sup> weekly for 4 weeks) is now planned; or
- 2 All of the following:
  - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura\*; and
  - 2.2 An initial response lasting at least 12 months was demonstrated; and
  - 2.3 Patient now requires repeat treatment.

Note: Indications marked with \* are unapproved indications.

### Initiation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

*Re-assessment required after 8 weeks*

Both:

- 1 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks; and
- 2 Either:
  - 2.1 Patient has thrombotic thrombocytopenic purpura\* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
  - 2.2 Patient has acute idiopathic thrombotic thrombocytopenic purpura\* with neurological or cardiovascular pathology.

Note: Indications marked with \* are unapproved indications.

### Continuation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

*Re-assessment required after 8 weeks*

All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura\*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Note: Indications marked with \* are unapproved indications.

### Initiation – pure red cell aplasia (PRCA)

Haematologist

*Re-assessment required after 6 weeks*

Patient has autoimmune pure red cell aplasia\* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with \* are unapproved indications.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

**Continuation – pure red cell aplasia (PRCA)**

Haematologist

*Re-assessment required after 6 weeks*

Patient was previously treated with rituximab for pure red cell aplasia\* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with \* are unapproved indications.

**Initiation – ANCA associated vasculitis**

*Re-assessment required after 8 weeks*

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis\*; and
- 2 The total rituximab dose would not exceed the equivalent of 375 mg/m<sup>2</sup> of body-surface area per week for a total of 4 weeks; and
- 3 Any of the following:
  - 3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
  - 3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
  - 3.3 Cyclophosphamide and methotrexate are contraindicated; or
  - 3.4 Patient is a female of child-bearing potential; or
  - 3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with \* are unapproved indications.

**Continuation – ANCA associated vasculitis**

*Re-assessment required after 8 weeks*

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis\*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m<sup>2</sup> of body-surface area per week for a total of 4 weeks.

Note: Indications marked with \* are unapproved indications.

**Initiation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE\*; and
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with \* are unapproved indications.

**Continuation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

- 1 Patient's SLE\* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with \* are unapproved indications.

**Initiation – Antibody-mediated organ transplant rejection**

Patient has been diagnosed with antibody-mediated organ transplant rejection\*.

Note: Indications marked with \* are unapproved indications.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Initiation – ABO-incompatible organ transplant

Patient is to undergo an ABO-incompatible solid organ transplant\*.

Note: Indications marked with \* are unapproved indications.

## Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)

Nephrologist

*Re-assessment required after 8 weeks*

All of the following:

- 1 Patient is a child with SDNS\* or FRNS\*; and
- 2 Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
- 3 Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
- 4 Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
- 5 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Note: Indications marked with a \* are unapproved indications.

## Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)

Nephrologist

*Re-assessment required after 8 weeks*

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome\*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Note: Indications marked with a \* are unapproved indications.

## Initiation – Steroid resistant nephrotic syndrome (SRNS)

Nephrologist

*Re-assessment required after 8 weeks*

All of the following:

- 1 Patient is a child with SRNS\* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
- 2 Treatment with tacrolimus for at least 3 months has been ineffective; and
- 3 Genetic causes of nephrotic syndrome have been excluded; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Note: Indications marked with a \* are unapproved indications.

## Continuation – Steroid resistant nephrotic syndrome (SRNS)

Nephrologist

*Re-assessment required after 8 weeks*

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome\*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Note: Indications marked with a \* are unapproved indications.

continued...



	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

**Initiation – Neuromyelitis Optica Spectrum Disorder (NMOSD)**

*Re-assessment required after 6 months*

Both:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m<sup>2</sup> administered weekly for four weeks; and
- 2 Either:
  - 2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
  - 2.2 All of the following:
    - 2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
    - 2.2.2 The patient is receiving treatment with mycophenolate; and
    - 2.2.3 The patients is receiving treatment with corticosteroids.

**Continuation – Neuromyelitis Optica Spectrum Disorder (NMOSD)**

*Re-assessment required after 2 years*

All of the following:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m<sup>2</sup> administered weekly for four weeks; and
- 2 The patients has responded to the most recent course of rituximab; and
- 3 The patient has not received rituximab in the previous 6 months.

**Initiation – Severe Refractory Myasthenia Gravis**

Neurologist

*Re-assessment required after 2 years*

Both:

- 1 One of the following dose regimens is to be used: 375 mg/m<sup>2</sup> of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 Either:
  - 2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
  - 2.2 Both:
    - 2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
    - 2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

**Continuation – Severe Refractory Myasthenia Gravis**

Neurologist

*Re-assessment required after 2 years*

All of the following:

- 1 One of the following dose regimens is to be used: 375 mg/m<sup>2</sup> of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Either:
  - 3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
  - 3.2 Both:
    - 3.2.1 The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
    - 3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

continued...

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

## Initiation – Severe antisynthetase syndrome

*Re-assessment required after 12 months*

All of the following:

- 1 Patient has confirmed antisynthetase syndrome; and
- 2 Patient has severe, immediately life or organ threatening disease, including interstitial lung disease; and
- 3 Either:
  - 3.1 Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not be effective at controlling active disease; or
  - 3.2 Rapid treatment is required due to life threatening complications; and
- 4 Maximum of four 1,000 mg infusions of rituximab.

## Continuation – Severe antisynthetase syndrome

*Re-assessment required after 12 months*

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in inflammatory markers, muscle strength and pulmonary function; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 Maximum of two cycles of 2 x 1,000 mg infusions of rituximab given two weeks apart.

## Initiation – graft versus host disease

All of the following:

- 1 Patient has refractory graft versus host disease following transplant; and
- 2 Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not be effective at controlling active disease; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

## Initiation – severe chronic inflammatory demyelinating polyneuropathy

Neurologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has severe chronic inflammatory demyelinating polyneuropathy (CIPD); and
- 2 Either:
  - 2.1 Both:
    - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
    - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
  - 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m<sup>2</sup> of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

## Continuation – severe chronic inflammatory demyelinating polyneuropathy

Neurologist or medical practitioner on the recommendation of a Neurologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function compared to baseline; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 One of the following dose regimens is to be used: 375 mg/m<sup>2</sup> of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

continued...

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

**Initiation – anti-NMDA receptor autoimmune encephalitis**

Neurologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has severe anti-NMDA receptor autoimmune encephalitis; and
- 2 Either:
  - 2.1 Both:
    - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
    - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
  - 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m<sup>2</sup> of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

**Continuation – anti-NMDA receptor autoimmune encephalitis**

Neurologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 The patient has experienced a relapse and now requires further treatment; and
- 4 One of the following dose regimens is to be used: 375 mg/m<sup>2</sup> of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

**Initiation – CD20+ low grade or follicular B-cell NHL**

*Re-assessment required after 9 months*

Either:

- 1 Both:
  - 1.1 The patient has CD20+ low grade or follicular B-cell NHL with relapsed disease following prior chemotherapy; and
  - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
  - 2.1 The patient has CD20+ low grade or follicular B-cell NHL requiring first-line systemic chemotherapy; and
  - 2.2 To be used for a maximum of 6 treatment cycles.

**Continuation – CD20+ low grade or follicular B-cell NHL**

*Re-assessment required after 24 months*

Both:

- 1 Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy; and
- 2 Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m<sup>2</sup> every 8 weeks (maximum of 12 cycles).

**Initiation – Membranous nephropathy**

*Re-assessment required after 6 weeks*

All of the following:

- 1 Either:
  - 1.1 Patient has biopsy-proven primary/idiopathic membranous nephropathy\*; or
  - 1.2 Patient has PLA2 antibodies with no evidence of secondary cause, and an eGFR of > 60ml/min/1.73m<sup>2</sup>; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2 Patient remains at high risk of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures (see Note); and
- 3 The total rituximab dose would not exceed the equivalent of 375mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

### Continuation – Membranous nephropathy

*Re-assessment required after 6 weeks*

All of the following:

- 1 Patient was previously treated with rituximab for membranous nephropathy\*; and
- 2 Either:
  - 2.1 Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment; or
  - 2.2 Patient achieved partial response to treatment and requires repeat treatment (see Note); and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m<sup>2</sup> of body surface area per week for a total of 4 weeks.

Notes:

- a) Indications marked with \* are unapproved indications.
- b) High risk of progression to end-stage kidney disease defined as > 5g/day proteinuria.
- c) Conservative measures include renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents unless contraindicated or the patient has experienced intolerable side effects.
- d) Partial response defined as a reduction of proteinuria of at least 50% from baseline, and between 0.3 grams and 3.5 grams per 24 hours.

### Initiation – B-cell acute lymphoblastic leukaemia/lymphoma\*

*Limited to 2 years treatment*

All of the following:

- 1 Patient has newly diagnosed B-cell acute lymphoblastic leukaemia/lymphoma\*; and
- 2 Treatment must be in combination with an intensive chemotherapy protocol with curative intent; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m<sup>2</sup> per dose for a maximum of 18 doses.

Note: Indications marked with \* are unapproved indications.

### Initiation – desensitisation prior to transplant

*Limited to 6 weeks treatment*

Both:

- 1 Patient requires desensitisation prior to mismatched allogenic stem cell transplant\*; and
- 2 Patient would receive no more than two doses at 375 mg/m<sup>2</sup> of body-surface area.

Note: Indications marked with \* are unapproved indications.

### Initiation – pemphigus\*

Dermatologist or relevant specialist

*Re-assessment required after 6 months*

Either:

- 1 All of the following:
  - 1.1 Patient has severe rapidly progressive pemphigus; and
  - 1.2 Is used in combination with systemic corticosteroids (20 mg/day); and
  - 1.3 Any of the following:
    - 1.3.1 Skin involvement is at least 5% body surface area; or
    - 1.3.2 Significant mucosal involvement (10 or more mucosal erosions) or diffuse gingivitis or confluent large erosions; or
    - 1.3.3 Involvement of two or more mucosal sites; or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

2 Both:

- 2.1 Patient has pemphigus; and
- 2.2 Patient has not experienced adequate clinical benefit from systemic corticosteroids (20 mg/day) in combination with a steroid sparing agent, unless contraindicated.

Note: Indications marked with \* are unapproved indications.

**Continuation – pemphigus\***

Dermatologist or relevant specialist

*Re-assessment required after 6 months*

Both:

- 1 Patient has experienced adequate clinical benefit from rituximab treatment, with improvement in symptoms and healing of skin ulceration and reduction in corticosteroid requirement; and
- 2 Patient has not received rituximab in the previous 6 months.

Note: Indications marked with \* are unapproved indications.

**Initiation – immunoglobulin G4-related disease (IgG4-RD\*)**

*Re-assessment required after 6 weeks*

All of the following:

- 1 Patient has confirmed diagnosis of IgG4-RD\*; and
- 2 Either:
  - 2.1 Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs for at least 3 months has been ineffective in lowering corticosteroid dose below 5 mg per day (prednisone equivalent) without relapse; or
  - 2.2 Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs is contraindicated or associated with evidence of toxicity or intolerance; and
- 3 Total rituximab dose used should not exceed a maximum of two 1000 mg infusions of rituximab given two weeks apart.

Note: Indications marked with \* are unapproved indications.

**Continuation – immunoglobulin G4-related disease (IgG4-RD\*)**

*Re-assessment required after 12 months*

All of the following:

- 1 Either:
  - 1.1 Treatment with rituximab for IgG4-RD\* was previously successful and patient's disease has demonstrated sustained response, but the condition has relapsed; or
  - 1.2 Patient is receiving maintenance treatment for IgG4-RD\*; and
- 2 Rituximab re-treatment not to be given within 6 months of previous course of treatment; and
- 3 Maximum of two 1000 mg infusions of rituximab given two weeks apart.

Note: Indications marked with \* are unapproved indications.

**SECUKINUMAB – Restricted** see terms [below](#)

↓ Inj 150 mg per ml, 1 ml prefilled syringe.....	799.50	1	Cosentyx
	1,599.00	2	Cosentyx

➔ **Restricted (RS1863)**

**Initiation – severe chronic plaque psoriasis, second-line biologic**

Dermatologist

*Re-assessment required after 4 months*

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a Te Whatu Ora Hospital, for severe chronic plaque psoriasis; and
- 2 Either:
  - 2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or

continued...

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

- 2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and
- 3 A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

### Continuation – severe chronic plaque psoriasis, second-line biologic

Dermatologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
  - 1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

### Initiation – severe chronic plaque psoriasis, first-line biologic

Dermatologist

*Re-assessment required after 4 months*

All of the following:

- 1 Either:
  - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
  - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

### Continuation – severe chronic plaque psoriasis, first-line biologic

Dermatologist

*Re-assessment required after 6 months*

Both:

- 1 Either:
  - 1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
  - 1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

**Initiation – ankylosing spondylitis, second-line biologic**

Rheumatologist

*Re-assessment required after 3 months*

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
- 2 Either:
  - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
  - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

**Continuation – ankylosing spondylitis, second-line biologic**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Following 12 weeks initial treatment of secukinumab treatment, BASDAI has improved by 4 or more points from pre-secukinumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefitted from treatment and that continued treatment is appropriate; and
- 3 Secukinumab to be administered at doses no greater than 150 mg monthly.

**Initiation – psoriatic arthritis**

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 Patient has had an initial Special Authority approval for adalimumab, etanercept or infliximab for psoriatic arthritis; and
  - 1.2 Either:
    - 1.2.1 Patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
    - 1.2.2 Patient has received insufficient benefit from adalimumab, etanercept or infliximab to meet the renewal criteria for adalimumab, etanercept or infliximab for psoriatic arthritis; or
- 2 All of the following:
  - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
  - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
  - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
  - 2.4 Either:
    - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
    - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
  - 2.5 Any of the following:
    - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
    - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
    - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Continuation – psoriatic arthritis

Rheumatologist

*Re-assessment required after 6 months*

Both:

1 Either:

- 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior secukinumab treatment in the opinion of the treating physician; and

2 Secukinumab to be administered at doses no greater than 300 mg monthly.

## SILTUXIMAB – **Restricted** see terms [below](#)

⚡ Inj 100 mg vial .....	770.57	1	Sylvant
⚡ Inj 400 mg vial .....	3,082.33	1	Sylvant

➔ **Restricted (RS1525)**

### Initiation

Haematologist or rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

### Continuation

Haematologist or rheumatologist

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

## TIXAGEVIMAB WITH CILGAVIMAB – **Restricted** see terms [below](#)

⚡ Inj 100 mg per ml, 1.5 ml vial with cilgavimab 100 mg per ml, 1.5 ml vial .....	0.00	1	Evusheld
---	------	---	----------

➔ **Restricted (RS1911)**

### Initiation

Only if patient meets access criteria (as per <https://pharmac.govt.nz/Evusheld>). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability.

## TOCILIZUMAB – **Restricted** see terms [below](#)

⚡ Inj 20 mg per ml, 4 ml vial .....	220.00	1	Actemra
⚡ Inj 20 mg per ml, 10 ml vial .....	550.00	1	Actemra
⚡ Inj 20 mg per ml, 20 ml vial .....	1,100.00	1	Actemra

➔ **Restricted (RS1924)**

### Initiation – cytokine release syndrome

*Therapy limited to 3 doses*

Either:

- 1 All of the following:
  - 1.1 The patient is enrolled in the Children's Oncology Group AALL1731 trial; and
  - 1.2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
  - 1.3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg); or
- 2 All of the following:

continued...



Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
- 2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
- 2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

**Initiation – previous use**

Any relevant practitioner

*Limited to 6 months treatment*

Both:

- 1 Patient was being treated with tocilizumab prior to 1 February 2019; and
- 2 Any of the following:
  - 2.1 rheumatoid arthritis; or
  - 2.2 systemic juvenile idiopathic arthritis; or
  - 2.3 adult-onset Still's disease; or
  - 2.4 polyarticular juvenile idiopathic arthritis; or
  - 2.5 idiopathic multicentric Castleman's disease.

**Initiation – Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Limited to 6 months treatment*

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
  - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
  - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
  - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
  - 3.2 Both:
    - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a Te Whatu Ora Hospital; and
    - 3.2.2 Either:
      - 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
      - 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

**Initiation – Rheumatoid Arthritis**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 2 Tocilizumab is to be used as monotherapy; and
- 3 Either:
  - 3.1 Treatment with methotrexate is contraindicated; or
  - 3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
- 4 Either:
  - 4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or

continued...

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

- 4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
- 5 Either:
  - 5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
  - 5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 6 Either:
  - 6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

### Initiation – systemic juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

### Initiation – adult-onset Still's disease

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Both:
  - 1.1 Either:
    - 1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or
    - 1.1.2 The patient has been started on tocilizumab for AOSD in a Te Whatu Ora Hospital; and
  - 1.2 Either:
    - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
    - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
  - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
  - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
  - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

### Initiation – polyarticular juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 4 months*

Either:

- 1 Both:
  - 1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and
  - 1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or
- 2 All of the following:

continued...

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

- 2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
- 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
- 2.3 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.4 Any of the following:
  - 2.4.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
  - 2.4.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
  - 2.4.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

**Initiation – idiopathic multicentric Castleman's disease**

Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

**Initiation – moderate to severe COVID-19**

*Therapy limited to 1 dose*

All of the following:

- 1 Patient has confirmed (or probable) COVID-19; and
- 2 Oxygen saturation of < 92% on room air, or requiring supplemental oxygen; and
- 3 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and
- 4 Tocilizumab is to be administered at doses no greater than 8mg/kg IV for a maximum of one dose; and
- 5 Tocilizumab is not to be administered in combination with baricitinib.

**Continuation – Rheumatoid Arthritis**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

**Continuation – systemic juvenile idiopathic arthritis**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

**Continuation – adult-onset Still's disease**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

the patient has a sustained improvement in inflammatory markers and functional status.

**Continuation – polyarticular juvenile idiopathic arthritis**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
  - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

### Continuation – idiopathic multicentric Castleman's disease

Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist

*Re-assessment required after 12 months*

the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB – **Restricted** see terms [below](#)

⚡ Inj 150 mg vial .....	1,350.00	1	Herceptin
⚡ Inj 440 mg vial .....	3,875.00	1	Herceptin

➔ **Restricted (RS1996)**

### Initiation – Early breast cancer

*Limited to 12 months treatment*

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
  - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
  - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
  - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
  - 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
  - 3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

### Initiation – metastatic breast cancer (patients previously treated with trastuzumab)

*Limited to 12 months treatment*

Either:

- 1 All of the following:
  - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  - 1.2 Either:
    - 1.2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
    - 1.2.2 Both:
      - 1.2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerable side effects; and
      - 1.2.2.2 The cancer did not progress whilst on lapatinib; and
  - 1.3 Either:
    - 1.3.1 Trastuzumab will not be given in combination with pertuzumab; or
    - 1.3.2 All of the following:
      - 1.3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
      - 1.3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
      - 1.3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 1.4 Trastuzumab not to be given in combination with lapatinib; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1.5 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
  - 2.1 Patient has previously discontinued treatment with trastuzumab in the metastatic setting for reasons other than severe toxicity or disease progression; and
  - 2.2 Patient has signs of disease progression; and
  - 2.3 Disease has not progressed during previous treatment with trastuzumab.

**Initiation – Metastatic breast cancer (trastuzumab-naive patients)**

*Limited to 12 months treatment*

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
  - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
  - 2.2 Both:
    - 2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
    - 2.2.2 The cancer did not progress whilst on lapatinib; and
- 3 Either:
  - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
  - 3.2 All of the following:
    - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
    - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
    - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab not to be given in combination with lapatinib; and
- 5 Trastuzumab to be discontinued at disease progression.

**Continuation – Metastatic breast cancer**

*Re-assessment required after 12 months*

Either:

- 1 All of the following:
  - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
  - 1.2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
  - 1.3 Trastuzumab not to be given in combination with lapatinib; and
  - 1.4 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
  - 2.1 Patient has previously discontinued treatment with trastuzumab for reasons other than severe toxicity or disease progression; and
  - 2.2 Patient has signs of disease progression; and
  - 2.3 Disease has not progressed during previous treatment with trastuzumab.

TRASTUZUMAB EMTANSINE – **Restricted** see terms [below](#)

⚡ Inj 100 mg vial .....	2,320.00	1	Kadcyla
⚡ Inj 160 mg vial .....	3,712.00	1	Kadcyla

➔ **Restricted (RS1908)**

**Initiation – early breast cancer**

All of the following:

continued...

# ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has early breast cancer expressing HER2 IHC3+ or ISH+; and
- 2 Documentation of pathological invasive residual disease in the breast and/or auxiliary lymph nodes following completion of surgery; and
- 3 Patient has completed systemic neoadjuvant therapy with trastuzumab and chemotherapy prior to surgery; and
- 4 Disease has not progressed during neoadjuvant therapy; and
- 5 Patient has left ventricular ejection fraction of 45% or greater; and
- 6 Adjuvant treatment with trastuzumab emtansine to be commenced within 12 weeks of surgery; and
- 7 Trastuzumab emtansine to be discontinued at disease progression; and
- 8 Total adjuvant treatment duration must not exceed 42 weeks (14 cycles).

## Initiation – metastatic breast cancer

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
- 3 Either:
  - 3.1 The patient has received prior therapy for metastatic disease\*; or
  - 3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy\*; and
- 4 Patient has a good performance status (ECOG 0-1); and
- 5 Either:
  - 5.1 Patient does not have symptomatic brain metastases; or
  - 5.2 Patient has brain metastases and has received prior local CNS therapy; and
- 6 Patient has not received prior funded trastuzumab emtansine treatment; and
- 7 Treatment to be discontinued at disease progression.

## Continuation – metastatic breast cancer

*Re-assessment required after 6 months*

Both:

- 1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab emtansine; and
- 2 Treatment to be discontinued at disease progression.

Note: \*Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

USTEKINUMAB – **Restricted** see terms [below](#)

⚡ Inj 130 mg vial .....	4,162.00	1	Stelara
⚡ Inj 90 mg per ml, 1 ml prefilled syringe .....	4,162.00	1	Stelara

➡ **Restricted (RS1942)**

## Initiation – Crohn's disease - adults

*Re-assessment required after 6 months*

Either:

- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or
- 2 Both:
  - 2.1 Patient has active Crohn's disease; and
  - 2.2 Either:
    - 2.2.1 Patient has had an initial approval for prior biologic therapy for Crohn's disease and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
    - 2.2.2 Both:
      - 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for Crohn's disease; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2.2.2.2 Other biologics for Crohn's disease are contraindicated.

**Continuation – Crohn's disease - adults**

*Re-assessment required after 12 months*

Both:

- 1 Any of the following:
  - 1.1 CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy; or
  - 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
  - 1.3 The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed; and
- 2 Ustekinumab to be administered at a dose no greater than 90 mg every 8 weeks.

**Initiation – Crohn's disease - children\***

*Re-assessment required after 6 months*

Either:

- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or
- 2 Both:
  - 2.1 Patient has active Crohn's disease; and
  - 2.2 Either:
    - 2.2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
    - 2.2.2 Both:
      - 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for Crohn's disease; and
      - 2.2.2.2 Other biologics for Crohn's disease are contraindicated.

Note: Indication marked with \* is an unapproved indication.

**Continuation – Crohn's disease - children\***

*Re-assessment required after 12 months*

Both:

- 1 Any of the following:
  - 1.1 PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy; or
  - 1.2 PCDAI score is 15 or less; or
  - 1.3 The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Ustekinumab to administered at a dose no greater than 90 mg every 8 weeks.

Note: Indication marked with \* is an unapproved indication.

**Initiation – ulcerative colitis**

*Re-assessment required after 6 months*

Either:

- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or
- 2 Both:
  - 2.1 Patient has active ulcerative colitis; and
  - 2.2 Either:
    - 2.2.1 Patient has had an initial approval for prior biologic therapy for ulcerative colitis and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
    - 2.2.2 Both:
      - 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for ulcerative colitis; and
      - 2.2.2.2 Other biologics for ulcerative colitis are contraindicated.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

## Continuation – ulcerative colitis

*Re-assessment required after 12 months*

Both:

1 Either:

- 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy; or
- 1.2 PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy\*; and

2 Ustekinumab will be used at a dose no greater than 90 mg intravenously every 8 weeks.

Note: Criterion marked with \* is for an unapproved indication.

VEDOLIZUMAB – **Restricted** see terms [below](#)

‡ Inj 300 mg vial .....	3,313.00	1	Entyvio
-------------------------	----------	---	---------

➔ **Restricted (RS1943)**

## Initiation – Crohn's disease - adults

*Re-assessment required after 6 months*

All of the following:

1 Patient has active Crohn's disease; and

2 Any of the following:

- 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
- 2.2 Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10; or
- 2.3 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
- 2.4 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
- 2.5 Patient has an ileostomy or colostomy, and has intestinal inflammation; and

3 Any of the following:

- 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
- 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
- 3.3 Immunomodulators and corticosteroids are contraindicated.

## Continuation – Crohn's disease - adults

*Re-assessment required after 2 years*

Both:

1 Any of the following:

- 1.1 CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy; or
- 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
- 1.3 The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed; and

2 Vedolizumab to administered at a dose no greater than 300 mg every 8 weeks.

## Initiation – Crohn's disease - children\*

*Re-assessment required after 6 months*

All of the following:

1 Paediatric patient has active Crohn's disease; and

2 Any of the following:

- 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
- 2.2 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or

continued...



Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.3 Patient has extensive small intestine disease; and
- 3 Any of the following:
  - 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
  - 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
  - 3.3 Immunomodulators and corticosteroids are contraindicated.

Note: Indication marked with \* is an unapproved indication.

**Continuation – Crohn's disease - children\***

*Re-assessment required after 2 years*

Both:

- 1 Any of the following:
  - 1.1 PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy; or
  - 1.2 PCDAI score is 15 or less; or
  - 1.3 The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Vedolizumab to administered at a dose no greater than 300mg every 8 weeks.

Note: Indication marked with \* is an unapproved indication.

**Initiation – ulcerative colitis**

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Any of the following:
  - 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
  - 2.2 Patient has a SCCAI score is greater than or equal to 4; or
  - 2.3 Patient's PUCAI score is greater than or equal to 20\*; and
- 3 Any of the following:
  - 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
  - 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
  - 3.3 Immunomodulators and corticosteroids are contraindicated.

Note: Indication marked with \* is an unapproved indication.

**Continuation – ulcerative colitis**

*Re-assessment required after 2 years*

Both:

- 1 Either:
  - 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy; or
  - 1.2 The PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy \*; and
- 2 Vedolizumab will be used at a dose no greater than 300 mg intravenously every 8 weeks.

Note: Indication marked with \* is an unapproved indication.

**Programmed Cell Death-1 (PD-1) Inhibitors**

ATEZOLIZUMAB – **Restricted** see terms [below](#)

⬇ Inj 60 mg per ml, 20 ml vial.....9,503.00 1 Tecentriq

➡ **Restricted (RS1986)**

**Initiation – non-small cell lung cancer second line monotherapy**

Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist

*Re-assessment required after 4 months*

All of the following:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has locally advanced or metastatic non-small cell lung cancer; and
- 2 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 3 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- 4 Patient has an ECOG 0-2; and
- 5 Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy; and
- 6 Atezolizumab is to be used as monotherapy at a dose of 1200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and
- 7 Baseline measurement of overall tumour burden is documented clinically and radiologically.

### Continuation – non-small cell lung cancer second line monotherapy

Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist

*Re-assessment required after 4 months*

All of the following:

- 1 Any of the following:
  - 1.1 Patient's disease has had a complete response to treatment; or
  - 1.2 Patient's disease has had a partial response to treatment; or
  - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Atezolizumab to be used at a maximum dose of 1200 mg every three weeks (or equivalent); and
- 6 Treatment with atezolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

DURVALUMAB – **Restricted** see terms [below](#)

⚡ Inj 50 mg per ml, 10 ml vial.....	4,700.00	1	Imfinzi
⚡ Inj 50 mg per ml, 2.4 ml vial.....	1,128.00	1	Imfinzi

➔ **Restricted (RS1926)**

### Initiation – Non-small cell lung cancer

Medical oncologist

*Re-assessment required after 3 months*

All of the following:

- 1 Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC); and
- 2 Patient has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy; and
- 3 Patient has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation therapy treatment; and
- 4 Patient has a ECOG performance status of 0 or 1; and
- 5 Patient has completed last radiation dose within 8 weeks of starting treatment with durvalumab; and
- 6 Patient must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition; and
- 7 Either:
  - 7.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or
  - 7.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and
- 8 Treatment with durvalumab to cease upon signs of disease progression.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

**Continuation – Non-small cell lung cancer**

Medical oncologist

*Re-assessment required after 3 months*

All of the following:

- 1 The treatment remains clinically appropriate and the patient is benefitting from treatment; and
- 2 Either:
  - 2.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or
  - 2.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and
- 3 Treatment with durvalumab to cease upon signs of disease progression; and
- 4 Total continuous treatment duration must not exceed 12 months.

**NIVOLUMAB – Restricted** see terms [below](#)

↓ Inj 10 mg per ml, 4 ml vial.....	1,051.98	1	Opdivo
↓ Inj 10 mg per ml, 10 ml vial.....	2,629.96	1	Opdivo

→ **Restricted (RS1891)**

**Initiation**

Medical oncologist

*Re-assessment required after 4 months*

All of the following:

- 1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Patient has measurable disease as defined by RECIST version 1.1; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
  - 4.1 Patient has not received funded pembrolizumab; or
  - 4.2 Both:
    - 4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
    - 4.2.2 The cancer did not progress while the patient was on pembrolizumab; and
- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that funded treatment with nivolumab will not be continued if their disease progresses.

**Continuation**

Medical oncologist

*Re-assessment required after 4 months*

Either:

- 1 All of the following:
  - 1.1 Any of the following:
    - 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
    - 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
    - 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
  - 1.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and
  - 1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
  - 1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
  - 2.1 Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

2.2 Patient has signs of disease progression; and

2.3 Disease has not progressed during previous treatment with nivolumab.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks.

Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB – **Restricted** see terms [below](#)

⚡ Inj 25 mg per ml, 4 ml vial.....4,680.00      1      Keytruda

➔ **Restricted (RS1987)**

## Initiation

Medical oncologist

*Re-assessment required after 4 months*

All of the following:

- 1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Patient has measurable disease as defined by RECIST version 1.1; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
  - 4.1 Patient has not received funded nivolumab; or
  - 4.2 Both:
    - 4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
    - 4.2.2 The cancer did not progress while the patient was on nivolumab; and
- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that funded treatment with pembrolizumab will not be continued if their disease progresses.

## Continuation

Medical oncologist

*Re-assessment required after 4 months*

Either:

- 1 All of the following:
  - 1.1 Any of the following:
    - 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
    - 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
- 1.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and
- 1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
- 1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
  - 2.1 Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and
  - 2.2 Patient has signs of disease progression; and
  - 2.3 Disease has not progressed during previous treatment with pembrolizumab.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks.

Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

**Initiation – non-small cell lung cancer first-line monotherapy**

Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist

*Re-assessment required after 4 months*

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
- 2 Patient has not had chemotherapy for their disease in the palliative setting; and
- 3 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 4 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- 5 Pembrolizumab to be used as monotherapy; and
- 6 Either:
  - 6.1 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 50% as determined by a validated test unless not possible to ascertain; or
  - 6.2 Both:
    - 6.2.1 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 1% as determined by a validated test unless not possible to ascertain; and
    - 6.2.2 Chemotherapy is determined to be not in the best interest of the patient based on clinician assessment; and
- 7 Patient has an ECOG 0-2; and
- 8 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and

continued...

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

9 Baseline measurement of overall tumour burden is documented clinically and radiologically.

### Continuation – non-small cell lung cancer first-line monotherapy

Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist

*Re-assessment required after 4 months*

All of the following:

- 1 Any of the following:
  - 1.1 Patient's disease has had a complete response to treatment; or
  - 1.2 Patient's disease has had a partial response to treatment; or
  - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 6 Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

### Initiation – non-small cell lung cancer first-line combination therapy

Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist

*Re-assessment required after 4 months*

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
- 2 The patient has not had chemotherapy for their disease in the palliative setting; and
- 3 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 4 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- 5 Pembrolizumab to be used in combination with platinum-based chemotherapy; and
- 6 Patient has an ECOG 0-2; and
- 7 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and
- 8 Baseline measurement of overall tumour burden is documented clinically and radiologically.

### Continuation – non-small cell lung cancer first-line combination therapy

Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist

*Re-assessment required after 4 months*

All of the following:

- 1 Any of the following:
  - 1.1 Patient's disease has had a complete response to treatment; or
  - 1.2 Patient's disease has had a partial response to treatment; or
  - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 6 Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

## Other Immunosuppressants

ANTITHYMOCYTE GLOBULIN (EQUINE)

Inj 50 mg per ml, 5 ml ampoule .....	2,774.48	5	ATGAM
--------------------------------------	----------	---	-------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ANTITHYMOCYTE GLOBULIN (RABBIT)</b>			
Inj 25 mg vial			
<b>AZATHIOPRINE</b>			
Tab 25 mg – 5% DV Apr-23 to 2025 .....	7.36	60	<b>Azamun</b>
Tab 50 mg – 5% DV Mar-23 to 2025 .....	8.10	100	<b>Azamun</b>
Inj 50 mg vial			
Inj 100 mg vial			
<b>BACILLUS CALMETTE-GUERIN (BCG) – Restricted see terms below</b>			
↓ Inj 2-8 x 10 <sup>8</sup> CFU vial .....	149.37	1	OncoTICE
➔ <b>Restricted (RS1206)</b>			
<b>Initiation</b>			
For use in bladder cancer.			
<b>EVEROLIMUS – Restricted see terms below</b>			
↓ Tab 5 mg .....	4,555.76	30	Afinitor
↓ Tab 10 mg .....	6,512.29	30	Afinitor
➔ <b>Restricted (RS1811)</b>			
<b>Initiation</b>			
Neurologist or oncologist			
<i>Re-assessment required after 3 months</i>			
Both:			
1 Patient has tuberous sclerosis; and			
2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.			
<b>Continuation</b>			
Neurologist or oncologist			
<i>Re-assessment required after 12 months</i>			
All of the following:			
1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and			
2 The treatment remains appropriate and the patient is benefiting from treatment; and			
3 Everolimus to be discontinued at progression of SEGAs.			
<b>MYCOPHENOLATE MOFETIL</b>			
Tab 500 mg .....	35.90	50	CellCept
Cap 250 mg .....	35.90	100	CellCept
Powder for oral liq 1 g per 5 ml.....	187.25	165 ml	CellCept
Inj 500 mg vial .....	133.33	4	CellCept
<b>PICIBANIL</b>			
Inj 100 mcg vial			
<b>SIROLIMUS – Restricted see terms below</b>			
↓ Tab 1 mg .....	749.99	100	Rapamune
↓ Tab 2 mg .....	1,499.99	100	Rapamune
↓ Oral liq 1 mg per ml .....	449.99	60 ml	Rapamune
➔ <b>Restricted (RS1991)</b>			
<b>Initiation</b>			
For rescue therapy for an organ transplant recipient.			
Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:			
<ul style="list-style-type: none"> <li>• GFR &lt; 30 ml/min; or</li> <li>• Rapidly progressive transplant vasculopathy; or</li> </ul>			

continued...

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease

### Initiation – severe non-malignant lymphovascular malformations\*

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has severe non-malignant lymphovascular malformation\*; and
- 2 Any of the following:
  - 2.1 Malformations are not adequately controlled by sclerotherapy and surgery; or
  - 2.2 Malformations are widespread/extensive and sclerotherapy and surgery are not considered clinically appropriate; or
  - 2.3 Sirolimus is to be used to reduce malformation prior to consideration of surgery; and
- 3 Patient is being treated by a specialist lymphovascular malformation multi-disciplinary team; and
- 4 Patient has measurable disease as defined by RECIST version 1.1 (see Note).

### Continuation – severe non-malignant lymphovascular malformations\*

*Re-assessment required after 12 months*

All of the following:

- 1 Either:
  - 1.1 Patient's disease has had either a complete response or a partial response to treatment, or patient has stable disease according to RECIST version 1.1 (see Note); or
  - 1.2 Patient's disease has stabilised or responded clinically and disease response to treatment has been clearly documents in patient notes; and
- 2 No evidence of progressive disease; and
- 3 The treatment remains clinically appropriate and the patient is benefitting from the treatment.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer et al. Eur J Cancer 2009;45:228-47)

Indications marked with \* are unapproved indications

### Initiation – renal angiomyolipoma(s) associated with tuberous sclerosis complex\*

Nephrologist or urologist

*Re-assessment required after 6 months*

Both:

- 1 Patient has tuberous sclerosis complex\*; and
- 2 Evidence of renal angiomyolipoma(s) measuring 3 cm or greater and that have shown interval growth.

### Continuation – renal angiomyolipoma(s) associated with tuberous sclerosis complex\*

*Re-assessment required after 12 months*

All of the following:

- 1 Documented evidence of renal angiomyolipoma reduction or stability by magnetic resonance imaging (MRI) or ultrasound; and
- 2 Demonstrated stabilisation or improvement in renal function; and
- 3 The patient has not experienced angiomyolipoma haemorrhage or significant adverse effects to sirolimus treatment; and
- 4 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indications marked with \* are unapproved indications

### Initiation – refractory seizures associated with tuberous sclerosis complex\*

Neurologist

*Re-assessment required after 6 months*

All of the following:

- 1 Patient has epilepsy with a background of documented tuberous sclerosis complex\*; and

continued...



	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

2 Either:

2.1 Both:

- 2.1.1 Vigabatrin has been trialled and has not adequately controlled seizures; and
- 2.1.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least two of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); or

2.2 Both:

- 2.2.1 Vigabatrin is contraindicated; and
- 2.2.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least three of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); and

3 Seizures have a significant impact on quality of life; and

4 Patient has been assessed and surgery is considered inappropriate for this patient, or the patient has been assessed and would benefit from mTOR inhibitor treatment prior to surgery.

Note: Those of childbearing potential are not required to trial phenytoin sodium, sodium valproate, and topiramate. Those who can father children are not required to trial sodium valproate.

**Continuation – refractory seizures associated with tuberous sclerosis complex\***

Neurologist

*Re-assessment required after 12 months*

demonstrated significant and sustained improvement in seizure rate (e.g. 50% reduction in seizure frequency) or severity and/or patient quality of life compared with baseline prior to starting sirolimus treatment.

Note: Indications marked with \* are unapproved indications

**JAK inhibitors**

BARICITINIB – **Restricted** see terms [below](#)

↓ Tab 2 mg .....	0.00	28	Olumiant
↓ Tab 4 mg .....	0.00	28	Olumiant

→ **Restricted (RS1876)**

**Initiation – moderate to severe COVID-19\***

*Limited to 14 days treatment*

All of the following:

- 1 Patient has confirmed (or probable) COVID-19\*; and
- 2 Oxygen saturation of < 92% on room air, or requiring supplemental oxygen; and
- 3 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and
- 4 Baricitinib is to be administered at doses no greater than 4 mg daily for up to 14 days; and
- 5 Baricitinib is not to be administered in combination with tocilizumab.

Note: Indications marked with \* are unapproved indications.

UPADACITINIB – **Restricted** see terms [below](#)

↓ Tab 15 mg .....	1,271.00	28	RINVOQ
-------------------	----------	----	--------

→ **Restricted (RS1861)**

**Initiation – Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)**

Rheumatologist

*Limited to 6 months treatment*

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:

continued...

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

- 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
- 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
  - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
  - 3.2 Both:
    - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a Te Whatu Ora Hospital; and
    - 3.2.2 Either:
      - 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
      - 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

### Continuation – Rheumatoid Arthritis

Rheumatologist

*Re-assessment required after 6 months*

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Antiallergy Preparations

### Allergic Emergencies

ADRENALINE – **Restricted** see terms [below](#)

↓ Inj 0.15 mg per 0.3 ml auto-injector – <b>5% DV Jul-23 to 2025</b> .....	90.00	1	<b>Epipen Jr</b>
↓ Inj 0.3 mg per 0.3 ml auto-injector – <b>5% DV Jul-23 to 2025</b> .....	90.00	1	<b>Epipen</b>

→ **Restricted (RS1944)**

**Initiation – anaphylaxis**

Either:

- 1 Patient has experienced a previous anaphylactic reaction which has resulted in presentation to a hospital or emergency department; or
- 2 Patient has been assessed to be at significant risk of anaphylaxis by a relevant practitioner.

ICATIBANT – **Restricted** see terms [below](#)

↓ Inj 10 mg per ml, 3 ml prefilled syringe .....	2,668.00	1	Firazyr
--	----------	---	---------

→ **Restricted (RS1501)**

**Initiation**

Clinical immunologist or relevant specialist

*Re-assessment required after 12 months*

Both:

- 1 Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and
- 2 The patient has undergone product training and has agreed upon an action plan for self-administration.

**Continuation**

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient is benefiting from treatment.

### Allergy Desensitisation

BEE VENOM – **Restricted** see terms [below](#)

↓ Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent			
↓ Inj 550 mcg vial with diluent			
↓ Initiation Kit - 5 vials freeze dried venom with diluent .....	305.00	1	VENOX
↓ Maintenance Kit - 1 vial freeze dried venom with diluent .....	305.00	1	VENOX

→ **Restricted (RS1117)**

**Initiation**

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

PAPER WASP VENOM – **Restricted** see terms [below](#)

↓ Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent			
↓ Inj 550 mcg vial with diluent			

→ **Restricted (RS1118)**

**Initiation**

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

YELLOW JACKET WASP VENOM – **Restricted** see terms [on the next page](#)

↓ Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent			
↓ Inj 550 mcg vial with diluent			

# RESPIRATORY SYSTEM AND ALLERGIES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## ➔ Restricted (RS1119)

### Initiation

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

## Allergy Prophylactics

### BUDESONIDE

Nasal spray 50 mcg per dose.....	2.54	200 dose	SteroClear
Nasal spray 100 mcg per dose.....	2.84	200 dose	SteroClear

### FLUTICASON PROPRIONATE

Nasal spray 50 mcg per dose – 5% DV Dec-21 to 2024 .....	1.98	120 dose	<b>Flixonase Hayfever &amp; Allergy</b>
--	------	----------	---

### IPRATROPIUM BROMIDE

Aqueous nasal spray 0.03%.....	5.23	15 ml	Univent
--------------------------------	------	-------	---------

### SODIUM CROMOGLICATE

Nasal spray 4%

## Antihistamines

### CETIRIZINE HYDROCHLORIDE

Tab 10 mg – 5% DV Sep-23 to 2026 .....	1.71	100	<b>Zista</b>
Oral liq 1 mg per ml – 5% DV Jan-22 to 2024 .....	2.84	200 ml	<b>Histaclear</b>

### CHLORPHENIRAMINE MALEATE

Oral liq 0.4 mg per ml  
Inj 10 mg per ml, 1 ml ampoule

### CYPROHEPTADINE HYDROCHLORIDE

Tab 4 mg

### FEXOFENADINE HYDROCHLORIDE

Tab 60 mg  
Tab 120 mg  
Tab 180 mg

### LORATADINE

Tab 10 mg – 5% DV Feb-23 to 2025 .....	1.78	100	<b>Lorafix</b>
Oral liq 1 mg per ml .....	1.43	100 ml	<b>Haylor Syrup</b>

### PROMETHAZINE HYDROCHLORIDE

Tab 10 mg – 5% DV Sep-22 to 2025 .....	1.39	50	<b>Allersoothe</b>
Tab 25 mg – 5% DV Sep-22 to 2025 .....	1.58	50	<b>Allersoothe</b>
Oral liq 1 mg per ml .....	3.39	100 ml	Allersoothe
Inj 25 mg per ml, 2 ml ampoule .....	21.09	5	Hospira

## Anticholinergic Agents

### IPRATROPIUM BROMIDE

Aerosol inhaler 20 mcg per dose			
Nebuliser soln 250 mcg per ml, 1 ml ampoule			
Nebuliser soln 250 mcg per ml, 2 ml ampoule .....	11.73	20	Univent

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Anticholinergic Agents with Beta-Adrenoceptor Agonists

#### SALBUTAMOL WITH IPRATROPIUM BROMIDE

Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose

Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml

ampoule – 5% DV Jan-22 to 2024	11.04	20	Duolin
--------------------------------	-------	----	--------

### Long-Acting Muscarinic Agents

#### GLYCOPYRRONIUM

Note: inhaled glycopyrronium treatment must not be used if the patient is also receiving treatment with subsidised tiotropium or umeclidinium.

Powder for inhalation 50 mcg per dose	61.00	30 dose	Seebri Breezhaler
---------------------------------------	-------	---------	-------------------

#### TIOTROPIUM BROMIDE

Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.

Soln for inhalation 2.5 mcg per dose	50.37	60 dose	Spiriva Respimat
--------------------------------------	-------	---------	------------------

Powder for inhalation 18 mcg per dose	50.37	30 dose	Spiriva
---------------------------------------	-------	---------	---------

#### UMECLIDINIUM

Note: Umeclidinium must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.

Powder for inhalation 62.5 mcg per dose	61.50	30 dose	Incruse Ellipta
---	-------	---------	-----------------

### Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

➔ **Restricted (RS1518)**

#### Initiation

*Re-assessment required after 2 years*

Both:

- 1 Patient has been stabilised on a long acting muscarinic antagonist; and
- 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

#### Continuation

*Re-assessment required after 2 years*

Both:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined).

Note: Combination long acting muscarinic antagonist and long acting beta-2 agonist must not be used if the patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

GLYCOPYRRONIUM WITH INDACATEROL – **Restricted** see terms [above](#)

† Powder for Inhalation 50 mcg with indacaterol 110 mcg	81.00	30 dose	Ultibro Breezhaler
---	-------	---------	--------------------

TIOTROPIUM BROMIDE WITH OLODATEROL – **Restricted** see terms [above](#)

† Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg	81.00	60 dose	Spiolto Respimat
---	-------	---------	------------------

UMECLIDINIUM WITH VILANTEROL – **Restricted** see terms [above](#)

† Powder for inhalation 62.5 mcg with vilanterol 25 mcg	77.00	30 dose	Anoro Ellipta
---	-------	---------	---------------

### Antifibrotics

NINTEDANIB – **Restricted** see terms [on the next page](#)

↓ Cap 100 mg	2,554.00	60	Ofev
--------------	----------	----	------

↓ Cap 150 mg	3,870.00	60	Ofev
--------------	----------	----	------

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted (RS1813)**

**Initiation – idiopathic pulmonary fibrosis**

Respiratory specialist

*Re-assessment required after 12 months*

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Nintedanib is to be discontinued at disease progression (See Note); and
- 4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 5 Any of the following:
  - 5.1 The patient has not previously received treatment with pirfenidone; or
  - 5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
  - 5.3 Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

**Continuation – idiopathic pulmonary fibrosis**

Respiratory specialist

*Re-assessment required after 12 months*

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

**PIRFENIDONE – Restricted** see terms [below](#)

⚡ Tab 267 mg .....	1,215.00	90	Esbriet
⚡ Tab 801 mg .....	3,645.00	90	Esbriet

➔ **Restricted (RS1814)**

**Initiation – idiopathic pulmonary fibrosis**

Respiratory specialist

*Re-assessment required after 12 months*

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Pirfenidone is to be discontinued at disease progression (See Notes); and
- 4 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 5 Any of the following:
  - 5.1 The patient has not previously received treatment with nintedanib; or
  - 5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
  - 5.3 Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

**Continuation – idiopathic pulmonary fibrosis**

Respiratory specialist

*Re-assessment required after 12 months*

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Beta-Adrenoceptor Agonists</b>			
<b>SALBUTAMOL</b>			
Oral liq 400 mcg per ml – <b>5% DV Mar-22 to 2024</b> .....	40.00	150 ml	<b>Ventolin</b>
Inj 500 mcg per ml, 1 ml ampoule			
Inj 1 mg per ml, 5 ml ampoule			
Aerosol inhaler, 100 mcg per dose.....	3.80	200 dose	SalAir
	6.20		Ventolin
Nebuliser soln 1 mg per ml, 2.5 ml ampoule – <b>5% DV Jan-22 to 2024</b> .....	8.96	20	<b>Asthalin</b>
Nebuliser soln 2 mg per ml, 2.5 ml ampoule – <b>5% DV Jan-22 to 2024</b> .....	9.43	20	<b>Asthalin</b>
<b>TERBUTALINE SULPHATE</b>			
Powder for inhalation 250 mcg per dose			
Inj 0.5 mg per ml, 1 ml ampoule			
Powder for inhalation, 200 mcg per dose (equivalent to 250 mcg metered dose), breath activated.....	22.20	120 dose	Bricanyl Turbuhaler
<b>Decongestants</b>			
<b>OXYMETAZOLINE HYDROCHLORIDE</b>			
Aqueous nasal spray 0.25 mg per ml			
Aqueous nasal spray 0.5 mg per ml			
<b>PSEUDOEPHEDRINE HYDROCHLORIDE</b>			
Tab 60 mg			
<b>SODIUM CHLORIDE</b>			
Aqueous nasal spray isotonic			
<b>SODIUM CHLORIDE WITH SODIUM BICARBONATE</b>			
Soln for nasal irrigation			
<b>XYLOMETAZOLINE HYDROCHLORIDE</b>			
Aqueous nasal spray 0.05%			
Aqueous nasal spray 0.1%			
Nasal drops 0.05%			
Nasal drops 0.1%			
<b>Inhaled Corticosteroids</b>			
<b>BECLOMETHASONE DIPROPIONATE</b>			
Aerosol inhaler 50 mcg per dose.....	8.54	200 dose	Beclazone 50
	14.01		Qvar
Aerosol inhaler 100 mcg per dose.....	12.50	200 dose	Beclazone 100
	17.52		Qvar
Aerosol inhaler 250 mcg per dose.....	22.67	200 dose	Beclazone 250
<b>BUDESONIDE</b>			
Nebuliser soln 250 mcg per ml, 2 ml ampoule			
Nebuliser soln 500 mcg per ml, 2 ml ampoule			
Powder for inhalation 100 mcg per dose			
Powder for inhalation 200 mcg per dose			
Powder for inhalation 400 mcg per dose			

## RESPIRATORY SYSTEM AND ALLERGIES

	Price		Brand or Generic Manufacturer
	(ex man. excl. GST) \$	Per	
<b>FLUTICASONE</b>			
Aerosol inhaler 50 mcg per dose.....	7.19	120 dose	Flixotide
Powder for inhalation 50 mcg per dose.....	8.61	60 dose	Flixotide Accuhaler
Powder for inhalation 100 mcg per dose.....	7.81	60 dose	Flixotide Accuhaler
Aerosol inhaler 125 mcg per dose.....	13.60	120 dose	Flixotide
Aerosol inhaler 250 mcg per dose.....	24.62	120 dose	Flixotide
Powder for inhalation 250 mcg per dose.....	11.93	60 dose	Flixotide Accuhaler

### Leukotriene Receptor Antagonists

<b>MONTELUKAST</b>			
Tab 4 mg – 5% DV Sep-23 to 2025.....	3.10	28	Montelukast Mylan <b>Montelukast Viatris</b>
Tab 5 mg – 5% DV Jul-23 to 2025.....	3.10	28	Montelukast Mylan <b>Montelukast Viatris</b>
Tab 10 mg – 5% DV Sep-23 to 2025.....	2.90	28	Montelukast Mylan <b>Montelukast Viatris</b>

(Montelukast Mylan Tab 4 mg to be delisted 1 February 2024)

(Montelukast Mylan Tab 5 mg to be delisted 1 January 2024)

(Montelukast Mylan Tab 10 mg to be delisted 1 February 2024)

### Long-Acting Beta-Adrenoceptor Agonists

<b>EFORMOTEROL FUMARATE</b>			
Powder for inhalation 12 mcg per dose			
<b>EFORMOTEROL FUMARATE DIHYDRATE</b>			
Powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose)			
<b>INDACATEROL</b>			
Powder for inhalation 150 mcg per dose.....	61.00	30 dose	Onbrez Breezhaler
Powder for inhalation 300 mcg per dose.....	61.00	30 dose	Onbrez Breezhaler
<b>SALMETEROL</b>			
Aerosol inhaler 25 mcg per dose.....	26.25	120 dose	Serevent
Powder for inhalation 50 mcg per dose.....	26.25	60 dose	Serevent Accuhaler

### Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

<b>BUDESONIDE WITH EFORMOTEROL</b>			
Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg			
Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg			
Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg			
Powder for inhalation 160 mcg with 4.5 mcg eformoterol fumarate per dose (equivalent to 200 mcg budesonide with 6 mcg eformoterol fumarate metered dose).....	41.50	120 dose	DuoResp Spiromax
Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg.....	33.74	120 dose	Symbicort Turbuhaler
Powder for inhalation 320 mcg with 9 mcg eformoterol fumarate per dose (equivalent to 400 mcg budesonide with 12 mcg eformoterol fumarate metered dose).....	82.50	120 dose	DuoResp Spiromax
Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg.....	33.74	60 dose	Symbicort Turbuhaler
<b>FLUTICASONE FUROATE WITH VILANTEROL</b>			
Powder for inhalation 100 mcg with vilanterol 25 mcg.....	44.08	30 dose	Breo Ellipta



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>FLUTICASONE WITH SALMETEROL</b>			
Aerosol inhaler 50 mcg with salmeterol 25 mcg .....	25.79	120 dose	Seretide
Powder for inhalation 100 mcg with salmeterol 50 mcg .....	33.74	60 dose	Seretide Accuhaler
Aerosol inhaler 125 mcg with salmeterol 25 mcg .....	32.60	120 dose	Seretide
Powder for inhalation 250 mcg with salmeterol 50 mcg .....	44.08	60 dose	Seretide Accuhaler

### Methylxanthines

<b>AMINOPHYLLINE</b>			
Inj 25 mg per ml, 10 ml ampoule .....	180.00	5	DBL Aminophylline
<b>CAFFEINE CITRATE</b>			
Oral liq 20 mg per ml (caffeine 10 mg per ml) .....	15.10	25 ml	Biomed
Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule .....	63.25	5	Biomed
<b>THEOPHYLLINE</b>			
Tab long-acting 250 mg .....	23.94	100	Nuelin-SR
Oral liq 80 mg per 15 ml .....	17.62	500 ml	Nuelin

### Mucolytics and Expectorants

**DORNASE ALFA – Restricted** see terms [below](#)

↓ Nebuliser soln 2.5 mg per 2.5 ml ampoule ..... 250.00      6      Pulmozyme

→ **Restricted (RS1787)**

**Initiation – cystic fibrosis**

Respiratory physician or paediatrician

*Re-assessment required after 12 months*

All of the following:

- 1 Patient has a confirmed diagnosis of cystic fibrosis; and
- 2 Patient has previously undergone a trial with, or is currently being treated with, hypertonic saline; and
- 3 Any of the following:
  - 3.1 Patient has required one or more hospital inpatient respiratory admissions in the previous 12 month period; or
  - 3.2 Patient has had 3 exacerbations due to CF, requiring oral or intravenous (IV) antibiotics in the previous 12 month period; or
  - 3.3 Patient has had 1 exacerbation due to CF, requiring oral or IV antibiotics in the previous 12 month period and a Brasfield score of < 22/25; or
  - 3.4 Patient has a diagnosis of allergic bronchopulmonary aspergillosis (ABPA).

**Continuation – cystic fibrosis**

Respiratory physician or paediatrician

The treatment remains appropriate and the patient continues to benefit from treatment.

**Initiation – significant mucus production**

*Limited to 4 weeks treatment*

Both:

- 1 Patient is an in-patient; and
- 2 The mucus production cannot be cleared by first line chest techniques.

**Initiation – pleural emphyema**

*Limited to 3 days treatment*

Both:

- 1 Patient is an in-patient; and
- 2 Patient diagnoses with pleural emphyema.

# RESPIRATORY SYSTEM AND ALLERGIES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ELEXACAFTOR WITH TEZACAFTOR, IVACAFTOR AND IVACAFTOR – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 37.5 mg (56) and ivacaftor 75 mg (28).....	27,647.39	84	Trikafta
⚡ Tab elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg (56) and ivacaftor 150 mg (28).....	27,647.39	84	Trikafta
➔ <b>Restricted (RS1950)</b>			
<b>Initiation</b>			
All of the following:			
1 Patient has been diagnosed with cystic fibrosis; and			
2 Patient is 6 years of age or older; and			
3 Either:			
3.1 Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele); or			
3.2 Patient has a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection system; and			
4 Either:			
4.1 Patient has a heterozygous or homozygous F508del mutation; or			
4.2 Patient has a G551D mutation or other mutation responsive in vitro to elexacaftor/tezacaftor/ivacaftor (see note a); and			
5 The treatment must be the sole funded CFTR modulator therapy for this condition; and			
6 Treatment with elexacaftor/tezacaftor/ivacaftor must be given concomitantly with standard therapy for this condition.			
Note:			
a) Eligible mutations are listed in the Food and Drug Administration (FDA) Trikafta prescribing information <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004lbl.pdf</a> .			
<b>IVACAFTOR – Restricted</b> see terms <a href="#">below</a>			
⚡ Tab 150 mg .....	29,386.00	56	Kalydeco
⚡ Oral granules 50 mg, sachet .....	29,386.00	56	Kalydeco
⚡ Oral granules 75 mg, sachet .....	29,386.00	56	Kalydeco
➔ <b>Restricted (RS1818)</b>			
<b>Initiation</b>			
Respiratory specialist or paediatrician			
All of the following:			
1 Patient has been diagnosed with cystic fibrosis; and			
2 Either:			
2.1 Patient must have G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene on at least 1 allele; or			
2.2 Patient must have other gating (class III) mutation (G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N and S549R) in the CFTR gene on at least 1 allele; and			
3 Patients must have a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection system; and			
4 Treatment with ivacaftor must be given concomitantly with standard therapy for this condition; and			
5 Patient must not have an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing treatment with ivacaftor; and			
6 The dose of ivacaftor will not exceed one tablet or one sachet twice daily; and			
7 Applicant has experience and expertise in the management of cystic fibrosis.			
<b>SODIUM CHLORIDE</b>			
Nebuliser soln 7%, 90 ml bottle.....	24.50	90 ml	Biomed

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Pulmonary Surfactants**

BERACTANT

Soln 200 mg per 8 ml vial

PORACTANT ALFA

Soln 120 mg per 1.5 ml vial .....	425.00	1	Curosurf
-----------------------------------	--------	---	----------

Soln 240 mg per 3 ml vial .....	695.00	1	Curosurf
---------------------------------	--------	---	----------

**Respiratory Stimulants**

DOXAPRAM

Inj 20 mg per ml, 5 ml vial

**Sclerosing Agents**

TALC

Powder

Soln (slurry) 100 mg per ml, 50 ml

# SENSORY ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Anti-Infective Preparations</b>			
<b>Antibacterials</b>			
CHLORAMPHENICOL			
Eye oint 1% – 5% DV Dec-22 to 2025 .....	1.09	5 g	Devatis
Ear drops 0.5%			
Eye drops 0.5% – 5% DV Sep-23 to 2025 .....	1.45	10 ml	Chlorsig
Eye drops 0.5%, single dose			
CIPROFLOXACIN			
Eye drops 0.3% – 5% DV Nov-21 to 2024 .....	9.73	5 ml	Ciprofloxacin Teva
FRAMYCETIN SULPHATE			
Ear/eye drops 0.5%			
GENTAMICIN SULPHATE			
Eye drops 0.3%			
SODIUM FUSIDATE [FUSIDIC ACID]			
Eye drops 1% .....	5.29	5 g	Fucithalmic
SULPHACETAMIDE SODIUM			
Eye drops 10%			
TOBRAMYCIN			
Eye oint 0.3% .....	10.45	3.5 g	Tobrex
Eye drops 0.3% .....	11.48	5 ml	Tobrex
<b>Antifungals</b>			
NATAMYCIN			
Eye drops 5%			
<b>Antivirals</b>			
ACICLOVIR			
Eye oint 3% – 5% DV Sep-21 to 2024 .....	14.88	4.5 g	ViruPOS
<b>Combination Preparations</b>			
CIPROFLOXACIN WITH HYDROCORTISONE			
Ear drops ciprofloxacin 0.2% with 1% hydrocortisone.....	16.30	10 ml	Ciproxin HC Otic
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml			
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE			
Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g .....	5.39	3.5 g	Maxitrol
Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml .....	4.50	5 ml	Maxitrol
DEXAMETHASONE WITH TOBRAMYCIN			
Eye drops 0.1% with tobramycin 0.3% .....	12.64	5 ml	Tobradex
FLUMETASONE PIVALATE WITH CLIOQUINOL			
Ear drops 0.02% with clioquinol 1%			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN</b>			
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g .....	5.16	7.5 ml	Kenacomb

## Anti-Inflammatory Preparations

### Corticosteroids

<b>DEXAMETHASONE</b>			
Eye oint 0.1% .....	5.86	3.5 g	Maxidex
Eye drops 0.1% .....	4.50	5 ml	Maxidex
↓ Ocular implant 700 mcg.....	1,444.50	1	Ozurdex

#### → Restricted (RS1606)

##### Initiation – Diabetic macular oedema

Ophthalmologist

*Re-assessment required after 12 months*

All of the following:

- 1 Patients have diabetic macular oedema with pseudophakic lens; and
- 2 Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
- 3 Either:
  - 3.1 Patient's disease has progressed despite 3 injections with bevacizumab; or
  - 3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

##### Continuation – Diabetic macular oedema

Ophthalmologist

*Re-assessment required after 12 months*

Both:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

##### Initiation – Women of child bearing age with diabetic macular oedema

Ophthalmologist

*Re-assessment required after 12 months*

All of the following:

- 1 Patients have diabetic macular oedema; and
- 2 Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
- 3 Patient is of child bearing potential and has not yet completed a family; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

##### Continuation – Women of child bearing age with diabetic macular oedema

Ophthalmologist

*Re-assessment required after 12 months*

All of the following:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Patient is of child bearing potential and has not yet completed a family; and
- 3 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

## SENSORY ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
FLUOROMETHOLONE			
Eye drops 0.1% .....	3.09	5 ml	FML
PREDNISOLONE ACETATE			
Eye drops 0.12% .....		5 ml	Pred Forte
Eye drops 1% .....	7.00	10 ml	Prednisolone- AFT
	6.92		
PREDNISOLONE SODIUM PHOSPHATE			
Eye drops 0.5%, single dose (preservative free).....	41.20	20 dose	Minims Prednisolone

### Non-Steroidal Anti-Inflammatory Drugs

DICLOFENAC SODIUM			
Eye drops 0.1% – 5% DV Nov-21 to 2024.....	8.80	5 ml	<b>Voltaren Ophtha</b>
KETOROLAC TROMETAMOL			
Eye drops 0.5%			
NEPAFENAC			
Eye drops 0.3%			

### Decongestants and Antiallergics

#### Antiallergic Preparations

LEVOCABASTINE			
Eye drops 0.05%			
LODOXAMIDE			
Eye drops 0.1% .....	8.71	10 ml	Lomide
OLOPATADINE			
Eye drops 0.1% – 5% DV Dec-22 to 2025 .....	2.17	5 ml	<b>Olopatadine Teva</b>
SODIUM CROMOGLICATE			
Eye drops 2% – 5% DV Mar-23 to 2025 .....	2.62	10 ml	<b>Allerfix</b>

#### Decongestants

NAPHAZOLINE HYDROCHLORIDE			
Eye drops 0.1% .....	4.15	15 ml	Naphcon Forte

### Diagnostic and Surgical Preparations

#### Diagnostic Dyes

FLUORESCEIN SODIUM			
Eye drops 2%, single dose			
Inj 10%, 5 ml vial .....	125.00	12	Fluorescite
Ophthalmic strips 1 mg			
FLUORESCEIN SODIUM WITH LIGNOCAINE HYDROCHLORIDE			
Eye drops 0.25% with lignocaine hydrochloride 4%, single dose			
LISSAMINE GREEN			
Ophthalmic strips 1.5 mg			
ROSE BENGAL SODIUM			
Ophthalmic strips 1%			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Irrigation Solutions</b>			
<b>MIXED SALT SOLUTION FOR EYE IRRIGATION</b>			
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 15 ml dropper bottle .....	5.00	15 ml	Balanced Salt Solution
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml			<i>e.g. Balanced Salt Solution</i>
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml bag			<i>e.g. Balanced Salt Solution</i>
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml bottle.....	10.50	500 ml	Balanced Salt Solution
<b>Ocular Anaesthetics</b>			
<b>OXYBUPROCAINE HYDROCHLORIDE</b>			
Eye drops 0.4%, single dose			
<b>PROXYMETACAINE HYDROCHLORIDE</b>			
Eye drops 0.5%			
<b>TETRACAINE [AMETHOCAINE] HYDROCHLORIDE</b>			
Eye drops 0.5%, single dose			
Eye drops 1%, single dose			
<b>Viscoelastic Substances</b>			
<b>HYPROMELLOSE</b>			
Inj 2%, 1 ml syringe			
Inj 2%, 2 ml syringe			
<b>SODIUM HYALURONATE [HYALURONIC ACID]</b>			
Inj 14 mg per ml, 0.85 ml syringe .....	50.00	1	Healon GV
Inj 18 mg per ml, 0.85 ml syringe – 5% DV Dec-22 to 2025 .....	50.00	1	<b>Healon GV Pro</b>
Inj 23 mg per ml, 0.6 ml syringe – 5% DV Dec-22 to 2025 .....	60.00	1	<b>Healon 5</b>
Inj 10 mg per ml, 0.85 ml syringe – 5% DV Dec-22 to 2025 .....	28.50	1	<b>Healon</b>
<b>SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROITIN SULPHATE</b>			
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe .....	64.00	1	Duovisc
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe .....	74.00	1	Duovisc
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml syringe.....	67.00	1	Viscoat
<b>Other</b>			
<b>DISODIUM EDETATE</b>			
Inj 150 mg per ml, 20 ml ampoule			
Inj 150 mg per ml, 20 ml vial			
Inj 150 mg per ml, 100 ml vial			

## SENSORY ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>RIBOFLAVIN 5-PHOSPHATE</b>			
Soln trans epithelial riboflavin			
Inj 0.1%			
Inj 0.1% plus 20% dextran T500			

### Glaucoma Preparations

#### Beta Blockers

<b>BETAXOLOL</b>			
Eye drops 0.25% .....	11.80	5 ml	Betoptic S
Eye drops 0.5% .....	7.50	5 ml	Betoptic
<b>TIMOLOL</b>			
Eye drops 0.25% – 5% DV Mar-24 to 2026 .....	2.42	5 ml	<b>Arrow-Timolol</b>
Eye drops 0.5% – 5% DV Mar-24 to 2026 .....	2.50	5 ml	<b>Arrow-Timolol</b>
➔ Eye drops 0.5%, gel forming – <b>Restricted:</b> For continuation only .....	3.78	2.5 ml	Timoptol XE
<i>(Timoptol XE Eye drops 0.5%, gel forming to be delisted 1 March 2024)</i>			

#### Carbonic Anhydrase Inhibitors

<b>ACETAZOLAMIDE</b>			
Tab 250 mg .....	17.03	100	Diamox
Inj 500 mg			
<b>BRINZOLAMIDE</b>			
Eye drops 1% – 5% DV Sep-21 to 2024 .....	7.30	5 ml	<b>Azopt</b>
<b>DORZOLAMIDE – Restricted:</b> For continuation only			
➔ Eye drops 2%			
<b>DORZOLAMIDE WITH TIMOLOL</b>			
Eye drops 2% with timolol 0.5% – 5% DV Dec-21 to 2024 .....	2.73	5 ml	<b>Dortimopt</b>

#### Miotics

<b>ACETYLCHOLINE CHLORIDE</b>			
Inj 20 mg vial with diluent			
<b>CARBACHOL</b>			
Inj 150 mcg vial			
<b>PILOCARPINE HYDROCHLORIDE</b>			
Eye drops 1% .....	4.26	15 ml	Isopto Carpine
Eye drops 2% .....	5.35	15 ml	Isopto Carpine
Eye drops 4% .....	7.99	15 ml	Isopto Carpine
<b>PILOCARPINE NITRATE</b>			
Eye drops 2%, single dose			

#### Prostaglandin Analogues

<b>BIMATOPROST</b>			
Eye drops 0.03% – 5% DV Apr-22 to 2024 .....	5.95	3 ml	<b>Bimatoprost Multichem</b>
<b>LATANOPROST</b>			
Eye drops 0.005% – 5% DV Feb-22 to 2024 .....	1.82	2.5 ml	<b>Teva</b>
<b>LATANOPROST WITH TIMOLOL</b>			
Eye drops 0.005% with timolol 0.5% – 5% DV Mar-24 to 2026 .....	4.95	2.5 ml	<b>Arrow - Lattim</b>



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TRAVOPROST Eye drops 0.004% – <b>5% DV Dec-21 to 2024</b> .....	9.75	2.5 ml	<b>Travatan</b>
<b>Sympathomimetics</b>			
APRACLONIDINE Eye drops 0.5% .....	19.77	5 ml	lopidine
BRIMONIDINE TARTRATE Eye drops 0.2% – <b>5% DV Jan-22 to 2024</b> .....	4.29	5 ml	<b>Arrow-Brimonidine</b>
BRIMONIDINE TARTRATE WITH TIMOLOL Eye drops 0.2% with timolol 0.5%			
<b>Mydriatics and Cycloplegics</b>			
<b>Anticholinergic Agents</b>			
ATROPINE SULPHATE Eye drops 0.5% Eye drops 1%, single dose Eye drops 1% – <b>5% DV Feb-24 to 2026</b> .....	18.27	15 ml	<b>Atropt</b>
CYCLOPENTOLATE HYDROCHLORIDE Eye drops 0.5%, single dose Eye drops 1% .....	8.76	15 ml	Cyclogyl
TROPICAMIDE Eye drops 0.5% .....	7.15	15 ml	Mydriacyl
Eye drops 0.5%, single dose Eye drops 1% .....	8.66	15 ml	Mydriacyl
Eye drops 1%, single dose			
<b>Sympathomimetics</b>			
PHENYLEPHRINE HYDROCHLORIDE Eye drops 2.5%, single dose Eye drops 10%, single dose			
<b>Ocular Lubricants</b>			
CARBOMER Ophthalmic gel 0.3%, single dose .....	8.25	30	Poly Gel
Ophthalmic gel 0.2%			
CARMELLOSE SODIUM WITH PECTIN AND GELATINE Eye drops 0.5% Eye drops 0.5%, single dose Eye drops 1% Eye drops 1%, single dose			
HYPROMELLOSE Eye drops 0.5% .....	19.50	15 ml	Methopt
HYPROMELLOSE WITH DEXTRAN Eye drops 0.3% with dextran 0.1%.....	2.30	15 ml	Poly-Tears
Eye drops 0.3% with dextran 0.1%, single dose			

## SENSORY ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN Eye oint 42.5% with soft white paraffin 57.3%			
PARAFFIN LIQUID WITH WOOL FAT Eye oint 3% with wool fat 3% .....	3.63	3.5 g	Poly-Visc
POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL Eye drops 0.4% with propylene glycol 0.3% preservative free, single dose....	10.78	30	Systane Unit Dose
POLYVINYL ALCOHOL WITH POVIDONE Eye drops 1.4% with povidone 0.6%, single dose			
RETINOL PALMITATE Oint 138 mcg per g .....	3.80	5 g	VitA-POS
SODIUM HYALURONATE [HYALURONIC ACID] Eye drops 1 mg per ml – 5% DV Jan-22 to 2024 .....	13.85	10 ml	Hylo-Fresh

### Other Otolgical Preparations

ACETIC ACID WITH PROPYLENE GLYCOL Ear drops 2.3% with propylene glycol 2.8%
DOCUSATE SODIUM Ear drops 0.5%

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Agents Used in the Treatment of Poisonings

### Antidotes

<b>ACETYL CYSTEINE</b>			
Tab eff 200 mg			
Inj 200 mg per ml, 10 ml ampoule .....	52.88	10	Martindale Pharma
<b>AMYL NITRITE</b>			
Liq 98% in 3 ml capsule			
<b>DIGOXIN IMMUNE FAB</b>			
Inj 38 mg vial			
Inj 40 mg vial			
<b>ETHANOL</b>			
Liq 96%			
<b>ETHANOL WITH GLUCOSE</b>			
Inj 10% with glucose 5%, 500 ml bottle			
<b>ETHANOL, DEHYDRATED</b>			
Inj 100%, 5 ml ampoule			
Inj 96%			
<b>FLUMAZENIL</b>			
Inj 0.1 mg per ml, 5 ml ampoule – 5% DV Feb-22 to 2024 .....	110.12	10	<b>Hameln</b>
<b>HYDROXOCOBALAMIN</b>			
Inj 5 g vial			
Inj 2.5 g vial			
<b>NALOXONE HYDROCHLORIDE</b>			
Inj 400 mcg per ml, 1 ml ampoule – 5% DV Feb-23 to 2024 .....	35.26	10	<b>Hameln</b>
<b>PRALIDOXIME IODIDE</b>			
Inj 25 mg per ml, 20 ml ampoule			
<b>SODIUM NITRITE</b>			
Inj 30 mg per ml, 10 ml ampoule			
<b>SODIUM THIOSULFATE</b>			
Inj 250 mg per ml, 100 ml vial			
Inj 250 mg per ml, 10 ml vial			
Inj 250 mg per ml. 50 ml vial			
Inj 500 mg per ml, 10 ml vial			
Inj 500 mg per ml, 20 ml ampoule			
<b>SOYA OIL</b>			
Inj 20%, 500 ml bag			
Inj 20%, 500 ml bottle			

### Antitoxins

<b>BOTULISM ANTITOXIN</b>			
Inj 250 ml vial			
<b>DIPHThERIA ANTITOXIN</b>			
Inj 10,000 iu vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Antivenoms**

RED BACK SPIDER ANTIVENOM

Inj 500 u vial

SNAKE ANTIVENOM

Inj 50 ml vial

**Removal and Elimination**

CHARCOAL

Oral liq 200 mg per ml ..... 43.50      250 ml      Carbasorb-X

DEFERASIROX – **Restricted** see terms [below](#)

⚡ Tab 125 mg dispersible .....	276.00	28	Exjade
⚡ Tab 250 mg dispersible .....	552.00	28	Exjade
⚡ Tab 500 mg dispersible .....	1,105.00	28	Exjade

➔ **Restricted (RS1444)**

**Initiation**

Haematologist

*Re-assessment required after 2 years*

All of the following:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
- 2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
- 3 Any of the following:
  - 3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2\*; or
  - 3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
  - 3.3 Treatment with deferiprone has resulted in arthritis; or
  - 3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per µL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per µL).

**Continuation**

Haematologist

*Re-assessment required after 2 years*

Either:

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2\* and liver MRI T2\* levels; or
- 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2\* and liver MRI T2\* levels. .

DEFERIPRONE – **Restricted** see terms [below](#)

⚡ Tab 500 mg .....	533.17	100	Ferriprox
⚡ Oral liq 100 mg per ml .....	266.59	250 ml	Ferriprox

➔ **Restricted (RS1445)**

**Initiation**

Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia.

DESFERRIOXAMINE MESILATE

Inj 500 mg vial ..... 151.31      10      DBL Desferrioxamine Mesylate for Inj BP

DICOBALT EDETATE

Inj 15 mg per ml, 20 ml ampoule

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>DIMERCAPROL</b>			
Inj 50 mg per ml, 2 ml ampoule			
<b>DIMERCAPTOSUCCINIC ACID</b>			
Cap 100 mg			e.g. PCNZ, Optimus Healthcare, Chemet
Cap 200 mg			e.g. PCNZ, Optimus Healthcare, Chemet
<b>SODIUM CALCIUM EDETATE</b>			
Inj 50 mg per ml, 10 ml ampoule			
Inj 200 mg per ml, 2.5 ml ampoule			
Inj 200 mg per ml, 5 ml ampoule			

### Antiseptics and Disinfectants

<b>CHLORHEXIDINE</b>			
Soln 4%			
Soln 5% .....	15.50	500 ml	healthE
<b>CHLORHEXIDINE WITH CETRIMIDE</b>			
Crm 0.1% with cetrimide 0.5%			
Foaming soln 0.5% with cetrimide 0.5%			
<b>CHLORHEXIDINE WITH ETHANOL</b>			
Soln 0.5% with ethanol 70%			
Soln 2% with ethanol 70%			
Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml .....	1.55	1	healthE
<b>IODINE WITH ETHANOL</b>			
Soln 1% with ethanol 70%			
<b>ISOPROPYL ALCOHOL</b>			
Soln 70%, 500 ml .....	5.65	1	healthE
<b>POVIDONE-IODINE</b>			
↓ Vaginal tab 200 mg			
➔ <b>Restricted (RS1354)</b>			
<b>Initiation</b>			
Rectal administration pre-prostate biopsy.			
Oint 10% .....	7.40	65 g	Betadine
Soln 10% – <b>5% DV Mar-22 to 2024</b> .....	4.15	100 ml	<b>Riodine</b>
Soln 5%			
Soln 7.5%			
Soln 10%, .....	3.83	15 ml	Riodine
	5.40	500 ml	Riodine
Pad 10%			
Swab set 10%			
<b>POVIDONE-IODINE WITH ETHANOL</b>			
Soln 10% with ethanol 30%			
Soln 10% with ethanol 70%			
<b>SODIUM HYPOCHLORITE</b>			
Soln			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Contrast Media</b>			
<b>Iodinated X-ray Contrast Media</b>			
<b>DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE</b>			
Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle.....	30.00	100 ml	Gastrografin
Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle.....	90.00	1	Urografin
<b>DIATRIZOATE SODIUM</b>			
Oral liq 370 mg per ml, 10 ml sachet.....	156.12	50	Ioscan
<b>IODISED OIL</b>			
Inj 38% w/w (480 mg per ml), 10 ml ampoule .....	410.00	1	Lipiodol Ultra Fluid
<b>IODIXANOL</b>			
Inj 270 mg per ml (iodine equivalent), 50 ml bottle.....	260.00	10	Visipaque
Inj 270 mg per ml (iodine equivalent), 100 ml bottle.....	480.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 50 ml bottle.....	260.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 100 ml bottle.....	480.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 200 ml bottle.....	950.00	10	Visipaque
<b>IOHEXOL</b>			
Inj 240 mg per ml (iodine equivalent), 50 ml bottle.....	94.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 20 ml bottle.....	89.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 50 ml bottle.....	96.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 100 ml bottle.....	166.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 50 ml bottle.....	98.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 75 ml bottle.....	130.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 100 ml bottle.....	170.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 200 ml bottle.....	330.00	10	Omnipaque
Inj 350 mg per ml, 500 ml bottle .....	515.00	6	Omnipaque
<b>Non-iodinated X-ray Contrast Media</b>			
<b>BARIUM SULPHATE</b>			
Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet.....	507.50	50	E-Z-Cat Dry
Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle .....	17.39	148 g	Varibar - Thin Liquid
Oral liq 600 mg per g (60% w/w), tube .....	36.51	454 g	E-Z-Paste
Oral liq 400 mg per ml (40% w/v), bottle .....	155.35	250 ml	Varibar - Honey
	38.40	240 ml	Varibar - Nectar
	145.04	230 ml	Varibar - Pudding
Enema 1,250 mg per ml (125% w/v), 500 ml bag .....	282.30	12	Liquibar
Oral liq 22 mg per g (2.2% w/w), 250 ml bottle.....	175.00	24	CT Plus+
Oral liq 22 mg per g (2.2% w/w), 450 ml bottle.....	220.00	24	CT Plus+
Oral liq 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle .....	441.12	24	Volumen
Oral liq 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle .....	140.94	24	Readi-CAT 2
Powder for oral soln 97.65% w/w, 300 g bottle .....	237.76	24	X-Opaque-HD
Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle .....	52.35	3	Tagitol V
Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle.....	91.77	1	Liquibar
<b>BARIUM SULPHATE WITH SODIUM BICARBONATE</b>			
Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet.....	102.93	50	E-Z-Gas II

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**CITRIC ACID WITH SODIUM BICARBONATE**

Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet

*e.g. E-Z-GAS II*

**Paramagnetic Contrast Media**

**GADOBENIC ACID**

Inj 334 mg per ml, 10 ml vial.....	324.74	10	Multihance
Inj 334 mg per ml, 20 ml vial.....	636.28	10	Multihance

**GADOBUTROL**

Inj 1 mmol per ml, 15 ml vial			
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 5 ml prefilled syringe.....	120.00	5	Gadovist 1.0
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled syringe.....	180.00	5	Gadovist 1.0
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled syringe.....	700.00	10	Gadovist 1.0

**GADOTERIC ACID**

Inj 279.30 mg per ml, 10 ml prefilled syringe			<i>e.g. Clariscan</i>
Inj 279.30 mg per ml, 10 ml vial			<i>e.g. Clariscan</i>
Inj 279.30 mg per ml, 15 ml prefilled syringe			<i>e.g. Clariscan</i>
Inj 279.30 mg per ml, 20 ml vial			<i>e.g. Clariscan</i>
Inj 279.30 mg per ml, 5 ml vial			<i>e.g. Clariscan</i>
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe.....	172.00	10	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle.....	25.35	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe.....	258.00	10	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe.....	344.00	10	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle.....	14.30	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle.....	28.90	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle.....	9.10	1	Dotarem

**GADOXETATE DISODIUM**

Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefilled syringe.....	300.00	1	Primovist
---	--------	---	-----------

**MEGLUMINE GADOPENTETATE**

Inj 469 mg per ml, 10 ml prefilled syringe.....	95.00	5	Magnevist
Inj 469 mg per ml, 10 ml vial.....	185.00	10	Magnevist

**MEGLUMINE IOTROXATE**

Inj 105 mg per ml, 100 ml bottle.....	159.00	100 ml	Biisocopin
---------------------------------------	--------	--------	------------

**Ultrasound Contrast Media**

**PERFLUTREN**

Inj 1.1 mg per ml, 1.5 ml vial.....	180.00	1	Definity
	720.00	4	Definity

**Diagnostic Agents**

**ARGININE**

Inj 50 mg per ml, 500 ml bottle  
Inj 100 mg per ml, 300 ml bottle

## VARIOUS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>HISTAMINE ACID PHOSPHATE</b>			
Nebuliser soln 0.6%, 10 ml vial			
Nebuliser soln 2.5%, 10 ml vial			
Nebuliser soln 5%, 10 ml vial			
<b>MANNITOL</b>			
Powder for inhalation			<i>e.g. Aridol</i>
<b>METHACHOLINE CHLORIDE</b>			
Powder 100 mg			
<b>SECRETIN PENTAHYDROCHLORIDE</b>			
Inj 100 u vial			
Inj 80 u vial			
Inj 100 u ampoule			
<b>SINCALIDE</b>			
Inj 5 mcg per vial			

### Diagnostic Dyes

<b>BONNEY'S BLUE DYE</b>			
Soln			
<b>INDIGO CARMINE</b>			
Inj 4 mg per ml, 5 ml ampoule			
Inj 8 mg per ml, 5 ml ampoule			
<b>INDOCYANINE GREEN</b>			
Inj 25 mg vial			
<b>METHYLTHIONIUM CHLORIDE [METHYLENE BLUE]</b>			
Inj 5 mg per ml, 10 ml ampoule .....	240.35	5	Proveblue
<b>PATENT BLUE V</b>			
Inj 2.5%, 2 ml ampoule .....	440.00	5	Obex Medical
Inj 2.5%, 5 ml prefilled syringe .....	420.00	5	InterPharma

### Irrigation Solutions

**CHLORHEXIDINE WITH CETRIMIDE**  
 † Irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle

➔ **Restricted (RS1683)**

#### Initiation

*Re-assessment required after 3 months*

All of the following:

- 1 Patient has burns that are greater than 30% of total body surface area (BSA); and
- 2 For use in the perioperative preparation and cleansing of large burn areas requiring debridement/skin grafting; and
- 3 The use of 30 ml ampoules is impractical due to the size of the area to be covered.

#### Continuation

*Re-assessment required after 3 months*

The treatment remains appropriate for the patient and the patient is benefiting from the treatment.

Irrigation soln 0.015% with cetrimide 0.15%, 100 ml bottle .....	155.76	24	Baxter
Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule .....	29.76	30	Pfizer
<b>GLYCINE</b>			
Irrigation soln 1.5%, 3,000 ml bag .....	33.50	4	B Braun



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>SODIUM CHLORIDE</b>			
Irrigation soln 0.9%, 3,000 ml bag .....	28.80	4	B Braun
Irrigation soln 0.9%, 30 ml ampoule .....	10.00	20	Interpharma
Irrigation soln 0.9%, 1,000 ml bottle .....	16.10	10	Baxter Sodium Chloride 0.9%
Irrigation soln 0.9%, 250 ml bottle .....	17.64	12	Fresenius Kabi
<b>WATER</b>			
Irrigation soln, 3,000 ml bag .....	30.95	4	B Braun
Irrigation soln, 1,000 ml bottle .....	18.60	10	Baxter Water for Irrigation
Irrigation soln, 250 ml bottle .....	17.64	12	Fresenius Kabi

## Surgical Preparations

### BISMUTH SUBNITRATE AND IODOFORM PARAFFIN

Paste

### DIMETHYL SULFOXIDE

Soln 50%

Soln 99%

### PHENOL

Inj 6%, 10 ml ampoule

### PHENOL WITH IOXAGLIC ACID

Inj 12%, 10 ml ampoule

### SODIUM HYDROXIDE

Soln 10%

### TROMETAMOL

Inj 36 mg per ml, 500 ml bottle

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Cardioplegia Solutions**

**ELECTROLYTES**

- Inj 15 mmol/l sodium chloride, 9 mmol/l potassium chloride, 1 mmol/l potassium hydrogen 2-ketoglutarate, 4 mmol/l magnesium chloride, 18 mmol/l histidine hydrochloride, 180 mmol/l histidine, 2 mmol/l tryptophan, 30 mmol/l mannitol, 0.015 mmol/l calcium chloride, 1,000 ml bag *e.g. Custodiol-HTK*
  
- Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, glutamic acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.80768 mg per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2369 mg per ml, 364 ml bag *e.g. Cardioplegia Enriched Paed. Soln.*
  
- Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, glutamic acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg per ml, sodium hydroxide 5.133 mg per ml and trometamol 9.097 mg per ml, 527 ml bag *e.g. Cardioplegia Enriched Solution*
  
- Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg per ml, potassium chloride 2.181 mg per ml, sodium chloride 1.788 mg per ml, sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per ml, 523 ml bag *e.g. Cardioplegia Base Solution*
  
- Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml bag *e.g. Cardioplegia Solution AHB7832*
  
- Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magnesium and 1.2 mmol/l calcium, 1,000 ml bag *e.g. Cardioplegia Electrolyte Solution*

**MONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE**

Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bottle

**MONOSODIUM L-ASPARTATE**

Inj 14 mmol per 10 ml, 10 ml

**Cold Storage Solutions**

**SODIUM WITH POTASSIUM**

Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag

# EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price	Brand or
(ex man. excl. GST)	\$	Generic
	Per	Manufacturer

## Extemporaneously Compounded Preparations

ACETIC ACID		
Liq		
ALUM		
Powder BP		
ARACHIS OIL [PEANUT OIL]		
Liq		
ASCORBIC ACID		
Powder		
BENZOIN		
Tincture compound BP		
BISMUTH SUBGALLATE		
Powder		
BORIC ACID		
Powder		
CARBOXYMETHYLCELLULOSE		
Soln 1.5%		
CETRIMIDE		
Soln 40%		
CHLORHEXIDINE GLUCONATE		
Soln 20 %		
CHLOROFORM		
Liq BP		
CITRIC ACID		
Powder BP		
CLOVE OIL		
Liq		
COAL TAR		
Soln BP .....	36.25	200 ml    Midwest
CODEINE PHOSPHATE		
Powder		
COLLODION FLEXIBLE		
Liq		
COMPOUND HYDROXYBENZOATE		
Soln .....	30.00	100 ml    Midwest
CYSTEAMINE HYDROCHLORIDE		
Powder		
DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHOSPHATE		
Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml ampoule		
DITHRANOL		
Powder		
GLUCOSE [DEXTROSE]		
Powder		

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

## EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GLYCERIN WITH SODIUM SACCHARIN Suspension.....	30.95	473 ml	Ora-Sweet SF
GLYCERIN WITH SUCROSE Suspension.....	30.95	473 ml	Ora-Sweet
GLYCEROL Liq.....	3.23	500 ml	healthE Glycerol BP Liquid
HYDROCORTISONE Powder .....	49.95	25 g	ABM
LACTOSE Powder			
MAGNESIUM HYDROXIDE Paste			
MENTHOL Crystals			
METHADONE HYDROCHLORIDE Powder			
METHYL HYDROXYBENZOATE Powder .....	8.98	25 g	Midwest
METHYLCELLULOSE Powder .....	36.95	100 g	Midwest
Suspension.....	30.95	473 ml	Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN Suspension.....	30.95	473 ml	Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE Suspension.....	30.95	473 ml	Ora-Blend
OLIVE OIL Liq			
PARAFFIN Liq			
PHENOBARBITONE SODIUM Powder			
PHENOL Liq			
PILOCARPINE NITRATE Powder			
POLYHEXAMETHYLENE BIGUANIDE Liq			
POVIDONE K30 Powder			
SALICYLIC ACID Powder			
SILVER NITRATE Crystals			
SODIUM BICARBONATE Powder BP.....	10.05	500 g	Midwest

↑ Item restricted (see → above); ↓ Item restricted (see → below)  
e.g. *Brand* indicates brand example only. It is not a contracted product.

## EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SODIUM CITRATE Powder			
SODIUM METABISULFITE Powder			
STARCH Powder			
SULPHUR Precipitated Sublimed			
SYRUP Liq (pharmaceutical grade).....	14.95	500 ml	Midwest
THEOBROMA OIL Oint			
TRI-SODIUM CITRATE Crystals			
TRICHLORACETIC ACID Grans			
UREA Powder BP			
WOOL FAT Oint, anhydrous			
XANTHAN Gum 1%			
ZINC OXIDE Powder			

	Price (ex man. excl. GST)	Brand or Generic Manufacturer
	\$	Per

## Food Modules

### Carbohydrate

#### ➔ Restricted (RS1467)

##### Initiation – Use as an additive

Any of the following:

- 1 Cystic fibrosis; or
- 2 Chronic kidney disease; or
- 3 Cancer in children; or
- 4 Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 5 Faltering growth in an infant/child; or
- 6 Bronchopulmonary dysplasia; or
- 7 Premature and post premature infant; or
- 8 Inborn errors of metabolism.

##### Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

CARBOHYDRATE SUPPLEMENT – **Restricted** see terms [above](#)

† Powder 95 g carbohydrate per 100 g, 368 g can

† Powder 96 g carbohydrate per 100 g, 400 g can

*e.g. Polycal*

### Fat

#### ➔ Restricted (RS1468)

##### Initiation – Use as an additive

Any of the following:

- 1 Patient has inborn errors of metabolism; or
- 2 Faltering growth in an infant/child; or
- 3 Bronchopulmonary dysplasia; or
- 4 Fat malabsorption; or
- 5 Lymphangiectasia; or
- 6 Short bowel syndrome; or
- 7 Infants with necrotising enterocolitis; or
- 8 Biliary atresia; or
- 9 For use in a ketogenic diet; or
- 10 Chyle leak; or
- 11 Ascites; or
- 12 Patient has increased energy requirements, and for whom dietary measures have not been successful.

##### Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

LONG-CHAIN TRIGLYCERIDE SUPPLEMENT – **Restricted** see terms [above](#)

† Liquid 50 g fat per 100 ml, 200 ml bottle

*e.g. Calogen*

† Liquid 50 g fat per 100 ml, 500 ml bottle

*e.g. Calogen*

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 50 g fat per 100 ml, 250 ml bottle			e.g. <i>Liquigen</i>
† Liquid 95 g fat per 100 ml, 500 ml bottle			e.g. <i>MCT Oil</i>
<b>WALNUT OIL – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liq			

## Protein

### → Restricted (RS1469)

#### Initiation – Use as an additive

Either:

- 1 Protein losing enteropathy; or
- 2 High protein needs.

#### Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

#### PROTEIN SUPPLEMENT – Restricted

 see terms [above](#)

† Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can			
† Powder 6 g protein per 7 g, can .....	8.95	227 g	Resource Beneprotein
† Powder 89 g protein, < 1.5 g carbohydrate and 2 g fat per 100 g, 225 g can			e.g. <i>Protifar</i>

## Other Supplements

#### BREAST MILK FORTIFIER

Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet			e.g. <i>FM 85</i>
Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet			e.g. <i>S26 Human Milk Fortifier</i>
Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet			e.g. <i>Nutricia Breast Milk Fortifer</i>

#### CARBOHYDRATE AND FAT SUPPLEMENT – Restricted

 see terms [below](#)

↓ Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can			e.g. <i>Super Soluble Duocal</i>
--	--	--	----------------------------------

### → Restricted (RS1212)

#### Initiation

Both:

- 1 Infant or child aged four years or under; and
- 2 Any of the following:
  - 2.1 Cystic fibrosis; or
  - 2.2 Cancer in children; or
  - 2.3 Faltering growth; or
  - 2.4 Bronchopulmonary dysplasia; or
  - 2.5 Premature and post premature infants.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Food/Fluid Thickeners

### NOTE:

While pre-thickened drinks and supplements have not been included in Section H, Te Whatu Ora Hospitals may continue to use such products for patients with dysphagia, provided that:

- use was established prior to 1 July 2013; and
- the product has not been specifically considered and excluded by Pharmac; and
- use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

Pharmac intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

### CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN

Powder

e.g. *Feed Thickener  
Karcare Aptamil*

### GUAR GUM

Powder

e.g. *Guarcol*

### MAIZE STARCH

Powder

e.g. *Resource Thicken  
Up; Nutilis*

### MALTODEXTRIN WITH XANTHAN GUM

Powder

e.g. *Instant Thick*

### MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID

Powder

e.g. *Easy Thick*

## Metabolic Products

### ➔ Restricted (RS1232)

#### Initiation

Any of the following:

- 1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidemia, propionic acidemia, methylmalonic acidemia, tyrosinemia or urea cycle disorders; or
- 2 Patient has adrenoleukodystrophy; or
- 3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

## Glutaric Aciduria Type 1 Products

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN) – **Restricted** see terms [above](#)

† Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can

e.g. *GA1 Anamix Infant*

† Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can

e.g. *XLYS Low TRY  
Maxamaid*



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Homocystinuria Products

AMINO ACID FORMULA (WITHOUT METHIONINE) – **Restricted** see terms [on the previous page](#)

- |  |  |  |                           |
|--|--|--|---------------------------|
| † Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can  |  |  | e.g. HCU Anamix Infant    |
| † Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can                             |  |  | e.g. XMET Maxamaid        |
| † Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can                             |  |  | e.g. XMET Maxamum         |
| † Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle |  |  | e.g. HCU Anamix Junior LQ |

## Isovaleric Acidaemia Products

AMINO ACID FORMULA (WITHOUT LEUCINE) – **Restricted** see terms [on the previous page](#)

- |   |  |  |                        |
|---|--|--|------------------------|
| † Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can |  |  | e.g. IVA Anamix Infant |
| † Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can                            |  |  | e.g. XLEU Maxamaid     |
| † Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can                            |  |  | e.g. XLEU Maxamum      |

## Maple Syrup Urine Disease Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) – **Restricted** see terms [on the previous page](#)

- |  |  |  |                            |
|--|--|--|----------------------------|
| † Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can  |  |  | e.g. MSUD Anamix Infant    |
| † Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can                             |  |  | e.g. MSUD Maxamum          |
| † Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle |  |  | e.g. MSUD Anamix Junior LQ |

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Phenylketonuria Products</b>			
AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – <b>Restricted</b> see terms on page 272			
† Tab 8.33 mg			e.g. <i>Phlexy-10</i>
† Powder 20 g protein, 3.8 g carbohydrate and 0.23 g fibre per 28 g sachet			e.g. <i>PKU Lophlex Powder (neutral)</i>
† Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet			e.g. <i>PKU Anamix Junior (van/choc/neutral)</i>
† Powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			e.g. <i>PKU Anamix Infant</i>
† Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			e.g. <i>XP Maxamum</i>
† Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet			e.g. <i>Phlexy-10</i>
† Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle			e.g. <i>PKU Lophlex LQ 10</i>
† Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle			e.g. <i>PKU Lophlex LQ 20</i>
† Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle	13.10	125 ml	PKU Anamix Junior LQ (Berry) PKU Anamix Junior LQ (Orange) PKU Anamix Junior LQ (Unflavoured)
† Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle			e.g. <i>PKU Lophlex LQ 20</i>
† Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle			e.g. <i>PKU Lophlex LQ 10</i>
† Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle			e.g. <i>PKU Lophlex LQ 20</i>
† Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle			e.g. <i>PKU Lophlex LQ 10</i>
† Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton			e.g. <i>Easiphen</i>
† Semi-solid 18.3 g protein, 18.5 g carbohydrate and 0.92 g fibre per 100 g, 109 g pot			e.g. <i>PKU Lophlex Sensations 20 (berries)</i>

**Propionic Acidaemia and Methylmalonic Acidaemia Products**

AMINO ACID FORMULA (WITHOUT Isoleucine, Methionine, Threonine and Valine) – **Restricted** see terms on page 272

† Powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			e.g. <i>MMA/PA Anamix Infant</i>
† Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			e.g. <i>XMTVI Maxamaid</i>
† Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			e.g. <i>XMTVI Maxamum</i>

**Protein Free Supplements**

PROTEIN FREE SUPPLEMENT – **Restricted** see terms on page 272

† Powder nil added protein and 67 g carbohydrate per 100 g, 400 g can			e.g. <i>Energivit</i>
---	--	--	-----------------------

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer

**Tyrosinaemia Products**

AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE) – **Restricted** see terms [on page 272](#)

- |   |  |                               |
|---|--|-------------------------------|
| † | Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet |                               |
|   |  | <i>e.g. TYR Anamix Junior</i> |
- |   |   |                               |
|---|---|-------------------------------|
| † | Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can |                               |
|   |   | <i>e.g. TYR Anamix Infant</i> |
- |   |  |                                 |
|---|--|---------------------------------|
| † | Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can |                                 |
|   |  | <i>e.g. XPHEN, TYR Maxamaid</i> |
- |   |  |                                  |
|---|--|----------------------------------|
| † | Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle |                                  |
|   |  | <i>e.g. TYR Anamix Junior LQ</i> |

**Urea Cycle Disorders Products**

AMINO ACID SUPPLEMENT – **Restricted** see terms [on page 272](#)

- |   |  |                       |
|---|--|-----------------------|
| † | Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can |                       |
|   |  | <i>e.g. Dialamine</i> |
- |   |  |                                      |
|---|--|--------------------------------------|
| † | Powder 79 g protein per 100 g, 200 g can |                                      |
|   |  | <i>e.g. Essential Amino Acid Mix</i> |

**X-Linked Adrenoleukodystrophy Products**

GLYCEROL TRIERUCATE – **Restricted** see terms [on page 272](#)

- † Liquid, 1,000 ml bottle

GLYCEROL TRIOLEATE – **Restricted** see terms [on page 272](#)

- † Liquid, 500 ml bottle

**Specialised Formulas**

**Diabetic Products**

➔ **Restricted (RS1215)**

**Initiation**

Any of the following:

- 1 For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
- 2 For patients with pancreatic insufficiency; or
- 3 For patients who have, or are expected to, eat little or nothing for 5 days; or
- 4 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
- 5 For use pre- and post-surgery; or
- 6 For patients being tube-fed; or
- 7 For tube-feeding as a transition from intravenous nutrition.

LOW-GI ENTERAL FEED 1 KCAL/ML – **Restricted** see terms [above](#)

- |   |   |      |        |                        |
|---|---|------|--------|------------------------|
| † | Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 500 ml bottle..... | 3.75 | 500 ml |                        |
|   |   |      |        | <i>Glucerna Select</i> |
- |   |   |                                      |
|---|---|--------------------------------------|
| † | Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bottle |                                      |
|   |   | <i>e.g. Nutrison Advanced Diason</i> |

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LOW-GI ORAL FEED 1 KCAL/ML – <b>Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 7 g protein, 10.9 g carbohydrate, 2.7 g fat and 2 g fibre per 100 ml, bottle.....	2.10	200 ml	Nutren Diabetes (Vanilla)
† Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle			<i>e.g. Diasip</i>

## Elemental and Semi-Elemental Products

### ➔ **Restricted (RS1216)**

#### Initiation

Any of the following:

- 1 Malabsorption; or
- 2 Short bowel syndrome; or
- 3 Enterocutaneous fistulas; or
- 4 Eosinophilic enteritis (including oesophagitis); or
- 5 Inflammatory bowel disease; or
- 6 Acute pancreatitis where standard feeds are not tolerated; or
- 7 Patients with multiple food allergies requiring enteral feeding.

AMINO ACID ORAL FEED – **Restricted** see terms [above](#)

† Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet..... 4.50 80 g Vivonex TEN

AMINO ACID ORAL FEED 0.8 KCAL/ML – **Restricted** see terms [above](#)

† Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton *e.g. Elemental 028 Extra*

PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML – **Restricted** see terms [above](#)

† Liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bottle *e.g. Nutrison Advanced Peptisorb*

PEPTIDE-BASED ENTERAL FEED 1.5 KCAL/ML – **Restricted** see terms [above](#)

† Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle.... 18.06 1,000 ml Vital

PEPTIDE-BASED ORAL FEED – **Restricted** see terms [above](#)

† Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can *e.g. Peptamen Junior*

† Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can *e.g. MCT Peptide; MCT Peptide 1+*

PEPTIDE-BASED ORAL FEED 1 KCAL/ML – **Restricted** see terms [above](#)

† Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, carton..... 4.95 237 ml Peptamen OS 1.0 (Vanilla)

## Fat Modified Products

FAT-MODIFIED FEED – **Restricted** see terms [below](#)

‡ Powder 12.8 g protein, 68.6 g carbohydrate and 12.9 g fat per 100 g, 400 g can *e.g. Monogen*

### ➔ **Restricted (RS1470)**

#### Initiation

Any of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or
- 3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

## Hepatic Products

→ **Restricted (RS1217)**

### Initiation

For children (up to 18 years) who require a liver transplant.

HEPATIC ORAL FEED – **Restricted** see terms [above](#)

† Powder 12 g protein, 56 g carbohydrate and 22 g fat per 100 g, can .....	78.97	400 g	Heparon Junior
--	-------	-------	----------------

## High Calorie Products

→ **Restricted (RS1317)**

### Initiation

Any of the following:

- 1 Patient is fluid volume or rate restricted; or
- 2 Patient requires low electrolyte; or
- 3 Both:
  - 3.1 Any of the following:
    - 3.1.1 Cystic fibrosis; or
    - 3.1.2 Any condition causing malabsorption; or
    - 3.1.3 Faltering growth in an infant/child; or
    - 3.1.4 Increased nutritional requirements; and
  - 3.2 Patient has substantially increased metabolic requirements.

ENTERAL FEED 2 KCAL/ML – **Restricted** see terms [above](#)

† Liquid 10 g protein, 17.5 g carbohydrate and 10 g fat per 100 ml, bag .....	6.50	500 ml	Fresubin 2kcal HP
† Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle .....	5.50	500 ml	Nutrison Concentrated
† Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle .....	11.00	1,000 ml	Ensure Two Cal HN RTH

ORAL FEED 2 KCAL/ML – **Restricted** see terms [above](#)

† Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle .....	1.90	200 ml	Two Cal HN
--	------	--------	------------

PEPTIDE-BASED ENTERAL FEED 1KCAL/ML – **Restricted** see terms [above](#)

† Liquid 4.5 g protein, 14.3 g carbohydrate and 2.8 g fat per 100 ml, bag .....	9.60	500 ml	Survimed OPD
---	------	--------	--------------

## High Protein Products

HIGH PROTEIN ENTERAL FEED 1.2 KCAL/ML – **Restricted** see terms [below](#)

† Liquid 10 g protein, 12.9 g carbohydrate and 3.2 g fat and 0.64 g fibre per 100 ml, bag .....	9.60	500 ml	Fresubin Intensive
--	------	--------	--------------------

→ **Restricted (RS1327)**

### Initiation

Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
  - 2.1 Patient has liver disease; or
  - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
  - 2.3 Patient is fluid restricted; or
  - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML – **Restricted** see terms [below](#)

⚡ Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml, 1,000 ml bottle

*e.g. Nutrison Protein Plus*

➔ **Restricted (RS1327)**

### Initiation

Both:

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
  - 2.1 Patient has liver disease; or
  - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
  - 2.3 Patient is fluid restricted; or
  - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ENTERAL FEED 1.26 KCAL/ML – **Restricted** see terms [below](#)

⚡ Liquid 10 g protein, 10.4 g carbohydrate and 4.9 g fat per 100 ml, bottle ..... 5.78

500 ml

Nutrison Protein Intense

➔ **Restricted (RS1327)**

### Initiation

Both:

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
  - 2.1 Patient has liver disease; or
  - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
  - 2.3 Patient is fluid restricted; or
  - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML – **Restricted** see terms [below](#)

⚡ Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bottle

*e.g. Nutrison Protein Plus Multi Fibre*

➔ **Restricted (RS1327)**

### Initiation

Both:

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
  - 2.1 Patient has liver disease; or
  - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
  - 2.3 Patient is fluid restricted; or
  - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>Infant Formulas</b>			
AMINO ACID FORMULA – <b>Restricted</b> see terms <a href="#">below</a>			
↓ Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can			e.g. <i>Neocate</i>
↓ Powder 13 g protein, 49 g carbohydrate and 23 g fat per 100 g, 400 g can			e.g. <i>Neocate SYNEO unflavoured</i>
↓ Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can			e.g. <i>Neocate Junior Unflavoured</i>
↓ Powder 13.3 g protein, 57 g carbohydrate and 24.6 g fat per 100 g, can	43.60	400 g	Alfamino
↓ Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can	53.00	400 g	Neocate Gold (Unflavoured)
↓ Powder 14.8 g protein, 51.4 g carbohydrate and 23 g fat per 100 g, can	53.00	400 g	Neocate Junior Vanilla
↓ Powder 15 g protein, 56 g carbohydrate and 20 g fat per 100 g, can	43.60	400 g	Alfamino Junior
↓ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can	53.00	400 g	Elecare LCP (Unflavoured)
↓ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can	53.00	400 g	Elecare (Unflavoured) Elecare (Vanilla)

→ **Restricted (RS1867)**

**Initiation**

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows' milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis; or
- 4 Ultra-short gut; or
- 5 Severe Immune deficiency.

**Continuation**

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
- 3 Amino acid formula is required for a nutritional deficit.

**Initiation – patients who are currently funded under RS1502 or SA1557**

Limited to 3 months treatment

All of the following:

- 1 Patient has a valid initiation or renewal approval for extensively hydrolysed formula (RS1502); and
- 2 Patient is unable to source funded Aptamil powder at this time; and
- 3 The approval only applies to funded dispensings of Neocate Gold and Neocate Syneo.

Note: This criteria is short term funding to cover an out-of-stock situation on some extensively hydrolysed formula powder funded under Hospital Restriction RS1502. There is no continuation criteria under this criterion.

ENTERAL LIQUID PEPTIDE FORMULA – **Restricted** see terms [below](#)

↓ Liquid 4.2 g protein, 18.6 g carbohydrate and 6.58 g fat per 100 ml ..... 15.68 500 ml Nutrini Peptisorb Energy

→ **Restricted (RS1775)**

**Initiation**

All of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable; and
- 2 Any of the following:
  - 2.1 Severe malabsorption; or
  - 2.2 Short bowel syndrome; or
  - 2.3 Intractable diarrhoea; or
  - 2.4 Biliary atresia; or
  - 2.5 Cholestatic liver diseases causing malabsorption; or
  - 2.6 Cystic fibrosis; or
  - 2.7 Proven fat malabsorption; or
  - 2.8 Severe intestinal motility disorders causing significant malabsorption; or
  - 2.9 Intestinal failure; or
  - 2.10 Both:
    - 2.10.1 The patient is currently receiving funded amino acid formula; and
    - 2.10.2 The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula; and
- 3 Either:
  - 3.1 A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable; or
  - 3.2 For step down from intravenous nutrition.

Note: A reasonable trial is defined as a 2-4 week trial.

## Continuation

Both:

- 1 An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken; and
- 2 The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula.

## EXTENSIVELY HYDROLYSED FORMULA – **Restricted** see terms [below](#)

↓ Powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can.....	30.42	900 g	Allerpro Syneo 1
↓ Powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can.....	30.42	900 g	Allerpro Syneo 2
↓ Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can			<i>e.g. Pepti-Junior</i>

→ **Restricted (RS1502)**

## Initiation

Any of the following:

- 1 Both:
  - 1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
  - 1.2 Either:
    - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
    - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malabsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or

continued...



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
9 Severe intestinal motility disorders causing significant malabsorption; or			
10 Intestinal failure; or			
11 For step down from Amino Acid Formula.			
Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.			
<b>Continuation</b>			
Both:			
1 An assessment as to whether the infant can be transitioned to a cows' milk protein or soy infant formula has been undertaken; and			
2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.			
<b>FRUCTOSE-BASED FORMULA</b>			
Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g, 400 g can			<i>e.g. Galactomin 19</i>
<b>LACTOSE-FREE FORMULA</b>			
Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml, 900 g can			<i>e.g. Karicare Aptamil Gold De-Lact</i>
Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g can			<i>e.g. S26 Lactose Free</i>
<b>LOW-CALCIUM FORMULA</b>			
Powder 14.6 g protein, 55.2 g carbohydrate and 25.8 g fat per 100 g, 400 g can			<i>e.g. Locasol</i>
<b>PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML – <b>Restricted</b> see terms <a href="#">below</a></b>			
↓ Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, bottle .....	2.35	125 ml	Infatrin
→ <b>Restricted (RS1614)</b>			
<b>Initiation – Fluid restricted or volume intolerance with faltering growth</b>			
Both:			
1 Either:			
1.1 The patient is fluid restricted or volume intolerant; or			
1.2 The patient has increased nutritional requirements due to faltering growth; and			
2 Patient is under 18 months old and weighs less than 8kg.			
Note: "Volume intolerant" patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialed appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.			
<b>PRETERM FORMULA – <b>Restricted</b> see terms <a href="#">below</a></b>			
↓ Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, bottle .....	0.75	100 ml	S26 LBW Gold RTF
↓ Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 90 ml bottle			<i>e.g. Pre Nan Gold RTF</i>
↓ Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml, 70 ml bottle			<i>e.g. Karicare Aptamil Gold+Preterm</i>
→ <b>Restricted (RS1224)</b>			
<b>Initiation</b>			
For infants born before 33 weeks' gestation or weighing less than 1.5 kg at birth.			
<b>THICKENED FORMULA</b>			
Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can			<i>e.g. Karicare Aptamil Thickened AR</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Ketogenic Diet Products

HIGH FAT FORMULA – **Restricted** see terms [below](#)

↓ Powder 14.3 g protein, 2.8 g carbohydrate and 69.2 g fat per 100 g, can .....	35.50	300 g	Ketocal 4:1 (Unflavoured)
↓ Powder 15.4 g protein, 7.2 g carbohydrate and 68.6 g fat per 100 g, can .....	35.50	300 g	Ketocal 4:1 (Vanilla) Ketocal 3:1 (Unflavoured)

→ **Restricted** (RS1225)

### Initiation

For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

## Paediatric Products

→ **Restricted** (RS1473)

### Initiation

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
  - 2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
  - 2.2 Any condition causing malabsorption; or
  - 2.3 Faltering growth in an infant/child; or
  - 2.4 Increased nutritional requirements; or
  - 2.5 The child is being transitioned from TPN or tube feeding to oral feeding; or
  - 2.6 The child has eaten, or is expected to eat, little or nothing for 3 days.

PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – **Restricted** see terms [above](#)

↑ Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag.....	4.00	500 ml	Nutrini Low Energy Multifibre RTH
--	------	--------	--------------------------------------

PAEDIATRIC ENTERAL FEED 1 KCAL/ML – **Restricted** see terms [above](#)

↑ Liquid 2.5 g protein, 12.5 g carbohydrate and 4.4 g fat per 100 ml.....	6.50	500 ml	Frebini Original
↑ Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag.....	2.68	500 ml	Pediasure RTH
↑ Liquid 2.7 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bottle			<i>e.g. Nutrini RTH</i>

PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – **Restricted** see terms [above](#)

↑ Liquid 3.8 g protein, 18.7 g carbohydrate and 6.7 g fat per 100 ml.....	6.50	500 ml	Frebini Energy
↑ Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bottle.....	6.00	500 ml	Nutrini Energy Multi Fibre
↑ Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bottle			<i>e.g. Nutrini Energy RTH</i>

PAEDIATRIC ENTERAL FEED WITH FIBRE 1 KCAL/ML – **Restricted** see terms [above](#)

↑ Liquid 2.5 g protein, 12.1 g carbohydrate, 4.5g fat and 0.8 g fibre per 100 ml.....	7.00	500 ml	Frebini Original Fibre
--	------	--------	------------------------

PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5 KCAL/ML – **Restricted** see terms [above](#)

↑ Liquid 3.8 g protein, 18.1 g carbohydrate, 6.7 g fat and 1.1 g fibre per 100 ml.....	7.00	500 ml	Frebini Energy Fibre
---	------	--------	----------------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bottle .....	1.07	200 ml	Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla) Pediasure (Vanilla)
† Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, can .....	1.34	250 ml	Pediasure (Vanilla)
<b>PAEDIATRIC ORAL FEED 1.5 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 500 ml bottle			<i>e.g. Pediasure Plus</i>
† Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle			<i>e.g. Fortini</i>
† Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle			<i>e.g. Fortini Multifibre</i>

## Renal Products

**LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML – Restricted** see terms [below](#)

‡ Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre  
per 100 ml, bottle..... 6.08 500 ml Nepro HP RTH

→ **Restricted (RS1229)**

### Initiation

For patients with acute or chronic kidney disease.

**LOW ELECTROLYTE ORAL FEED – Restricted** see terms [below](#)

‡ Powder 7.5 g protein, 57.6 g carbohydrate and 25.9 g fat per 100 g,  
400 g can *e.g. Kindergen*

→ **Restricted (RS1227)**

### Initiation

For children (up to 18 years) with acute or chronic kidney disease.

**LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML**

‡ Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per  
100 ml, carton..... 2.67 220 ml Nepro HP (Strawberry)  
Nepro HP (Vanilla)

→ **Restricted (RS1228)**

### Initiation

For patients with acute or chronic kidney disease.

**LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – Restricted** see terms [below](#)

‡ Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml  
bottle

‡ Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml  
carton *e.g. Renilon 7.5*

‡ Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, 200 ml  
bottle..... 13.24 4 Novasource Renal  
(Vanilla)

→ **Restricted (RS1228)**

### Initiation

For patients with acute or chronic kidney disease.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Surgical Products

HIGH ARGININE ORAL FEED 1.4 KCAL/ML – **Restricted** see terms [below](#)

↓ Liquid 10.4 g protein, 8 g carbohydrate, 4.4 g fat and 0 g fibre per 100 ml, 250 ml carton.....	56.00	10	Impact Advanced Recovery
---	-------	----	--------------------------

→ **Restricted (RS1231)**

### Initiation

Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery.

PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML – **Restricted** see terms [below](#)

↓ Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml bottle.....	6.80	4	preOp
--	------	---	-------

→ **Restricted (RS1415)**

### Initiation

Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery.

## Standard Feeds

→ **Restricted (RS1214)**

### Initiation

Any of the following:

For patients with malnutrition, defined as any of the following:

- 1 Any of the following:
  - 1.1 BMI < 18.5; or
  - 1.2 Greater than 10% weight loss in the last 3-6 months; or
  - 1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
- 2 For patients who have, or are expected to, eat little or nothing for 5 days; or
- 3 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
- 4 For use pre- and post-surgery; or
- 5 For patients being tube-fed; or
- 6 For tube-feeding as a transition from intravenous nutrition; or
- 7 For any other condition that meets the community Special Authority criteria.

ENTERAL FEED 1.5 KCAL/ML – **Restricted** see terms [above](#)

↑ Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bottle.....	7.00	1,000 ml	Nutrison Energy
↑ Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bottle			<i>e.g. Nutrison Energy Multi Fibre</i>
↑ Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can.....	1.75	250 ml	Ensure Plus HN
↑ Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag.....	7.00	1,000 ml	Ensure Plus HN RTH
↑ Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag.....	7.00	1,000 ml	Jevity HiCal RTH
↑ Liquid 7.5 g protein, 17 g carbohydrate and 5.8 g fat per 100 ml, bag.....	9.60	1,000 ml	Fresubin HP Energy

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ENTERAL FEED 1 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 3.8 g protein, 13.8 g carbohydrate and 3.4 g fat per 100 ml, bag.....	6.50	1,000 ml	Fresubin Original
† Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bottle			<i>e.g. Nutrison Multi Fibre</i>
† Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle .....	5.29	1,000 ml	Osmolite RTH
† Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle.....	5.29	1,000 ml	Jevity RTH
† Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bag			<i>e.g. NutrisonStdRTH; NutrisonLowSodium</i>
† Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bottle			<i>e.g. Nutrison Low Sodium; NutrisonStdRTH</i>
<b>ENTERAL FEED 1.2 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag			<i>e.g. Jevity Plus RTH</i>
<b>ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre per 100 ml, bottle.....	5.29	1,000 ml	Nutrison 800 Complete Multi Fibre
<b>ENTERAL FEED WITH FIBRE 1 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 3.8 g protein, 13.0 g carbohydrate, 3.4 g fat and 1.5 g fibre per 100 ml, bag.....	7.00	1,000 ml	Fresubin Original Fibre
<b>ENTERAL FEED WITH FIBRE 1.5 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 7.5 g protein, 16.2 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, bag.....	9.80	1,000 ml	Fresubin HP Energy Fibre
<b>HIGH PROTEIN ORAL FEED 2.4 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
Only to be used for patients currently on or would be using Fortisip or Fortisip Multi Fibre			
† Liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle			<i>e.g. Fortisip Compact Protein</i>
<i>(e.g. Fortisip Compact Protein Liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle to be delisted 1 December 2023)</i>			
<b>ORAL FEED – Restricted</b> see terms <a href="#">on the previous page</a>			
† Powder 15.9 g protein, 57.4 g carbohydrate and 14 g fat per 100 g, can .....	26.00	850 g	Ensure (Chocolate) Ensure (Vanilla)
† Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can .....	14.00	840 g	Sustagen Hospital Formula (Chocolate) Sustagen Hospital Formula (Vanilla)
<b>ORAL FEED 1 KCAL/ML – Restricted</b> see terms <a href="#">on the previous page</a>			
† Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml, 237 ml carton			<i>e.g. Resource Fruit Beverage</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
<b>ORAL FEED 1.5 KCAL/ML – Restricted</b> see terms <a href="#">on page 284</a>			
† Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can .....	1.33	237 ml	Ensure Plus (Vanilla)
† Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, carton.....	1.26	200 ml	Ensure Plus (Banana) Ensure Plus (Chocolate) Ensure Plus (Fruit of the Forest) Ensure Plus (Vanilla) <i>e.g. Fortijuice</i>
† Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle			
† Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle			<i>e.g. Fortisip</i>
† Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle			<i>e.g. Fortisip Multi Fibre</i>

## Other Supplements for PKU

AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – **Restricted** see terms [below](#)

‡ Powder 20 g protein, 1.7 g carbohydrate per 32 g sachet.....	898.56	30	PKU Build 20 Chocolate PKU Build 20 Raspberry Lemonade PKU Build 20 Smooth PKU Build 20 Vanilla
‡ Powder 20 g protein, 4.9 g carbohydrate per 33.4 g sachet.....	936.00	30	PKU GMPro Ultra Lemonade
‡ Powder 20 g protein, 6.0 g carbohydrate per 35 g sachet.....	930.00	30	PKU sphere20 Lemon
‡ Powder 20 g protein, 6.3 g carbohydrate per 35 g sachet.....	930.00	30	PKU sphere20 Chocolate PKU sphere20 Red Berry PKU sphere20 Vanilla
‡ Powder 20 g protein, 6.7 g carbohydrate per 35 g sachet.....	930.00	30	PKU sphere20 Banana

*(PKU Build 20 Chocolate Powder 20 g protein, 1.7 g carbohydrate per 32 g sachet to be delisted 1 January 2024)*

*(PKU Build 20 Raspberry Lemonade Powder 20 g protein, 1.7 g carbohydrate per 32 g sachet to be delisted 1 January 2024)*

*(PKU Build 20 Smooth Powder 20 g protein, 1.7 g carbohydrate per 32 g sachet to be delisted 1 January 2024)*

*(PKU Build 20 Vanilla Powder 20 g protein, 1.7 g carbohydrate per 32 g sachet to be delisted 1 January 2024)*

*(PKU GMPro Ultra Lemonade Powder 20 g protein, 4.9 g carbohydrate per 33.4 g sachet to be delisted 1 December 2023)*

*(PKU sphere20 Lemon Powder 20 g protein, 6.0 g carbohydrate per 35 g sachet to be delisted 1 January 2024)*

*(PKU sphere20 Chocolate Powder 20 g protein, 6.3 g carbohydrate per 35 g sachet to be delisted 1 January 2024)*

*(PKU sphere20 Red Berry Powder 20 g protein, 6.3 g carbohydrate per 35 g sachet to be delisted 1 January 2024)*

*(PKU sphere20 Vanilla Powder 20 g protein, 6.3 g carbohydrate per 35 g sachet to be delisted 1 January 2024)*

*(PKU sphere20 Banana Powder 20 g protein, 6.7 g carbohydrate per 35 g sachet to be delisted 1 January 2024)*

➔ **Restricted (RS1972)**

### Initiation

All of the following:

- 1 Patient was previously receiving, or would receive PKU Sensation Berries under (RS1232); and
- 2 PKU Sensation Berries is unable to be sourced at this time; and
- 3 Patient has trialled the currently funded PKU Lophlex products and these were not tolerated.

Note: These criteria are attached to short term funding to cover an out-of-stock situation on PKU Sensation Berries supplied by Nutricia.

Price	Brand or
(ex man. excl. GST)	Generic
\$	Manufacturer
Per	

## Bacterial and Viral Vaccines

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – **Restricted** see terms [below](#)

↓ Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe  
 – 0% DV Oct-20 to 2024..... 0.00 10 **Infanrix IPV**  
 → **Restricted (RS1387)**

**Initiation**

Any of the following:

- 1 A single dose for children up to the age of 7 who have completed primary immunisation; or
- 2 A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
- 3 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 4 Five doses will be funded for children requiring solid organ transplantation.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE –

**Restricted** see terms [below](#)

↓ Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B  
 – 0% DV Oct-20 to 2024..... 0.00 10 **Infanrix-hexa**  
 → **Restricted (RS1478)**

**Initiation**

Any of the following:

- 1 Up to four doses for children up to and under the age of 10 for primary immunisation; or
- 2 An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 3 Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

## Bacterial Vaccines

BACILLUS CALMETTE-GUERIN VACCINE – **Restricted** see terms [below](#)

↓ Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain  
 1331, live attenuated, vial with diluent – 0% DV Oct-20 to 2024..... 0.00 10 **BCG Vaccine**  
 → **Restricted (RS1233)**

**Initiation**

All of the following:

For infants at increased risk of tuberculosis defined as:

- 1 Living in a house or family with a person with current or past history of TB; and
- 2 Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; and
- 3 During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.

Note: A list of countries with high rates of TB are available at <http://www.health.govt.nz/tuberculosis> (Search for Downloads) or [www.bcgatlas.org/index.php](http://www.bcgatlas.org/index.php)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – Restricted** see terms [below](#)

† Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe – 0% DV Oct-20 to 2024.....	0.00	10	<b>Boostrix</b>
--	------	----	-----------------

→ **Restricted (RS1790)**

**Initiation**

Any of the following:

- 1 A single dose for pregnant women in the second or third trimester of each pregnancy; or; or
- 2 A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or; or
- 3 A course of up to four doses is funded for children from age 7 up the age of 18 years inclusive to complete full primary immunisation; or
- 4 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 5 A single dose for vaccination of patients aged from 65 years old; or
- 6 A single dose for vaccination of patients aged from 45 years old who have not had 4 previous tetanus doses; or
- 7 For vaccination of previously unimmunised or partially immunised patients; or
- 8 For revaccination following immunosuppression; or
- 9 For boosting of patients with tetanus-prone wounds.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

**HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Restricted** see terms [below](#)

† Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml .....	0.00	1	<b>Hiberix</b>
---	------	---	----------------

→ **Restricted (RS1520)**

**Initiation**

*Therapy limited to 1 dose*

Any of the following:

- 1 For primary vaccination in children; or
- 2 An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or
- 3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

**MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE – Restricted** see terms [below](#)

† Inj 10 mcg of each meningococcal polysaccharide conjugated to a total of approximately 55 mcg of tetanus toxoid carrier per 0.5 ml vial .....	0.00	1	<b>MenQuadfi</b>
---	------	---	------------------

→ **Restricted (RS1934)**

**Initiation**

Either:

- 1 Any of the following:
  - 1.1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
  - 1.2 One dose for close contacts of meningococcal cases of any group; or
  - 1.3 One dose for person who has previously had meningococcal disease of any group; or
  - 1.4 A maximum of two doses for bone marrow transplant patients; or

continued...



	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

1.5 A maximum of two doses for person pre and post-immunosuppression\*; or

2 Both:

- 2.1 Person is aged between 13 and 25 years, inclusive; and
- 2.2 One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

\*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL B MULTICOMPONENT VACCINE – **Restricted** see terms [below](#)

↓ Inj 175 mcg per 0.5 ml prefilled syringe.....0.00 1 Bexsero

➔ **Restricted (RS1947)**

**Initiation – Primary immunisation for children up to 12 months of age**

*Therapy limited to 3 doses*

Either:

- 1 Three doses for children up to 12 months of age (inclusive) for primary immunisation; or
- 2 Up to three doses (dependent on age at first dose) for a catch-up programme for children from 13 months to 59 months of age (inclusive) for primary immunisation, from 1 March 2023 to 31 August 2025.

**Initiation – Person is one year of age or over**

Any of the following:

- 1 up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
- 2 up to two doses for close contacts of meningococcal cases of any group; or
- 3 up to two doses for person who has previously had meningococcal disease of any group; or
- 4 up to two doses for bone marrow transplant patients; or
- 5 up to two doses for person pre- and post-immunosuppression\* .

**Initiation – Person is aged between 13 and 25 years (inclusive)**

*Therapy limited to 2 doses*

Both:

- 1 Person is aged between 13 and 25 years (inclusive); and
- 2 Either:
  - 2.1 Two doses for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons; or
  - 2.2 Two doses for individuals who are currently living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons, from 1 March 2023 to 28 February 2024.

Note: \*Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL C CONJUGATE VACCINE – **Restricted** see terms [below](#)

↓ Inj 10 mcg in 0.5 ml syringe.....0.00 1 Neisvac-C

➔ **Restricted (RS1935)**

**Initiation – Children under 12 months of age**

Any of the following:

- 1 Up to three doses for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
- 2 Two doses for close contacts of meningococcal cases of any group; or
- 3 Two doses for child who has previously had meningococcal disease of any group; or
- 4 A maximum of two doses for bone marrow transplant patients; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

5 A maximum of two doses for child pre- and post-immunosuppression\*.

Notes: children under 12 months of age require two doses 8 weeks apart. Refer to the Immunisation Handbook for recommended booster schedules with meningococcal ACWY vaccine.

\*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

**PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE – Restricted** see terms [below](#)

† inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml prefilled syringe – <b>0% DV Oct-20 to 2024</b> ..... 0.00	10	<b>Synflorix</b>
---	----	------------------

⇒ **Restricted (RS1768)**

**Initiation**

A primary course of three doses for previously unvaccinated individuals up to the age of 59 months inclusive.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

**PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – Restricted** see terms [below](#)

† Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe ..... 0.00	1	Prevenar 13
	10	Prevenar 13

⇒ **Restricted (RS1936)**

**Initiation – Primary course for previously unvaccinated children aged under 5 years**

*Therapy limited to 3 doses*

A primary course of three doses for previously unvaccinated children up to the age of 59 months inclusive.

**Initiation – High risk individuals who have received PCV10**

*Therapy limited to 2 doses*

Two doses are funded for high risk individuals (over the age of 12 months and under 18 years) who have previously received two doses of the primary course of PCV10.

**Initiation – High risk children aged under 5 years**

*Therapy limited to 4 doses*

Both:

- 1 Up to an additional four doses (as appropriate) are funded for the (re)immunisation of high-risk children aged under 5 years; and
- 2 Any of the following:
  - 2.1 on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
  - 2.2 primary immune deficiencies; or
  - 2.3 HIV infection; or
  - 2.4 renal failure, or nephrotic syndrome; or
  - 2.5 are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
  - 2.6 cochlear implants or intracranial shunts; or
  - 2.7 cerebrospinal fluid leaks; or
  - 2.8 receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
  - 2.9 chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
  - 2.10 pre term infants, born before 28 weeks gestation; or
  - 2.11 cardiac disease, with cyanosis or failure; or
  - 2.12 diabetes; or
  - 2.13 Down syndrome; or
  - 2.14 who are pre- or post-splenectomy, or with functional asplenia.

continued...

Price		Brand or Generic Manufacturer
(ex man. excl. GST)	Per	
\$		

continued...

**Initiation – High risk individuals 5 years and over**

*Therapy limited to 4 doses*

Up to an additional four doses (as appropriate) are funded for the (re-)immunisation of individuals 5 years and over with HIV, pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, intracranial shunts, cerebrospinal fluid leaks or primary immunodeficiency.

**Initiation – Testing for primary immunodeficiency diseases**

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – **Restricted** see terms [below](#)

↓ Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) – **0% DV Oct-20 to 2024** ..... 0.00 1 **Pneumovax 23**

→ **Restricted (RS1587)**

**Initiation – High risk patients**

*Therapy limited to 3 doses*

For patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy; or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

**Initiation – High risk children**

*Therapy limited to 2 doses*

Both:

- 1 Patient is a child under 18 years for (re-)immunisation; and
- 2 Any of the following:
  - 2.1 On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
  - 2.2 With primary immune deficiencies; or
  - 2.3 With HIV infection; or
  - 2.4 With renal failure, or nephrotic syndrome; or
  - 2.5 Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
  - 2.6 With cochlear implants or intracranial shunts; or
  - 2.7 With cerebrospinal fluid leaks; or
  - 2.8 Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
  - 2.9 With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
  - 2.10 Pre term infants, born before 28 weeks gestation; or
  - 2.11 With cardiac disease, with cyanosis or failure; or
  - 2.12 With diabetes; or
  - 2.13 With Down syndrome; or
  - 2.14 Who are pre-or post-splenectomy, or with functional asplenia.

**Initiation – Testing for primary immunodeficiency diseases**

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

SALMONELLA TYPHI VACCINE – **Restricted** see terms [below](#)

↓ Inj 25 mcg in 0.5 ml syringe

→ **Restricted (RS1243)**

**Initiation**

For use during typhoid fever outbreaks.

# VACCINES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Viral Vaccines

HEPATITIS A VACCINE – **Restricted** see terms [below](#)

⚡ Inj 720 ELISA units in 0.5 ml syringe – 0% DV Oct-20 to 2024	0.00	1	Havrix Junior
⚡ Inj 1440 ELISA units in 1 ml syringe – 0% DV Oct-20 to 2024	0.00	1	Havrix

→ **Restricted** (RS1638)

### Initiation

Any of the following:

- 1 Two vaccinations for use in transplant patients; or
- 2 Two vaccinations for use in children with chronic liver disease; or
- 3 One dose of vaccine for close contacts of known hepatitis A cases.

HEPATITIS B RECOMBINANT VACCINE

⚡ Inj 10 mcg per 0.5 ml prefilled syringe	0.00	1	Engerix-B
---	------	---	-----------

→ **Restricted** (RS1588)

### Initiation

Any of the following:

- 1 For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
- 2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
- 3 For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
- 4 For HIV positive patients; or
- 5 For hepatitis C positive patients; or
- 6 for patients following non-consensual sexual intercourse; or
- 7 For patients following immunosuppression; or
- 8 For solid organ transplant patients; or
- 9 For post-haematopoietic stem cell transplant (HSCT) patients; or
- 10 Following needle stick injury.

⚡ Inj 20 mcg per 1 ml prefilled syringe – 0% DV Oct-20 to 2024	0.00	1	Engerix-B
--	------	---	-----------

→ **Restricted** (RS1671)

### Initiation

Any of the following:

- 1 For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
- 2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
- 3 For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
- 4 For HIV positive patients; or
- 5 For hepatitis C positive patients; or
- 6 for patients following non-consensual sexual intercourse; or
- 7 For patients following immunosuppression; or
- 8 For solid organ transplant patients; or
- 9 For post-haematopoietic stem cell transplant (HSCT) patients; or
- 10 Following needle stick injury; or
- 11 For dialysis patients; or
- 12 For liver or kidney transplant patients.

HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] – **Restricted** see terms [on the next page](#)

⚡ Inj 270 mcg in 0.5 ml syringe – 0% DV Oct-20 to 2024	0.00	10	Gardasil 9
--	------	----	------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted (RS1693)**

**Initiation – Children aged 14 years and under**

*Therapy limited to 2 doses*

Children aged 14 years and under.

**Initiation – other conditions**

Either:

- 1 Up to 3 doses for people aged 15 to 26 years inclusive; or
- 2 Both:
  - 2.1 People aged 9 to 26 years inclusive; and
  - 2.2 Any of the following:
    - 2.2.1 Up to 3 doses for confirmed HIV infection; or
    - 2.2.2 Up to 3 doses for transplant (including stem cell) patients; or
    - 2.2.3 Up to 4 doses for Post chemotherapy.

**Initiation – Recurrent Respiratory Papillomatosis**

All of the following:

- 1 Either:
  - 1.1 Maximum of two doses for children aged 14 years and under; or
  - 1.2 Maximum of three doses for people aged 15 years and over; and
- 2 The patient has recurrent respiratory papillomatosis; and
- 3 The patient has not previously had an HPV vaccine.

**INFLUENZA VACCINE**

↓ Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine).....	11.00	1	Afluria Quad Junior (2023 Formulation)
--	-------	---	---

➔ **Restricted (RS1948)**

**Initiation – children 6 months to 35 months of age**

Children 6 months to 35 months of age (inclusive) from 1 April 2023 to 31 December 2023.

↓ Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine).....	50.00	5	FluQuadri (2023 Formulation)
---	-------	---	---------------------------------

➔ **Restricted (RS1978)**

**Initiation – children 6 months to 35 months of age**

Children 6 months to 35 months of age (inclusive) from 1 July 2023 to 31 December 2023..

↓ Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine).....	110.00	10	Afluria Quad (2023 Formulation)
--	--------	----	------------------------------------

➔ **Restricted (RS1949)**

**Initiation – People over 65**

The patient is 65 years of age or over.

**Initiation – People of Māori or any Pacific ethnicity**

People 55 to 64 years of age (inclusive) and is Māori or of any Pacific ethnicity, from 1 April 2023 to 31 December 2023.

**Initiation – cardiovascular disease for patients 3 years and over**

Any of the following:

- 1 Ischaemic heart disease; or
- 2 Congestive heart failure; or
- 3 Rheumatic heart disease; or
- 4 Congenital heart disease; or
- 5 Cerebro-vascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

**Initiation – chronic respiratory disease for patients 3 years and over**

Either:

- 1 Asthma, if on a regular preventative therapy; or
- 2 Other chronic respiratory disease with impaired lung function.

Note: asthma not requiring regular preventative therapy is excluded from funding.

**Initiation – Other conditions for patients 3 years and over**

Either:

- 1 Any of the following:
  - 1.1 Diabetes; or
  - 1.2 chronic renal disease; or
  - 1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
  - 1.4 Autoimmune disease; or
  - 1.5 Immune suppression or immune deficiency; or
  - 1.6 HIV; or
  - 1.7 Transplant recipient; or
  - 1.8 Neuromuscular and CNS diseases/ disorders; or
  - 1.9 Haemoglobinopathies; or
  - 1.10 Is a child on long term aspirin; or
  - 1.11 Has a cochlear implant; or
  - 1.12 Errors of metabolism at risk of major metabolic decompensation; or
  - 1.13 Pre and post splenectomy; or
  - 1.14 Down syndrome; or
  - 1.15 Is pregnant; or
  - 1.16 Is a child 3 to 4 years of age (inclusive) who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or
- 2 Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a Public Hospital.

**Initiation – Serious mental health conditions or addiction**

Any of the following:

- 1 schizophrenia; or
- 2 major depressive disorder; or
- 3 bipolar disorder; or
- 4 schizoaffective disorder; or
- 5 person is currently accessing secondary or tertiary mental health and addiction services.

**Initiation – children from 3 to 12 years of age (inclusive)**

Children 3 to 12 years of age (inclusive) from 1 April 2023 to 31 December 2023.

*(FluQuadri (2023 Formulation) Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) to be delisted 1 January 2024)*

**MEASLES, MUMPS AND RUBELLA VACCINE – Restricted see terms below**

↓ Injection, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml – <b>0% DV Oct-20 to 2024</b> .....	0.00	10	<b>Priorix</b>
--	------	----	----------------

→ **Restricted (RS1487)**

**Initiation – first dose prior to 12 months**

*Therapy limited to 3 doses*

Any of the following:

- 1 For primary vaccination in children; or
- 2 For revaccination following immunosuppression; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 3 For any individual susceptible to measles, mumps or rubella.

**Initiation – first dose after 12 months**

*Therapy limited to 2 doses*

Any of the following:

- 1 For primary vaccination in children; or
- 2 For revaccination following immunosuppression; or
- 3 For any individual susceptible to measles, mumps or rubella.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

POLIOMYELITIS VACCINE – **Restricted** see terms [below](#)

↓ Inj 80 D-antigen units in 0.5 ml syringe – 0% DV Oct-20 to 2024.....	0.00	1	<b>IPOL</b>
--	------	---	-------------

→ **Restricted (RS1398)**

**Initiation**

*Therapy limited to 3 doses*

Either:

- 1 For partially vaccinated or previously unvaccinated individuals; or
- 2 For revaccination following immunosuppression.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

RABIES VACCINE

Inj 2.5 IU vial with diluent

ROTAVIRUS ORAL VACCINE – **Restricted** see terms [below](#)

↓ Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator – 0% DV Oct-20 to 2024.....	0.00	10	<b>Rotarix</b>
---	------	----	----------------

↓ Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, squeezable tube .....	0.00	10	Rotarix
---	------	----	---------

→ **Restricted (RS1590)**

**Initiation**

*Therapy limited to 2 doses*

Both:

- 1 First dose to be administered in infants aged under 14 weeks of age; and
- 2 No vaccination being administered to children aged 24 weeks or over.

VARICELLA VACCINE [CHICKENPOX VACCINE]

↓ Inj 1350 PFU prefilled syringe – 0% DV Oct-20 to 2024.....	0.00	1	<b>Varivax</b>
		10	<b>Varivax</b>

→ **Restricted (RS1591)**

**Initiation – primary vaccinations**

*Therapy limited to 1 dose*

Either:

- 1 Any infant born on or after 1 April 2016; or
- 2 For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox).

**Initiation – other conditions**

*Therapy limited to 2 doses*

Any of the following:

- 1 Any of the following:  
for non-immune patients:

continued...

	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

continued...

- 1.1 With chronic liver disease who may in future be candidates for transplantation; or
- 1.2 With deteriorating renal function before transplantation; or
- 1.3 Prior to solid organ transplant; or
- 1.4 Prior to any elective immunosuppression\*; or
- 1.5 For post exposure prophylaxis who are immune competent inpatients; or
- 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or
- 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or
- 4 For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
- 5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or
- 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
- 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: \* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

⚡ Inj 2000 PFU prefilled syringe plus vial

➡ **Restricted (RS1777)**

**Initiation – infants between 9 and 12 months of age**

*Therapy limited to 2 doses*

Any of the following:

- 1 Any of the following:
  - for non-immune patients:
    - 1.1 With chronic liver disease who may in future be candidates for transplantation; or
    - 1.2 With deteriorating renal function before transplantation; or
    - 1.3 Prior to solid organ transplant; or
    - 1.4 Prior to any elective immunosuppression\*; or
    - 1.5 For post exposure prophylaxis who are immune competent inpatients; or
  - 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or
  - 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or
  - 4 For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
  - 5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or
  - 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
  - 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: \* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

**VARICELLA ZOSTER VACCINE [SHINGLES VACCINE] – Restricted see terms on the next page**

⚡ Inj 50 mcg per 0.5 ml vial plus vial.....0.00 1 Shingrix



Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted (RS1916)**

**Initiation – people aged 65 years (Zostavax)**

*Therapy limited to 1 dose*

One dose for all people aged 65 years.

**Initiation – people aged 65 years (Shingrix)**

*Therapy limited to 2 doses*

Two doses for all people aged 65 years.

**Diagnostic Agents**

TUBERCULIN PPD [MANTOUX] TEST

Inj 5 TU per 0.1 ml, 1 ml vial – <b>0% DV Oct-20 to 2024</b> .....	0.00	1	<b>Tubersol</b>
--	------	---	-----------------

## PART III: OPTIONAL PHARMACEUTICALS

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

### Optional Pharmaceuticals

#### NOTE:

In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a range of hospital medical devices are listed in an addendum to Part III which is available at [schedule.pharmac.govt.nz](http://schedule.pharmac.govt.nz). The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.

#### BLOOD GLUCOSE DIAGNOSTIC TEST METER

1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips .....	20.00	1	CareSens N Premier
	10.00		Caresens N
			Caresens N POP

#### BLOOD GLUCOSE DIAGNOSTIC TEST STRIP

Blood glucose test strips.....	10.56	50 test	CareSens N
Test strips.....	10.56	50 test	CareSens PRO

#### BLOOD KETONE DIAGNOSTIC TEST STRIP

Test strips.....	15.50	10 strip	KetoSens
------------------	-------	----------	----------

#### DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER

Meter with 50 lancets, a lancing device, and 10 blood glucose diagnostic test strips .....	20.00	1	CareSens Dual
--	-------	---	---------------

#### MASK FOR SPACER DEVICE

Small.....	2.70	1	e-chamber Mask
------------	------	---	----------------

#### PEAK FLOW METER

Low Range .....	9.54	1	Mini-Wright AFS Low Range
Normal Range .....	9.54	1	Mini-Wright Standard

#### PREGNANCY TEST - HCG URINE

Cassette .....	12.00	40 test	Smith BioMed Rapid Pregnancy Test
----------------	-------	---------	-----------------------------------

#### SODIUM NITROPRUSSIDE

Test strip.....	22.00	50 strip	Ketostix
-----------------	-------	----------	----------

#### SPACER DEVICE

220 ml (single patient) .....	3.65	1	e-chamber Turbo
510 ml (single patient) .....	5.95	1	e-chamber La Grande
800 ml.....	6.50	1	Volumatic

<b>- Symbols -</b>		
8-methoxypsoralen.....	71	
<b>- A -</b>		
A-Scabies.....	68	
Abacavir sulphate.....	102	
Abacavir sulphate with lamivudine.....	102	
Abacavir/lamivudine Viartis.....	102	
Abciximab.....	175	
Abiraterone acetate.....	164	
Acarbose.....	9	
Accarb.....	9	
Accuretic 10.....	43	
Accuretic 20.....	43	
Acetazolamide.....	256	
Acetec.....	43	
Acetic acid		
Extemporaneously Compounded Preparations.....	267	
Genito-Urinary.....	74	
Acetic acid with hydroxyquinoline, glycerol and ricinoleic acid.....	74	
Acetic acid with propylene glycol.....	258	
Acetylcholine chloride.....	256	
Acetylcysteine.....	259	
Aciclovir		
Infections.....	105	
Sensory.....	252	
Aciclovir-Baxter.....	105	
Acid Citrate Dextrose A.....	35	
Acidex.....	5	
Acipimox.....	53	
Acitretin.....	71	
Actemra.....	224	
Actinomycin D.....	147	
Adalimumab (Amgevita).....	175	
Adalimumab (Humira - alternative brand).....	184	
Adapalene.....	68	
Adenocor.....	45	
Adenosine.....	45	
Adrenaline		
Cardiovascular.....	53	
Respiratory.....	243	
Advantan.....	70	
Advate.....	34	
Adynovate.....	34	
Aerrane.....	119	
Afinitor.....	239	
Aflibercept.....	191	
Afluria Quad		
(2023 Formulation).....	293	
Afluria Quad Junior		
(2023 Formulation).....	293	
Agents Affecting the Renin-Angiotensin System.....	43	
Agents for Parkinsonism and Related Disorders.....	118	
Agents Used in the Treatment of Poisonings.....	259	
Ajmaline.....	45	
Albendazole.....	99	
Alchemy Caspofungin.....	97	
Alchemy Oxaliplatin.....	156	
Alchemy Oxybutynin.....	76	
Aldurazyme.....	19	
Alecensa.....	156	
Alectinib.....	156	
Alendronate sodium.....	111	
Alendronate sodium with colecalciferol.....	111	
Alfacalcidol.....	27	
Alfamino.....	279	
Alfamino Junior.....	279	
Alfentanil.....	123	
Alglucosidase alfa.....	16	
Alinia.....	100	
Allerfix.....	254	
Allerpro Syneo 1.....	280	
Allerpro Syneo 2.....	280	
Allersoothe.....	244	
Allmercap.....	149	
Allopurinol.....	114	
Alpha tocopheryl.....	27	
Alpha tocopheryl acetate.....	28	
Alpha-Adrenoceptor Blockers.....	45	
Alphamox.....	92	
Alphamox 125.....	92	
Alphamox 250.....	92	
Alprolix.....	33	
Alprostadil.....	54	
Alprostadil hydrochloride.....	54	
Alteplase.....	38	
Alum.....	267	
Aluminium chloride.....	31	
Aluminium hydroxide.....	5	
Aluminium hydroxide with magnesium hydroxide and simeticone.....	5	
Amantadine hydrochloride.....	118	
AmBisome.....	96	
Ambrisentan.....	55	
Ambrisentan Mylan.....	55	
Ambrisentan Viartis.....	55	
Amethocaine		
Nervous.....	122	
Sensory.....	255	
Amgevita.....	175	
Amikacin.....	88	
Amiloride hydrochloride.....	49	
Amiloride hydrochloride with furosemide.....	49	
Amiloride hydrochloride with hydrochlorothiazide.....	49	
Aminolevulinic acid hydrochloride.....	167	
Aminophylline.....	249	
Amiodarone hydrochloride.....	45	
Amisulpride.....	132	
Amitriptyline.....	125	
Amlodipine.....	47	
Amorolfine.....	67	
Amoxicillin.....	92	
Amoxicillin with clavulanic acid.....	92	
Amoxiclav multichem.....	92	
Amphotericin B		
Alimentary.....	24	
Infections.....	96	
Amsacrine.....	150	
Amyl nitrite.....	259	
Anabolic Agents.....	78	
Anaesthetics.....	119	
Anagrelide hydrochloride.....	150	
Analgescics.....	122	
Anastrozole.....	167	
Anatrole.....	167	
Andriol Testocaps.....	78	
Androderm.....	78	
Androgen Agonists and Antagonists.....	78	
Anoro Ellipta.....	245	
Antabuse.....	144	
Antacids and Antiflatulents.....	5	
Anti-Infective Agents.....	74	
Anti-Infective Preparations		
Dermatological.....	67	
Sensory.....	252	
Anti-Inflammatory Preparations.....	253	
Antiacne Preparations.....	68	
Antiallergy Preparations.....	243	
Antianaemics.....	29	
Antiarrhythmics.....	45	
Antibacterials.....	88	
Anticholinergic Agents.....	244	
Anticholinesterases.....	111	
Antidepressants.....	125	
Antidiarrhoeals and Intestinal Anti-Inflammatory Agents.....	5	
Antiepilepsy Drugs.....	127	
Antifibrinolytics, Haemostatics and Local Sclerosants.....	31	

Antifibrotics.....	245	Arrow-Quinapril 10.....	43	Aztreonam.....	94
Antifungals.....	96	Arrow-Quinapril 20.....	43	<b>- B -</b>	
Antihypotensives.....	46	Arrow-Quinapril 5.....	43	Bacillus calmette-guerin (BCG).....	239
Antimigraine Preparations.....	130	Arrow-Roxithromycin.....	91	Bacillus calmette-guerin vaccine.....	287
Antimycobacterials.....	98	Arrow-Timolol.....	256	Baclofen.....	115
Antinausea and Vertigo Agents.....	130	Arrow-Topiramate.....	129	Bacterial and Viral Vaccines.....	287
Antiparasitics.....	99	Arrow-Tramadol.....	125	Bacterial Vaccines.....	287
Antipruritic Preparations.....	68	Arsenic trioxide.....	150	Balanced Salt Solution.....	255
Antipsychotic Agents.....	132	Artemether with lumefantrine.....	100	Baricitinib.....	241
Antiretrovirals.....	101	Artesunate.....	100	Barium sulphate.....	262
Antirheumatoid Agents.....	111	Articaine hydrochloride.....	120	Barium sulphate with sodium bicarbonate.....	262
Antiseptics and Disinfectants.....	261	Articaine hydrochloride with adrenaline.....	120	Barrier Creams and Emollients.....	68
Antispaasmodics and Other Agents Altering Gut Motility.....	7	Asacol.....	6	Basiliximab.....	192
Anti-thrombotics.....	35	Ascorbic acid Alimentary.....	27	BCG Vaccine.....	287
Antithymocyte globulin (equine).....	238	Extemporaneously Compounded Preparations.....	267	BD PosiFlush.....	41
Antithymocyte globulin (rabbit).....	239	Aspen Adrenaline.....	53	Beclazone 100.....	247
Antulcerants.....	7	Aspirin Blood.....	36	Beclazone 250.....	247
Antivirals.....	104	Nervous.....	122	Beclazone 50.....	247
Anxiolytics.....	135	Asthalin.....	247	Beclomethasone dipropionate.....	247
Apidra.....	10	Atazanavir Mylan.....	103	Bedaquiline.....	98
Apidra Solostar.....	10	Atazanavir sulphate.....	103	Bee venom.....	243
APO-Atomoxetine.....	141	Atenolol.....	46	Bendamustine hydrochloride.....	146
APO-Candesartan HCTZ 16/12.5.....	44	Atenolol Viatrix.....	46	Bendrofluzide.....	50
APO-Candesartan HCTZ 32/12.5.....	44	Atenolol-AFT.....	46	Bendroflumethiazide [Bendrofluzide].....	50
Apomorphine hydrochloride.....	118	Atezolizumab.....	233	Benralizumab.....	192
Apraclonidine.....	257	ATGAM.....	238	Benzathine benzylpenicillin.....	92
Aprepitant.....	130	Ativan.....	135	Benzatropine mesylate.....	118
Apresoline.....	55	Atomoxetine.....	141	Benzbromaron AL 100.....	114
Aprotinin.....	31	Atorvastatin.....	51	Benzbromaron.....	114
Aqueous cream.....	69	Atovaquone with proguanil hydrochloride.....	100	Benzocaine.....	120
Arachis oil [Peanut oil].....	267	Atracurium besylate.....	115	Benzocaine with tetracaine hydrochloride.....	120
Aratac.....	45	Atropine sulphate Cardiovascular.....	45	Benzoic.....	267
Arava.....	111	Sensory.....	257	Benzoyl peroxide.....	68
Arginine Alimentary.....	17	Atropt.....	257	Benzotrop.....	118
Various.....	263	Aubagio.....	137	Benzydamine hydrochloride.....	24
Argipressin [Vasopressin].....	87	Augmentin.....	92	Benzydamine hydrochloride with cetylpyridinium chloride.....	24
Aripiprazole.....	132	Aurorix.....	126	Benzylpenicillin sodium [Penicillin G].....	92
Aripiprazole Sandoz.....	132	Avallon.....	123	Beractant.....	251
Aristocort.....	71	Avelox.....	93	Beta Cream.....	70
Artotex-Prazosin S29.....	45	Avonex.....	137	Beta Ointment.....	70
Arrow - Clopid.....	36	Avonex Pen.....	137	Beta Scalp.....	72
Arrow - Lattim.....	256	Azacitidine.....	148	Beta-Adrenoceptor Agonists.....	247
Arrow-Amitriptyline.....	125	Azacitidine Dr Reddy's.....	148	Beta-Adrenoceptor Blockers.....	46
Arrow-Bendrofluzide.....	50	Azactam.....	94	Betadine.....	261
Arrow-Brimonidine.....	257	Azamun.....	239	Betahistine dihydrochloride.....	131
Arrow-Diazepam.....	135	Azathioprine.....	239	Betaine.....	17
Arrow-Fluoxetine.....	127	Azilect.....	119	Betaloc CR.....	47
Arrow-Losartan & Hydrochlorothiazide.....	44	Azithromycin.....	90	Betamethasone.....	79
Arrow-Norfloxacin.....	93	Azopt.....	256	Betamethasone dipropionate.....	70
Arrow-Ornidazole.....	100	AZT.....	103	Betamethasone dipropionate with	

calcipotriol.....	71	Breo Ellipta .....	248	Candesartan cilexetil with	
Betamethasone sodium phosphate		Brevinor 1/28 .....	74	hydrochlorothiazide .....	44
with betamethasone acetate.....	79	Bricanyl Turbuhaler .....	247	Candestar .....	44
Betamethasone valerate.....	70, 72	Brimonidine tartrate .....	257	Capecitabine.....	149
Betamethasone valerate with		Brimonidine tartrate with		Capecitabine Viatris.....	149
clioquinol.....	71	timolol .....	257	Capercit .....	149
Betamethasone valerate with sodium		Brinzolamide.....	256	Capoten .....	43
fusidate [Fusidic acid].....	71	Bromocriptine .....	118	Capsaicin	
Betaxolol .....	256	Brufen SR .....	116	Musculoskeletal .....	117
Betnovate .....	70	Budesonide		Nervous.....	122
Betoptic.....	256	Alimentary.....	5	Captopril .....	43
Betoptic S .....	256	Respiratory.....	244, 247	Carbachol .....	256
Bevacizumab .....	193	Budesonide with eformoterol .....	248	Carbamazepine .....	127
Bexsero .....	289	Bumetanide .....	49	Carbasorb-X .....	260
Bezafibrate .....	51	Bupafen .....	120	Carbimazole .....	86
Bezalip.....	51	Bupivacaine hydrochloride .....	120	Carbomer.....	257
Bezalip Retard .....	51	Bupivacaine hydrochloride with		Carboplatin .....	156
Bicalutamide .....	165	adrenaline .....	120	Carboplatin Ebewe .....	156
Bicillin LA .....	92	Bupivacaine hydrochloride with		Carboprost trometamol .....	75
BiCNU.....	147	fentanyl.....	120	Carboxymethylcellulose	
Bile and Liver Therapy.....	9	Bupivacaine hydrochloride with		Alimentary.....	24
Biisocopin .....	263	glucose .....	120	Extemporaneously Compounded	
Bimatoprost .....	256	Buprenorphine Naloxone BNM .....	143	Preparations .....	267
Bimatoprost Multichem .....	256	Buprenorphine with naloxone.....	143	Cardinol LA .....	47
Binarex .....	165	Bupropion hydrochloride.....	144	Cardizem CD .....	48
Binocrit.....	29	Burinex .....	49	CareSens Dual .....	298
Biodone .....	124	Buscopan.....	7	Caresens N.....	298
Biodone Extra Forte.....	124	Buserelin.....	82	Caresens N POP .....	298
Biodone Forte.....	124	Buspirone hydrochloride .....	135	CareSens N Premier .....	298
Biotin.....	17	Buspirone Viatris .....	135	CareSens PRO.....	298
Bisacodyl .....	16	Busulfan.....	147	Carglumic acid.....	17
Bisacodyl Viatris .....	16			Carmellose sodium with pectin and	
Bismuth subgallate .....	267			gelatine	
Bismuth subnitrate and iodoform				Alimentary.....	24
paraffin.....	265			Sensory.....	257
Bisoprolol fumarate.....	46	Cabergoline .....	81	Carmustine .....	147
Bisoprolol Mylan .....	46	Caffeine .....	141	Carvedilol.....	47
Bisoprolol Viatris.....	46	Caffeine citrate .....	249	Carvedilol Sandoz .....	47
Bivalirudin .....	35	Calamine .....	68	Casirivimab and imdevimab .....	194
Bleomycin sulphate .....	147	Calamine-AFT .....	68	Caspopungin .....	97
Blood glucose diagnostic test		Calci-Tab 500 .....	22	Catapres .....	49
meter .....	298	Calcipotriol.....	71	Ceenu .....	147
Blood glucose diagnostic test		Calcitonin.....	78	Cefaclor .....	89
strip.....	298	Calcitriol.....	27	Cefalexin.....	89
Blood ketone diagnostic test		Calcitriol-AFT.....	27	Cefalexin Sandoz .....	89
strip.....	298	Calcium carbonate.....	5, 22	Cefazolin .....	89
Bonney's blue dye .....	264	Calcium carbonate PAI.....	5	Cefazolin-AFT.....	89
Boostrix.....	288	Calcium Channel Blockers .....	47	Cefepime .....	90
Boric acid.....	267	Calcium chloride.....	39	Cefepime Kabi .....	90
Bortezomib .....	150	Calcium folinate .....	163	Cefotaxime .....	89
Bosentan .....	58	Calcium Folate Ebewe .....	163	Cefotaxime Sandoz .....	89
Bosentan Dr Reddy's.....	58	Calcium Folate Sandoz.....	163	Cefoxitin .....	89
Bosvate.....	46	Calcium gluconate		Blood.....	39
Botox .....	115	Dermatological.....	73	Ceftaroline fosamil .....	90
Botulism antitoxin .....	259	Calcium Homeostasis.....	78	Ceftazidime.....	89
Bplex.....	27	Calcium polystyrene sulphonate.....	41	Ceftazidime Kabi .....	89
		Calcium Resonium .....	41	Ceftazidime-AFT.....	89
		Candesartan cilexetil .....	44		

**- C -**

Ceftriaxone .....	89	Cinaclet Devatis.....	78	Coal tar .....	267
Ceftriaxone-AFT .....	89	Cinchocaine hydrochloride with hydrocortisone.....	7	Coal tar with salicylic acid and sulphur.....	71
Cefuroxime .....	89	Cipflox.....	93	Cocaine hydrochloride.....	121
Cefuroxime-AFT .....	89	Ciprofloxacin		Cocaine hydrochloride with adrenaline.....	121
Celapram .....	126	Infections.....	93	Codine phosphate	
Celecoxib .....	116	Sensory.....	252	Extemporaneously Compounded Preparations .....	267
Celecoxib Pfizer.....	116	Ciprofloxacin Kabi.....	93	Nervous.....	123
Celiprolol.....	47	Ciprofloxacin Teva.....	252	Coenzyme Q10.....	17
CellCept.....	239	Ciprofloxacin with hydrocortisone.....	252	Colchicine.....	114
Centrally-Acting Agents.....	48	Ciproxin HC Otic.....	252	Colecalciferol.....	27
Cephalexin ABM.....	89	Cisplatin.....	156	Colestimethate.....	94
Cetirizine hydrochloride .....	244	Citalopram hydrobromide .....	126	Colestipol hydrochloride .....	52
Cetomacrogol .....	69	Citanest .....	122	Colestyramine.....	52
Cetomacrogol with glycerol .....	69	Citrate sodium .....	35	Colestyramine - Mylan.....	52
Cetomacrogol-AFT .....	69	Citric acid.....	267	Colgout.....	114
Cetrimide .....	267	Citric acid with magnesium oxide and sodium picosulfate.....	14	Colifoam .....	6
Cetuximab .....	194	Citric acid with sodium bicarbonate.....	263	Colistin sulphomethate [Colestimethate].....	94
Charcoal .....	260	Cladribine .....	149	Colistin-Link.....	94
Chemotherapeutic Agents.....	146	Clarithromycin.....	91	Collodion flexible .....	267
Chickenpox vaccine.....	295	Clexane .....	35	Colloidal bismuth subcitrate.....	8
Chloral hydrate .....	138	Clexane Forte.....	35	Colofac .....	7
Chlorambucil.....	147	Clindamycin .....	94	Colony-Stimulating Factors .....	38
Chloramphenicol		Clinicians .....	27	Coloxyl.....	15
Infections.....	94	Clinicians Multivit & Mineral Boost .....	25	Compound electrolytes.....	39, 41
Sensory.....	252	Clinicians Renal Vit.....	25	Compound electrolytes with glucose [Dextrose].....	39, 41
Chlorhexidine.....	261	Clobazam.....	127	Compound hydroxybenzoate.....	267
Chlorhexidine gluconate		Clobetasol propionate.....	70, 72	Compound sodium lactate [Hartmann's solution].....	40
Alimentary.....	24	Clobetasone butyrate .....	70	Comtan.....	118
Extemporaneously Compounded Preparations .....	267	Clofazimine .....	98	Concerta.....	142
Genito-Urinary.....	74	Clomazol		Condyline.....	72
Chlorhexidine with cetrimide .....	261, 264	Dermatological.....	67	Contraceptives.....	74
Chlorhexidine with ethanol .....	261	Genito-Urinary.....	74	Contrast Media .....	262
Chloroform.....	267	Clomifene citrate.....	81	Copaxone .....	137
Chloroquine phosphate .....	100	Clomipramine hydrochloride.....	125	Copper.....	22
Chlorothiazide.....	50	Clomipramine Teva .....	125	Copper chloride .....	22
Chlorpheniramine maleate .....	244	Clonazepam .....	127, 135	Corticorelin (ovine) .....	82
Chlorpromazine hydrochloride.....	132	Clonidine.....	48	Corticosteroids	
Chlorsig .....	252	Clonidine hydrochloride.....	49	Dermatological.....	70
Chlortalidone [Chlorthalidone] .....	50	Clonidine Teva.....	49	Hormone Preparations.....	79
Chlorthalidone .....	50	Clopidogrel .....	36	Cosentyx.....	221
Choice Load 375 .....	75	Clopine.....	132	Cosmegen .....	147
Choice TT380 Short .....	75	Clopixol.....	133, 135	Coversyl.....	43
Choice TT380 Standard .....	75	Clostridium botulinum type A toxin.....	115	Creon 10000.....	13
Cholestyramine.....	52	Clostridium botulinum type A toxin.....	115	Creon 25000.....	13
Choline salicylate with cetalkonium chloride.....	24	Clostridium botulinum type A toxin.....	115	Creon Micro.....	13
Chorionadotropin alfa .....	82	Clostridium botulinum type A toxin.....	115	Crotamiton.....	68
Ciclopirox olamine .....	67	Clostridium botulinum type A toxin.....	115	Crystaderm.....	67
Ciclosporin.....	167	Clostridium botulinum type A toxin.....	115	CT Plus+.....	262
Cidofovir .....	105	Clostridium botulinum type A toxin.....	115	Cubicin.....	94
Cilazapril.....	43	Clostridium botulinum type A toxin.....	115	Curam.....	92
Cilicaine VK.....	92	Clostridium botulinum type A toxin.....	115		
Cimetidine.....	8	Clostridium botulinum type A toxin.....	115		
Cinacalcet.....	78	Clostridium botulinum type A toxin.....	115		

Curam Duo 500/125.....	92	DBL Pethidine Hydrochloride .....	125	Diamide Relief.....	5
Curosurf.....	251	DBL Vincristine Sulfate.....	164	Diamox.....	256
Cyvite .....	27	Decongestants.....	247	Diatrizoate meglumine with sodium amidotrizoate.....	262
Cyclizine hydrochloride.....	131	Antiallergics.....	254	Diatrizoate sodium.....	262
Cyclizine lactate.....	131	Decozol.....	25	Diazepam.....	127, 135
Cyclogyl.....	257	Deferasirox.....	260	Diazoxide.....	
Cyclonex.....	147	Deferiprone.....	260	Alimentary.....	9
Cyclopentolate hydrochloride.....	257	Defibrotide.....	35	Cardiovascular.....	54
Cyclophosphamide.....	147	Definity.....	263	Dichlorobenzyl alcohol with amylmetacresol.....	24
Cycloserine.....	98	Demeclocycline hydrochloride.....	94	Diclofenac Sandoz.....	116
Cymevene.....	105	Denosumab.....	112	Diclofenac sodium Musculoskeletal.....	116
Cyproheptadine hydrochloride.....	244	Deolate.....	98	Sensory.....	254
Cyproterone acetate.....	78	Deoxycoformycin.....	154	Dicobalt edetate.....	260
Cyproterone acetate with ethinyloestradiol.....	74	Depo-Medrol.....	80	Diflucan.....	96
Cystadane.....	17	Depo-Provera.....	75	Diflucortolone valerate.....	70
Cysteamine hydrochloride.....	267	Depo-Testosterone.....	78	Digestives Including Enzymes.....	13
Cytarabine.....	149	Deprim.....	95	Digoxin.....	45
Cytotec.....	7	Dermol.....	70, 72	Digoxin immune Fab.....	259
<b>- D -</b>					
D-Penamine.....	111	Desferrioxamine mesilate.....	260	Dihydrocodeine tartrate.....	123
Dabigatran.....	35	Desflurane.....	119	Dihydroergotamine mesylate.....	130
Dacarbazine.....	151	Desmopressin.....	87	Diltiazem CD Clinect.....	48
Dactinomycin [Actinomycin D].....	147	Desmopressin acetate.....	87	Diltiazem hydrochloride.....	48
Daivobet.....	71	Desmopressin-PH&T.....	87	Dimercaprol.....	261
Daivonex.....	71	Dexamethasone Hormone Preparations.....	79	Dimercaptosuccinic acid.....	261
Dalacin C.....	94	Sensory.....	253	Dimethicone.....	67-68
Danaparoid.....	35	Dexamethasone phosphate.....	80	Dimethyl fumarate.....	136
Dantrium.....	115	Dexamethasone with framycetin and gramicidin.....	252	Dimethyl sulfoxide.....	265
Dantrium IV.....	115	Dexamethasone with neomycin sulphate and polymyxin B sulphate.....	252	Dinoprostone.....	75
Dantrolene.....	115	Dexamethasone with tobramycin.....	252	Dipentum.....	7
Daonil.....	10	Dexamfetamine sulfate.....	141	Diphemanil metilsulfate.....	72
Dapa-Tabs.....	50	Dexmedetomidine.....	119	Diphenoxylate hydrochloride with atropine sulphate.....	5
Dapsone.....	98	Dexmedetomidine-Teva.....	119	Diphtheria antitoxin.....	259
Daptomycin.....	94	Dexmethosone.....	79	Diphtheria, tetanus and pertussis vaccine.....	288
Daptomycin Dr Reddy's.....	94	Dexrazoxane.....	163	Diphtheria, tetanus, pertussis and polio vaccine.....	287
Darunavir.....	103	Dextrose Alimentary.....	9	Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine.....	287
Darunavir Mylan.....	103	Blood.....	39-41	Diprosone.....	70
Darunavir Viatrix.....	103	Extemporaneously Compounded Preparations.....	267	Dipyridamole.....	36
Dasatinib.....	157	Dextrose with sodium citrate and citric acid [Acid Citrate Dextrose A].....	35	Disodium edetate.....	255
Daunorubicin.....	148	DHC Continus.....	123	Disodium hydrogen phosphate with sodium dihydrogen phosphate.....	267
DBL Adrenaline.....	53	Diabetes.....	9	Disopyramide phosphate.....	45
DBL Amikacin.....	88	Diacomit.....	129	Disulfiram.....	144
DBL Aminophylline.....	249	Diagnostic Agents Vaccines.....	297	Dithranol.....	267
DBL Bleomycin Sulfate.....	147	Various.....	263	Diuretics.....	49
DBL Bortezomib.....	150	Diagnostic and Surgical Preparations.....	254	Dobutamine.....	53
DBL Cefotaxime.....	89			Dobutamine-hameln.....	53
DBL Cisplatin.....	156			Docetaxel.....	163
DBL Dacarbazine.....	151				
DBL Desferrioxamine Mesylate for Inj BP.....	260				
DBL Docetaxel.....	163				
DBL Ergometrine.....	75				
DBL Gentamicin.....	88				
DBL Leucovorin Calcium.....	163				
DBL Methotrexate Onco-Vial.....	149				

Docusate sodium	E-Z-Paste	262	Entacapone	118
Alimentary	Econazole nitrate	67	Entecavir	104
Sensory	Edrophonium chloride	111	Entecavir (Rex)	104
Docusate sodium with	Efavirenz	101	Entecavir Sandoz	104
sennosides	Efavirenz with emtricitabine and		Entresto 24/26	44
Dolutegravir	tenofovir disoproxil	102	Entresto 49/51	44
Domperidone	Eformoterol fumarate	248	Entresto 97/103	44
Domperidone Viatrix	Eformoterol fumarate dihydrate	248	Entyvio	232
Donepezil hydrochloride	Eftrenonacog alfa [Recombinant		Enzymes	114
Donepezil-Rex	factor IX]	33	Ephedrine	54
Dopamine hydrochloride	Efudix	72	Epilim IV	129
Dornase alfa	eg Clinicians selenium oral		Epipen	243
Dortimopt	drops	24	Epipen Jr	243
Dorzolamide	Elaprase	18	Epirubicin Ebewe	148
Dorzolamide with timolol	Elecare (Unflavoured)	279	Epirubicin hydrochloride	148
Dostinex	Elecare (Vanilla)	279	Eplerenone	49
Dosulepin [Dothiepin]	Elecare LCP (Unflavoured)	279	Epoetin alfa	29
hydrochloride	Electral	41	Epoetin beta	30
Dosulepin Mylan	Electrolytes	266	Epoprostenol	62
Dosulepin Viatrix	Elelyso	21	Eptacog alfa [Recombinant factor	
Dotarem	Elhexacaftor with tezacaftor, ivacaftor		Vlla]	33
Dothiepin	and ivacaftor	250	Eptifibatide	37
Doxapram	Elidel	71	Eptifibatide Viatrix	37
Doxazosin	Elocon	70	Erbixit	194
Doxazosin Clinect	Elocon Alcohol Free	70	Ergometrine maleate	75
Doxepin hydrochloride	Eltrombopag	31	Erlotinib	157
Doxine	Emend Tri-Pack	130	Ertapenem	88
Doxorubicin Ebewe	Emicizumab	32	Erythrocin IV	91
Doxorubicin hydrochloride	EMLA	121	Erythromycin (as	
Doxycycline	Empagliflozin	13	ethylsuccinate)	91
DP Lotn HC	Empagliflozin with metformin		Erythromycin (as lactobionate)	91
DP-Allopurinol	hydrochloride	13	Erythromycin (as stearate)	91
Dr Reddy's Omeprazole	Emtricitabine	102	Esbriet	246
Drofat	Emtricitabine with tenofovir		Escitalopram	126
Droperidol	disoproxil	106	Escitalopram (Ethics)	126
Droperidol Panpharma	Emtriva	102	Esmolol hydrochloride	47
Drugs Affecting Bone	Emulsifying ointment	69	Essential Prednisolone	7
Metabolism	Emulsifying Ointment ADE	69	Estradot	80
Dual blood glucose and blood ketone	Enalapril maleate	43	Etanercept	168
diagnostic test meter	Enbrel	168	Ethambutol hydrochloride	98
Dulaglutide	Endocrine Therapy	164	Ethanol	259
Dulcolax SP Drop	Endoxan	147	Ethanol with glucose	259
Duolin	Engerix-B	292	Ethanol, dehydrated	259
DuoResp Spiromax	Enlax XR	126	Ethics Aspirin	122
Duovisc	Enoxaparin sodium	35	Ethics Aspirin EC	36
Duride	Enstilar	71	Ethics Lisinopril	43
Durvalumab	Ensure (Chocolate)	285	Ethinylloestradiol with	
Dynastat	Ensure (Vanilla)	285	desogestrel	74
Dysport	Ensure Plus (Banana)	286	Ethinylloestradiol with	
	Ensure Plus (Chocolate)	286	levonorgestrel	74
	Ensure Plus (Fruit of the		Ethinylloestradiol with	
	Forest)	286	norethisterone	74
	Ensure Plus (Vanilla)	286	Ethosuximide	127
	Ensure Plus HN	284	Ethyl chloride	121
	Ensure Plus HN RTH	284	Etomidate	119
	Ensure Two Cal HN RTH	277	Etopophos	151
<b>- E -</b>				
e-chamber La Grande		298		
e-chamber Mask		298		
e-chamber Turbo		298		
E-Mycin		91		
E-Z-Cat Dry		262		
E-Z-Gas II		262		



Etoposide.....	151	Flecainide acetate .....	46	Food/Fluid Thickeners .....	272
Etoposide (as phosphate).....	151	Flecainide BNM .....	46	Forteo .....	113
Etoricoxib .....	116	Flecainide Controlled Release Teva.....	46	Fosamax.....	111
Etravirine .....	102	Fleet Phosphate Enema .....	15	Fosamax Plus.....	111
Evara .....	69	Flixonase Hayfever & Allergy ..	244	Foscarnet sodium.....	105
Everet .....	128	Flixotide .....	248	Fosfomycin .....	94
Everolimus .....	239	Flixotide Accuhaler .....	248	Framycetin sulphate .....	252
Evista.....	113	Florinef.....	80	Frebini Energy .....	282
Evrysdi.....	140	Fluanxol.....	133	Frebini Energy Fibre.....	282
Evusheld.....	224	Flucil .....	92	Frebini Original .....	282
Exemestane.....	167	Flucloxacillin .....	92	Frebini Original Fibre.....	282
Exjade.....	260	Flucloxacillin-AFT .....	92	Fresofol 1% MCT/LCT .....	119
Extemporaneously Compounded Preparations .....	267	Flucloxin .....	92	Fresubin 2kcal HP .....	277
Eylea.....	191	Fluconazole .....	96	Fresubin HP Energy .....	284
Ezetimibe.....	52	Fluconazole-Baxter.....	96	Fresubin HP Energy Fibre .....	285
Ezetimibe Sandoz.....	52	Flucytosine .....	98	Fresubin Intensive.....	277
Ezetimibe with simvastatin .....	52	Fludara Oral.....	149	Fresubin Original .....	285
<b>- F -</b>					
Factor eight inhibitor bypassing fraction.....	33	Fludarabine Ebewe.....	149	Fresubin Original Fibre.....	285
Famotidine.....	8	Fludarabine phosphate.....	149	Frusemide.....	49
Fasenna .....	192	Fludrocortisone acetate.....	80	Fucidin.....	95
Faslodex .....	165	Fluids and Electrolytes .....	39	Fucithalmic .....	252
Fatty Cream AFT .....	69	Flumazenil.....	259	Fulvestrant.....	165
Febuxostat .....	114	Flumetasone pivalate with clioquinol.....	252	Fungilin .....	24
Febuxostat multichem .....	114	Fluocortolone caproate with fluocortolone pivalate and cinchocaine.....	7	Furosemide [Frusemide].....	49
FEIBA NF .....	33	Fluorescein sodium .....	254	Furosemide-Baxter .....	49
Felo 10 ER.....	47	Fluorescein sodium with lignocaine hydrochloride .....	254	Fusidic acid Dermatological.....	67, 71
Felo 5 ER.....	47	Fluorescite .....	254	Infections.....	95
Felodipine .....	47	Fluorometholone.....	254	Sensory.....	252
Fentanyl.....	124	Fluorouracil.....	149	<b>- G -</b>	
Fentanyl Sandoz.....	124	Fluorouracil Accord.....	149	Gabapentin.....	127
Ferinject.....	23	Fluorouracil sodium .....	72	Gacet .....	123
Ferodan .....	23	Fluox .....	127	Gadobenic acid.....	263
Ferric subsulfate.....	32	Fluoxetine hydrochloride .....	127	Gadobutrol.....	263
Ferriprox .....	260	Flupenthixol decanoate .....	133	Gadoteric acid .....	263
Ferro-F-Tabs .....	23	FluQuadri (2023 Formulation) .....	293	Gadovist 1.0 .....	263
Ferro-tab.....	23	Flutamide .....	165	Gadoxetate disodium.....	263
Ferrograd.....	23	Flutamin.....	165	Galsulfase .....	18
Ferrosig .....	23	Fluticasone .....	248	Galvumet .....	11
Ferrous fumarate.....	23	Fluticasone furoate with vilanterol .....	248	Galvus .....	11
Ferrous fumarate with folic acid .....	23	Fluticasone propionate .....	244	Ganciclovir .....	105
Ferrous gluconate with ascorbic acid.....	23	Fluticasone with salmeterol.....	249	Gardasil 9.....	292
Ferrous sulfate.....	23	Flynn.....	89	Gastrodenol.....	8
Ferrous sulfate with ascorbic acid.....	23	FML.....	254	Gastrografin.....	262
Fexofenadine hydrochloride .....	244	Foban .....	67	Gazyva .....	204
Filgrastim .....	39	Folic acid .....	30	Gefitinib .....	158
Finasteride.....	76	Folic Acid multichem.....	30	Gelatine, succinylated .....	42
Fingolimod.....	137	Folic Acid Mylan .....	30	Gelofusine .....	42
Firazyr.....	243	Folic Acid Viatrix.....	30	GEM Aqueous Cream .....	69
Flagyl.....	100	Fondaparinux sodium .....	36	Gemcitabine .....	149
Flagyl-S.....	100	Food Modules.....	270	Gemcitabine Ebewe .....	149
Flamazine .....	67			Gemtuzumab ozogamicin.....	195
				Gentamicin sulphate Infections.....	88
				Sensory.....	252
				Gestrinone.....	81

Gilena .....	137	Hartmann's solution.....	40	and lanolin .....	70
Ginet.....	74	Harvoni.....	105	Hydrocortisone butyrate .....	70, 72
Glatiramer acetate.....	137	Havrix.....	292	Hydrocortisone with miconazole.....	71
Glaucoma Preparations.....	256	Havrix Junior.....	292	Hydrocortisone with natamycin and neomycin.....	71
Glecaprevir with pibrentasvir.....	105	Haylor Syrup.....	244	Hydrogen peroxide.....	67
Glibenclamide.....	10	Healon.....	255	Hydroxocobalamin	
Gliclazide.....	10	Healon 5.....	255	Alimentary.....	26
Gliolan.....	167	Healon GV.....	255	Various.....	259
Glipizide.....	10	Healon GV Pro.....	255	Hydroxocobalamin Panpharma.....	26
Glivec.....	158	healthE Calamine Aqueous.....	68	hydroxycarbamide.....	151
Glizide.....	10	healthE Dimethicone 10%.....	68	Hydroxychloroquine.....	111
Glucagen Hypokit.....	9	healthE Dimethicone 4% Lotion.....	67	Hydroxyurea	
Glucagon hydrochloride.....	9	healthE Dimethicone 5%.....	68	[hydroxycarbamide].....	151
Glucerna Select.....	275	healthE Fatty Cream.....	69	Hygroton.....	50
Glucose [Dextrose]		healthE Glycerol BP Liquid.....	268	Hylo-Fresh.....	258
Alimentary.....	9	healthE Urea Cream.....	70	Hyoscine butylbromide.....	7
Blood.....	40	Hemlibra.....	32	Hyoscine hydrobromide.....	131
Extemporaneously Compounded Preparations.....	267	Heparin sodium.....	36	Hyperuricaemia and Antigout.....	114
Glucose with potassium chloride.....	40	Heparin Sodium Panpharma.....	36	HypoPak Glucose.....	9
Glucose with potassium chloride and sodium chloride.....	40	Heparinised saline.....	36	Hypromellose.....	255, 257
Glucose with sodium chloride.....	40	Heparon Junior.....	277	Hypromellose with dextran.....	257
Glucose with sucrose and fructose.....	9	Hepatitis A vaccine.....	292	- I -	
Glycerin with sodium saccharin.....	268	Hepatitis B recombinant vaccine.....	292	Ibiamox.....	92
Glycerin with sucrose.....	268	Herceptin.....	228	Ibrance.....	159
Glycerol		Hiberix.....	288	Ibrutinib.....	151
Alimentary.....	15	Hiprex.....	95	Ibuprofen.....	116
Extemporaneously Compounded Preparations.....	268	Histaclear.....	244	Icatibant.....	243
Glycerol with paraffin.....	69	Histamine acid phosphate.....	264	Idarubicin hydrochloride.....	148
Glyceryl trinitrate		Holoxan.....	147	Idarucizumab.....	33
Alimentary.....	7	Hormone Replacement Therapy.....	80	Idursulfase.....	18
Cardiovascular.....	53	HPV.....	292	Ifosfamide.....	147
Glycine.....	264	Humalog Mix 25.....	10	Ikorel.....	55
Glycopyrep-O.....	14	Humalog Mix 50.....	10	Ilomedin.....	63
Glycopyrronium.....	245	Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV].....	292	Iloprost.....	63
Glycopyrronium bromide.....	7	Humatin.....	88	Imaging Agents.....	167
Glycopyrronium with indacaterol.....	245	Humira.....	184	Imatinib mesilate.....	158
Glypressin.....	87	HumiraPen.....	184	Imatinib-Rex.....	159
Gonadorelin.....	82	Hyaluronic acid		Imbruvica.....	151
Goserelin.....	82	Alimentary.....	25	Imfinzi.....	234
Granisetron.....	131	Sensory.....	255, 258	Imigran.....	130
- H -		Hyaluronic acid with lidocaine [lignocaine].....	25	Imipenem with cilastatin.....	88
Habitrol.....	144	Hyaluronidase.....	114	Imipenem+Cilastatin RBX.....	88
Habitrol (Fruit).....	144	Hydralazine hydrochloride.....	55	Imipramine hydrochloride.....	126
Habitrol (Mint).....	144	Hydrocortisone		Imiquimod.....	72
Haem arginate.....	18	Dermatological.....	70	Immune Modulators.....	108
Haemophilus influenzae type B vaccine.....	288	Extemporaneously Compounded Preparations.....	268	Immunosuppressants.....	167
Haldol.....	133	Hormone Preparations.....	80	Impact Advanced Recovery.....	284
Haldol Concentrate.....	133	Hydrocortisone acetate.....	6	Incruse Ellipta.....	245
Haloperidol.....	132	Hydrocortisone acetate with pramoxine hydrochloride.....	6	Indacaterol.....	248
Haloperidol decanoate.....	133	Hydrocortisone and paraffin liquid		Indapamide.....	50
				Indigo carmine.....	264
				Indinavir.....	103
				Indocyanine green.....	264
				Indometacin [Indomethacin].....	117
				Indomethacin.....	117

Infanrix IPV.....	287	Isoproterenol.....	54	Laevolac.....	15	
Infanrix-hexa.....	287	Isoptin.....	48	Lagevrio.....	108	
Infatrin.....	281	Isoptin SR.....	48	Lamictal.....	128	
Infliximab.....	195	Isopto Carpine.....	256	Lamivudine.....	102, 104	
Influenza vaccine.....	293	Isosorbide mononitrate.....	53	Lamivudine Alphapharm.....	102	
Inhaled Corticosteroids.....	247	Isotretinoin.....	68	Lamivudine Viatrix.....	102	
Inspira.....	49	Ispaghula (psyllium) husk.....	14	Lamivudine/Zidovudine Viatrix.....	103	
Instillagel Lido.....	121	Isradipine.....	48	Lamotrigine.....	128	
Insulin aspart.....	10	Itch-Soothe.....	68	Lanoxin.....	45	
Insulin aspart with insulin aspart protamine.....	9	Itraconazole.....	96	Lanoxin PG.....	45	
Insulin glargine.....	10	Itrazole.....	96	Lansoprazole.....	8	
Insulin glulisine.....	10	Ivabradine.....	46	Lantus.....	10	
Insulin isophane.....	9	Ivacaftor.....	250	Lantus SoloStar.....	10	
Insulin lispro.....	10	Ivermectin.....	99	Lanzol Relief.....	8	
Insulin lispro with insulin lispro protamine.....	10	<b>- J -</b>			Lapatinib.....	159
Insulin neutral.....	10	Jadelle.....	75	Largactil.....	132	
Insulin neutral with insulin isophane.....	10	Jakavi.....	161	Laronidase.....	19	
Intelence.....	102	Jardiamet.....	13	Lasix.....	49	
Interferon alfa-2b.....	108	Jardiance.....	13	Latanoprost.....	256	
Interferon beta-1-alpha.....	137	Jaydess.....	75	Latanoprost with timolol.....	256	
Interferon beta-1-beta.....	137	Jevity HiCal RTH.....	284	Lax-Suppositories.....	16	
Interferon gamma.....	108	Jevity RTH.....	285	Lax-suppositories Glycerol.....	15	
Intra-uterine device.....	75	Jinarc.....	50	Laxatives.....	14	
Invanz.....	88	Juno Pemetrexed.....	150	Laxsol.....	15	
Invega Sustenna.....	134	<b>- K -</b>			Ledipasvir with sofosbuvir.....	105
Invega Trinza.....	134	Kadcyla.....	229	Leflunomide.....	111	
Iodine.....	86	Kalydeco.....	250	Lenalidomide.....	152	
Iodine with ethanol.....	261	Kenacomb.....	253	Letrole.....	167	
Iodised oil.....	262	Kenacort-A 10.....	80	Letrozole.....	167	
Iodixanol.....	262	Kenacort-A 40.....	80	Leukotriene Receptor Antagonists.....	248	
Iohexol.....	262	Kenalog in Orabase.....	24	Leuprorelin acetate.....	82	
Iopidine.....	257	Ketalar.....	119	Leustatin.....	149	
Ioscan.....	262	Ketamine.....	119	Levetiracetam.....	128	
IPCA-Frusemide.....	49	Ketocal 3:1 (Unflavoured).....	282	Levetiracetam-AFT.....	128	
IPCA-Metoprolol.....	47	Ketocal 4:1 (Unflavoured).....	282	Levocabastine.....	254	
IPCA-Propranolol.....	47	Ketocal 4:1 (Vanilla).....	282	Levocarnitine.....	19	
IPOL.....	295	Ketoconazole.....		Levodopa with benserazide.....	119	
Ipratropium bromide.....	244	Dermatological.....	67	Levodopa with carbidopa.....	119	
Iressa.....	158	Infections.....	96	Levomepromazine.....	133	
Irinotecan hydrochloride.....	151	Ketoprofen.....	117	Levomepromazine hydrochloride.....	133	
Iron (as ferric carboxymaltose).....	23	Ketorolac trometamol.....	254	Levonorgestrel.....	75	
Iron (as sucrose).....	23	KetoSens.....	298	Levonorgestrel BNM.....	75	
Iron polymaltose.....	23	Ketostix.....	298	Levosimendan.....	53	
Irrigation Solutions.....	264	Keytruda.....	236	Levothyroxine.....	87	
Isentress.....	104	Klacid.....	91	Lidocaine [Lignocaine].....	121	
Isentress HD.....	104	Klean Prep.....	14	Lidocaine [Lignocaine] hydrochloride.....	121	
Ismo 20.....	53	Kogenate FS.....	34	Lidocaine [Lignocaine] hydrochloride with adrenaline.....	121	
Ismo 40 Retard.....	53	Konakion MM.....	35	Lidocaine [Lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride.....	121	
Isoflurane.....	119	Konsyl-D.....	14	Lidocaine [Lignocaine] hydrochloride with chlorhexidine.....	121	
Isoniazid.....	99	Kuvan.....	20			
Isoniazid with rifampicin.....	99	<b>- L -</b>				
Isoprenaline [Isoproterenol].....	54	L-ornithine L-aspartate.....	9			
Isopropyl alcohol.....	261	Labetalol.....	47			
		Lacosamide.....	128			
		Lactose.....	268			
		Lactulose.....	15			

Lidocaine [Lignocaine] hydrochloride with phenylephrine hydrochloride.....	121	- M -	Marine Blue Lotion SPF 50+ .....	72
Lidocaine [Lignocaine] with prilocaine.....	121	m-Eslon .....	Martindale Pharma .....	259
Lidocaine-Baxter.....	121	Mabthera .....	Mask for spacer device.....	298
lignocaine		Macrobid.....	Maviret.....	105
Alimentary.....	25	Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride.....	Maxidex.....	253
Nervous.....	121	Macrogol 3350 with ascorbic acid, potassium chloride, sodium chloride and citric acid with magnesium oxide and sodium picosulfate .....	Maxitrol.....	252
Lincomycin.....	95	Macrogol 3350 with potassium chloride and sodium chloride with/ without sodium sulfate, sodium ascorbate, ascorbic acid.....	Measles, mumps and rubella vaccine .....	294
Linezolid.....	95	Macrogol 3350 with potassium chloride and sodium chloride with/ without sodium sulfate, sodium ascorbate, ascorbic acid.....	Mebendazole.....	100
Linezolid Kabi.....	95	Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride .....	Mebeverine hydrochloride .....	7
Lioresal Intrathecal.....	115	Macrogol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate.....	Medrol.....	80
Liothyronine sodium .....	87	Madopar 125 .....	Medroxyprogesterone.....	81
Lipid-Modifying Agents .....	51	Madopar 250 .....	Medroxyprogesterone acetate Genito-Urinary.....	75
Lipiodol Ultra Fluid.....	262	Madopar 62.5 .....	Hormone Preparations.....	81
Liquibar.....	262	Madopar HBS.....	Mefenamic acid .....	117
Liraglutide.....	11	Madopar Rapid.....	Mefloquine .....	100
Lisinopril .....	43	Mafenide acetate.....	Meglumine gadopentetate .....	263
Lissamine green.....	254	Magnesium amino acid chelate.....	Meglumine iotroxate .....	263
Lithium carbonate.....	133	Magnesium chloride.....	Melatonin.....	138
LMX4.....	121	Magnesium hydroxide	Melpha.....	147
Lo-Oralcon 20 ED.....	74	Alimentary.....	Melphalan.....	147
Local Preparations for Anal and Rectal Disorders.....	7	Extemporaneously Compounded Preparations .....	Meningococcal (A, C, Y and W-135) conjugate vaccine.....	288
Locoid.....	70, 72	Magnesium oxide.....	Meningococcal B multicomponent vaccine .....	289
Locoid Crelo.....	70	Magnesium oxide with magnesium aspartate, magnesium amino acid chelate and magnesium citrate.....	Meningococcal C conjugate vaccine .....	289
Locoid Lipocream.....	70	Magnesium sulphate .....	MenQuadfi.....	288
Lodoxamide.....	254	Magnevist.....	Menthol.....	268
Logem.....	128	Malarone.....	Mepivacaine hydrochloride.....	121
Lomide.....	254	Malarone Junior.....	Mepivacaine hydrochloride with adrenaline.....	122
Lomustine.....	147	Malathion [Maldison].....	Mepolizumab.....	203
Long-Acting Beta-Adrenoceptor Agonists.....	248	Maldison .....	Mercaptopurine.....	149
Loniten.....	55	Mannitol	Meropenem.....	89
Loperamide hydrochloride .....	5	Cardiovascular.....	Meropenem-AFT .....	89
Lopinavir with ritonavir.....	104	Various.....	Mesalazine.....	6
Lopinavir/Ritonavir Mylan.....	104	Mantoux.....	Mesna.....	163
Lorafix.....	244	Maprotiline hydrochloride .....	Mestinon .....	111
Loratadine.....	244	Marcain.....	Metabolic Disorder Agents .....	16
Lorazepam.....	127, 135	Marcain Heavy.....	Metabolic Products .....	272
Lormetazepam.....	138	Marcain Isobaric.....	Metaraminol.....	54
Lorstat.....	51	Marcain with Adrenaline .....	Metformin hydrochloride .....	11
Losartan Actavis.....	44	Marevan.....	Metformin Mylan.....	11
Losartan potassium.....	44		Metformin Viatriis.....	11
Losartan potassium with hydrochlorothiazide .....	44		Methacholine chloride.....	264
Lovir.....	105		Methadone BNM.....	124
Loxamine.....	127		Methadone hydrochloride Extemporaneously Compounded Preparations .....	268
Lucrin Depot 1-month.....	82		Nervous.....	124
Lucrin Depot 3-month.....	82		Methenamine (Hexamine) hippurate.....	95
Lyderm.....	68		Methohexital sodium.....	119
Lynparza.....	152		Methopt.....	257
Lysine acetylsalicylate [Lysine aspirin].....	37			
Lysine aspirin.....	37			

Methotrexate.....	149	Mifepristone.....	75	Myambutol.....	98
Methotrexate DBL Onco-Vial.....	149	Milrinone.....	55	Mycobutin.....	99
Methotrexate Ebewe.....	149	Milrinone-Baxter.....	55	MycoNail.....	67
Methotrexate Sandoz.....	149	Minerals.....	22	Mycophenolate mofetil.....	239
Methoxsalen		Mini-Wright AFS Low Range.....	298	Mydriacyl.....	257
[8-methoxypsoralen].....	71	Mini-Wright Standard.....	298	Mydriatics and Cycloplegics.....	257
Methoxyflurane.....	122	Minidiab.....	10	Mylan (24 hr release).....	48
Methyl aminolevulinate		Minims Prednisolone.....	254	Mylan Atenolol.....	46
hydrochloride.....	72	Minirin.....	87	Mylan Clomiphene.....	81
Methyl hydroxybenzoate.....	268	Minirin Melt.....	87	Mylan Italy (24 hr release).....	48
Methylcellulose.....	268	Minocycline.....	94	Mylan Midazolam.....	139
Methylcellulose with glycerin and		Minoxidil.....	55	Myleran.....	147
sodium saccharin.....	268	Mirena.....	75	Mylotarg.....	195
Methylcellulose with glycerin and		Mirtazapine.....	126	Myozyme.....	16
sucrose.....	268	Misoprostol.....	7		
Methyldopa.....	49	Mitomycin C.....	148	<b>- N -</b>	
Methyldopa Mylan.....	49	Mitozantrone.....	148	Nadolol.....	47
Methylene blue.....	264	Mitozantrone Ebewe.....	148	Nadolol BNM.....	47
Methylnaltrexone bromide.....	15	Mivacurium chloride.....	115	Naglazyme.....	18
Methylphenidate ER - Teva.....	142	Mixed salt solution for eye		Naloxone hydrochloride.....	259
Methylphenidate hydrochloride.....	142	irrigation.....	255	Naltracord.....	144
Methylprednisolone (as sodium		Moclobemide.....	126	Naltrexone AOP.....	144
succinate).....	80	Modafinil.....	142	Naltrexone hydrochloride.....	144
Methylprednisolone aceponate.....	70	Modavigil.....	142	Naphazoline hydrochloride.....	254
Methylprednisolone acetate.....	80	Molaxole.....	15	Naphcon Forte.....	254
Methylthionium chloride [Methylene		Molnupiravir.....	108	Naprosyn SR 1000.....	117
blue].....	264	Mometasone furoate.....	70	Naprosyn SR 750.....	117
Methylxanthines.....	249	Monosodium glutamate with sodium		Naproxen.....	117
Metoclopramide Actavis 10.....	131	aspartate.....	266	Naropin.....	122
Metoclopramide hydrochloride.....	131	Monosodium l-aspartate.....	266	Natalizumab.....	137
Metoclopramide hydrochloride with		Montelukast.....	248	Natamycin.....	252
paracetamol.....	130	Montelukast Mylan.....	248	Natulan.....	154
Metolazone.....	50	Montelukast Viatris.....	248	Nausafix.....	132
Metoprolol IV Mylan.....	47	Morocotocog alfa [Recombinant factor		Nausicalm.....	131
Metoprolol IV Viatris.....	47	VIII].....	34	Navelbine.....	164
Metoprolol succinate.....	47	Morphine hydrochloride.....	124	Nefopam hydrochloride.....	122
Metoprolol tartrate.....	47	Morphine sulphate.....	124	Neisvac-C.....	289
Metrogyl.....	100	Morphine tartrate.....	124	Neo-Mercazole.....	86
Metronidazole		Motetis.....	118	Neocate Gold (Unflavoured).....	279
Dermatological.....	67	Mouth and Throat.....	24	Neocate Junior Vanilla.....	279
Infections.....	100	Movapo.....	118	Neoral.....	167
Metyrapone.....	81	Moxifloxacin.....	93	Neostigmine metilsulfate.....	111
Mexiletine hydrochloride.....	46	Moxifloxacin Kabi.....	93	glycopyrronium bromide.....	111
Miacalcin.....	78	Mozobil.....	38	Neosynephrine HCL.....	54
Mianserin hydrochloride.....	126	Mucolytics and Expectorants.....	249	Nepafenac.....	254
Micolette.....	15	Mucosoothe.....	121	Nepro HP (Strawberry).....	283
Miconazole.....	25	Multihance.....	263	Nepro HP (Vanilla).....	283
Miconazole nitrate		Multiple Sclerosis Treatments.....	136	Nepro HP RTH.....	283
Dermatological.....	67	Multivitamin and mineral		Neupogen.....	39
Genito-Urinary.....	74	supplement.....	25	NeuroTabs.....	22
Micreme.....	74	Multivitamin renal.....	25	Nevirapine.....	102
Micreme H.....	71	Multivitamins.....	26	Nevirapine Alphapharm.....	102
Microlut.....	75	Mupirocin.....	67	Nevirapine Viatris.....	102
Midazolam.....	139	Muscle Relaxants and Related		Nicardipine hydrochloride.....	48
Midazolam Viatris.....	139	Agents.....	115	Nicorandil.....	55
Midodrine.....	46	Mvite.....	26	Nicotine.....	144

## INDEX: Generic Chemicals and Brands

Nifedipine.....	48	RTH.....	282	Oncaspar LYO.....	153
Nifuran.....	95	Nutrini Peptisorb Energy.....	279	OncoTICE.....	239
Nilotinib.....	159	Nutrison 800 Complete Multi Fibre.....	285	Ondansetron.....	131
Nilstat		Nutrison Concentrated.....	277	Ondansetron Kabi.....	131
Alimentary.....	25	Nutrison Energy.....	284	Ondansetron ODT-DRLA.....	131
Genito-Urinary.....	74	Nutrison Protein Intense.....	278	Ondansetron-AFT.....	131
Infections.....	96	Nyefax Retard.....	48	One-Alpha.....	27
Nimodipine.....	48	Nystatin		Opdivo.....	235
Nimotop.....	48	Alimentary.....	25	Optional Pharmaceuticals.....	298
Nintedanib.....	245	Dermatological.....	67	Ora-Blend.....	268
Nirmatrelvir with ritonavir.....	108	Genito-Urinary.....	74	Ora-Blend SF.....	268
Nitazoxanide.....	100	Infections.....	96	Ora-Plus.....	268
Nitrates.....	53	- O -		Ora-Sweet.....	268
Nitroderm TTS 10.....	53	Obinutuzumab.....	204	Ora-Sweet SF.....	268
Nitroderm TTS 5.....	53	Obstetric Preparations.....	75	Oralcon 30 ED.....	74
Nitrofurantoin.....	95	Ocrelizumab.....	137	Oratane.....	68
Nitrolingual Pump Spray.....	53	Ocrevus.....	137	Ornidazole.....	100
Nivestim.....	39	Octocog alfa [Recombinant factor VIII] (Advate).....	34	Orphenadrine citrate.....	115
Nivolumab.....	235	Octocog alfa [Recombinant factor VIII] (Kogenate FS).....	34	Oruvail SR.....	117
Nodia.....	5	Octreotide.....	165	Oseltamivir.....	107
Noflam 250.....	117	Octreotide Depot Teva.....	165	Osmolite RTH.....	285
Noflam 500.....	117	Ocular Lubricants.....	257	Other Cardiac Agents.....	53
Non-Steroidal Anti-Inflammatory Drugs.....	116	Oestradiol.....	80-81	Other Endocrine Agents.....	81
Nonacog gamma, [Recombinant factor IX].....	34	Oestradiol valerate.....	80	Other Oestrogen Preparations.....	81
Noradrenaline.....	54	Oestradiol with norethisterone acetate.....	81	Other Otological Preparations.....	258
Noradrenaline BNM.....	54	Oestriol		Other Progestogen Preparations.....	81
Norethisterone		Genito-Urinary.....	76	Other Skin Preparations.....	72
Genito-Urinary.....	75	Hormone Preparations.....	81	Other Supplements for PKU.....	286
Hormone Preparations.....	82	Oestrogens.....	76	Ovestin	
Norethisterone with mestranol.....	74	Oestrogens (conjugated equine).....	80	Genito-Urinary.....	76
Norflex.....	115	Oestrogens with medroxyprogesterone acetate.....	81	Hormone Preparations.....	81
Norfloracin.....	93	Ofev.....	245	Oxaliplatin.....	156
Noriday 28.....	75	Oil in water emulsion.....	69	Oxandrolone.....	78
Normison.....	139	Oily phenol [Phenol oily].....	7	Oxazepam.....	135
Norpress.....	126	Olanzapine.....	133-134	Oxpentifylline.....	55
Nortriptyline hydrochloride.....	126	Olaparib.....	152	Oxybuprocaine hydrochloride.....	255
Norvir.....	104	Olive oil.....	268	Oxybutynin.....	76
Noumed Paracetamol.....	123	Olopatadine.....	254	Oxycodone hydrochloride.....	125
Noumed Pethidine.....	125	Olopatadine Teva.....	254	Oxycodone Sandoz.....	125
Noumed Phenobarbitone.....	128	Olsalazine.....	7	Oxymetazoline hydrochloride.....	247
Novasource Renal (Vanilla).....	283	Olumiant.....	241	OxyNorm.....	125
Novatretin.....	71	Omaliuzumab.....	205	Oxytocin.....	75
NovoMix 30 FlexPen.....	9	Omeprazole.....	8	Oxytocin BNM.....	75
NovoRapid FlexPen.....	10	Omeprazole actavis 10.....	8	Oxytocin with ergometrine maleate.....	75
NovoSeven RT.....	33	Omeprazole actavis 20.....	8	Ozurdex.....	253
Nozinan.....	133	Omeprazole actavis 40.....	8		
Nucala.....	203	Omezol IV.....	8	- P -	
Nuelin.....	249	Omnipaque.....	262	Pacifen.....	115
Nuelin-SR.....	249	Omnitrope.....	82	Pacimol.....	123
Nupentin.....	127	Onbrez Breezhaler.....	248	Paclitaxel.....	163
Nusinersen.....	139			Paclitaxel Ebewe.....	163
Nutren Diabetes (Vanilla).....	276			Palbociclib.....	159
Nutrini Energy Multi Fibre.....	282			Paliperidone.....	134
Nutrini Low Energy Multifibre				Paliperidone palmitate.....	134
				Palivizumab.....	206

Pamidronate disodium.....	112	Perhexiline maleate.....	48	Pivmecillinam.....	95
Pamisol.....	112	Pericyazine.....	133	Pizotifen.....	130
Pamol.....	123	Perindopril.....	43	PKU Anamix Junior LQ (Berry).....	274
Pancreatic enzyme.....	13	Periset.....	131	PKU Anamix Junior LQ (Orange).....	274
Pancuronium bromide.....	115	Periset ODT.....	131	PKU Anamix Junior LQ (Unflavoured).....	274
Pantoprazole.....	8	Perjeta.....	207	PKU Build 20 Chocolate.....	286
Panzop Relief.....	8	Permethrin.....	68	PKU Build 20 Raspberry Lemonade.....	286
Papaverine hydrochloride.....	55	Perrigo.....	72	PKU Build 20 Smooth.....	286
Paper wasp venom.....	243	Pertuzumab.....	207	PKU Build 20 Vanilla.....	286
Para-aminosalicylic Acid.....	99	Peteha.....	99	PKU GMPro Ultra Lemonade.....	286
Paracetamol.....	123	Pethidine hydrochloride.....	125	PKU sphere20 Banana.....	286
Paracetamol (Ethics).....	123	Pexsig.....	48	PKU sphere20 Chocolate.....	286
Paracetamol Kabi.....	123	Pfizer Exemestane.....	167	PKU sphere20 Lemon.....	286
Paracetamol with codeine.....	125	Pheburane.....	20	PKU sphere20 Red Berry.....	286
Paraffin.....		Phenasein.....	150	PKU sphere20 Vanilla.....	286
Alimentary.....	15	Phenelzine sulphate.....	126	Plaquenil.....	111
Dermatological.....	69	Phenindione.....	36	Plasma-Lyte 148.....	39
Extemporaneously Compounded Preparations.....	268	Phenobarbitone.....	128, 139	Plasma-Lyte 148 & 5% Glucose.....	39
Paraffin liquid with soft white paraffin.....	258	Phenobarbitone sodium.....	268	Plendil ER.....	47
Paraffin liquid with wool fat.....	258	Phenol.....		Plenvu.....	14
Paraffin with wool fat.....	70	Extemporaneously Compounded Preparations.....	268	Plerixafor.....	38
Paraldehyde.....	127	Various.....	265	Pneumococcal (PCV10) conjugate vaccine.....	290
Parecoxib.....	117	Phenol oily.....	7	Pneumococcal (PCV13) conjugate vaccine.....	290
Paromomycin.....	88	Phenol with ioxaglic acid.....	265	Pneumococcal (PPV23) polysaccharide vaccine.....	291
Paroxetine.....	127	Phenothrin.....	68	Pneumovax 23.....	291
Paser.....	99	Phenoxybenzamine hydrochloride.....	45	Podophyllotoxin.....	72
Patent blue V.....	264	Phenoxyethylpenicillin [Penicillin V].....	92	Polidocanol.....	32
Paxam.....	135	Phentolamine mesylate.....	45	Poliomyelitis vaccine.....	295
Paxlovid.....	108	Phenylephrine hydrochloride Cardiovascular.....	54	Poloxamer.....	15
Pazopanib.....	160	Sensory.....	257	Poly Gel.....	257
Peak flow meter.....	298	Phenytoin.....	128	Poly-Tears.....	257
Peanut oil.....	267	Phenytoin sodium.....	127-128	Poly-Visc.....	258
Pedialyte - Bubblegum.....	41	Phosphorus.....	41	Polyethylene glycol 400 and propylene glycol.....	258
Pediasure (Chocolate).....	283	Phytomenadione.....	35	Polyhexamethylene biguanide.....	268
Pediasure (Strawberry).....	283	Picibanil.....	239	Polyvinyl alcohol with povidone.....	258
Pediasure (Vanilla).....	283	Pilocarpine hydrochloride.....	256	Poractant alfa.....	251
Pediasure RTH.....	282	Pilocarpine nitrate Extemporaneously Compounded Preparations.....	268	Posaconazole.....	96
Pegaspargase.....	153	Sensory.....	256	Posaconazole Juno.....	96
Pegasys.....	108	Pimafucort.....	71	Potassium chloride.....	40, 42
Pegfilgrastim.....	39	Pimecrolimus.....	71	Potassium chloride with sodium chloride.....	40
Pegylated interferon alfa-2a.....	108	Pine tar with trolamine laurilsulfate and fluorescein.....	72	Potassium citrate.....	76
Pembrolizumab.....	236	Pinetarsol.....	72	Potassium dihydrogen phosphate.....	40
Pemetrexed.....	150	Pioglitazone.....	11	Potassium iodate.....	
Penicillamine.....	111	Piperacillin with tazobactam.....	92	Alimentary.....	22
Penicillin G.....	92	Pipothiazine palmitate.....	135	Hormone Preparations.....	87
Penicillin V.....	92	PipTaz-AFT.....	92	Potassium iodate with iodine.....	22
Pentacarinat.....	100	Pirfenidone.....	246	Potassium perchlorate.....	87
Pentagastrin.....	81	Pituitary and Hypothalamic Hormones and Analogues.....	82		
Pentamidine isethionate.....	100				
Pentasa.....	6				
Pentostatin [Deoxycoformycin].....	154				
Pentoxifylline [Oxpentifylline].....	55				
Peptamen OS 1.0 (Vanilla).....	276				
Perflutren.....	263				

Potassium permanganate.....	72	Protirelin .....	87	Resonium A.....	42
Povidone K30 .....	268	Proveblue .....	264	Resource Beneprotein.....	271
Povidone-iodine.....	261	Provera .....	81	Respiratory Stimulants .....	251
Povidone-iodine with ethanol.....	261	Provera HD.....	81	Retinol .....	26
Pradaxa .....	35	Proxymetacaine hydrochloride .....	255	Retinol Palmitate .....	258
Pralidoxime iodide .....	259	Pseudoephedrine .....		ReTrieve .....	68
Pramipexole hydrochloride.....	119	hydrochloride .....	247	Retrovir .....	103
Pravastatin.....	51	Psoriasis and Eczema .....		Retrovir IV.....	103
Pravastatin Mylan.....	51	Preparations .....	71	Revimid.....	152
Pravastatin Viatris.....	51	PTU .....	87	Revolade .....	31
Praxbind .....	33	Pulmonary Surfactants .....	251	Riboflavin.....	19
Praziquantel.....	100	Pulmozyme .....	249	Riboflavin 5-phosphate .....	256
Prazosin.....	45	Puri-nethol .....	149	Ribomustin.....	146
Pred Forte.....	254	Puria .....	27	Ricit.....	76
Prednisolone.....	80	Pyrazinamide.....	99	Rifabutin .....	99
Prednisolone acetate.....	254	Pyridostigmine bromide.....	111	Rifadin .....	99
Prednisolone sodium.....	7	Pyridoxal-5-phosphate .....	19	Rifampicin.....	99
Prednisolone sodium .....		Pyridoxine hydrochloride .....	26	Rifaximin .....	9
phosphate .....	254	Pyridoxine multichem .....	26	Rifinah .....	99
Prednisolone- AFT.....	254	Pyrimethamine.....	101	Rilutek .....	118
Prednisone .....	80	Pytazen SR.....	36	Riluzole.....	118
Prednisone Clinect .....	80			Ringer's solution .....	40
Pregabalin .....	129	<b>- Q -</b>		RINVOQ .....	241
Pregabalin Pfizer .....	129	Quetapel.....	133	Riodine .....	261
Pregnancy test - hCG urine .....	298	Quetiapine .....	133	Risdiplam.....	140
preOp.....	284	Quinapril.....	43	Risedronate Sandoz.....	112
Prevenar 13.....	290	Quinapril with .....		Risedronate sodium.....	112
Priadel .....	133	hydrochlorothiazide .....	43	Risperdal Consta .....	135
Prilocaine hydrochloride .....	122	Quinine dihydrochloride.....	101	Risperidone .....	133, 135
Prilocaine hydrochloride with .....		Qvar .....	247	Risperidone (Teva).....	133
felypressin .....	122			Risperone .....	133
Primaquine .....	100	<b>- R -</b>		Ritalin.....	142
Primidone .....	129	RA-Morph .....	124	Ritalin LA .....	142
Primolut N.....	82	Rabies vaccine .....	295	Ritonavir .....	104
Primovist.....	263	Raloxifene.....	113	Rituximab (mabthera) .....	208
Priorix .....	294	Raltegravir potassium.....	104	Rituximab (riximyo) .....	210
Probenecid .....	115	Ramipex .....	119	Rivaroxaban .....	36
Procaine penicillin.....	92	Ranbaxy-Cefaclor.....	89	Rivastigmine .....	143
Procarbazine hydrochloride.....	154	Ranibizumab.....	208	Rivastigmine Patch BNM 10.....	143
Prochlorperazine .....	132	Ranitidine.....	8	Rivastigmine Patch BNM 5.....	143
Proctosedyl .....	7	Rapamune.....	239	Riximyo.....	210
Procyclidine hydrochloride.....	118	Rasagiline .....	119	RIXUBIS .....	34
Progesterone .....	75	Rasburicase.....	115	Rizamelt .....	130
Proglicem.....	9	Readi-CAT 2.....	262	Rizatriptan .....	130
Proglycem.....	9	Reandron 1000.....	78	Robinul .....	7
Prognovna .....	80	Recombinant factor IX.....	33-34	Rocuronium bromide .....	115
Prolia .....	112	Recombinant factor VIIa .....	33	Ronapreve .....	194
Promethazine hydrochloride .....	244	Recombinant factor VIII.....	34	Ropin .....	119
Propafenone hydrochloride .....	46	Rectogesic.....	7	Ropinrole hydrochloride.....	119
Propofol .....	119	Red back spider antivenom .....	260	Ropivacaine hydrochloride .....	122
Propranolol .....	47	Redipred .....	80	Ropivacaine hydrochloride with .....	
Propylthiouracil.....	87	Relenza Rotadisk .....	107	fentanyl.....	122
Prostin E2 .....	75	Relistor .....	15	Ropivacaine Kabi.....	122
Prostin VR .....	54	Remdesivir.....	108	Rose bengal sodium.....	254
Protamine sulphate.....	36	Remicade .....	195	Rosuvastatin.....	51
Protonamide .....	99	Remifentanil.....	125	Rosuvastatin Viatris.....	51
		Remifentanil-AFT.....	125		



Rotarix .....	295	Simvastatin .....	52	Sensory .....	255, 258
Rotavirus oral vaccine .....	295	Simvastatin Mylan .....	52	Sodium hyaluronate [Hyaluronic acid] with chondroitin sulphate .....	255
Roxithromycin .....	91	Simvastatin Viatrix .....	52	Sodium hydroxide .....	265
Rubifen .....	142	Sinacalide .....	264	Sodium hypochlorite .....	261
Rubifen SR .....	142	Sinemet .....	119	Sodium metabisulfite .....	269
Rurioctocog alfa pegol [Recombinant factor VIII] .....	34	Sinemet CR .....	119	Sodium nitrite .....	259
Ruxolitinib .....	161	Sirolimus .....	239	Sodium nitroprusside .....	
<b>- S -</b>					
S26 LBW Gold RTF .....	281	Sirturo .....	98	Cardiovascular .....	55
Sabril .....	129	Siterone .....	78	Optional Pharmaceuticals .....	298
Sacubitril with valsartan .....	44	Slow-Lopresor .....	47	Sodium phenylbutyrate .....	20
SalAir .....	247	Smith BioMed Rapid Pregnancy Test .....	298	Sodium phosphate with phosphoric acid .....	15
Salazopyrin .....	7	Snake antivenom .....	260	Sodium picosulfate .....	16
Salazopyrin EN .....	7	Sodibic .....	42	Sodium polystyrene sulphonate .....	42
Salbutamol .....	247	Sodium acetate .....	40	Sodium stibogluconate .....	101
Salbutamol with ipratropium bromide .....	245	Sodium acid phosphate .....	41	Sodium tetradecyl sulphate .....	33
Salicylic acid .....	268	Sodium alginate with magnesium alginate .....	5	Sodium thiosulfate .....	259
Salmeterol .....	248	Sodium alginate with sodium bicarbonate and calcium carbonate .....	5	Sodium valproate .....	129
Salmonella typhi vaccine .....	291	Sodium aurothiomalate .....	111	Sodium with potassium .....	266
Sandimmun .....	167	Sodium benzoate .....	20	Solifenacin Mylan .....	77
Sandomigran .....	130	Sodium bicarbonate .....		Solifenacin succinate .....	77
Sapropterin Dihydrochloride .....	20	Blood .....	41-42	Solifenacin Viatrix .....	77
Scalp Preparations .....	72	Extemporaneously Compounded Preparations .....	268	Solu-Cortef .....	80
Scandonest 3% .....	121	Sodium benzoate .....	20	Solu-Medrol .....	80
Sclerosing Agents .....	251	Sodium bicarbonate .....		Solu-Medrol Act-O-Vial .....	80
Scopoderm TTS .....	131	Blood .....	41-42	Somatropin .....	82
Sebizole .....	67	Extemporaneously Compounded Preparations .....	268	Sotalol .....	47
Secretin pentahydrochloride .....	264	Sodium chloride .....		Soya oil .....	259
Secukinumab .....	221	Blood .....	41-42	Spacer device .....	298
Sedatives and Hypnotics .....	138	Respiratory .....	247, 250	Span-K .....	42
Seebri Breezhaler .....	245	Various .....	265	Spazmol .....	7
Selegiline hydrochloride .....	119	Sodium chloride with sodium bicarbonate .....	247	Specialised Formulas .....	275
Selenium .....	24	Sodium citrate .....		Spinal Muscular Atrophy .....	139
Sennosides .....	16	Alimentary .....	5	Spinraza .....	139
Serc .....	131	Extemporaneously Compounded Preparations .....	269	SpioLto Respimat .....	245
Serenace .....	132	Sodium citrate with sodium chloride and potassium chloride .....	36	Spiractin .....	50
Seretide .....	249	Sodium citrate with sodium lauryl sulphoacetate .....	15	Spiramycin .....	101
Seretide Accuhaler .....	249	Sodium citro-tartrate .....	76	Spiriva .....	245
Serevent .....	248	Sodium cromoglicate .....		Spiriva Respimat .....	245
Serevent Accuhaler .....	248	Alimentary .....	7	Spiroonolactone .....	50
Sertraline .....	127	Respiratory .....	244	Sprycel .....	157
Setrona .....	127	Sensory .....	254	Standard Feeds .....	284
Sevoflurane .....	120	Sodium dihydrogen phosphate [Sodium acid phosphate] .....	41	Starch .....	269
Sevredol .....	124	Sodium fluoride .....	22	Stavudine .....	103
Shingles vaccine .....	296	Sodium fusidate [Fusidic acid] Dermatological .....	67	Stelara .....	230
Shingrix .....	296	Infections .....	95	Sterculia with frangula .....	15
Sildenafil .....	60	Sensory .....	252	SteroClear .....	244
Siltuximab .....	224	Sodium hyaluronate [Hyaluronic acid] Alimentary .....	25	Stesolid .....	127
Silver nitrate .....				Stimulants / ADHD Treatments .....	141
Dermatological .....	72			Stiripentol .....	129
Extemporaneously Compounded Preparations .....	268			Stocrin .....	101
Simeticone .....	5			Streptomycin sulphate .....	88
Simulect .....	192			Stromectol .....	99

## INDEX: Generic Chemicals and Brands

Sugammadex .....	116	Temazepam.....	139	olodaterol.....	245
Sugammadex BNM .....	116	Temozolomide.....	154	Tivicay .....	104
Sulfadiazine silver.....	67	Tenecteplase.....	38	Tixagevimab with cilgavimab.....	224
Sulfasalazine .....	7	Tenofovir disoproxil .....	105	TMP .....	95
Sulindac.....	117	Tenofovir Disoproxil Emtricitabine		Tobradex .....	252
Sulphacetamide sodium .....	252	Mylan.....	106	Tobramycin	
Sulphadiazine.....	95	Tenofovir Disoproxil Emtricitabine		Infections.....	88
Sulphur .....	269	Viatr .....	106	Sensory.....	252
Sulprix.....	132	Tenofovir Disoproxil Mylan .....	105	Tobramycin BNM.....	88
Sumagran .....	130	Tenofovir Disoproxil Viatris.....	105	Tobramycin Mylan.....	88
Sumatriptan .....	130	Tenoxicam.....	117	Tobrex .....	252
Sunitinib .....	161	Tensipine MR10 .....	48	Tocilizumab .....	224
Sunitinib Pfizer.....	161	Terazosin.....	45	Tofranil.....	126
Sunscreen, proprietary.....	72	Terbinafine.....	98	Tolcapone.....	119
Suprane.....	119	Terbutaline.....	76	Tolvaptan.....	50
Surgical Preparations .....	265	Terbutaline sulphate.....	247	Topamax .....	129
Survimed OPD.....	277	Teriflunomide.....	137	Topical Products for Joint and	
Sustagen Hospital Formula		Teriparatide .....	113	Muscular Pain.....	117
(Chocolate).....	285	Teripressin .....	87	Topiramate .....	129
Sustagen Hospital Formula		Testosterone.....	78	Topiramate Actavis.....	129
(Vanilla) .....	285	Testosterone cipionate .....	78	Torbay .....	54
Suxamethonium chloride.....	115	Testosterone esters.....	78	Tracrium .....	115
Sylvant.....	224	Testosterone undecanoate.....	78	Tramadol hydrochloride.....	125
Symbicort Turbuhaler .....	248	Tetrabenazine.....	118	Tramal 100 .....	125
Symmetrel .....	118	Tetracaine [Amethocaine] hydrochloride		Tramal 50 .....	125
Sympathomimetics .....	53	Nervous.....	122	Tramal SR 100 .....	125
Synacthen.....	82	Sensory.....	255	Tramal SR 150 .....	125
Synacthen Depot.....	82	Tetracosactide [Tetracosactrin].....	82	Tramal SR 200 .....	125
Synagis.....	206	Tetracosactrin .....	82	Trandate .....	47
Synflorix.....	290	Tetracycline .....	94	Tranexamic acid .....	33
Syntometrine .....	75	Teva Lisinopril .....	43	Tranexamic-AFT.....	33
Syrup .....	269	Thalidomide.....	155	Tranlycypromine sulphate .....	126
Systane Unit Dose.....	258	Thalomid.....	155	Trastuzumab.....	228
<b>- T -</b>					
Tacrolimus		Theobroma oil.....	269	Trastuzumab emtansine.....	229
Dermatological.....	72	Theophylline.....	249	Travatan .....	257
Oncology.....	167	Thiamine hydrochloride .....	27	Travoprost .....	257
Tacrolimus Sandoz.....	167	Thiamine multichem .....	27	Treatments for Dementia.....	143
Tagitol V .....	262	Thioguanine.....	150	Treatments for Substance	
Talc.....	251	Thiopental [Thiopentone]		Dependence .....	143
Taliglucerase alfa .....	21	sodium.....	120	Tretinoin	
Tambocor .....	46	Thiopentone.....	120	Dermatological.....	68
Tamoxifen citrate.....	167	Thiotepa.....	147	Oncology.....	155
Tamoxifen Sandoz.....	167	Thrombin .....	33	Trexate .....	149
Tamsulosin hydrochloride.....	76	Thyroid and Antithyroid		Tri-sodium citrate.....	269
Tamsulosin-Rex.....	76	Preparations .....	86	Triamcinolone acetonide	
Targocid.....	95	Thyrotropin alfa.....	82	Alimentary .....	24
Tasigna.....	159	Ticagrelor.....	37	Dermatological.....	71
Tasmar .....	119	Ticagrelor Sandoz .....	37	Hormone Preparations.....	80
Taurine .....	22	Ticarillin with clavulanic acid.....	92	Triamcinolone acetonide with	
Tecentriq.....	233	Ticlopidine .....	38	gramicidin, neomycin and	
Tecfidera.....	136	Tigecycline.....	94	nystatin .....	253
Tegretol .....	127	Tilcotil .....	117	Triamcinolone acetonide with	
Tegretol CR.....	127	Timolol.....	256	neomycin sulphate, gramicidin	
Teicoplanin .....	95	Timoptol XE .....	256	and nystatin .....	71
Temaccord.....	154	Tiotropium bromide.....	245	Triamcinolone hexacetoneide.....	80
		Tiotropium bromide with			

Triazolam.....	139	vaccine].....	296	Vttack.....	97
Trichloroacetic acid.....	269	Varivax.....	295	- W -	
Trientine dihydrochloride.....	22	Vasodilators.....	54	Warfarin sodium.....	36
Trikafta.....	250	Vasopressin.....	87	Wart Preparations.....	72
Trimethoprim.....	95	Vasopressin Agents.....	87	Water	
Trimethoprim with		Vasorex.....	47	Blood.....	41
sulphamethoxazole		Vebulis.....	63	Various.....	265
[Co-trimoxazole].....	95	Vecuronium bromide.....	115	White Soft Liquid Paraffin AFT.....	69
Trisul.....	95	Vedafil.....	60	Wool fat	
Trometamol.....	265	Vedolizumab.....	232	Dermatological.....	70
Tropicamide.....	257	Veklury.....	108	Extemporaneously Compounded	
Tropisetron.....	132	Veletri.....	62	Preparations.....	269
Trulicity.....	11	Venclexta.....	155	- X -	
Tryzan.....	43	Venetoclax.....	155	X-Opaque-HD.....	262
Tuberculin PPD [Mantoux] test.....	297	Venlafaxine.....	126	Xanthan.....	269
Tubersol.....	297	Venofer.....	23	Xarelto.....	36
Two Cal HN.....	277	VENOX.....	243	Xifaxan.....	9
Tykerb.....	159	Ventolin.....	247	Xolair.....	205
Tysabri.....	137	Vepesid.....	151	Xylocaine.....	121
- U -		Verapamil hydrochloride.....	48	Xylometazoline hydrochloride.....	247
Ultibro Breezhaler.....	245	Vermox.....	100	Xyntha.....	34
Ultraproct.....	7	Versacloz.....	132	- Y -	
Umeclidinium.....	245	Vesanoid.....	155	Yellow jacket wasp venom.....	243
Umeclidinium with vilanterol.....	245	Vexazone.....	11	- Z -	
Univent.....	244	Vfend.....	97	Zanamivir.....	107
Upadacitinib.....	241	Victoza.....	11	Zapril.....	43
Ural.....	76	Vigabatrin.....	129	Zarontin.....	127
Urea		Vigisom.....	138	Zavedos.....	148
Dermatological.....	70	Vildagliptin.....	11	Zeffix.....	104
Extemporaneously Compounded		Vildagliptin with metformin		Zematop.....	72
Preparations.....	269	hydrochloride.....	11	Zetlam.....	104
Urex Forte.....	49	Vimpat.....	128	Ziagen.....	102
Urografin.....	262	Vinblastine sulphate.....	164	Zidovudine [AZT].....	103
Urokinase.....	38	Vincristine sulphate.....	164	Zidovudine [AZT] with	
Urologicals.....	76	Vinorelbine.....	164	lamivudine.....	103
Uromitexan.....	163	Vinorelbine Te Arai.....	164	Ziextenzo.....	39
Ursodeoxycholic acid.....	13	Viral Vaccines.....	292	Zimybe.....	52
Ursosan.....	13	Viramune Suspension.....	102	Zinc	
Ustekinumab.....	230	ViruPOS.....	252	Alimentary.....	24
Utrogestan.....	75	Viscoat.....	255	Dermatological.....	68
- V -		Visipaque.....	262	Zinc and castor oil.....	69
Vaclovir.....	105	Vit.D3.....	27	Zinc chloride.....	24
Valaciclovir.....	105	VitA-POS.....	258	Zinc oxide.....	269
Valganciclovir.....	105	Vital.....	276	Zinc sulphate.....	24
Valganciclovir Mylan.....	105	Vitamin B complex.....	27	Zinc with wool fat.....	69
Valganciclovir Viatrix.....	105	Vitamin B6 25.....	26	Zincaps.....	24
Vancomycin.....	95	Vitamins.....	25	Zinforo.....	90
Varenicline.....	144	Vivonex TEN.....	276	Ziprasidone.....	133
Varenicline Pfizer.....	144	Voltaren.....	116	Zista.....	244
Varibar - Honey.....	262	Voltaren D.....	116	Zithromax.....	90
Varibar - Nectar.....	262	Voltaren Ophtha.....	254	Zoledronic acid	
Varibar - Pudding.....	262	Voltaren SR.....	116	Hormone Preparations.....	79
Varibar - Thin Liquid.....	262	Volumatic.....	298	Musculoskeletal.....	112
Varicella vaccine [Chickenpox		VolLumen.....	262	Zoledronic acid Mylan.....	79
vaccine].....	295	Voriconazole.....	97	Zoledronic acid Viatrix	
Varicella zoster vaccine [Shingles		Votrient.....	160	Hormone Preparations.....	79

Musculoskeletal .....	112
Zopiclone .....	139
Zostrix .....	117
Zostrix HP .....	122
Zuclopenthixol acetate .....	133
Zuclopenthixol decanoate .....	135
Zuclopenthixol hydrochloride .....	133
Zusdone .....	133
Zyban .....	144
Zypine .....	133
Zypine ODT .....	133
Zyprexa Relprev .....	134
Zytiga .....	164
Zyvox .....	95







